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SUMMARY 
Chronic musculoskeletal pain (CMP), characterised by pain in the muscle and joints for more 
than three months, affects one in five people in Australia and internationally. Chronic 
musculoskeletal pain is associated with reduced quality of life, loss of productivity, and 
increased health expenditures to the patients and the society. Chronic musculoskeletal pain is 
accompanied with comorbidities and accompanying symptoms. Comorbidities increase the 
burden to health management and deteriorate quality of life.  
Current management for CMP includes pharmacotherapies, surgical procedures, physiotherapy, 
multimodal pain management, exercise therapy, psychological interventions, and acupuncture. 
Pharmacotherapies including opioid medication (OM) are routinely used but are associated 
with many and serious adverse effects, such as risks of addiction, dependence, uncertain 
long-term benefit and death.  
Chinese medicine (CM) including acupuncture has more than 3,000 years of history and it has 
been used to treat CMP. Clinical decision making is based on the diagnostic pattern guided by 
the CM unique theory and determined by evaluating the presenting pain and non-pain 
symptoms of CMP patients. For example, low back pain due to CM kidney deficiency pattern 
would also have non-pain symptoms such as lassitude, feverish sensation in the palms/soles or 
cold limbs. Chinese medicine incorporates the accompanying symptoms and/or comorbidities 
to understand and manage CMP which reflects the holistic approach. However, such an 
approach has not been evaluated by clinical trials to determine the value of pattern 
identification in the CM management for CMP, particularly for users of OM for CMP control.  
In order to establish a basis for further research into CM for CMP, there is a need to identify the 
CM patterns of CMP and assess their differences with clinical outcomes measured by validated 
tools. 
The Objectives of this thesis were to: 
1) identify the comorbidities and symptomatologies of CMP through a systematic review;  
2) develop and validate a Chinese medicine Pain Questionnaire (CMPQ) for pattern 
 XXI 
 
identification in CMP patients who are OM users; 
3) differentiate the CM patterns of CMP who use OM for pain control using cluster analysis; 
and determine the cluster differences in demography, pain intensity, OM consumption, 
depression, quality of life, and disability; and 
4) determine the differences between CM patterns and clinical outcomes of electro acupuncture 
(EA) based on the change in CMPQ symptoms, pain intensity, OM consumption, depression, 
and quality of life. 
To address Objective one, a systematic review was completed. Major English databases were 
searched and 72 studies were included with 61 of them being categorised into three main groups: 
chronic spinal pain, arthritis, and fibromyalgia. The findings showed the association between 
CMP and comorbidities and accompanying pain or non-pain symptoms for chronic spinal pain 
and arthritis but not for fibromyalgia. Chronic spinal pain (20 studies) was associated with 
(odds ratio 1.33-7.9) arthritis, headache/migraine, depression, and panic attacks/disorder, 
hypertension, heart diseases, general anxiety disorder, mood disorder, alcohol use disorder, 
and digestive ulcer. Arthritis (37 studies) was associated with (odds ratio 1.48 – 8.7) chronic 
spinal pain, depression, panic disorder, post traumatic stress disorder, heart disease/attack, 
asthma, headache, any chronic pain, and any physical disease. The current systematic review 
revealed that 15 fibromyalgia studies did not report odds ratio data on the same comorbidities. 
The association between comorbidities and fibromyalgia remains unconfirmed. Fibromyalgia 
patients were found to suffer from fatigue (95%), depression/depressiveness (90.9%), anxiety 
(77.7%), irritable bowel syndrome (62%), and irritable bladder (58%). 
To address Objective two, CM literature was reviewed and a draft CMPQ was developed. 
Chinese medicine pain questionnaire contained 187 questions in the following six domains: 
pain regions, pain quality, pain rhythm, pain aggravators, pain alleviators, and other 
accompanying symptoms. These questions were reviewed by a group of CM researchers for 
face and content validities. The draft CMPQ was subsequently tested amongst CMP who used 
OM for pain control. This procedure was incorporated into a clinical trial titled 
“Electroacupuncture on opioid consumption by patients with chronic musculoskeletal pain: a 
randomised controlled trial” 1. The CMPQ was completed by these subjects four times 
throughout the trial at pre-baseline (week one), baseline (just before randomisation and 
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commencement of the three assigned treatments - real EA, sham EA and no-EA) (week five), 
mid treatment (week 10), and at the end of treatment (week 14). In total 108 participants were 
recruited. The participants mostly had seven or more pain sites (55.6%). Many of them had 
pain in the lower back (78.20%), knee (48.50%), hip (47.50%), neck (44.60%), shoulder 
(41.60%), middle back (41.60%), and thigh (40.60%). Most of them had sharp pain (58.4%), 
pain at a fixed location (42.6%), pain all the time (63.4%), and worse pain when first getting up 
(42.6%). They were often accompanied with: feeling tired easily (69.20%), insomnia (59.40%), 
limited movement (56.40%), poor concentration (55.40%), poor memory (48.50%), feeling 
depressed (47.50%), irritable (45.50%), constipation (44.50%), and low libido (41.60%). 
Chinese medicine pain questionnaire demonstrated good face validity, content validity, 
test-retest reliability (Correlation coefficient=0.846 for overall questionnaire), and internal 
consistency (Cronbach’s α=0.931). 
To address Objective three, the CMPQ data gathered throughout the trial was analysed firstly 
using principal components analysis to extract 36 factors from the five CMPQ domains (except 
for pain region). Then the extracted factors were clustered using K-means cluster analysis into 
six clusters. Cluster four (n=48) and cluster five (n=41) had the largest number of participants 
and they were diagnosed as CM “heat pattern” (cluster four), and “cold with deficiency pattern” 
(cluster five) respectively by the CM cluster analysis group experts. Of the remaining clusters, 
only clusters two and six had more than one participant. Multivariate analysis of variance on 
their demographic data showed cluster four had the shortest mean pain history (10.14 years) 
whereas cluster six had the longest pain history (24.71 years). When the CM “heat pattern” 
(cluster four) was compared with the CM “cold with deficiency” pattern (cluster five), the CM 
“heat pattern” was associated with the better quality of life and mild depression whereas the 
CM “cold with deficiency pattern” was associated with worse quality of life and moderate 
depression. 
To address Objective four, baseline and end of treatment weeks CMPQ data were used. The 
comparison was within individual changes rather than between group changes. It was shown 
that real EA was the only group without deterioration, sham EA and pain and medication 
management (PMM) alone both had two symptom deteriorations. Sham EA was the group with 
most symptom improvements (nine symptoms) followed by PMM alone (four symptoms) and 
real EA (two symptoms).  
 XXIII 
 
To identify which pattern reported better response to real EA, cluster four “heat pattern” and 
cluster five “cold with deficiency pattern” were used as they had more participants. This 
comparison was within individual changes rather than group changes. The heat pattern 
subgroup reported improvement in one more symptom on CMPQ in response to real EA than 
the cold with deficiency pattern subgroup.  
Baseline and end of treatment weeks data of pain intensity, OM consumption, depression, and 
quality of life of the three treatment groups and the two CM patterns (clusters four and five) 
were compared. These were group mean comparisons and not changes within individuals. 
There were no differences between the three treatment groups, neither was there any 
difference in how the two CM patterns responded to the three treatments. 
In conclusion, this project employed an evidence-based medicine approach to identify 
symptom presentation in CMP patients who use OM for pain control, developed and validated 
the CMPQ for clinical sub grouping guided by CM theory and diagnosis. Furthermore, a 
preliminary analysis on potential relationship between CM patterns and clinical outcome was 
conducted as part of a multicentre RCT on EA for CMP who used OM. The finding of distinct 
heat and cold with deficiency patterns in CMP indicates the importance of incorporating some 
form of heat therapy, such as moxibustion, into future acupuncture studies for chronic pain.  
The main limitation of this thesis is the small sample size during the evaluation of treatment 
effect of the three treatments and when the real EA group was further sub grouped into the two 
CM patterns. Further validation of the CMPQ in larger and different study populations is 
needed to determine the clinical benefit of CM patterns in clinical practice of EA for CMP. In 
addition, the use of likert scales instead of a dichotomous format to capture subtle changes after 
intervention is recommended. It is anticipated that a validated CMPQ may enhance the clinical 
benefit of multidisciplinary approach for the management of CMP.  
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1. Introduction 
1.1 Problems associated with CMP and its management  
Chronic musculoskeletal pain, a chronic muscle and bone disorder, is defined as pain that lasts 
beyond three months 2. Chronic musculoskeletal pain affects a great portion of people. Both 
Australian data and the Netherlands national survey results found one in five people had CMP 
3,4. Chronic musculoskeletal pain affects patient’s quality of life (QoL) 5, working status 6, and 
is costly to manage 7. In Australia, the absenteeism cost due to chronic pain is estimated to be 
1.4 billion/year, and the cost rises to 5.1 billion/year if reduced work performance is added 8. 
Chronic pain causes approximately one in five patients to lose their job 9, and is an international 
health priority in the industrialised nations 10. Chronic musculoskeletal pain has no cure 11, is 
considered to be a disease of its own in modern pain medicine 12, and should be understood and 
treated differently from acute pain 13.  
Apart from pain, CMP is often accompanied with other diseases or health conditions (i.e. 
comorbidities) 14. A systematic review (SR) 15 showed that the prevalence of comorbid 
hypertension in arthritis (50.8%) was almost three times as much as in asthma (18%). 
Comorbidities associated with CMP increase the disease burden to individuals and the society. 
A Swedish study in 2012 found that the cost per person for managing osteoarthritis (OA) plus 
depression (53619 Swedish Krona (SEK) (equivalent to 7,803 Australian dollars (AUD)) was 
1.52 times more than managing osteoarthritis alone (35046 SEK (equivalent to 5100 AUD)); 
and the cost for managing back pain plus depression (46909 SEK (equivalent to 6,827 AUD) 
was almost twice as much as managing back pain alone (26152 SEK (equivalent to 3,806 AUD) 
in the year of 2006 16. Such impacts create wealth depletion in later life to the individual 17, not 
to mention the impact of comorbidity on CMP patients’ social functioning 18. All of these 
impede CMP patient’s ability to fulfil their role within their work and relationships with 
relatives, reduce their QoL 19, and negatively impact their financial status. Comorbid pain at 
multiple sites reduces patient’s physical functioning 20. Unless these multiple sites of pain are 
addressed well together, the disability remains 20. Comorbidities should be addressed 
concurrently when managing CMP for a better health results. There is a need to identify the 
comorbidity and the accompanying symptoms of CMP and their association with CMP in order 
to better understand CMP. 
Currently the management of CMP focuses on pain relief and pain coping through the use 
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ofpharmacotherapies and non-pharmacotherapies. Pharmacotherapies include non-steroidal 
anti-inflammatory drugs (NSAIDs), steroids, and opioids 21. Strong opioids is the World Health 
Organization’s (WHO’s) last stage of pharmacotherapy for pain management 22. The Australia 
data shows the prescription of oxycodone, in mg/capita, has increased more than 90 times 
from 1980 to 2014 23 and the number of prescriptions has increased 152% from 35.3/1000 
adult population in 2002-2003 to 89.2/1000 adult population in 2007-2008 in the population 24. 
This indicates an enormous increase of demand and almost one in ten adult Australians 
consumes oxycodone. 
These pharmacotherapies come with severe side effects including opioid misuse which can lead 
to death of the patient 25. Studies have shown pharmacotherapy may induce comorbidities. 
NSAIDs can cause hypertension 26,27 and congestive heart failure 27, and steroids can cause 
diabetes mellitus 28. Old age and female populations are prone to multimorbidity 29,30. This may 
be due to the older person having poorer functioning of liver and kidney which can cause the 
drugs to stay in the body for a longer period and increase the risk of side effects 31. These 
figures show that CMP comes with multiple comorbidities and raise issues about the 
effectiveness, management adequacy, safety, and suitability of current pharmacotherapy, 
especially opioids, for addressing CMP.  
1.2 Acupuncture and its role in pain management  
One of the non-pharmacotherapies for CMP is acupuncture 21. Acupuncture is recommended 
for joint pain/stiffness, post-operative pain, and muscle spasm by the United State of America 
(USA) Agency for Healthcare Research and Quality (AHRQ) guideline 32 and has shown 
consistent improvements for insomnia 33, and chronic low back pain (LBP) with depression 34. 
Currently there are conflicting recommendations for CMP from various SRs. Some support the 
use of acupuncture for CMP 35 whereas some remain inconclusive 36,37. One problem with 
acupuncture clinical trials is the acupuncture protocol. Traditionally acupuncture treatment is 
based on the CM patterns which are the basis for formulating the treatment principles 38. 
Chinese medicine patterns are subgroups within conditions/diseases. They are diagnosed based 
on the presenting symptoms and signs of patients 38. For instance, in chronic LBP, if the chronic 
LBP is accompanied with heaviness in the body/head/lumbar area, then such chronic LBP is 
due to the CM pattern of “dampness retention”; if chronic LBP is sharp in nature, at a fixed 
location, worse at night and better during the day, then such chronic LBP is due to CM pattern 
of “blood stasis”. It is clear that chronic LBP in CM is not just about pain in the low back area. 
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It encompasses non-pain signs and symptoms that are often associated with LBP. The 
treatments for different CM patterns differ and different CM patterns may respond to the same 
acupuncture protocol differently. Viewing all accompanying symptoms together with CMP to 
identify comorbidities and co-occurring symptoms has been proposed by Hartvigsen et al. as 
the first line of CMP diagnosis 39. This is in line with CM’s holistic view of health and the 
principles of CM diagnosis. 
Research data on CM patterns for CMP are, however, lacking. The current textbook 
information has been generated by experts based on their own experience, but is not based on 
research and whether such information reflects reality is unknown. In addition, CMP is a 
western medicine concept. Its closest CM counterpart is “Bi syndrome”, which refers to pain of 
muscles and joints and is similar to the western medicine disease category ‘arthritis’. While 
some instances of CMP are due to arthritis, others are not. There is a need to identify the CM 
patterns of CMP using evidence-based approaches. In order to achieve this, valid CM pattern 
identifications are needed and an objective and reliable tool reflecting CM theory is required. 
Such a tool needs to be scientifically sound and scientifically developed. 
In order to address this knowledge gap, this project, which was embedded in an EA trial, 
utilised evidence based approaches to develop and validate the CMPQ, using the convenience 
sample of the clinical trial participants to identify the CM patterns of people with CMP who use 
OM for pain control. 
1.3 Aims and objectives 
The aims of this study were to develop and validate CMPQ through an evidence based approach 
for people with CMP who use OM for pain control; to explore the CM patterns present; and to 
evaluate the effects of a standard EA protocol on different CM patterns. 
Specifically the objectives were to:  
1) identify the comorbidities and symptomatologies of CMP through a SR (Chapter three);  
2) develop and validate a CMPQ for pattern identification in CMP patients who are OM users 
(Chapters five and six); 
 4 
 
3) differentiate the CM patterns of CMP who use OM for pain control using cluster analysis; 
and determine the cluster differences in demography, pain intensity, OM consumption, 
depression, QoL, and disability (Chapter seven); 
4) determine the differences between CM patterns and clinical outcomes of EA treatment based 
on the change in CMPQ symptoms, pain intensity, OM consumption, depression, and QoL 
(Chapter eight). 
These aims, objectives, and the structure of the thesis are outlined in Figure 1.1. 
 
CM: Chinese medicine 
CMPQ: Chinese medicine pain questionnaire 
EA: Electro acupuncture 
OM: Opioid medication 
QoL: Quality of life 
Figure 1.1 The structure of the thesis 
1.4 Organization of the thesis 
This project was embedded in a clinical trial titled “Electroacupuncture on opioid consumption 
by patients with chronic musculoskeletal pain: a randomised controlled trial” (EAOM trial) 1. 
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To develop and validate CMPQ, data collected from CMP patients who took part in the clinical 
trial were used. The design and methods of the EAOM trial is described from Chapter 4.2 Initial 
development of CMPQ (p. 141) to Chapter 4.2.3 Procedure of the EAOM trial (p. 142) and 
Chapter 8.2.1 Participants (p. 260). 
A comparison of the time points of various data collections and interventions between the trial 
and this current project is illustrated in Figure 1.2. 
 
1) pre-baseline week refers to data collected on week one 
2) baseline week refers to data collected on week five, prior to randomisation and 
commencement of the three assigned treatments (real EA, sham EA, and PMM alone), and 
baseline weeks refers to the average data from week one to four.  
3) mid treatment week refers to data collected in week 10 of the trial (week ten); and  
4) end of treatment week refers to data collected in week 14, at the end of the trial, and end of 
treatment weeks refers to the average of data from week 11 to week 14. 
Figure 1.2 CMPQ data time point in relation to EAOM trial time point 
Table 1.1 Time points and their data usage in CMPQ validation, CM pattern identification, and 
evaluation of treatment effects 
CMPQ validation 
and other 
applications 
Pre-baseline 
weeks 
Baseline 
week 
Mid 
treatment 
week 
End of 
treatment 
week 
Internal consistency x    
Reproducibility 
(test-retest reliability) 
x x   
Responsiveness  x x x 
CM pattern 
identification 
 x   
Evaluation of 
treatment effect. 
 x  x 
 
The CMPQ properties, CM pattern identification, and treatment effects with regard to CMPQ 
data usage are illustrated in Figure 1.2 and Table 1.1. Internal consistency was evaluated using 
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the CMPQ data collected at pre-baseline week. Reproducibility was evaluated using the CMPQ 
data collected at pre-baseline and baseline weeks (Table 1.1). Chinese medicine patterns were 
diagnosed based on factor and cluster analysis of symptoms using baseline week CMPQ data 
(Table 1.1). Responsiveness was evaluated using CMPQ data of baseline, mid treatment, and 
end of treatment weeks (Table 1.1).  
The relationships of the two largest CM patterns and the commonly used outcome measures for 
CMP, including pain and medication data, Medical Outcome Short Form Health Survey 36 
items (SF36) for QoL, and Beck Depression Inventory (BDI) for depression, were also 
explored. The changes in the three treatment groups between baseline and end of treatment 
weeks were also evaluated for the two largest CM patterns with CMPQ, and the other 
commonly used outcome measures (Table 1.1).  
The thesis consists of nine chapters. These are briefly described below:  
Chapter one introduces the background information and the outline of the project. 
Chapter two outlines the epidemiology, impact, current management, comorbidities of CMP as 
well as a brief introduction to CM, including how CM diagnoses CMP, the efficacy of 
acupuncture for pain management, and current issues with acupuncture in pain management. 
This chapter identifies the knowledge gaps in current pain management and the CM pattern 
diagnosis of CMP.  
Chapter three presents a SR on the comorbidities and accompanying symptoms of CMP 
following the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 
statement 40. Data from 72 cohort, case-control, and cross sectional studies were collected and 
analysed. Risk of bias was assessed using Newcastle Ottawa Scale (NOS) 41. The methods of 
comorbidity assessment, odds ratio (OR) and percentage data of comorbidities and 
accompanying symptoms of three major types of CMP are reported. The results are grouped 
based on International Classification of Disease into twelve categories 42. This chapter 
identifies the multiple comorbidities of CMP and their degree of association. 
Chapter four describes the methodology used for the development and validation of CMPQ. 
Fundamental information on the reliability and validity of the questionnaire are presented here 
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as well as the composition of the expert groups for assessing the validities of CMPQ and CM 
pattern diagnosis of the clusters identified in chapter seven. The EAOM trial methods are also 
described here. 
Chapter five describes the item generation of the CMPQ. Information on the construction and 
domains of CMPQ and the CM interpretation of the generated items are described. 
Chapter six presents the validation result of CMPQ, specifically the content and face validities, 
reproducibility, internal consistency, and responsiveness data. The frequency analysis of signs 
and symptoms collected with CMPQ at pre-baseline week are also presented. Refer to Table 
1.1 for the usage of CMPQ data time points and CMPQ validities. 
Chapter seven presents the CM pattern identification using the factor and cluster analyses of 
baseline week CMPQ data. The two CM patterns of “heat”, and “cold with deficiency” that 
were identified are discussed. 
Chapter eight examines the treatment effect on the CM patterns. It presents the effect of EA 
(both real and sham) and PMM alone on CMP patients who took OM for pain control on 
changes in pain and non-pain symptoms. The treatment effects in the two largest clusters (or 
CM patterns) were compared. Both baseline and end of treatment week CMPQ data were used 
for treatment effect evaluation. Moreover, the association between the two largest CM patterns 
and the other outcome measures were explored.  
CM “heat pattern” was associated with better QoL and depression whereas CM “cold with 
deficiency pattern” was associated with worse QoL and depression. The two CM patterns did 
differ in their pain and OM consumption. 
Chapter nine is the general discussion of the overall findings of the project. Limitations and 
recommendations for both clinical practice and future researches are discussed 
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2. Literature review 
2.1 Chronic pain 
“Pain is an unpleasant sensory and emotional experience associated with actual or potential 
tissue damage, or described in terms of such damage” 43. Chronic pain is defined as having such 
an unpleasant experience persistently for three months or more 44. Musculoskeletal is defined as 
pertaining to muscles and skeleton 45(p1135). Chronic musculoskeletal pain includes pain in the 
cervical thoracic, lumbar, sacral, and coccygeal regions of the spine as well as pain in the 
shoulder, upper arm, elbow, forearm, wrist, hand, finger, hip, thigh, knee, leg, foot, and toes. 
Diseases and conditions leading to CMP include OA, rheumatoid arthritis (RA), rheumatic 
arthritis, fibromyalgia/chronic widespread pain, frozen shoulder, and tennis elbow. Chronic 
musculoskeletal pain also includes pain due to vertebral disc protrusion but does not include 
carpal tunnel syndrome according to International Classification of Disease by WHO 46.  
2.2 Prevalence of CMP 
In Australia, one in five people are affected by CMP 3 and 55.8% of women and more than 40.5% 
of men over the age of 65 years are affected by arthritis or rheumatism 47. Different countries 
have reported different prevalences for CMP. A recent study in Norway found that the 
prevalence of musculoskeletal pain ranged from 9.8% to 34.7% amongst adults (n=3179) 48. A 
Swedish study found the most common musculoskeletal pain areas were back (22.7%) and 
shoulder (21.0%) among people between 20-64 years old 49. A cross sectional postal survey 
found chronic widespread muscle pain and chronic localized muscle pain affected 22% and 25% 
of Norwegian women respectively (n=2264) 50 whereas a review found generalized 
musculoskeletal pain was present in 38-57% of population 51. An international collaborative 
survey in Colombia, Mexico, USA, Belgium, France, Germany, Italy, Netherlands, Spain, 
Ukraine, Israel, Lebanon, Nigeria, South Africa, Japan, China (Beijing and Shanghai), and 
New Zealand found 16.5% to 20% of adults in the general public suffered from arthritis/joint 
pain and chronic back pain respectively. In general, over one in four people suffered from 
CMP. 
Musculoskeletal pain affected all age groups. A Brazilian epidemiological study on 3,269 
children aged between 10 – 17 years old found that more than 15% of children had neck, knee, 
wrist or hand, or upper back pain 52. The 451 working children amongst them had pain in the 
neck (42.9%), shoulder (19.0%), wrists or hands (42.9%), upper back (23.8%), and thigh 
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(19.0%) 52. Hungarian data showed 25.8% of young Hungarian women aged 15-24 years old 
(n=3,615) had CMP 53. According to an epidemiologyical study in the Uppland region of 
Sweden on adults aged 20-64 years (n=4,506) the prevalence of CMP increased with age 49 
whereas another Swedish study in a rural population found the prevalence of chronic pain 
increased up to 50-59 years for both genders and then decreased 54. A USA prospective cohort 
study that included 1,002 community dwelling women older than 65 years identified that up to 
one in four suffered from chronic widespread pain 55. 
2.3 Impact of CMP 
Musculoskeletal pain impacts a person in many different ways. The following sections list its 
impact on QoL, working status, and cost of pain. 
2.3.1 Impact on QoL 
A Swdish study, published in 2008, investigated the association between health factors and 
health related QoL with an eight year follow up amongst participants with and without CMP, 
with subjects’ age ranging from 20 to 74 years 56. The study found CMP patients scored 
significantly lower (ranged from 50s to just above 80) than participants without CMP (ranged 
from low 70s to above 90) in all of SF36 domains at both the baseline and the eighth year follow 
up (p<0.001). This study only provided graphical comparisons without any mean and standard 
deviation. 
An Irish study (n=498), published in 2008, reported CMP patients had lower health appraisals, 
especially among the elderly aged over 60 years, when compared with the average of the whole 
sample (average age not supplied in the manuscript) 5. As people got older, fewer and fewer 
patients believed they were in a good health 5. Amongst the patients, 49% were limited in some 
work activities and 44% accomplished less than they had expected in the previous four weeks 5. 
As assessed with Medical Outcome Short Form Health Survey 12-Item (SF12), 67% of the 
patients had poorer QoL in comparison with the average health appraisal (mean data not 
provided) 5. 
A Hong Kong study, published in 2009, investigated the impact of musculoskeletal pain in 
elderly Chinese 57. It included 4,000 participants with equal numbers of both genders 57. This 
study found CMP patients had reduced grip force, slower walking speed, reduced step length, 
 10 
 
lower level of physical activity, poorer perception of self health, depressive symptoms, and 
lower QoL score (assessed with SF12). Their daily activities were significantly impacted 57. 
Women were affected similarly to men except that women had increased fracture incidence 57. 
2.3.2 Working status 
An Australian study examined the impact of chronic pain on working status 58, and found that 
over six months, workers with chronic pain had 83.8 working days with pain and a 14.2% 
reduction in work effectiveness. They also lost 4.5 working days due to pain. When the 
working days with pain and reduced work effectiveness were added to the 4.5 lost working 
days, in total the workers lost 16.4 working days equivalence over six months. 
One Finnish study, published in 2009, looked at the effect of upper extremity disorders on 
working status 6. It included 168 patients with upper extremity disorders 6. Amongst the patients, 
64% were nurses and other health care workers, 25% were secretaries and other clerical 
workers, 8% were warehouse workers, and 87% of them were females 6. Thirty seven percent 
of the patients had sickness absence in the last 12 months due to upper extremity disorders. 
Reduced productivity due to upper extremity disorder was reported by 56% of females and 59% 
of males 6. The average loss in production was 34% in comparison to a normal work day 6. 
A Norwegian study showed that LBP resulted in absence from work. The median duration of 
absence was 43 days with the 25th and 75th percentiles being 23 and 103 days. Only 35%, 70%, 
and 85% of these workers returned to work after one, three, and six months of sick leave. Of 
these workers, LBP with radiating pain resulted in longer duration of absence. The medians 
(25th-75th percentile) of days of absence for LBP with radiation versus LBP without radiation 
were 59 days (28-152 days) and 38 days (21-86 days) respectively 59. 
2.3.3 Cost of pain 
Reports published by Australian Institute of Health and Welfare in 2005 and 2010 showed the 
cost of health expenditure for musculoskeletal diseases to be 3.076 billion and 3.864 billion 
AUD for the period between 2000-2001 and 2004-2005 respectively 60. This was a 26% 
increase in expenditure, higher than the average increase of 20%. Musculoskeletal disease 
group was also the third most expensive health expenditure amongst the list of the allocated 
health expenditure groups between 2004-2005 period 60. 
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Other costs for chronic pain in Australia in 2007 included loss of productivity due to 
absenteeism and presenteeism (3.8 billion AUD) and loss of potential tax revenue (including 
both personal income tax, and indirect personal tax) amounting to 3.69 billion AUD, and a dead 
weight loss of 1.06 billion AUD in additional taxation 8. Dead weight loss here referred to the 
loss of tax when workers were unable to work due to sicknesses which led to reduced income 
and tax output. 
Primary carers, who often were relatives and friends of chronic pain patients, were estimated to 
spend on average 26 hours per week to provide informal care for chronic pain patients which 
was estimated to cost 1.3 billion AUD in 2007 8. Other additional costs for chronic pain patients 
included aids, such as walking frames, walking sticks, crutches, wheelchairs, and modification 
around the home. The estimated cost for these was 331.7 million AUD in 2007.  
Altogether the Australian data showed a total loss of 15.8 billion AUD per year for the 
non-medical costs, including the productivity loss, cost of carer, cost of aids and modifications, 
and cost of deadweight loss for chronic pain 8.  
USA patients with chronic pain of spinal origin were estimated to spend 4,000 to 19,000 USD 
per year per patient on pharmacotherapy and physician visits 61. The cost of an intrathecal 
implant was between 53,468 and 125,102 USD over five years 7. Another review has quoted 
from Coyote et al. that in 1994 alone, the total cost of musculoskeletal disorders in Canada, 
including both direct and indirect costs, exceeded 25 billion Canadian dollars 62. The direct 
costs here referred to expenses of hospital and other institutions, health professionals, 
pharmacotherapies, research, and other items not specified 63. The indirect costs referred to 
productivity lost due to disability and premature mortality 63. 
2.4 Current management of chronic pain 
This section describes the common approaches of CMP management. They include 
pharmacotherapy, non-pharmacotherapy treatments, and multidisciplinary pain management 
(MPM).  
2.4.1 Pharmacotherapies, its efficacy and safety  
Pharmacotherapies for CMP include paracetamol (simple analgesic and antipyretic drug), oral 
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or topical NSAIDs, intra-articular corticosteroid injection, weak and strong opioids 21.  
Paracetamol is simple analgesic and antipyretic drug 64. Its mechanism on pain alleviation is 
uncertain but is thought of related to actions on cyclooxygenase three, the serotoninergic 
system, or on bradykinin-sensitive chemoreceptors 65.  
Evidence for the effectiveness of paracetamol for arthritis is conflicting. One SR published in 
2006 that included 15 randomised controlled trials, with a total of 5,986 participants, concluded 
that paracetamol was found to have a similar safety profile as placebo but worked less 
effectively than NSAIDs for knee or hip OA 66. Another recent SR published in 2015 that 
included 13 studies with 5366 spinal pain (SP), OA of hip or knee participants concluded 
paracetamol was ineffective and only provided minimal short term benefit for OA 67. A recent 
study had shown an association between paracetamol and increased incidence of hypertension 
68. Furthermore, paracetamol accounted for 11% of all pharmaceutical poisoning cases between 
2009 and 2010 in Australia 69. 
Non-steroidal anti-inflammatory drugs include aspirin, other salicylic acid derivatives, 
propionic acid derivatives, acetic acid derivatives, oxicam derivatives, fenamates, heteroaryl 
acetic acids, nabumetone, and celecoxib 70. They act by inhibiting cyclooxygenase enzymes, 
which catalysed prostanoid biosynthesis, and lead to reduced prostaglandin production 70. 
Prostaglandin has a function to regulate inflammation, pain, and fever 70.  
One published expert consensus indicated the evidence for NSAIDs in treating hip OA is 1a, 
which means the highest level of evidence based on a meta-analysis of randomised controlled 
trials (RCTs) 71. Topical NSAIDs for knee OA showed a good result, after four weeks of 
application, in comparison with placebo or vehicle 72. The recommendation made for hip OA 
also indicated 1b for opioids, chondroitin sulphate, avocado soybean unsaponifiable, diacerhein, 
intra-articular steroid, and education; III for weight loss, hyaluronic acid, osteotomy, and total 
hip replacement 71. 
Another SR investigated the efficacy of NSAIDs on LBP 73. This SR included 65 trials with 
11,237 participants and concluded NSAIDs were effective for short term relief of acute and 
chronic LBP without sciatica with a small effect size. The pain reduction ranged from -0.21 to 
-12.4 on a 100 mm visual analogue scale (VAS). The comparisons included placebo and 
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paracetamol.  
Intra-articular corticosteroid injection: Steroids work by suppressing the inflammatory 
responses by affecting the concentration, distribution, and function of peripheral leukocytes, 
and suppressing the inflammatory cytokines and chemokines and other inflammatory 
mediators 28. When glucocorticoids were applied, neutrophils increased while T and B cells, 
monocytes, eosinophils, and basophils decreased 28. Glucocorticoids activated phospholipase 
A2 which reduced prostaglandin, leukotriene, and platelet-activating factor synthesis and 
glucocorticoids reduced the expression of cyclooxygenase-two and subsequently reduced the 
available prostaglandins and reduced the inflammatory response 28.  
Intra-articular corticosteroid administration has been shown to provide short-term symptomatic 
management for knee and hip OA 21. Intra-articular corticosteroid was associated with 
complications and risks such as allergic reaction, swelling at site of injection, haematoma, fluid 
retention, hyperglycaemia (high blood sugar), and hypertension 21. Even though it was effective 
for OA, its use was limited to three to four times per year with at least three months interval 
between each administration 21. 
A SR assessed neuromodulators for RA 74 includeing nefopam, topical capsaicin and an 
oro-mucosal cannabis spray. The authors concluded there was weak evidence supporting these 
neuromodulators in reducing RA pain but the side effects of nefopam and oro-mucosal cannabis 
spray outweighed the benefit they produced. 
2.4.1.1 Side effects of the above mentioned drugs 
The above-mentioned three classes of drugs all have side effects (Table 2.1), which range from 
mild side effects, e.g. dizziness, nausea, insomnia, to severe side effects, e.g. hepatotoxicity 
with centrilobular necrosis, renal tubular necrosis, gastrointestinal ulceration/perforation. Care 
should be taken when prescribing these drugs. 
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Table 2.1 Side effects of pharmacotherapy 
Pharmacotherapy Side effects 
Paracetamol Increased hepatic enzyme, dizziness, excitement, disorientation, 
hepatotoxicity with centrilobular necrosis, renal tubular necrosis, 
haemolytic anaemia, methemoglobinemia  
NSAIDs Epigastric distress, abdominal pain, nausea, vomiting, dyspepsia to 
gastric bleeding, gastrointestinal ulceration, upper gastrointestinal 
perforation and bleeding, endoscopically detected gastroduodenal 
erosions, diarrhoea, prolonged bleeding time, bronchoconstriction, 
respiratory depression and a combination of uncompensated respiratory 
and metabolic acidosis, hyperthermia (large dose of salicylates), urticaria, 
angioedema, Reye syndrome, headache, tinnitus, dizziness, and 
haemolytic anaemia, peripheral oedema, hypertension, increased 
bleeding time, increased risk of myocardial infarction and ischaemic 
stroke  
Intra-articular 
corticosteroid 
injection 
Iatrogenic Cushing’s syndrome, diabetes mellitus, 
hypothalamus/pituitary/adrenal suppression, proximal myopathy, tendon 
rupture, impaired growth (in children), vascular necrosis of bone, 
immunosuppression, peptic ulcer and haemorrhage, depression and 
psychosis, euphoria, insomnia, aggravation of schizophrenia and 
epilepsy, raised intracranial pressure with papilloedema, posterior 
subscapular lens cataract, glaucoma, corneal or scleral thinning, 
menstrual disorder, delayed tissue healing, thromboembolism, and 
paradoxical hypersensitivity reaction.  
Information extracted from 26,28,70,75 
NSAID: Non-steroidal anti-inflammatory drug 
. 
2.4.1.2 Opioid medications (OMs) 
Opioid medication works by binding to the opioid receptors (μ, δ, and κ), which are also 
known as the G-protein -coupled receptors 76. These receptors are located in the brain and 
pain transmitting and modulating regions in the spinal cord. When an opioid binds to the 
opioid receptors, it closes the Ca2+ channels and opens the K+ channels 76,77. Such action 
inhibits the release of neurotransmitters, e.g. glutamate, acetylcholine, norepinephrine, 
serotonin, and substance P 76,77, and subsequently reduces pain sensation.  
Opioid medication s can be differentiated based on their binding to particular opioid receptors 
and whether they are agonists e.g. morphine and hydromorphone or partial agonists e.g. 
codeine or hydrocodone, or are a mixture of agonist and antagonist e.g. nalbuphine and 
buprenorphine (Table 2.2). 
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Table 2.2 OM, agonist and antagonist to the receptor type 
OM Receptor type 
μ δ Κ 
Sufentanil  + + 
Morphine +  + 
Hydromorphone +   
Oxymorphone +   
Methadone +   
Meperidine +   
Fentanil +   
Alfentanil +   
Remifentanil +   
Levorphenol +   
Oxycodone +   
Codeine ^   
Hydrocodone ^   
Pentazocine ^  + 
Butorphenol ^  + 
Nalbuphine -  + 
Buprenorphine ^ - - 
+: strong agonist 
^ : partial agonist 
-:antagonist 
OM: Opioid medication 
Empty cell means not this type of receptor. 
 
Side effects of OM include: respiratory depression, tolerance, dependence, addiction, 
behavioural restlessness, tremulousness, increased intracranial pressure, postural hypotension 
accentuated by hypovolaemia, urinary retention, itching around nose, and urticaria. In 
addition, OM is associated with behaviours such as diversion of prescription opioids, opioid 
misuse in patients with chronic pain, activation of reward response (which may result in opioid 
dependence and opioid seeking behaviour, and difficulties in weaning patients off OMs), 
opioid-induced hyperalgesia, gastrointestinal side effects (such as constipation, delayed gastric 
emptying, nausea and vomiting), sleep disturbance, reduced sex hormones, and interference 
with the immune system 78. A SR 79 reported the occurrence of long term OM side effects with 
apnea having the highest occurrance and opioid overdose and serious intestinal blockage 
having the least occurrance (Table 2.3). 
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Table 2.3 Side effects due to long term use of OM 
Opioid side effects Rate of occurrence.
Mild to severe central and/or obstructive apnea As high as 75% 
Cardiovascular events (myocardial infarction and heart failure) 77% increased risk 
Comorbid depression Up to 38% 
Constipation 30-45% 
Depression, anxiety, deactivation, apathy 30-40% 
Hypogonadism, impotence, infertility, osteoporosis 25-75% 
Opioid misuse ~25% 
Nausea 25% 
Breathing problems during sleep 25% 
Disruption of sleep 25% 
Dry mouth that may cause tooth decay 25% 
Sedation 15% 
Addiction, misuse, and diversion 5-30% 
Falls causing hip and pelvis fracture 1-2% per year 
Opioid overdose <1% per year 
Serious intestinal blockage <1% per year 
Hyperalgesia, myoclonus Not known 
Data extracted from Baldini et al. 79 
Opioid medications have a moderate effect on treating musculoskeletal pain and neuropathic 
pain with a pain reduction of at least 30% 80. About 80% of the participants experienced at least 
one kind of side effect 80. Opioid short term efficacy on CMP or neuropathic pain had been 
proven to be good with its long term efficacy being uncertain 21,80. Long term (more than one 
year) effect of OM was not found in a SR 81, which reviewed literature from 2008 to 2014. 
Another clinical trial, with a 10 year follow-up period, on 160 chronic non-malignant pain 
patients found 60% of the patients still used OM at 10 year follow-up 82. Withdrawal symptoms, 
including rhinorrhoea, tearing, yawning, chills, goosebumps, hyperventilation, hyperthermia, 
dilatation of pupil, muscle aches, vomiting, diarrhoea, anxiety, and hostility, would develop for 
patients who try to quit using OM 70. It was found that patients on pre-existing OM 
consumption were 1.5 times more likely to drop out of a functional restoration programme, in 
comparison with patients who did not consume OM before the programme, where weaning off 
OM was a requirement 83. 
2.4.2 Non-pharmacotherapy treatments of chronic pain 
There are several non-pharmaceutical treatments available to treat chronic pain, including 
physiotherapy, multimodal physical therapy, self management education programmes, MPM, 
acupuncture, and surgery 21,71 and psychology 84. 
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2.4.2.1 Non-pharmacotherapy, invasive interventions and their efficacy 
Non-pharmacotherapy, invasive interventions for CMP include acupuncture and surgery.  
Surgery: The findings of studies of surgery for various musculoskeletal conditions/diseases are 
presented in Appendix 1. These SRs have recommended surgery for carpal tunnel syndrome 85 
and symptomatic spondylolysis 86. However, the best surgical procedure for sciatica due to disc 
herniation could not be confirmed 87, and there was a weak recommendation for surgery for 
lower extremity pain due to disc protrusion and no recommendation for surgery for axial pain 
due to disc protrusion 88. Furthermore, there was no evidence to support the use of surgery for 
acromioclavicular dislocation 89 and rotator cuff disease 90. Side effects/adverse 
reactions/complications of surgery (Appendix 2) include hardware complications such as screw 
breakage, screw pull out, wire breakage; and surgical procedure related complications such as 
wound infection, wound haematoma, delayed wound healing; or other complications such as 
stiffness at the operated site, pain, skin irritation, and reflex sympathetic dystrophy 85-90.  
Acupuncture: Several SRs have assessed the effects of acupuncture on musculoskeletal 
disorders/diseases (Table 2.4). Acupuncture has shown effectiveness and efficacy on the 
severity of neck pain and related disabilities 91, severity of chronic LBP and function 92, and 
chronic pain 35. Effectiveness refers to whether or not an intervention works in a routine setting 
and generally compares the intervention with another known intervention 93. Efficacy refers to 
how beneficial is a specific intervention under an ideal situation 93 e.g. randomised 
sham/placebo controlled trial. Acupuncture was found to: 1) be inconclusive for lateral elbow 
pain 36; 2) have a small but statistically significant effect for peripheral joint pain 94 when 
compared with sham control; 3) have no evidence for acute LBP 92 due to small sample size 
and low methodological quality; and 4) have little or no evidence for shoulder pain 37 when 
compared with placebo due to small number of trials and heterogeneity. The USA AHRQ 
guideline recommended acupuncture for joint pain/stiffness, soft tissue pain and inflammation, 
paraesthesia, post-operative pain, muscle spasm, and scar tissue pain 32. 
For chronic pain, the SR by Vicker et al. 35 identified the effect sizes for acupuncture in 
comparison to sham control were a small (0.23 (95% C.I. 0.13, 0.33)) for back and neck pain, 
very small to small (0.16 (95% C.I. 0.07, 0.25)) for OA, and very small to small (0.15 (95% C.I. 
0.07, 0.24)) for chronic headache; and the effect sizes for acupuncture in comparison to no 
acupuncture controls were medium (0.55 (95% C.I. 0.51, 0.58)) for back and neck pain, 
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medium (0.57 (95% C.I. 0.50, 0.64)) for OA and small to medium (0.42 (95% C.I. 0.37, 0.46)) 
for chronic headache. Effect size was interpreted according to Cohen 95(p25,26). 
MacPherson et al. conducted a survey in UK on the adverse events associated with acupuncture 
96. The author sent out questionnaires to patients receiving acupuncture treatment who agreed to 
participate the survey at the three months follow up after the acupuncture treatment (n=6,348). 
Their findings indicated the most frequent side effect/adverse event was severe tiredness or 
exhaustion (3.6%) (Table 2.5). 
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Table 2.4 Summary of different reviews on acupuncture for CMP 
Study Included 
studies 
Included 
participants
Condition / 
disease 
Intervention Comparison group Follow 
up 
Conclusion 
Gadau et 
al. 2014 36 
19 1190 Lateral elbow 
pain 
Acupuncture, electro 
acupuncture, 
moxibustion alone, or 
acupuncture plus 
moxibustion 
Sham acupuncture, 
conventional 
therapy (including 
triamcinolone 
acetonide injection, 
pulsated ultrasound 
and/or massage, 
prednisolone / 
hydrocortisone 
injection, 
meloxicam tablets), 
and acupuncture 
1 day to 
1 year 
Moderate quality studies 
suggest that acupuncture is 
more effective than sham 
acupuncture. The 
conclusion remains 
inconclusive due to 
included studies having at 
least one criterion rated as 
high risk of bias. The 
results were limited for 
other comparisons. 
Manheimer 
et al. 2010 
94 
16 3498 Peripheral 
joint arthritis 
Acupuncture or 
acupuncture plus other 
active treatment 
Sham, wait list, 
other active 
treatment  
8 and 26 
weeks 
Acupuncture shows 
statistically significant 
results when compared 
with sham or wait list. But 
such effect is small and can 
be due to 
expectation/placebo 
effects. 
Furlan et 
al. 2005 92 
35 2861 Low back 
pain 
Acupuncture, dry 
needling, or 
acupuncture added to 
another active 
treatment 
No treatment, 
placebo, sham 
therapy, other active 
treatment,  
3, 6, and 
12 
months 
No firm conclusion for 
acute LBP. For chronic 
LBP, acupuncture is not 
more effective than other 
interventions. Acupuncture 
is more effective than no 
treatment or sham 
treatment. 
Trinh et al. 
2016 91 
27 5462 Neck pain Acupuncture Sham acupuncture, 
inactive treatment, 
wait list 
3 
months, 
1 year, 
Moderate evidence for 
acupuncture more effective 
than sham acupuncture 
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Study Included 
studies 
Included 
participants
Condition / 
disease 
Intervention Comparison group Follow 
up 
Conclusion 
more 
than 1 
year 
post treatment. There is 
moderate evidence that 
acupuncture is more 
effective than sham 
acupuncture, wait list or 
inactive treatment at short 
term follow up (≤ 3 
months). 
Green et al. 
2005 37  
9 525 Shoulder 
pain 
Acupuncture, electro 
acupuncture, 
acupuncture plus 
mobilization/exercise 
Placebo, steroid 
injection, 
ultrasound, nerve 
block, acupuncture 
alone, exercise, 
tragar 
Only 
one trial 
had 20 
weeks 
follow 
up 
There is little evidence to 
support/not support 
acupuncture for shoulder 
pain. 
Vicker et 
al. 2012 35 
29 17922 Non-specific 
back/neck 
pain, 
shoulder 
pain, chronic 
headache or 
osteoarthritis 
Acupuncture Sham (placebo) 
acupuncture or no 
acupuncture control 
From 
one 
month to 
24 
months 
Acupuncture is effective 
for treating chronic pain 
conditions. And factors in 
addition to the specific 
effects of needling are 
important in the therapeutic 
effects of acupuncture 
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Table 2.5 Side effects of acupuncture treatment 
Adverse events Reported adverse event rate over 
3 months 
Adverse events associated with treatment response 
Severe tiredness or exhaustion 3.6% 
Prolonged or unacceptable pain at site of needling 1.6% 
Severe headache or migraine 1.2% 
Unexpected, severe or prolonged worsening of symptoms 1.2% 
Severe drowsiness (e.g. causing a potential hazard on the 
road) 
0.8% 
Severe dizziness or vertigo or loss of balance 0.8% 
Severe sleeplessness 0.7% 
Severe stiffness or numbness 0.7% 
Skin infection affecting either local area where needled or 
extensive area over body 
0.4% 
Diarrhoea 0.4% 
Severe agitation 0.4% 
Severe nausea  0.4% 
Severe nightmares 0.4% 
Severe panic 0.3% 
Vomiting 0.3% 
Fainting 0.2% 
Uncontrolled euphoria 0.2% 
Severe disorientation 0.1% 
Fit or seizure 0% 
Adverse events associated with practitioner behaviour or equipment 
Needle left in patient 0.9% 
Moxibustion burns to skin 0.4% 
Electro-acupuncture problems (e.g. too strong a current 
resulting in pain) 
0.2% 
Being left alone/unattended in the treatment room for too 
long 
0.2% 
Needle breaking <0.1% 
Punctured internal organ such as needle penetrating lung 0% 
Other events mentioned spontaneously by respondents 
Bruising at needling site 0.5% 
Other events 0.4% 
Aches and pains (not specified) 0.2% 
Emotional/psychological reaction 0.1% 
Tiredness/drowsiness 0.1% 
Bleeding at needling site 0.1% 
Information extracted from MacPherson et al. 96. 
2.4.2.2 Non-pharmacotherapy, non-invasive interventions and their efficacy 
Non-pharmacotherapy, non-invasive interventions include physiotherapy, multimodal physical 
therapy, self management education programmes 21, psychological therapy and MPM.  
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Physiotherapy: Physiotherapy includes treatments using various combinations of exercises, 
stretching, manipulation, ultrasound, superficial heat, short wave diathermy, laser therapy, 
Codman’s exercises, wall-climbing exercises, continuous passive motion, manual therapy, 
dumb-bell gymnastics and massage 97. One SR on the effect of exercise on knee OA showed 
both aerobic walking and quadriceps strengthening were helpful to reduce pain and disability 
associated with knee OA when compared with non-exercise controls which included education 
and lifestyle advice, support by telephone calls, no intervention, or sham exercise programme. 
The pooled effect size was between 0.32 to 0.52 for pain reduction and self reported disability 98. 
Their pain and disability outcome measures were not described in this SR. One drawback of 
this SR was the authors did not separate the groupings based on the control groups 98.  
An SR on manipulation or mobilisation for neck pain 99 included 27 trials which included 1,522 
participants who either had acute/subacute/chronic neck pain. The finding stated that cervical 
manipulation and mobilisation showed similar results. Both methods showed immediate or 
short term change and no long term data was available. Thoracic manipulation also showed an 
effect on the neck pain and function, but due to the low quality of the included trials, the author 
could only conclude that thoracic manipulation may improve neck pain and function. 
One SR on physiotherapy intervention for ankylosing spondylosis included 11 trials with 763 
participants 100. The authors found combined inpatient spa-exercise therapy followed by group 
physiotherapy was better than group physiotherapy only. Supervised physiotherapy was better 
than home exercise. Home exercise of supervised exercise was better than no treatment. 
Multimodal physical therapy: Based on one meta-analysis, the evidence showed multimodal 
physiotherapy, which involves quadriceps muscle retraining, patellofemoral joint mobilization, 
and patellar taping, and daily home exercises, provided short term (three months) relief for 
anterior knee pain when compared with placebo interventions (including flat insert orthoses, or 
sham physiotherapy which includes placebo taping, sham ultrasound, and the light application 
of a non-therapeutic gel) 101.  
Self-management education programme: A self-management education programme has 
been shown to help arthritis pain. A RCT involving self-management of arthritis and an 
education booklet group (n=406) was compared with education booklet group alone (n=406) 102. 
The self-management group was found to experience reduced anxiety, as assessed with 
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Hospital Anxiety and Depression Scale, without impact on pain, physical functioning and rate 
of general practitioner visits. 
A SR examined patient education for LBP 103. The review included 24 studies, of which three 
studies were on chronic LBP. Of the chronic back pain studies, patient education was less 
effective than non-educational interventions (e.g. physiotherapy, spinal stabilization, yoga, 
exercise, modified Swedish back school programme) for long-term back pain specific 
functional status. But there was generally no difference between patient education and 
non-educational intervention for pain, short term back pain specific function, general 
functional status, global improvement, and return to work. The short term was defined as 
between randomisation and six months whereas long term was defined as six months or more 
in this SR. The author could not confirm the effectiveness of patient education for chronic 
LBP. 
Psychological therapy: 
Cognitive behavioural therapy (CBT): A SR on CBT for any kind of chronic pain apart from 
headache and pain due to malignancy included 23 studies with 1,199 participants 104. The 
author defined follow up period as between six months to 12 months and if there were 
multiple follow ups in this period, the later one was used. The summary is listed in Table 2.6.  
The review found that CBT compared with treatment as usual (treatment not summarised in the 
review), showed statistically significant pain reduction after treatment (effect size -0.19 95% 
confidence interval (CI) -0.32 – -0.05) and a small improvement (effect size -0.16 95% CI -0.31 
- -0.01) at follow up for mood. Cognitive behavioural therapy’s effect on disability and mood 
was not statistically significant after treatment and at follow up for pain reduction and 
disability.  
When CBT was compared with active control (treatment not summarised in the review), 
disability improved after treatment (Z=2.20, p<0.05. The effect size was -0.16 with 95% CI 
-0.31 - -0.02). The follow up data showed CBT had a significant overall effect on pain (12 
studies with 935 participants, Z=2.27, p<0.05. The effect size was -0.15 with 95% CI -0.28 - 
-0.02), on disability (11 studies with 876 participants, Z=2.71, p<0.05. The effect size was -0.21 
with 95% CI -0.36 - -0.06), and on mood (12 studies with 934 participants, Z=2.44, p<0.05. The 
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effect size was -0.16 with 95% CI -0.29 - -0.03) when compared with active control (treatment 
not summarised in the review). The result on pain and mood were not significant after 
treatment between CBT and active control. 
Table 2.6 Summary of SRs of CBT for chronic pain 
Number 
of 
studies 
Number of 
participants 
Types of 
comparison 
Timing of 
assessment 
Types of 
assessment 
Effect 
size 
95% CI 
23 1199 Treatment as 
usual 
(treatment not 
summarised in 
the review) 
After 
treatment 
Pain -0.19 -0.32 – 
-0.05 
9 693 Follow up NS 
18 972 After 
treatment 
Disability NS 
8 496 Follow up 
16 839 After 
treatment 
mood NS 
9 684 Follow up -0.16 -0.31 - 
-0.01 
14 861 Active control 
(treatment not 
summarised in 
the review) 
After 
treatment 
pain NS 
12 935 Follow up -0.15 -0.28 - 
-0.02 
12 728 After 
treatment 
disability -0.16 -0.31 - 
-0.02 
11 876 Follow up -0.21 -0.36 - 
-0.06 
15 890 After 
treatment 
Mood NS 
12 934 Follow up -0.16 -0.29 - 
-0.03 
CI: Confidence interval 
NS: Not significant 
Information extracted from Eccleston et al. 104. 
Behavioural therapy (BT): The previously mentioned SR also assessed the effect of BT on 
chronic pain apart from headache and pain due to malignancy 104. The results are summarised in 
Table 2.7. The effect of BT was only better when compared with treatment as usual (treatment 
not summarised in the review) for pain after treatment (nine studies with 430 participants, 
Z=3.03, P<0.05. The effect size was -0.55 with 95% CI -0.90 - -0.19) but not at follow up (six 
to twelve months after treatment). For disability and mood, both after treatment and at follow 
up showed no difference. There was no difference between BT and active control (treatment 
not summarised in the review) for pain, disability, and mood both after treatment and at 
follow up. 
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Table 2.7 Summary of SR of BT for chronic pain 
Number 
of studies 
Number of 
participants 
Types of 
comparison 
Timing of 
assessment 
Types of 
assessment 
Effect 
size 
95% CI
1 39 Active control 
(treatment not 
summarised in 
the review)  
After 
treatment 
Pain NS 
1 39 Follow up 
2 110 After 
treatment 
disability NS 
2 110 Follow up 
2 110 After 
treatment 
mood NS 
2 110 Follow up 
9 430 Treatment as 
usual 
(treatment not 
summarised in 
the review) 
After 
treatment 
Pain 0.55 -0.90 - 
-0.19 
3 232 Follow up NS 
7 374 After 
treatment 
disability NS 
3 230 Follow up 
6 357 After 
treatment 
mood NS 
3 230 Follow up 
CI: Confidence interval 
NS: not significant 
Information extracted from Eccleston et al. 104. 
Multidisciplinary pain management  
Multidisciplinary pain management refers to the utilisation of multiple therapies to manage 
CMP 105. Such therapies include primary care physician, psychiatrist, physiotherapist, 
occupational therapist, and psychologist and/or trained counsellor. In addition, the MPM team 
may also include a recreational therapist, biofeedback specialist, social worker, case manager, 
an ergonomics therapist, pharmacist, addictionologist, dietician/nutritionist, and may include a 
priest 105. Some of the therapies have been described in this section. The following section 
focuses on MPM as a team rather than discussing the individual therapies. 
Multidisciplinary pain management has the following goals 105: 
1) To empower patients and family through educating them and enabling them to participate in 
treatment decisions; 
2) Improve patient’s function and activities of daily living through providing them knowledge 
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and training; 
3) Reduce patients’ dependence on drugs by reducing patients’ consumption of OM, 
benzodiazepine, antidepressant and antiseizure drugs. Benzodiazepine is a sedative which 
produces drowsiness and enhances the onset of sleep 106; 
4) Reduce patients’ dependence on health care systems by teaching the patient self 
management skills; 
5) Reduce patients’ reliance on family members and other people by encouraging family 
members and other people to show empathy rather than sympathy towards patients; 
6) Decrease patients’ pain behaviours by informing patients to have wellness behaviour; 
7) Enabling patients to return to work if possible and maybe a changing in job to enable the 
patients to commence work; and 
8) Improve patients’ QoL. 
A non-randomized clinical study that investigated the effect of MPM and usual care (UC), 
which comprised of non-multidisciplinary physiotherapy and non-surgical treatments, and 
showed improvement in QoL with significant differences between MPM and UC at six months 
follow-up in role limitations, physical (MPM:UC=19±39:7±31, p<0.01); bodily pain 
(MPM:UC=18±25:7±23, p<0.01); social functioning (MPM:UC=15±21:5±24, p<0.05); role 
limitations, emotional (MPM:UC=16:50:3±42, p<0.05.); emotional well-being domains 
(MPM:UC=8±17:3±16, p<0.05) and the physical (MPM:UC=4.9±8.0:2.6±6.8, p<0.05) and 
mental (MPM:UC=4.4±11:1.8±10, p=0.1) components summary in SF36, reduced days off 
work (average reduced 16 days off work in the MPM group in comparison to two additional 
days off work in the UC group), and 54% of patients in the MPM group and 24% of UC patients 
felt the restriction that LBP had in their life was better 107.  
A SR on MPM that included 11 studies, looked at the long term effectiveness of MPM at six 
months to 12 months, on chronic pain 108. The review found the treatment effect on pain 
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perception was still maintained at 12 months follow up, but the effect on self-efficacy 
decreased at 12 months follow up. The treatments mainly included education, pacing, 
relaxation, and goal setting. Three studies had the pain management in the inpatient setting 
whereas the other seven had it in the outpatient setting. One study did not describe the setting 
of the pain management. Other SR pointed out that MPM improved pain, mood and 
interference, as well as return to work status, and use of healthcare system 109. Overall, MPM 
may fail but does not carry the severe complication of surgery 105. 
In summary, physiotherapy was shown to benefit pain and disability of knee OA 98, pain and 
function of neck pain 99, and physiotherapy was better than no treatment for ankylosing 
spondylosis 100; multimodal physical therapy improved anterior knee pain with short term 
relief 101; and CBT and BT had weak effects in reducing chronic pain and minimal effects for 
disability associated with chronic pain. Cognitive behaviour therapy and BT were effective in 
altering mood outcomes, and such improvement might be maintained at six months follow up 
104. Multidisciplinary pain management improved chronic pain patient’s pain perception at 12 
months follow up 109 and various aspects of QoL at six months follow up 107. There was no 
firm conclusion for patient education for chronic LBP 103 and MPM did not show 
improvement in self-efficacy for chronic pain at 12 months follow up. 
2.5 Comorbidities and symptomatology of chronic pain – a new direction of 
pain management 
2.5.1 What is comorbidity? 
Comorbidity means coexistence of several diseases and chronic conditions 14 or any two or 
more diseases occurring in the same person at the same time 110. Examples of comorbidity may 
include comorbid migraine and gastric ulcer amongst patients who have neck pain or vice versa. 
Comorbidity in psychiatry can be further divided into heterotypic comorbidity, which means 
comorbidity from a different diagnostic disorder grouping such as depression and substance use 
disorder, or homotypic comorbidity, which means comorbidity from the same diagnostic 
disorder grouping such as alcohol drinking and use of marijuana 111. 
2.5.2 What are the causes of comorbidity? 
Figure 2.1 shows a schematic diagram of the causes and common risk factors of comorbidity. 
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The cause of comorbidity can be due to direct/indirect associations between the diseases 110, 
genetic susceptibility and family history 112, chance alone 110 or unknown of cause 113. For 
example the association between cervicogenic headache and neck pain is a direct association of 
comorbidity, and the association between diabetes and cardiovascular disease is an indirect 
association of comorbidity. Genetic susceptibility and familiar history may explain some of the 
causes of comorbidity, but patients who present with two co-existing diseases may not share the 
same genetic susceptibility to the two co-existing diseases 112.  
 
Figure 2.1 Causes and common risk factors of comorbidity 
Common risk factors for more than one disorder may be the causes and the risk factors of both 
the disease and the comorbidity 113,114. These common risk factors include social, 
environmental and biological factors 114. Social and environment factors such as social 
disadvantage, e.g. social isolation and exposure to conflictual social relationships, have been 
shown to increase or be associated with the likelihood of different types of substance use 
disorder and mental disorders 115-117.  
Biological factors can include the following categories: 
 29 
 
 Neurotransmitter function: Some neurotransmitters act on the similar areas of 
the brain and share the same neurotransmitter system with the comorbidity 114. 
Some neural substrates are similar in both mental disorders and substance use 
disorders 114.  
 Genetic factors: Tsuang et al. found that twin males who abused any category of 
drugs were associated with increased probability of abusing any other category 
of drugs 115. Kendler et al. investigated twin females and found genetics and 
family history were two probable factors for the association between major 
depression and cigarette smoking 118.  
 Individual factors: Neuroticism was associated with substance use disorder and 
mental health issues 114. 
Other than the above mentioned causes, there are still a lot of unknowns about the causes of 
comorbidity 113. 
2.5.3 What are some comorbidities associated with chronic pain? 
The evidence for comorbidities of chronic pain conditions has been documented in various 
reviews. Migraine increased the odds of getting depression, generalized anxiety disorder 
(GAD), and panic disorder 119,120. Moreover, migraine even increased the odds of having 
bipolar disorder by 2.9-7.3 times 119. Arthritis (defined as including arthritis, rheumatism, or 
other bone or joint diseases in the publication) in general was associated with increased odds of 
having depression (OR 1.39 95% CI 1.04-1.87) and GAD (OR 1.77 95% CI 1.04-3.02) 120. 
Rheummatoid arthritis had the comorbidity of anaemia 121. Fibromyalgia had psychiatric 
comorbidities such as anxiety, panic attacks, depression and post traumatic stress disorder 
(PTSD) 122, and was associated with the increased prevalence of obesity 123. Furthermore, the 
incidence of depression was higher in chronic pain patients than in other medical illnesses 124.  
Comorbidities of chronic neuropathic and non-neuropathic pains include 
hypercholesterolaemia 125, heart disease 125, disease of the digestive system 125, disease of 
musculoskeletal and connective tissue125, insomnia 126, depression 126, and anxiety 126. 
Moreover, post herpetic neuralgia patients experience chronic fatigue, anorexia, weight loss, 
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physical inactivity and insomnia, depression, and difficulties in concentration 124.  
So far no SR has been conducted to specially examine the comorbidities of CMP.  
2.5.4 What is symptomatology? 
Symptomatology as defined by Mosby’s medical dictionary is “the science of symptoms of 
disease in general or of the symptoms of a specific disease” 45. For example, morning stiffness, 
red and swollen joints, and painful joints, are all symptoms of RA; pain in many joints is a 
symptom of fibromyalgia. 
2.5.5 What are some common symptoms associated with chronic pain? 
Examples of symptomatology of chronic painful diseases are listed in Table 2.8. As shown in 
Table 2.8, the symptoms of chronic painful conditions/diseases are not just pain alone. They 
involve musculoskeletal, dermatological, neurological, and gastroenterological symptoms and 
dosrders of the endocrine system, emotional and psychological disorder, and problems of the 
ear, nose, and throat. 
Table 2.8 Common painful and non-painful symptoms and comorbidities of chronic painful 
conditions or diseases 
Conditions / 
diseases 
Painful 
symptoms 
Some of the non-painful 
symptoms 
Other comorbidity 
Dermatomyositis Muscle 
tenderness, 
multiple joints 
pain. 
Reddish purple rash, 
symmetrical muscle 
weakness, muscle atrophy, 
difficulty in swallowing. 
Raynaud’s phenomenon 
Sjogren’s 
syndrome 
Painful joints Hypersensitivity to light, 
dry mouth as well as 
dryness in the mucous 
membrane such as in the 
nose, throat, bronchus, 
external genitalia and 
vagina.  
Raynaud’s phenomenon 
Polymyalgia 
rheumatica 
Muscle pain and 
stiffness in the 
muscles of the 
neck, shoulder 
blade, and pelvic 
region. 
Muscle stiffness in the 
muscles of the neck, 
shoulder blade, and pelvic 
region. Weight loss, fever, 
depressiveness. 
No comorbidity is 
mentioned 
RA Painful joints Morning stiffness of the 
affected joints, red and 
swollen joints, forceless in 
No comorbidity is 
mentioned 
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Conditions / 
diseases 
Painful 
symptoms 
Some of the non-painful 
symptoms 
Other comorbidity 
the afternoon, poor 
appetite, general 
weakness, low grade 
fever, deformity of joints. 
Ankylosing 
spondylosis 
Back pain Low grade fever, fatigue, 
anorexia, weight loss. 
Anaemia 
Fibromyalgia Tenderness to 
touch or pressure 
affecting joints 
and muscles, 
pelvic pain. 
Depression or anxiety, 
fatigue, sleep problems 
(waking up unrefreshed), 
problems with memory or 
thinking clearly, irritable 
or overactive bladder. 
Migraine or tension 
headaches, irritable bowel 
syndrome or 
gastroesophageal reflux 
disease, 
temporomandibular 
disorder (including 
symptoms of face or jaw 
pain, jaw clicking and 
ringing in the ears) 
The information were extracted from The Merck Manual 18th Edition and the American 
College of Rheumatology website 
http://www.rheumatology.org/practice/clinical/patients/diseases_and_conditions/fibromyalgia.
asp 
RA: Rheumatoid arthritis 
2.5.6 The implications of comorbidities and symptomatology on pain 
management, burden to the health care system, and QoL 
As shown in the previous sections, chronic pain patients present with symptoms of more than 
just pain alone. Management for these patients requires inputs from a pain specialist, 
dermatologist, neurologist, gastroenterologist, endocrinologist, psychologist, psychiatrist, and 
ear, nose and throat specialists. The involvement of so many specialists creates a burden to the 
health care system. As mentioned by Access Economics, the cost of pain alone is already great 8, 
and managing these chronic pain patients will also incur costs involving the above mentioned 
specialist visits and treatments which increases health expenditure. One clinical trial looked at 
comorbid fibromyalgia amongst migraine patients 127. Its results showed migraine prophylaxis 
improved the monthly flare up and pain threshold of fibromyalgia symptoms as well as 
analgesics usage (p < 0.0001) (the study did not provide numerical value/VAS for the 
percentage of reduction). This provides an example of how treating comorbidity reduced the 
overall burden of disease. 
Comorbidities and symptomatology of chronic painful conditions/diseases include psychiatric 
issues, which affects the psychological well-being, and functional limitation of the person. 
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These directly or indirectly affect the patient’s social network and social support and 
subsequently their ability to function as a normal person, i.e. impaired QoL. This concept is in 
line with Hartvigsen who proposed to view CMP together with its comorbidities and 
accompanying symptoms as the first line in diagnosis since the multiple painful sites occurred 
together with the co-existing symptoms 39. 
2.5.7 Summary  
Considering the impact of comorbidities and symptomatology, it is clear that when managing 
chronic pain, one should also manage the co-existing conditions and non-pain symptoms in 
order to provide an enhanced QoL. Comorbidity worsens physical disabilities 128, so if 
comorbidities and multiple non-pain symptoms are not managed concurrently, one may be 
unable to function as a normal person. The next section will introduce a medical system that 
concurrently focuses on patients’ pain and non-pain symptomatology – CM. 
2.6 Chinese medicine 
2.6.1 What is CM 
Chinese medicine has been in existence for a few thousand of years 129(p.1). It is the key medical 
system in ancient and modern China 130(p.4). Chinese medicine includes treatment the modalities 
of Chinese herbal medicine, acupuncture, moxibustion, cupping, exercise therapy, diet therapy, 
emotional therapy 130(p.766, 773), and Tuina (Chinese therapeutic massage) 131(p.1).  
2.6.2 CM syndrome differentiation  
In CM diagnosis, conditions are classified into main types of syndromes by utilizing the ancient 
theories and philosophy of Yin Yang and five elements, and the medical understanding of the 
function of the body organs (Zang-Fu), meridians, three Jiaos, “Wei, Qi, Ying, and Xue phases” 
and CM eight guiding principles 38. Based on the pattern of symptoms and signs, a treatment 
principle is designed and applied to formulate the treatment 132(p.83-100). 
The CM Zang Fu organs have the same name as western medicine but focus more on the 
function of the organ than on the structure of the organ 133(p28-53). The CM Zang Fu organs and 
five elements have a close relationship which also correlates with other body parts, and 
emotions (Table 2.9). For example, the CM wood element is associated with the CM liver, the 
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CM gall bladder, the eye, tendons, and emotion of anger. When a person has red and painful 
eyes accompanied with excessive short temper, this person is said to have CM liver fire 
syndrome. Due to the interactions between the five elements, when the CM liver is in excess, as 
in this case, it will over control the earth element which is the digestive system represented by 
the CM spleen and CM stomach. Such person is prone to stomach pain, abdominal pain, or 
diarrhoea. 
Table 2.9 CM five elements and their associated CM Zang Fu organs and other relationships 
Five 
elements 
Zang organs Fu organs Five sensory 
organs 
Body 
tissues 
Emotions 
Wood CM liver CM gall bladder Eye Tendon Anger 
Five CM heart CM small intestine Tongue Vessels Joy 
Earth CM spleen CM stomach Mouth Muscle Overthinking
Metal CM lung CM large intestine Nose Skin Grief 
Water CM kidney CM urinary bladder Ear Bone Fear 
Information extracted from 133(p20) 
 
Chinese medicine syndrome differentiation, also known as CM pattern identification, is a 
holistic approach to the CM diagnosis of conditions. The way CM views and differentiates 
conditions is by means of checking all the accompanying symptoms and signs. Taking the 
example of LBP (Table 2.10). If the LBP is aggravated by change in the weather such as a rainy 
day, then the CM pattern for this LBP is CM dampness retention pattern. If the LBP is sharp in 
nature, at a fixed location, worse at night and better during the day, then this LBP is CM blood 
stasis pattern. For CM dampness retention pattern, the treatment principle will be to remove the 
CM dampness; and for CM blood stasis pattern, the treatment principle will be to activate the 
CM blood circulation. The Chinese herbal medicine will vary significantly depending on the 
pattern whereas the acupuncture treatment does not vary as significantly as the Chinese herbal 
medicine. 
Table 2.10 Chinese medicine patterns and treatments for LBP 
Chinese 
medicine 
patterns 
Signs and symptoms Treatment 
principle 
Acupuncture 
treatment 
Chinese 
herbal 
medicine 
treatment 
Cold 
dampness 
Cold pain and heaviness in the low 
back area, difficult to turn the low 
back, gradual deterioration. Resting 
does not alleviate the pain and 
overcasting or rainy day aggravates the 
Disperse 
cold and 
remove 
dampness, 
warm up 
BL23 (Shenshu), 
BL40 
(Weizhong), 
Huatuojiaji (extra 
point), Ashi point. 
Modified Gan 
Jiang Ling 
Zhi Tang 
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Chinese 
medicine 
patterns 
Signs and symptoms Treatment 
principle 
Acupuncture 
treatment 
Chinese 
herbal 
medicine 
treatment 
pain. Thin greasy tongue coating, deep 
and slow pulse 
and 
unobstruct 
the meridian
Moxibustion may 
be added. 
Damp heat 
retention 
Painful heaviness in low back region 
accompanied with feverish sensation. 
The pain is aggravated in either hot or 
rainy days. Pain alleviated by 
movement. Red and scanty urine. 
Greasy yellow tongue coating. Rapid 
and soft pulse or rapid and taut pulse. 
Clear heat 
and promote 
dampness 
removal via 
diuresis. 
Sooth the 
tendons and 
stop pain. 
No listed 
treatment*. 
Modified Si 
Miao Wan 
Blood 
stasis 
Sharp LBP at a fixed location, pain 
worse at night and better during the 
day. The mild case cannot bend their 
low back forwards and backwards, the 
severe case cannot turn on the side, 
refused to be touched at the tender 
area. Purple dark tongue body or 
accompanied with ecchymosis, uneven 
pulse. Some patients have history of 
trauma. 
Activate 
blood 
circulation 
and resolve 
the stasis, 
regulate Qi 
and stop 
pain. 
BL23 (Shenshu), 
BL40 
(Weizhong), 
Huatuojiaji (extra 
point), Ashi point. 
 
Plus BL17 
(Geshu), BL32 
(Ciliao) 
Modified 
Shen Tong 
Zhu Yu Tang
CM kidney 
deficiency 
Low back ache, prefers to be touched 
and pressed on the painful area, 
weakness in knee and leg, worse after 
exertion and better after bed resting, 
often occurs repetitively. 
 
For Yang deficiency: patient will 
present with abdominal spasm, pale 
complexion, cold limbs, fatigue, pale 
tongue, deep and thready pulse.  
 
For Yin deficiency: patient will have 
insomnia, irritability, dry mouth and 
throat, malar flush, feverish sensation 
in the palms and soles, red tongue with 
little coating, taut, thready, and rapid 
pulse. 
For Yang 
deficiency, 
warm and 
tonify CM 
kidney 
Yang. 
 
For Yin 
deficiency, 
nurture and 
tonify CM 
kidney Yin.
BL23 (Shenshu), 
BL40 
(Weizhong), 
Huatuojiaji (extra 
point), Ashi point. 
 
CM kidney Yang 
deficiency: Add 
and apply 
moxibustion on 
GV4 (Mingmen), 
and Yaoyan 
(Extra point) 
 
CM kidney Yin 
deficiency: BL52 
(Zhishi), KI3 
(Taixi) 
For Yang 
deficiency: 
modified You 
Gui Wan. 
 
For Yin 
deficiency: 
modified Zuo 
Gui Wan. 
LBP: low back pain 
Information extracted from Chinese medicine internal medicine 134(p266-267) and Lecture notes 
for KP610/COTH1040: Acupuncture practice 1 (Techniques and treatment) 135 
* There was no acupuncture treatment for CM damp heat retention pattern in LBP even after 
searches in other six textbooks/literatures 136(p91)137(p291-294.689)138(p362-364) 139-141. 
CM: Chinese medicine 
LBP: Low back pain 
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There is a CM pattern identification called the CM eight guiding principles 38. The CM eight 
guiding principles differentiate the presentation of symptoms into Exterior/Interior, Cold/Heat, 
Deficiency/Excess, and Yin/Yang types (Table 2.11). Exterior pattern symptoms include 
symptoms of fever and chills. These symptoms are the typical symptoms of the exterior 
pattern. Interior pattern symptoms include symptoms pertaining to the interior part of the 
body which can include high grade fever, irritability, thirst, and constipation. Cold pattern 
symptoms include cold limbs, aversion to cold and preference for warmth, and loose stool. 
Heat pattern symptoms include the opposite symptoms to the cold pattern e.g. constipation, 
fever, prefers cold temperature, thirst with preference for cold drinks. Deficiency pattern 
symptoms pertain more to weakness e.g. lassitude, fatigue and excess pattern symptoms 
pertain to higher temperature, irritation, and dryness, e.g. fever, irritability, and constipation. 
Yin and Yang patterns are the overarching patterns that dominate all the other six patterns. Yin 
pattern symptoms include symptoms of a more Yin nature which are similar to cold, interior, 
and deficient and may include fatigue, tiredness, forceless, feeble voice. Yang pattern 
symptoms include symptoms opposite to the Yin pattern symptoms and include fever, hot skin, 
coarse voice, and constipation. These eight patterns exist alone or in combination e.g. exterior 
excess cold pattern, interior excess heat pattern, or interior deficient cold pattern. 
Table 2.11 CM eight guiding principles symptom presentations 
CM eight guiding 
principles patterns 
Symptoms 
Exterior Fever, chills, headache and body aching, thin white tongue coating, 
floating pulse. May have a stuffy and running nose, itchy or sore 
throat, and cough. 
Interior High grade fever, irritability, delirium, thirst, abdominal pain, 
constipation or diarrhoea with nausea and vomiting, scanty red urine, 
yellow or white thick greasy tongue coating, deep pulse. 
Cold Aversion to cold and prefers warmth, pale complexion, cold limbs, 
sleeping with body curled up, bland taste in the tongue without thirst, 
clear and thin phlegm/saliva/nasal discharge, clear and profuse urine, 
loose stool, pale tongue with white coating and slippery texture, slow 
or tense pulse. 
Heat Fever and prefers cold temperature, thirsty with preference for cold 
drinks, red eyes and face, irritability and restlessness, yellow thick 
phlegm/nasal discharge, vomiting of blood or bleeding nose, red and 
scanty urine, dry hard stool, yellow and dry tongue coating, red 
tongue body, rapid pulse. 
Deficiency Pale or withered complexion, lassitude, fatigue, palpitations and 
shortness of breath, cold limbs and body, spontaneous sweating, 
incontinence, pale fat and delicate tongue body, deficient deep and 
slow pulse. Or “heat in the chest, palm, and soles”, emaciation, malar 
flush, dry mouth and throat, night sweating, tidal fever, red tongue 
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CM eight guiding 
principles patterns 
Symptoms 
with little coating, deficient thready and rapid pulse. 
Excess Fever, abdominal pain and refusal to be touched, chest stuffiness, 
irritability, maybe coma with delirious speech, rapid coarse 
breathing, excessive phlegm and saliva, constipation or dysentery, 
tenesmus, difficulty in urination, dripping or painful urination, tight 
and puffy tongue, thick greasy coating, forceful pulse. 
Yin Dark complexion, fatigue, heaviness sensation in the body, sleeping 
with body curled up, cold limbs and body, tired and forceless, feeble 
voice, poor appetite, bland taste in the mouth, without thirst, profuse 
and clear urine, pale puffy and delicate tongue body, deep slow or 
weak thready and uneven pulse. 
Yang Red complexion, fever, skin feels hot, irritability, coarse voice or 
manic speech, coarse breathing, wheezing, constipation, crimson 
tongue body, yellow black tongue coating with thorns. Floating, 
rapid, roaring, big, slippery, excess pulse. 
Information extracted from CM diagnosis by Deng et al. 38. 
2.6.3 How does CM view and differentiate CMP 
Chronic musculoskeletal pain is not a CM term. The closest CM concept of CMP is Bi 
syndrome, which means a blockage of Qi and Blood flow in the painful area in the muscles, 
tendons, bones or joints 132(p887). This interrupted flow of Qi and CM blood is associated with 
three factors: 1) invasion of external pathogens such as wind, cold, dampness, or damp-heat, 2) 
retention of pathological products, including CM phlegm and/or CM blood stasis, and 3) 
constitutional deficiency 132(p887-888).  
Figure 2.2 shows the pathogenesis of Bi syndrome. When a person is invaded by external 
pathogens, his or her constitution can be normal or weak. If the person is weak and not able to 
expel these external pathogens, these pathogens will then stay in the meridians, joints or 
muscles and mingle together with dampness and finally form Bi syndrome 132(p888). 
Alternatively when the external pathogens remain in the meridians, joints, or muscles, they will 
impede the Yang Qi flow in the meridian and cause the CM blood flow to stagnate and phlegm 
to form 132(p888). The stagnated CM blood and phlegm will further impede the flow of Yang Qi 
and subsequently make the local area malnourished 132(p888). Over a period of time, these 
external pathogens will enter into the organs and form the Bi syndrome of the five CM Zang 
organs, the CM liver, CM heart, CM spleen, CM lung, and CM kidney, especially the Bi 
syndrome of the CM heart organ 132 (p888).  
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Figure 2.2 Pathogenesis of Bi syndrome 
CM categorises Bi syndrome into different types (see Zhang et al. 134(p266-267). These types are 
listed in Table 2.12. 
Table 2.12 Diagnosis of different types of Bi syndrome and their associated acupuncture and 
CM herbal treatments  
CM Bi 
syndrome Symptoms 
Acupuncture 
treatment 
CM herbal 
treatment 
Wind 
dampness 
heat Bi 
syndrome 
Red, swollen, hot, and painful joints, better 
with cold temperature, dislikes being 
touched, may involve more than one joint, 
often accompanied with fever, aversion to 
wind, thirst, and irritability. Dry yellow 
tongue coating, slippery rapid pulse. 
GV14 (Da Zhui), 
LI11 (Qu Chi) 
Modified 
Bai Hu Gui 
Zhi Tang 
Wandering 
Bi syndrome 
Limbs and joints have pain that moves 
around, difficult to extend/flex the joint, 
aversion to wind, fever, thin white tongue 
coating, floating pulse. 
BL12 (Feng Men), 
BL17 (Ge Shu), 
BL18 (Gan Shu) + 
moxibustion 
Modified 
Fang Feng 
Tang 
Painful Bi 
syndrome 
Severe limb and joint pain at a fixed 
location, pain alleviated by warmth and 
aggravated by cold temperature, difficulty 
BL23 (Shen Shu), 
CV4 (Guan Yuan) + 
moxibustion 
Modified 
Wu Tou 
Tang 
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CM Bi 
syndrome Symptoms 
Acupuncture 
treatment 
CM herbal 
treatment 
in flexion/extension of the joint, local skin 
not red, and not warm to touch. Thin white 
tongue coating, thready taut pulse. 
Fixed Bi 
syndrome 
Ache in limbs and body, may have 
swelling in the joints, pain at fixed 
location, heaviness in the limbs, difficulty 
to move, as well as numbness in the 
affected skin. Greasy white tongue coating, 
soft and even pulse. 
BL20 (Pi Shu), 
ST36 (Zu San Li), 
SP9 (Yin Ling 
Quan) + 
moxibustion 
Modified Yi 
Yi Ren Tang
For acupuncture treatments, on top of the aforementioned prescriptions, the following 
prescriptions are for pain and/or dysfunction at each anatomical location: 
Shoulder: SJ14 (Jian Liao), LI15 (Jian Yu), SI10 (Nao Shu) 
Elbow: LI11 (Qu Chi), LI4 (He Gu), SJ10 (Tian Jing), SJ5 (Wai Guan), LU5 (Chi Ze) 
Wrist: SJ4 (Yang Chi), SJ5(Wai Guan), LI5 (Yang Xi), SI4 (Wan Gu) 
Spine: GV26 (Shui Gou), GV12 (Shen Zhu), GV3 (Yao Yang Guan) 
Thigh: GB30 (Huan Tiao), GB29 (Ju Liao), GB39 (Xuan Zhong) 
Hip: BL54 (Zhi Bian), BL36 (Cheng Fu), SP9 (Yin Ling Quan) 
Knee: ST35 (Du Bi), ST34 (Liang Qiu), GB34 (Yang Ling Quan), GB33 (Xi Yang Guan) 
Ankle: BL62 (Shen Mai), KI6 (Zhao Hai), BL60 (Kun Lun), GB41 (Qiu Xu). 
Source of information 134(p266-268)136(p91) 
 
 
Another classification method of Bi syndrome depends on the season or month of the year it 
occurs. If the Bi syndrome occurred during winter, spring, summer, June, or autumn, they are 
called bone Bi syndrome, tendon Bi syndrome, pulse/vessel Bi syndrome, muscle Bi syndrome, 
or skin Bi syndrome respectively 142(p. 268). 
After identifying the types of Bi syndrome, the CM pattern is then differentiated based on the 
accompanying symptoms and signs. Based on the textbook information by Wang et al. 
132(p890-895), there are ten CM patterns for Bi syndrome (Table 2.13). Subsequently, the principle 
of treatment is designed based on the CM pattern and the treatment will be given based on the 
treatment principle 132(p890-895). When the CM patterns differ, their treatment principle and the 
treatment rendered also differ. The treatment principle for “Cold dampness Bi obstruction 
(寒湿痹阻)” and “Damp heat Bi obstruction (湿热痹阻)” are completely different. Cold 
dampness Bi obstruction requires warming up the meridian and dispersing the cold whereas 
Damp heat Bi obstruction requires clearing heat and removing dampness. If the wrong 
treatment is prescribed, treatment recovery may not be possible, and symptom deterioration is 
expected. 
Table 2.13 CM pattern, treatment principle, and Chinese herbal medicine treatment for Bi 
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syndrome 
CM pattern Symptoms Treatment principle 
Chinese 
herbal 
medicine 
treatment
Wind 
dampness Bi 
obstruction 
(风湿痹阻) 
Aching, soreness, heaviness in joints and 
muscles, pain wanders around and occurs 
mainly in the major joints, swollen joints or 
muscles, inflexibility of joints, numbness on 
the skin/muscles. Symptoms often begin 
with exterior wind cold pathogen attack and 
fever. 
Remove cold and 
eliminate 
dampness, 
unobstruct the 
meridian and 
stop pain 
Modified 
Juan Bi 
Tang 
Cold 
dampness Bi 
obstruction 
(寒湿痹阻) 
Cold pain, heaviness, and pain at fixed 
location at the joints or limbs. Worse at 
night and better during the day. Pain 
aggravated by cold temperature and 
alleviated by warm temperature, or swelling 
at the painful sites, the skin is not red and 
does not feel feverish upon touching, no 
inflexibility of the joints. 
Warm the 
meridian and 
disperse the cold, 
remove 
dampness and 
unobstruct the 
meridian 
Modified 
Wu Tou 
Tang 
Cold and heat 
mixture (寒热
错杂) 
Swelling, feverish painful sensation at the 
limbs/muscle/joints. Aversion to cold at the 
pain site, or the patient feels a feverish 
sensation at the pain site but is not hot upon 
touching. The skin may have rashes but the 
extremities may turn blue when 
encountering cold temperature. Inflexibility 
of the joints which may be alleviated with 
warmth. The joints maybe stiff, deformed. 
The patient may feel feverish without a 
feverish sensation upon touching, fever with 
chills, feverish sensation and wants to cover 
up with sheets, thirsty with preference for 
hot drinks, or spontaneous sweating with 
cold body. 
Warm the 
meridian and 
disperse cold, 
clear heat and 
remove 
dampness 
Modified 
Gui Zhi 
Shao Yao 
Zhi Mu 
Tang 
Damp heat Bi 
obstruction 
(湿热痹阻) 
Red, hot, swollen, and painful muscles or 
joints, accompanied with heaviness 
sensation. May have fever, thirsty without 
craving for drinks, irritable, dark yellow 
urine, inflexibility of joints, difficulty with 
walking, or accompanied with rashes in 
joints. 
Clear heat and 
remove 
dampness, 
eliminate 
stagnation and 
unobstruct the 
meridian 
Modified 
Xuan Bi 
Tang and 
Dang Gui 
Nian 
TongTang 
Heat toxin Bi 
obstruction 
(热毒痹阻) 
Crimson feverish sensation at the joints, 
extremely painful and refuses to be touched. 
Feverish sensation upon touching and better 
with cold temperature. Accompanied with 
high body temperature and excessive thirst, 
or subcutaneous nodule, inflexibility of 
joints, red complexion, sore throat, red 
urine, constipation, may have delirium. 
Clear heat and 
relieve toxin, 
cool blood and 
unobstruct the 
meridian 
Modified 
Xi Jiao 
Tang 
Static blood Pins and needles sensation at the Activate blood Modified 
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CM pattern Symptoms Treatment principle 
Chinese 
herbal 
medicine 
treatment
Bi obstruction 
(瘀血痹阻) 
joints/muscles at a fixed location. The pain 
lasts for a long time, the painful area refuses 
to be touched. There may be ecchymosis or 
hard nodule at the local swelling, or dark 
complexion, dry and lusterless skin, dry 
mouth without preference to drink. 
circulation and 
resolve stasis, 
soothe the tendon 
and unobstruct 
the meridian 
Shen Tong 
Zhu Yu 
Tang and 
Huo Luo 
Xiao Ling 
Dan 
Phlegm 
turbidity Bi 
obstruction 
(痰浊痹阻) 
Swollen joints, numb and painful, or 
accompanied with phlegm nodule, dizziness 
and vertigo, head heaviness feels like a band 
around the head, stuffiness in the chest and 
fullness in the epigastrium, poor appetite 
with nausea, vomits out phlegm and froth, 
swollen eye lid. 
Resolve phlegm 
and activate Qi 
circulation, 
unobstruct the 
meridian and 
stop pain. 
Modified 
Ban Xia 
Bai Zhu 
Tian Ma 
Tang and 
Yang He 
Tang 
Phlegm stasis 
Bi obstruction 
(痰瘀痹阻) 
Chronic pain, pins and needles sensation in 
the joints/muscles at a fixed location, or 
dark purple swollen joints/skin, hard on 
palpation, numb and heavy sensation in the 
extremity or accompanied with deformed 
and stiff joints. Inflexible joints, there may 
be ecchymosis or hard nodule. Dark 
complexion, swollen eye lid, or stuffiness in 
the chest with copious phlegm. 
Activate blood 
circulation and 
resolve stasis, 
resolve phlegm 
and unobstruct 
the meridian 
Modified 
Shuang He 
San 
Deficiency of 
both Qi and 
Yin (blood) 
(气阴(血)两
虚) 
Painful, swollen, stiff, deformed bone and 
joints, may have tendon and muscle spasm. 
Thin body build, low grade fever, shortness 
of breath and weakness, palpitation, easily 
sweats, or muscle aching, pain and 
weakness. Symptoms aggravated after 
exercise. Pale nails, dizziness and vertigo, 
poor appetite with loose stool. Dry mouth 
without preference to drink, lusterless or 
numb skin, nodules, or ecchymosis in the 
skin. 
Benefit Qi and 
nurture Yin, 
activate blood 
circulation and 
unobstruct the 
meridian 
Modified 
Sheng Mai 
San and 
Huang Qi 
Gui Zhi 
Wu Wu 
Tang 
Deficiency of 
both CM liver 
and CM 
kidney (肝肾
两虚) 
Chronic Bi syndrome not cured, swollen and 
painful joints, tendons and muscles, stiff and 
deformed. Muscle becomes thin, and 
accompanied with low back and knees 
soreness and weakness. Patient may not be 
able to stand up and extend their neck (脊以
代头,尻以代踵)*, aversion to cold and 
prefers to sleep, cold extremities, or 
steaming bone sensation, spontaneous 
sweating and night sweating, thirsty without 
preference to drink or does not drink much. 
Tonify CM liver 
and CM kidney 
Modified 
Du Huo Ji 
Sheng 
Tang 
*This symptom is described as the patient can sit only but cannot walk. The patient can only 
lower the head but not lifting the head up. The patient’s coccyx is touching the ground and his 
cervical bones are slanting down and his spinal vertebrae are springing up. 
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According to the textbook information, there exist some discrepancies between textbooks on 
the Bi syndrome CM patterns and their treatment 134(p266-268)132(p890-895). Such differences are due 
to different experts having been involved in compiling the textbooks. This creates a problem in 
standardising CM patterns for Bi syndrome. 
2.6.4 CM understanding of the symptomatology of chronic pain  
Chinese medicine views the health of a person holistically 143(p28). All the parts in the body and 
medical conditions are considered related to one another via the relationships between the CM 
Zang Fu organs, the meridians, or the inter-relationship between the five elements 
143(p134-147,247-255, 268-315). These relationships are assessed when diagnosing the CM pattern of a 
condition. The aim of CM pattern identification is to identify the pattern of symptom 
presentation, and the mechanism of the illness – including the pathogenesis and sometimes the 
causes. Symptoms, signs, and conditions that come under the same CM pattern can happen 
concurrently. For example: LBP and tinnitus. These two symptoms are related to the low back 
and ear. The low back region in CM is the house of the CM kidney. The ear is the opening 
orifice of the CM kidney. If both symptoms occur concurrently, this pattern is considered as 
CM kidney deficiency. The locations of these symptoms can be linked together by the 
distribution of Foot Tai Yang bladder meridian, which is related to the CM kidney via the water 
element relationship of the five elements (see Table 2.9 and Figure 2.3). Another example is 
headache, sore and red eyes, tinnitus, and pain in the lower rib area. The temple area and the 
ear are where the gallbladder meridian passes (see Figure 2.4), and the lower rib area is where 
the CM liver meridian passes. The eyes are the opening orifices of the CM liver. The CM liver 
and CM gallbladder are a pair belonging to the wood element (Table 2.9). If the above 
symptoms occur concurrently, this pattern is called CM liver Yang Upsurging. 
As explained before, the body parts and CM organs are related to one another through the 
meridian system. For instance, the spreading of LBP to the upper back, neck, and head, or 
spreading to the hips and knees could be explained by the obstruction of the Qi and CM blood 
flow in the Foot Tai Yang bladder meridian as this meridian travels from the head to the feet 
144(p140) (Figure 2.3). 
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Apart from the anatomical locations and meridians, the CM organs also have their associated 
emotions. The five CM Zang organs (the solid internal organs), include the CM liver, CM heart, 
CM spleen, CM lung, and CM kidney. These are associated with anger, joy, overthinking, grief, 
and fear (Table 2.9, p. 33) 133(p20). In the case of the CM liver Yang upsurging pattern which 
involves the CM liver, this pattern could also present with grumpiness or anger due to there 
being excessive Yang.  
 
Figure 2.3 The distribution of Foot Tai Yang bladder meridian (marked in red)  
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Figure 2.4 The distribution of Foot Shao Yang gallbladder meridian (marked in red, dotted line 
indicates meridian path covered by arm) 
Overall, the symptomatology of CMP plays an important part in CM pattern identification. 
These seemingly unrelated symptoms may influence the resultant CM pattern identification and 
consequently the principle of treatment and the treatment rendered. 
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2.6.5 CM understanding of the side effects of pharmacotherapy 
Based on CM understanding, some of the side effects and withdrawal symptoms of OM can be 
categorised according to the CM heat or cold patterns. Side effects such as itching, urticaria, 
constipation, sleep disturbances and restlessness are heat type symptoms (Table 2.14) whereas 
the opposite cold type side effects include reduced sex drive (Table 2.14). The withdrawal 
symptoms of OM can also be categorised into heat or cold patterns (Table 2.14). In addition, 
there are some withdrawal symptoms such as anxiety, and increased tearing which cannot be 
categorised simply into either CM heat or cold patterns. 
 
Table 2.14 Side effects and withdrawal of OM categorised by CM heat and cold patterns 
CM patterns Side effects of OM Withdrawal symptoms of 
OM 
CM heat pattern itching around nose, and 
urticaria, constipation, 
delayed gastric emptying, 
sleep disturbance, 
behavioural restlessness 
Agitation, insomnia 
CM cold pattern nausea and vomiting and 
reduced sex hormone 
Muscle aches, runny nose, 
abdominal cramping, 
diarrhoea, nausea, vomiting. 
Information extracted from Schumacher et al. 76 and MedlinePlus 145. 
OM: Opioid medication 
 
These heat and cold patterns contain symptoms of the opposite nature. The heat pattern contains 
symptoms that are more hot, agitating, irritable, and dry. These symptoms are also considered to 
be Yang in nature. The cold pattern, on the other hand, contains symptoms that are more cool, 
painful, watery, sedative, and motiveless. These symptoms are more Yin in nature. 
2.6.6 CM pattern studies of chronic pain 
There were limited studies examining the CM patterns of CMP. In the lumbar disc protrusion 
study, the confirmed disc protrusion cases by computed tomography were 42 for the group 
with traumatic history, and 96 for the group without traumatic history. For the group with 
traumatic history, 36 of them (86.6%) were diagnosed with CM blood stasis pattern, and the 
remaining six (14.2%) were diagnosed with CM deficiency pattern. The CM deficiency 
pattern included CM Qi and blood deficiency pattern, CM liver and CM kidney deficiency 
pattern, or “acute sprain, strain, or contracting wind cold dampness pathogen during the 
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recovery period after chronic pain or major illness”. For the group without traumatic history, 
60 of them (62.5%) were diagnosed with CM cold dampness retention pattern, 32 of them 
(33%) were diagnosed with CM damp heat and phlegm retention pattern and the remaining 
four (4.2%) were diagnosed with CM deficiency pattern. Such a finding indicated a different 
view and understanding of LBP which was not limited by the structural pathology as indicated 
by computed tomography.  
2.7 Acupuncture and pain management 
2.7.1 Mechanisms of acupuncture 
Commonly there are a few forms of acupuncture, depending on the methods of acupuncture 
point stimulation. Stimulating acupuncture points with filiform needles alone is called manual 
acupuncture. When electrical current is delivered with an electroacupuncture (EA) machine 
attached to the inserted needles, this form is called EA 146. Acupuncture points can also be 
stimulated with laser, which is called laser acupuncture 147(p112); with warmth via applying 
moxibustion on top of the inserted needles, called warm needling 147(p55); with three edge 
needles to draw blood for the therapeutic purpose, called three edge needling 147(p61). 
Acupuncture can also be classified based on the types of points stimulated or the selection of 
treatment points, and this includes body acupuncture, eye acupuncture, ear acupuncture, scalp 
acupuncture, hand acupuncture, wrist and ankle acupuncture, and foot acupuncture 
148(p100-117) . 
There are currently six scientific theories for the mechanisms of acupuncture analgesia 149: 1) 
Natural opioid substance – endogenous opioid substance, 2) gate control theory, 3) 
endogenous corticosteroid release, 4) myofibrillary entanglement, 5) local blood flow, and 6) 
mesolimbic loop of analgesia.  
2.7.1.1 Natural opioid substance – endogenous opioid peptides 
Opioid substances including endorphin/endomorphin, and encephalin are activated by 2Hz EA 
while dynorphin is activated by 100 Hz EA stimulation 150. Endorphin and encephalin are 
potent analgesics for musculoskeletal pain while dynorphin is a potent analgesic for visceral 
pain 149.  
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2.7.1.2 Gate control theory 
Melzack et al. 151 proposed the gate control theory in 1965 which stated that pain signals sent 
through the small diameter fibres (C fibre) were inhibited by the substantia gelatinosa which 
received input from the large diameter fibres (Aβ). Acupuncture activates Aβ fibres which 
then inhibit the transmission of pain signals through Aβ C fibres. This explains how local point 
needling at the pain site might relieve painful sensations. 
2.7.1.3 Endogenous corticosteroid release 
Adrenocorticotrophic hormone is elevated after EA treatment 152. This suggests EA activated a 
stress response which is related to the release of the endogenous corticosteroids. Endogenous 
corticosteroids are well known to treat pain related conditions 153. 
2.7.1.4 Myofibrillary entanglement 
Trigger point injection has been used for treatment of painful conditions 154(p187-341). 
Acupuncture may relax the muscle fibres within the tissues. This effect of acupuncture on 
painful points is thought to be similar to trigger point injection into the painful trigger points 
149. 
2.7.1.5 Local blood flow 
Acupuncture treatment causes a small trauma to the body. Such treatment may increase the 
blood flow to the area surrounding the needles consequently triggering a healing process 149. 
2.7.1.6 Mesolimbic loop of analgesia 
Dopamine plays a crucial role in pain coping response and avoidance 155. Chronic pain impairs 
the mesolimbic dopamine activity that interferes with motivated behaviours 155. Acupuncture 
treatment can modulate the mesolimbic dopamine neurons and subsequently reset the 
pain-modulating pathway 156. 
2.7.2 Acupuncture treatment 
After a CM pattern identification is made, the acupuncture points may be selected for 
treatment. The point selection is based on 1) local and distal points, 2) the diseased meridian, 
3) the other involved meridians, 4) empirical points, and 5) Ashi points, which literally means 
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“ouch” points, and refers to points that are painful to touch or pressure 136(p15). For example, in 
Bi syndrome due to cold stagnation at the lumbosacral joints, the points selection includes 
local points such as Shenshu (BL23), distal points such as Weizhong (BL40) and Guanyuan 
(CV4), and moxibustion to disperse the cold and warm up the meridian along the spine from 
Dazhui (GV14) to Yaoshu (GV2), and the empirical point Renzhong (GV26) for LBP (Table 
2.15). 
Table 2.15 Acupuncture treatment for Bi syndrome due to cold stagnation at lumbosacral joints 
Types of Bi 
syndrome 
Local point Distal point Diseased meridian 
points 
Empirical 
points 
Bi syndrome due 
to cold stagnation 
at lumbosacral 
joints 
Shenshu (BL23)am, 
Dachangshu (BL25), 
Mingmen (GV4), 
Baliao (BL31-34) 
Guanyuan 
(CV4) am, 
Weizhong 
(BL40) 
Moxibustion* along 
the spine from 
Dazhui (GV14) to 
Yaoshu (GV2) 
Renzhong 
(GV26) 
Function of the 
points. 
Shenshu (BL23) and Guanyuan (CV4) to warm up Yang Qi and benefit the 
Qi, expel the cold pathogen. 
 
Moxibustion* along the spine from Dazhui (GV14) to Yaoshu (GV2). 
These points alone with the other local points, including Shenshu 
(BL23)am, Dachangshu (BL25), Mingmen (GV4), and Baliao (BL31-34), 
were to regulate the meridian, activate Qi and blood, expel the pathogen 
and pain. 
 
Weizhong (BL40) is a well known point for LBP. 
 
Renzhong (GV26) can be used to activate the Qi in the Du meridian 
which runs from just anterior to the coccyx going up the spine alone the 
mid line of the back, back of the head, top of the head, front of the head, 
and ends at the philtrum. 
* Moxibustion is a heat therapy by burning mugwort on or close to the skin in order to disperse 
cold, eliminate dampness, nourishing Qi or warming Yang 157(p402). 
LBP: Low back pain 
am: to apply acupuncture and moxibustion together. 
 
Currently there is no defined acupuncture treatment frequency. Acupuncture treatment 
frequency varies from once a day to once a month 158. A SR investigated different acupuncture 
regimens found two extreme frequencies were employed: 1) once to twice per week and 2) five 
to six times per week 159. There is currently no consensus on the better treatment frequency 
although Yuan et al. pointed out there may be a dose response for the controlled acupuncture 
trials conducted in China where daily acupuncture treatment per week are normally applied 
and authors reported 100% favouring acupuncture treatment over the controls 159. 
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2.7.3 Acupuncture in pain management and acupuncture treatment based 
on CM patterns 
Acupuncture, as described in Chapter 2.4.2.2 (p. 21), has shown effectiveness for painful 
conditions and been recommended by the USA AHRQ guidelines for painful conditions. Many 
of the SR identified acupuncture to be more effective than no intervention 91,92,94,160, sham 
acupuncture 36,91,161, inactive treatment (defined as sham TENS) 91, or as effective as other 
active intervention 92. However, another meta-analysis found no difference between 
acupuncture and sham acupuncture 162. One possible explanation for SRs not showing 
efficacy of acupuncture was heterogeneity amongst the trials 163. Such heterogeneity may be 
due to the fact that trials did not consider the individual CM patterns of the participants. As 
described in Yang et al. 162, although the included trials selected points based on the 
acupuncture literature and CM theory, there was no point selection based on the CM patterns 
of the individual patients.  
To date, knowledge of the CM patterns of CMP based on clinical data is still lacking. As 
indicated in Table 2.12, different acupuncture points as well as the utilisation of moxibustion 
were used for different CM patterns. The acupuncture treatment should be based on the CM 
pattern. As shown in the SRs where there was no difference or very small effect between 
acupuncture and sham acupuncture 37,94, none of the included studies treated the participants 
based on CM patterns. Another large acupuncture study (n=302) on migraine that showed no 
difference between acupuncture and sham acupuncture did not treat participants based on CM 
patterns 164. It is important to design acupuncture trials that treat participants based on CM 
pattern. 
2.7.4 Problems in current acupuncture research 
As described in Chapter 2.6.3 How does CM view and differentiate CMP (p. 36), CM views the 
body and diagnoses the condition/disease with its own unique theory and interpretation. 
Treatments for different kinds of CM patterns also differ (Table 2.12). It is not a surprise to find 
poor results when using the same acupuncture protocol for a given condition without further 
identifying the suitable CM pattern for such acupuncture protocol. It is important to identify the 
CM pattern of the condition and individualise the acupuncture treatment based on the CM 
pattern, as is routinely done in clincal practice, to achieve the optimal result. 
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In order to identify the CM pattern, it is important to standardise the procedure of CM pattern 
identification. The first step is to have a consistent consultation procedure which can be 
achieved using a CM questionnaire 165. Subsequently, the CM pattern reflecting the reality of a 
given condition, instead of being based on expert opinions as in the textbooks, should be 
identified. Then the acupuncture protocol for the given condition can be divised. 
There is a need to fill this knowledge gap of CM pattern in reality in order to improve the 
quality of acupuncture clinical trials. 
2.8 Chapter summary 
This chapter reviewed the current literature regarding CMP, management of CMP, 
comorbidities and symptomatologies, the CM views of CMP, the principles of CM 
syndrome/pattern identification and acupuncture in pain management. The next chapter will 
examine the current knowledge of comorbidities and symptomatologies of CMP through a 
SR.  
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3. Systematic review on comorbidityies and accompanying 
symptoms associated with CMP conditions 
3.1 Introduction 
Painful conditions come with comorbidities and accompanying symptoms such as depression 
and anxiety 166, migraine 167, and neck pain 168. Such accompanying illnesses/symptoms have 
huge implications for healthcare services and costs 169, such as increased physician visits, use 
of more medications, and are more likely to be hospitalised than people without 
accompanying illnesses/symptoms 170(p21,23). Research also shows that when a person has five 
or more chronic conditions, the health cost, which is 14,768 USD/capita health care spending, 
is almost 15 times more than for a person having no chronic conditions and five times more 
than for a person having only one chronic condition 170(p17). Moreover, comorbidities affect 
choice of treatment. For instance, when patients have comorbid peptic ulcer, NSAIDs are less 
likely to be prescribed; and when patients have comorbid hypertension, physical therapy 
(undefined in the publication) is less likely to be prescribed 171. The overall 
comorbidities/accompanying symptoms of CMP are not fully understood. This SR assesses 
the current literature on comorbidities/accompanying symptoms of CMP. The aims of the SR 
were to identify 1) the types of comorbidities/accompanying symptoms of CMP; 2) the 
percentages of comorbidities/accompanying symptoms in CMP; and 3) the association 
between CMP and comorbidity/accompanying symptoms of CMP. 
3.2 Method 
3.2.1 Selection criteria 
Types of study: cross-sectional, prospective cohort or clinical trial studies that described 
comorbidities and/or accompanying symptoms of CMP were included. Studies might apply a 
survey, questionnaire, or interview to obtain the data. Reviews, retrospective data from 
government or private health insurance databases, retrospective studies, and studies focused on 
non-musculoskeletal pain were excluded. 
Types of participants: All participants with CMP were considered regardless of age, gender, or 
ethnic group. Chronic musculoskeletal pain were defined as musculoskeletal pain lasting for 
more than three months regardless of the location of musculoskeletal pain. Such CMP might 
include chronic SP, arthritis, and widespread pain. Studies that included CMP due to 
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cancer/tumour/metastatic diseases were excluded. Studies that reported CMP as a 
comorbidity/accompanying symptom of other illnesses were also excluded. 
Types of comparison group: The comparison group were general population without the studied 
CMP. In an epidemiological/percentage study, there was no comparison group required. 
Studies that compared one kind of CMP to another kind of acute/chronic musculoskeletal pain 
were excluded. 
Types of interventions: No specific intervention was the interest of this study. Only baseline 
data of clinical trials were extracted if the baseline included the epidemiological/percentage 
data needed.  
Types of outcomes: Included studies reported comorbidities, accompanying symptoms, or 
related findings. Studies that reported musculoskeletal pain without specifying its location (e.g. 
back pain, or neck pain) were excluded. 
Language was restricted to both English and Chinese. Publications in other languages were 
excluded. 
3.2.2 Search strategy for identification of studies and study selection  
Search strategies for identifying studies included 
1) Databases: PubMed, CINAHL, EBSCO, PsycInfo, Cochrane library, and SCOPUS 
were searched from inception to 13/05/2015. 
2) When the required data was not found in the publication, the authors were contacted. 
3) References of the selected papers and reviews were searched.  
Search terms used in PubMed were included in Table 3.1. Similar search terms were used in 
other databases. 
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Table 3.1 Search terms used in PubMed 
1 Survey 
2 Epidemiology 
3 Epidemiological 
4 Prevalence 
5 #1 or #2 or #3 or #4 
6 Pain [tiab] 
7 Musculoskeletal [tiab] 
8 “Chronic pain” [tiab] 
9 Neck pain [tiab] 
10 Back pain [tiab] 
11 Shoulder pain [tiab] 
12 Elbow pain [tiab] 
13 Wrist pain [tiab] 
14 Joint pain [tiab] 
15 Hip pain [tiab] 
16 Thigh pain [tiab] 
17 Knee pain [tiab] 
18 Leg pain [tiab] 
19 Ankle pain [tiab] 
20 Foot pain [tiab] 
21 “Chronic non-cancer pain” [tiab] 
22 “Non-cancer pain” [tiab] 
23 #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 
or #20 or #21 or #22 
24 Symptomatology [ti] 
25 Co-morbidity [ti] 
26 comorbidity [ti] 
27 “Non-pain symptom” [ti] 
28 #24 or #25 or #26 or #27 
29 #5 AND #23 AND #28 
 
Once the electronic searches were completed, the titles and abstracts were downloaded to 
EndNote X4. Duplicated references were removed from EndNote by using the “Find 
Duplicates” in the “References” command as well as sorting the publications by titles and 
authors’ surname in alphabetical order and visually comparing the publication titles. Lu, S. 
screened the titles and abstracts to identify studies that met the selection criteria. When there 
was confusion on whether or not to include references, Zheng, Z. was then consulted. 
3.2.3 Data collection and extraction 
Participant characteristics, research method, types of comorbidity, accompanying symptoms, 
ORs, epidemiological/percentage/association data were extracted. If studies were described as 
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a cohort study but only the baseline data were used, then such studies were considered to be 
cross sectional. This rule applied to demographic, comorbidity, and accompanying symptom 
data as well where only baseline data were used. The results were grouped according to 
International Classification of Disease into twelve categories 42, diseases of the nervous 
system (migraine, tension type headache, sleep disorders), diseases of the musculoskeletal 
system and connective tissue, mental and behavioural disorders, diseases of the digestive 
system, diseases of circulatory system, “endocrine, nutritional and metabolic diseases”, 
diseases of the respiratory system, diseases of the genitourinary system, diseases of the eye 
and adnexa, disease of the ear and mastoid process, “symptoms, signs and abnormal clinical 
and laboratory findings, not elsewhere classified (headache)” and other categories. 
3.2.4 Methodological appraisal 
The methodological rigour of the selected studies was assessed using NOS 41 which was 
recommended by the Cochrane Library 172. NOS is a quality assessment tool that was designed 
for SRs of nonrandomised studies, such as case controlled and cohort studies 41. This scoring 
system consists of eight items on the selection of participants, comparability of the groups, and 
exposure or outcome of the assessment, depending on whether the study was case controlled 
or cohort, of the study designs. Except for comparability of the groups where two scores may 
be given, other questions scored one, if the criteria were fulfilled, or none, if the criteria were 
not met. Content validity and inter-rater reliability of NOS have been established 41. The 
quality of study was defined as very good if it scored eight or nine, good if it scored six to 
seven, satisfactory if it scored four to six, unsatisfactory if scored zero to three 173. 
3.3 Results 
3.3.1 Selection of studies 
3.3.1.1 Search results and study selection 
One thousand three hundred and ninety-three studies were found from databases searches 
(Table 3.2) and 798 studies were screened after duplication removed. 
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Table 3.2 Database search results 
Database Result 
PubMed 378 
CINAHL 52 
PsycInfo 144 
Cochrane Central 301 
EBSCO 204 
SCOPUS 314 
Total 1393 
Total after duplications removed 798 
 
Of the 798 studies, 735 studies were excluded. The reasons for exclusion are presented in Table 
3.3. Nine additional studies were obtained from hand searches of the included studies 174-182. In 
total 72 studies were included 166-168,174-242. The search procedure is illustrated in Figure 3.1. 
  Figure 3.1 PRISMA diagram of the study inclusion procedures 
 
The included studies had a range of 23 to 85,052 participants with a median of 590 and 635 and 
a total of 358,559 participants. Two studies reported the data from the same data set and were 
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only counted once in the total participants 176,202. 
Table 3.3 Reasons for exclusion 
Reasons for exclusion Study 
Non-musculoskeletal pain 153 studies 243-395 
No comorbidity/accompanying symptom/non-pain symptoms or 
no listed comorbidity/accompanying symptom 
131 studies 396-526 
Non pain study 86 studies 527-612 
Review 62 studies 119,120,122,169,613-670
No specific musculoskeletal pain (described as pain or bodily 
pain or the reporting of data is lumped together and unable to 
differentiate which part belongs to CMP) 
55 studies 53,125,671-723 
CMP as comorbidity of other illnesses/symptoms 47 studies 724-770 
Non-CMP or uncertain of chronicity of musculoskeletal pain 45 studies 18,49,771-813 
Non-English/Chinese paper 42 studies 395,814-854 
Non-survey/interview study 18 studies 855-872 
Retrospective study 16 studies 873-888 
Cancer 15 studies 889-903 
Control group is not musculoskeletal pain free 15 studies 904-918 
Protocol only 11studies 919-929 
Correspondence letter or comment 9 studies 930-938 
Redundant 7 studies 939-945 
Book section 5 studies 946-950 
Outcome assessment study 4 studies 951-954 
No full data provided 3 studies 955-957  
Outcome assessment item is not musculoskeletal pain only 2 studies 958,959 
Erratum 2 studies 960,961 
Uncertain if participants have been counted more than once 1 study 962 
Cannot separate prospective and retrospective groups 1 study 963 
Book 1 study 964 
Comorbid depression was specifically chosen as part of 
inclusion criteria and made CMP all have depression 
1 study 965 
Animal study 1 study 966 
Consensus 1 study 967 
Suspected duplication but EBSCO recorded this as new 
publication. 
1 study 968 
 
 
The scores for the NOS are listed in Appendix 3 and Appendix 4. The summaries are listed in 
Table 3.4 and Table 3.5. For the case controlled studies, the average score was 2.18 for each 
study. The highest scored item was “Same method of ascertainment for cases and controls” 
whereas the lowest scored item was “Ascertainment of exposure”. For the cohort study, the 
average score was 2.75. The highest scored item was “Was follow-up long enough for 
outcomes to occur” and the lowest scored items were “Selection of the non exposed cohort”, 
“Demonstration that outcome of interest was not present at start of study”, " Assessment of 
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outcome”, and “Adequacy of follow up of cohorts”. Based on the criteria, only 14 studies were 
of satisfactory quality (Range: 4-5) 176,177,183,186,187,190,193,202,203,206,213,231,232,234 whereas the 
remaining studies were of unsatisfactory quality (Range: 0-3).
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Table 3.4 NOS assessment summary of the included studies – case controlled studies (68 studies) 
 
Selection Comparability Exposure 
Total 
score 
Is the case 
definition 
adequate
Representativeness 
of the cases 
Selection 
of 
controls 
Definition 
of 
controls 
Comparability 
of cases and 
controls on the 
basis of the 
design or 
analysis 
Ascertainment 
of exposure 
Same method 
of 
ascertainment 
for cases and 
controls 
Non-Response 
rate 
Total 
score 16 25 11 23 24 6 34 9 148 
Average 0.25 0.367647059 0.23913043 
0.5476190
48 0.510638298 0.095238095 0.918918919 0.219512 2.18 
Range 0-1 0-1 0-1 0-1 0-2 0-1 0-1 0-1 0-5 
 
Table 3.5 NOS assessment summary of the included studies – cohort studies (4 studies) 
 
Selection Comparability Outcome 
Total 
score 
Representativeness 
of the exposed 
cohort 
Selection 
of the 
non 
exposed 
cohort 
Ascertainment 
of exposure 
Demonstration that 
outcome of interest was not 
present at start of study 
Comparability 
of cohorts on 
the basis of the 
design of 
analysis 
Assessment 
of outcome
Was 
follow-up 
long 
enough 
for 
outcomes 
to occur
Adequacy 
of follow 
up of 
cohorts 
Total 
score 3 0 3 0 1 0 4 0 11 
Average 0.75 0 0.75 0 0.5 0 1 0 2.75 
Range 0-1 0 0-1 0 0-1 0 1 0 2-3 
 
 58 
 
3.3.2 Characteristics of selected studies 
Comorbidities and accompanying symptoms of CMP 
Of the 72 studies that reported comorbidities and accompanying symptoms of CMP, the 
countries where the studies were conducted are listed in Table 3.6. The majority of them came 
from USA. 
Table 3.6 Country where the studies were taken 
Country  Study 
USA 31 studies 
167,175-178,181,183,185,186,195,200-203,205,209-212,216,217,219,223,224,226-228,232,234,237,239
Netherlands 5 studies 168,187,220,230,240 
Italy 4 studies 189,208,214,241 
Finland 3 studies 194,198,204 
Spain 3 studies 190,191,218 
Germany 3 studies 225,235,242 
Canada 5 studies 174,179,184,216,226 
Sweden 3 studies 180,197,199 
Norway 2 studies 196,213 
China 2 studies 166,229 
Turkey 1 study 188 
Possibly Turkey 1 study 182 
Not specified 1 study 215 
Columbia 1 study 231 
Online survey 1 study 221 
Slovenia 1 study 222 
Possibly Sweden 1 study 193 
Nigeria 1 study 192 
Possibly Netherlands 1 study 207 
International 
collaboration 
1 study 206 
Australia 1 study 233 
France 1 study 236 
Lebanon 1 study 238 
 
The designs of the included studies are listed in Table 3.7. Majority of the studies were cross 
sectional studies.  
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Table 3.7 Design of the included studies 
Design Study 
Cross sectional study 63 studies 
166-168,174-178,181-183,185-200,202-209,211-214,216-226,229-235,237-242
Cohort study 9 studies 179,180,184,201,210,215,227,228,236 
 
Types of study population 
Of the included studies, chronic SP, arthritis, and fibromyalgia/widespread pain were studied 
the most. Detailed information about those conditions is presented in the relevant sections. 
The number and types of participants are presented in Table 3.8. 
Table 3.8 Types of participants 
Types of pain Studies 
Chronic SP 20 studies 167,168,175,177,178,186-188,190,192,193,197,206,208,209,229,231-233,240 
Arthritis 37 studies 
166,176,177,179-181,185-187,190,194,200,202,206,207,210,212,213,217,219,220,222-224,227-232,
234-240 
Fibromyalgia/Widespre
ad pain 
15 studies182,184,188,189,196,197,201,203,204,214,216,218,225,226,241 
Other types of CMP  4 studies (3 non-specified CMP studies 174,191,199 and one study on 
chronic low back, hip, and knee pain 183) 
Facial pain/temporal 
mandibular joint 
disorder 
3 studies 195,215,242 
Shoulder 
pain/periarthritis 
3 studies 198,205,211,221 
*some studies have been counted more than once due to the inclusion of other types of CMP. 
 
Types of outcome measures 
Within the included studies, various outcome measures were used and listed from Table 3.9 to 
Table 3.11. The most frequently used questionnaire for physical comorbidity was self-reported 
physical illness followed by author developed comorbidity/accompanying symptom list. For 
mental comorbidities, the most frequently used questionnaire was World Mental Health Survey 
initiative version of the WHO composite international diagnostic interview (CIDI) or 
CIDI-short form, followed by BDI. The most frequently reported assessment for both physical 
and mental comorbidities was self-report of pre-defined diagnosed chronic illnesses. 
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Table 3.9 Outcome measures of physical comorbidities/accompanying symptoms 
Physical comorbidity assessment Studies 
Self-reported physical illnesses 8 studies 179,185,190,203,204,210,217,231 
Author made comorbidity/accompanying symptom list 7 studies 180,213,221,224,232,239,240 
A checklist of common physical disorders (name not 
given) 
2 studies 187,192 
Body mass index 4 studies 181,207,223,238 
Deyo Charlson index for comorbidity 3 studies 227,228,237 
Self reported pain 1 study 219 
Medical evaluation 1 study 198 
Non-standardized questions/questionnaires (a checklist 
of common physical disorders) 
1 study 187 
Common clinical characteristics of fibromyalgia 
syndrome such as non-restorative sleep, fatigue, 
tension-type headache, irritable bowel syndrome were 
also noted 
1 study 188 
National health interview survey` 1 study 202 
Musculoskeletal outcomes data evaluation and 
management system 
1 study 205 
Cumulative illness rating scale, cognitive screening 
test, Stroop color word test, Wechsler adult intelligence 
scale 
1 study 207 
General health survey for comorbidities 1 study 211 
Mattis Dementia Rating Scale 1 study 212 
Clinical and verbal questionnaire in relation to 
cranio-cervico-facial pain and otic symptomatology. 
1 study 215 
Fibromyalgia 18 tender spots 1 study 218 
Number of painful joint sites. 1 study 220 
Medical Outcomes Study sleep scale for sleep 
disturbances 
1 study 225 
PainDETECT questionnaire for sensory symptoms 1 study 225 
The Pittsburgh Sleep Quality Index 1 study 229 
Comorbidity is assessed with a self-reported health 
module of the Central Bureau of Statistics in the 
Netherlands which encompasses 24 chronic diseases  
1 study 230 
Functional comorbidity index 1 study 236 
Index of Sexual Satisfaction 1 study 241 
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Table 3.10 Outcome measures of mental comorbidities/accompanying symptoms 
Mental comorbidity assessment Studies 
World mental health survey initiative version of the WHO CIDI or 
CIDI-short form 
10 studies 
166,176,177,186,187,192,202,20
6,224,232 
BDI 4 studies 174,175,188,216 
Self-reported mental/psychiatric illnesses 4 studies 189,203,210,231 
Center for epidemiological studies-depression scale 2 studies 185,219 
Symptom checklist 90 or the revised version 2 studies 184,199 
Diagnostic interview schedule-version III-A, Hamilton rating scale for 
depression  
2 studies 175,214 
Zung depression scale 2 studies 193,222 
Hospital Anxiety and Depression Scale 2 studies 196,220 
Structured Clinical Interview for DSM-IV Axis I Disorders  2 studies 182,241 
Structured clinical interview for DSM-III-R 1 study 178 
Anxiety sensitivity index 1 study 174 
Marks and Mathews fear questionnaire, panic attack questionnaire, 
structured clinical interview for DSM-IV 
1 study 174 
Self-reported suicide plan or attempt 1 study 186 
Primary care evaluation of mental disorders 1 study 191 
Zung’s self rating anxiety scale 1 study 222 
Comprehensive psychopathological rating scale for self administration, 
Montgomery–Åsberg depression rating scale, structured clinical interview 
for diagnosis questionnaire, depression rating self-report questionnaire, 
employment/insurance-benefit status, periods of sick leave and/or partial 
(temporary or permanent) disability pension 
1 study 197 
Present state examination (mental disorder diagnoses) 1 study 198 
Temperament character inventory 1 study 199 
Neurological and psychiatrical assessment 1 study 208 
PTSD checklist 1 study 201 
Depression subscale of symptom checklist 25 1 study 204 
Geriatric Depression Scale. 1 study 212 
Kessler 10-item scale score (to screen populations for nonspecific 
psychological distress in the anxiety–depression spectrum and serious 
mental illness) 
1 study 231 
Fear-Avoidance Beliefs Questionnaire physical activity subscale, modified 
for the knee) 
1 study 219 
Beck Anxiety Index 1 study 219 
Tampa Scale for Kinesiophobia 1 study 220 
The Borderline Personality Disorder scale from the International 
Personality Disorder Examination Screening Questionnaire 
1 study 224 
Hazan and Shaver’s (1987) attachment style (measures secure, avoidant, 
and anxious attachments) 
1 study 232 
PHQ for depressive, panic, and anxiety disorders 1 study 225 
Adult Self-Report (anxiety and depression scales) 1 study 240 
Major Depression Inventory 1 study 242 
BDI: Beck depression inventory 
CIDI: composite international diagnostic interview 
PHQ: Patient Health Questionnaire  
PTSD: Post traumatic stress disorder 
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Table 3.11 Outcome measures of both physical and mental comorbidities/accompanying 
symptoms 
Both physical and mental comorbidity assessment Studies 
Self report of pre-defined diagnosed chronic illnesses 2 studies 190,235 
Patient questionnaire 1 study 219 
Interview and medical exam 1 study 212 
Medical/psychiatric evaluation 1 study 195 
National health interview survey` 1 study 202 
Symptom checklist 25 1 study 204 
Uncertain of questionnaire, author only mentioned comorbid diseases 
and psychiatric history were recorded. Mattis Dementia Rating Scale, and 
Geriatric Depression Scale. 
1 study 212 
The questionnaire was designed by the panel which consisted of eight 
domains: 
1) demographics, 2) physical and mental health status, 3) health 
insurance, 4) health care utilization and access to health care, 5) medical 
home, 6) family functioning, 7) parents’ health, and 8) neighbourhood 
characteristics. 
1 study 234 
Record from Survey of Disability, Ageing and Carers 1 study 233 
The checklist for fibromyalgia is adapted from the Memorial Symptom 
Assessment Scale (MSAS) 
1 study 226 
Comorbidity is assessed with a self-reported health module of the Central 
Bureau of Statistics in the Netherlands which encompasses 24 chronic 
diseases  
1 study 230 
 
3.3.2.1 Methods of data collection 
The methods of data collection are listed in Table 3.12. The majority of studies (86%) used 
interview/survey (33%), questionnaire (33%), or a combination of them (19%). Five clinical 
trials did not report the method used for collecting data. 
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Table 3.12 Method of data collection 
Method of data collection Study 
Interview or survey 24 studies 
166,167,175,176,182,183,185-187,192,195,201,203,208,210,213,217,224,227,228,232-234 
Questionnaire 24 studies 
168,180,181,184,193,194,196,199,204,205,209,214,221,222,225,226,229,230,236,237,239-242
Both interview/survey and 
questionnaire 
14 studies 174,177-179,189-191,197,198,202,206,220,231,238 
Clinical trial, only 
mentioned comorbid 
diseases will be recorded 
5 studies 200,212,215,216,218 
Physical examination, 
questionnaire, and 
interview/survey 
4 studies 207,219,223,235 
Physical examination and 
questionnaire 
2 studies188,211 
 
3.3.2.2 Summary of types of participants 
The types of participants are listed in Table 3.13. The majority of the studies recruited from the 
general public (31%) followed by arthritis/rheumatology clinic patients (22%) and 
fibromyalgia participants (13%). 
Table 3.13 CMP studies and their participants 
Participant Studies 
General population 22 studies 
166,167,176,177,185-187,190-192,198,202,204,206,213,224,231,232,234,238-240
Arthritis/rheumatology clinic 
patients  
16 studies 179,180,194,200,207,210,212,219,220,223,227,228,230,235-237 
Fibromyalgia 9 studies 184,189,196,214,216,218,225,226,241 
Chronic LBP 6 studies 175,178,183,188,193,233 
Shoulder pain (rotator cuff tear, 
capsulitis) 
3 studies 205,211,221 
Various physical illness groups 2 studies 208,209 
Labourer 1 study 168 
Attending treatment programme 1 studies 174 
Facial pain 1 study 195 
Non-specific musculoskeletal pain 1 study 199 
Sickness absentees 1 study 197 
Twins 1 study 203 
Adult women 1 study 201 
Otolaryngologic clinic patient 1 study 215 
Children with one or no chronic 
illnesses 
1 study 217 
Patients who visit GP 1 study 222 
High school student 1 study 229 
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Dental clinic 1 study 242 
Medicare beneficiaries 1 study 181 
Did not describe 1 study 182 
GP: General practitioner 
LBP: Low back pain 
 
As there were many studies that reported different types of pain, the data of the top three main 
pain groups were listed and described in the following sections. They were chronic SP, arthritis, 
and widespread pain/fibromyalgia. The summary of the comorbidities and accompanying 
symptoms are listed from Table 3.46 to Table 3.48 (p. 126). 
For the following section, several studies were included in two or all of the three major CMP 
types; and overlaps are specified in the footnotes of Table 3.14, Table 3.26, and Table 3.39. 
The characteristics of the included studies were presented in the table at the beginning of each 
section to avoid data duplication. 
3.3.3 Chronic spinal pain and its comorbidities 
Nineteen studies provided data for chronic SP. One study only provided p value for the 
association without any OR or percentage data 240. This study was included but not described 
in the following comorbidity and accompanying symptom categories. The comorbidities and 
accompanying symptoms can be categorised into diseases/accompanying symptoms of  
- the mental and behavioural disorders, 
- nervous system,  
- musculoskeletal system and connective tissue,  
- digestive system,  
- circulatory system,  
- “endocrine, nutritional and metabolic diseases/symptoms”,  
- respiratory system,  
- other kinds of pain,  
- genitourinary system,  
- eye and adnexa system,  
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- ear and mastoid process system,  
- symptoms, signs and abnormal clinical and laboratory findings, not elsewhere 
classified, and  
- others.  
The majority of the included studies reported findings of comorbid mental and behavioural 
disorders (13 studies), whereas fewer studies reported findings in accompanying “Symptoms, 
signs and abnormal clinical and laboratory findings, not elsewhere classified” (three studies).  
The main comorbidities/accompanying symptoms for chronic SP included headache, arthritis, 
depression, GAD, panic disorder, mood disorder, alcohol use disorder, digestive ulcer, heart 
disease, hypertension, other lung disease (apart from tuberculosis, and asthma), migraine, and 
chronic pain. 
The characteristics of the included 20 chronic SP studies are presented in Table 3.14. Except 
for one study which included school children 229, and another survey which included the 
general public from 15 years old and over 229, all studies included adult participants. Eight 
studies recruited participants from the general public 167,177,186,187,190,192,206,232 and seven studies 
specially recruited chronic SP participants 175,178,188,193,208,209,233. Seven studies identified 
chronic SP by using patient completed surveys 167,177,186,187,192,206,232, five studies identified 
chronic SP by using a pre-defined criteria 175,178,188,193,208. Seven studies were carried out in 
USA 167,175,177,178,186,209,232, one was an international collaboration 206, whereas the rest were 
from 11 other countries. 
Table 3.14 Characteristics of included 20 chronic SP studies  
Study Sample size/types of 
participant 
Method of 
CMP 
identification
Country of 
study 
Age of participants 
Atkinson et al. 
175 
n=146, 97 chronic LBP 
from medical centre 
and 49 healthy controls 
recruited from Veteran 
Administration 
volunteers, 
advertisements and 
service organization in 
San Diego. 
Pre-defined 
criteria 
requiring the 
presence of 
chronic SP. 
USA. Patient: 46.7 years 
(range 23-64) 
 
Healthy control who 
did not have LBP for 
more than one week: 
45.5 years (range 
22-65) 
Braden et al. 186 n=5689, G (27.9% 
arthritis, 33.5% chronic 
Patient’s 
response to a 
USA With lifetime 
self-reported pain:  
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Study Sample size/types of 
participant 
Method of 
CMP 
identification
Country of 
study 
Age of participants 
back/neck problems) survey 
checklist of 
arthritis/ 
rheumatism, 
chronic back or 
neck problems 
18-44 years: 42.7% 
45-64 years: 36.1% 
65 years and older: 
21.2% 
 
Without lifetime 
self-reported pain: 
18-44 years: 63.3% 
45-64 years: 25.0% 
65 years and older: 
11.4% 
Buist-Bouwman 
et al. 
187 
n=7076, G (9% chronic 
back trouble, 8.3% 
rheumatism) 
Survey 
question 
asking 
presence of 
chronic back 
trouble or 
rheumatism 
Netherland Not described 
Cakit et al., 188 n=123, 93 cervical 
myofascial pain 
females, 30 female 
healthy cervical pain 
free control. 
Participants 
fulfilling 
myofascial 
pain syndrome 
criteria 
including 
cervical 
myofascial 
pain syndrome 
lasting for 
more than 3 
months and 
with active 
trigger point in 
neck and upper 
back regions. 
Turkey Cervical myofascial 
pain group: 33.69± 
6.25 years (range, 18–
53) 
 
Healthy control: 
31.44±8.24 years 
(range, 22-45) 
Dominick et al. 
231 
n=12488, G (24.2% 
neck and back disorder, 
14.4% arthritis, 2.9% 
osteoporosis) 
Survey 
question 
asking 
presence of 
chronic pain 
and site of pain
New Zealand 15 years and over. 
Mean and SD not 
stated. 
Fernandez-de-L
as-Penas et al. 
190 
n=29478, G (7616 
arthritis (25.8%), 6654 
cervical pain (22.6%), 
6793 LBP (23%), 1945 
osteoporosis (6.6%)) 
Uncertain, 
authors only 
mentioned 
analysing 
presence of 
chronic 
diseases/sympt
oms 
Spain 16-30 years: 4536 
31-50 years: 11170  
51-70 years: 8198  
>70 years: 5574 
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Study Sample size/types of 
participant 
Method of 
CMP 
identification
Country of 
study 
Age of participants 
Gureje et al. 192 n=6752, G (16.4% 
chronic SP) 
Survey 
question 
asking 
presence of 
chronic SP 
Nigeria 18-29 years: 904 
30-44 years: 676 
45-59 years: 356 
60+ years: 209 
Hägg et al. 193 n=572, chronic LBP 
referred to orthopaedic 
department 
Pre-defined 
criteria 
requiring the 
presence of 
chronic SP. 
Does not 
mention, but 
the project is 
titled 
Swedish 
Spine Study. 
Chronic LBP: 43±8.3 
years 
 
General population 
with back pain (as 
collected by Central 
Statistical Bureau of 
Sweden, of which 
55% is Chronic LBP: 
46±8.5 years 
 
General population 
free of back pain: 
44±9.5 years 
Ijzelenberg & 
Burdorf, 2004 
168 
n=505, L (36(7%) had 
chronic LBP 
Survey 
question 
asking 
presence of 
chronic LBP 
Netherlands 41.5± 9.8 
 
Lachlan A. 
McWilliams & 
Bailey et al. 232 
 
n=5645, G (27.1% 
arthritis, 29.2% chronic 
back/neck problem 
Survey 
question 
asking 
presence of 
chronic 
back/neck 
problems or 
and arthritis 
USA Not described 
McWilliam et 
al. 2004 177 
n=3032, G (19.4% 
arthritis, 20.3% back 
pain 
Survey 
question 
asking 
presence of 
back pain and 
arthritis 
USA Not stated 
Polatin et al. 178 n=200, chronic LBP 
patients entering a 
functional restoration 
programme 
Pre-defined 
criteria 
requiring the 
presence of 
chronic SP. 
USA Not stated 
Schofield et al. 
233 
n=8864, general public 
with chronic LBP 
Health records Australia 45-64 years old  
Siu et al. 229 n=1518, H (173 have 
chronic pain only, and 
290 have chronic pain 
Uncertain, 
method of 
CMP 
SAR, China 11-13 years: 34.7% 
14-16 years: 49.1% 
17-19 years: 16.2% 
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Study Sample size/types of 
participant 
Method of 
CMP 
identification
Country of 
study 
Age of participants 
comorbid with sleep 
disturbances. Of 
chronic pain only, 9.1% 
have chronic LBP, 
9.1% have chronic 
upper back pain. Of 
chronic pain comorbid 
with sleep disturbances, 
17.2% are chronic LBP, 
10.9% are chronic 
upper back pain. 
identification 
not described 
in the 
publication 
Tsang et al. 206 n=85052, G (20% 
chronic SP, 16.5% 
arthritis) 
Survey 
question 
asking 
presence of 
chronic 
back/neck 
problems, 
arthritis, and 
rheumatism 
IntS Overall: 42.9 years  
 
Developing countries: 
38.2 years  
 
Developed countries: 
45.5 years 
Verri et al. 208 n=35, chronic LBP, 
source not described as 
the chronic LBP group 
is a control group 
Pre-defined 
criteria 
requiring the 
presence of 
chronic SP. 
Italy Chronic LBP: 44 years 
(range 20-72) 
Von Korff et al. 
167 
n=5692, G (Chronic SP 
lifetime prevalence 
29.3%, 12 months 
prevalence 19.0%) 
Patient’s 
response to a 
checklist of 
chronic SP. 
USA 18-29 years: 24.1% 
30-44 years: 32.1% 
45-59 years: 26.7% 
60+ years: 17.1% 
Whitson et al. 209 n=211, vertebral 
fracture,  
Vertebral 
fractures 
according to 
radiograph 
USA. Vertebral fracture 
cohort: 80.8±5.5 years
Linder, Ekholm, 
Jansen, Lundh, 
& Ekholm, 2009 
197 
n=630 long term sick 
leavers (119 (19%) 
were SP) 
Diagnosed by 
psychiatry, 
orthopaedic 
surgery and 
rehabilitation 
medicine 
specialists 
Sweden 45.6 ±8.5 years 
Ligthart et al.240 n=11948, twins and 
relatives of twins. 
Participants must have 
participated in the 
previous survey in order 
to be in the current 
survey (9.1% had 
chronic back pain and 
Survey 
question 
asking the 
location and 
frequency of 
pain. 
Netherlands All participants: 
44.5±15.7 years  
No pain group: 
43.4±16.3 years 
Occasional pain 
group: 44.3±15.4 
years 
Frequent pain group: 
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Study Sample size/types of 
participant 
Method of 
CMP 
identification
Country of 
study 
Age of participants 
6.4% had chronic neck 
pain 
45.7±16.2 years 
SAR: Special administrative region 
LBP: Low back pain 
SP: Spinal pain 
G: General population 
H: High school student 
L: Labourer 
IntS: International study including Colombia, Mexico, USA, Belgium, France, Germany, Italy, 
Netherlands, Spain, Ukraine, Israel, Lebanon, Nigeria, South Africa, Japan, PRC (Beijing and 
Shanghai),and New Zealand. 
USA: United State of America 
Six studies also provided data for arthritis and were also included in the arthritis section 
186,187,190,206,229,231 
Two studies also provided data for fibromyalgia and were also included in the fibromyalgia 
section 188,197 
 
3.3.3.1 Mental and behavioural disorders as comorbidities or 
accompanying symptoms of chronic SP 
Thirteen studies provided findings on mental and behavioural disorders as comorbidity or 
accompanying symptom of chronic SP 167,175,177,178,186,187,192,193,197,206,208,209,233. Their findings 
are summarized in the following paragraphs and presented from Table 3.15 to Table 3.16. 
Percentage data of mental and behavioural disorders as comorbidity or accompanying 
symptoms of chronic SP 
The percentage data summary of comorbid mental and behavioural disorders is listed in Table 
3.15. The percentage data of all the comorbid mental and behavioural disorders among the 
sampled population ranged from 0% to 97%. 
Of all the comorbid mental conditions, any kind of anxiety affected most of the chronic SP 
(minimally 21.6%) and bipolar I or II was least likely to occur in chronic SP (maximally 4.4%) 
amongst all the reported comorbid mental conditions. Except for axis II personality disorders 
and non-specified mental conditions, all other reported specific mental conditions were 
reported by at least two studies. 
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Table 3.15 Summary of occurrence of mental and behavioural disorders as comorbidities or 
accompanying symptoms of chronic SP 
Mental conditions Study Range of percentage 
Somatoform disorder 178,208 1% and 97% 
At least one psychiatric 
disorder (other than tobacco 
use disorder) 175 
81.4% 
GAD 167,175,178,208 2% to 65.7% 
Alcohol related disorders 167,175 2.1% and 64.9% 
Major depression/depression 167,175,178,193,197,208,209,233 11.4% to 64% 
All/any kinds of anxiety 
disorder 
167,175,178,209 21.6% to 45.7% 
Recent episode of 
psychiatric disorder 
175 41.2% (reported by one study only) 
Abuse or dependence of 
substance 
167,175,178 4.1% to 36%. One study showed non 
association between chronic SP and 
drug abuse/dependence. 
Phobias (including simple 
phobia, social phobia, and 
Specific phobia) 167,178,208 
0% to 25.7% 
Dysthymia 167,175,178,208 2% to 23.7% 
Any mood disorder 167 17.5% (reported by one study only) 
Obsessive compulsive 
disorder 
175,178,208 0% to 13.4% 
Panic disorder 167,175,178,208 2.8% to 8.2% 
PTSD 167,178 1% and 7.3%  
Bipolar I or II 167,178 2% and 4.4% 
GAD: Generalized anxiety disorder 
PTSD: Post traumatic stress disorder 
 
Odds ratios of mental and behavioural disorders as comorbidity or accompanying 
symptoms of chronic SP 
The OR summary of mental and behavioural disorders as comorbidities or accompanying 
symptoms of chronic SP are summarised in Table 3.16. The OR ranged from 1.4 to 6.2. 
Comorbid suicide ideation occurred 1.4 times more and comorbid major depressive/depression 
occurred 6.2 times more amongst chronic SP than patients without chronic SP (the studies did 
not provide data for whether the control group had other kinds of pain. The control groups 
were general public without chronic SP). On the minimum scale, patients with chronic SP 
were 2.54 times more likely to have GAD than patients without chronic SP; and on the 
maximum scale, those with chronic SP were at least 1.6 times more likely to have had suicidal 
ideation, suicide plan, and suicide attempt. There were conflicting findings in “all anxiety 
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disorders”, “abuse or dependence on other substances”, and phobia as comorbidities of 
chronic SP amongst the reports.  
Dysthymic disorder, PTSD, bipolar, secure/avoidant/anxious attachments, suicide ideation, 
suicide plan, and suicide attempt were studied by only one study. 
Table 3.16 Summary of OR ranges of mental and behavioural disorders as comorbidity or 
accompanying symptoms of chronic SP 
Mental conditions Study Comparison 
group 
Odds ratio 
Major depression 167,177,193,206 General public 
without SP 
2.5 to 6.2 
Abuse or dependence 
on other substances 
167,187,192 General public 
without SP 
1.3 to 3.2. One study reported no 
association between CMP and drug 
abuse/dependence 
Dysthymic disorder 167 General public 
without SP 
3.2 (reported by one study only) 
GAD 167,177 General public 
without SP 
2.54 and 2.6 
Panic disorder 167,177 General public 
without SP 
2.0 and 2.69 
PTSD 167 General public 
without SP 
2.6 (reported by one study only) 
Mood disorder 167,187,192 General public 
without SP 
1.7 to 2.5 
All anxiety disorders 167,187,192,206 General public 
without SP 
1.5 to 2.3. There was one study 
reported no increased chance 
associated with CMP. 
Other – any mental 
disorder 
167 General public 
without SP 
2.3 (reported by one study only) 
Phobia 167 General public 
without SP 
1.7 to 2.1. One study reported no 
association between CMP and 
agoraphobia without panic. 
(Findings on phobia were reported 
by one study only) 
Alcohol use disorder 167 General public 
without SP 
1.6 to 2.0 (reported by one study 
only) 
Bipolar 167 General public 
without SP 
2.0 (reported by one study only) 
Suicidal ideation, 
suicide plan, and 
suicide attempt 
186 General public 
without SP 
1.4 to 1.6 (reported by one study 
only) 
GAD: Generalized anxiety disorder 
GP: General practitioner 
PTSD: Post traumatic stress disorder 
SP: Spinal pain 
 
 72 
 
3.3.3.2 Diseases/symptom of the nervous system as comorbidities or 
accompanying symptoms of chronic SP 
Six studies reported findings in neurological disorders 167,188,190,209,229,233 (Table 3.17). Different 
conditions were studied in the five studies. The most common comorbidity was migraine. The 
percentage of accompanying migraine ranged from 12.5% to 25.39%. The percentages of 
neurological disorders ranged from 1.4% to 54%. Sleeping problems (insomnia, narcolepsy, 
non-restorative sleep, and disturbed sleep) ranged from 12.8% to 76%. Having chronic SP 
increased the odds of having epilepsy by 1.7 times 167 and migraine by 1.33-5.2 times. 
Table 3.17 Neurological disorders comorbidities and accompanying symptom of chronic SP 
Studies Percentage of 
comorbidity/accompanying 
symptoms 
OR and 95% CI 
Whitson et al. 209 Memory loss: 54%  
Feeling tired much of the time: 49.8%
Balance problems: 49.8% 
Muscle weakness: 45.5% 
Difficulty sleeping at night: 38.4% 
Numbness or tingling anywhere: 
30.3% 
Confused thinking: 23.2% 
Shakiness or trembling: 17.5% 
Sleep problems (insomnia, 
narcolepsy): 12.8% 
Parkinson's disease: 1.4% 
No data 
Siu et al. 229 Percentage of sleep disturbance 
amongst teenagers with a particular 
type of chronic pain are listed below: 
 
Low back(n=66): 76.0% 
Upper back (n=47): 66.8% 
Neck (n=91): 71.0% 
Schofield et al. 233 Diseases of the nervous system: 8.7% 
Von Korff et al. 167 Epilepsy: 3.0% (SE:0.5) 
Migraine: 12.5% (SE: 0.9) 
Compared with general 
public without chronic 
SP: 
Epilepsy: 1.7 (1.1-2.7) 
Migraine: 5.2 (4.1-6.4) 
Fernandez-de-Las-Penas 
et al. 190 
Migraine within chronic cervical pain: 
25.39% 
 
Migraine within chronic LBP: 21.43%
Compared with general 
public without chronic 
SP: 
The adjusted ORs for 
diseases independently 
significantly associated 
with a higher likelihood 
of suffering  
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Studies Percentage of 
comorbidity/accompanying 
symptoms 
OR and 95% CI 
Migraine (within chronic 
neck pain): 2.31 (1.98–
2.68) 
Migraine (within chronic 
Low back pain): 1.33 
(1.14-1.55) 
Cakit et al., 188 Non-restorative sleep: 68.8% 
Fatigue: 36.6% 
Tension type headache: 43% 
No data 
CI: Confidence interval 
LBP: Low back pain 
OR: Odds ratio 
SE: Standard error 
SP: Spinal pain 
 
3.3.3.3 Diseases of the musculoskeletal system and connective tissue as 
comorbidities or accompanying symptoms of chronic SP 
Six studies provided findings on CMP as comorbidities or accompanying symptom of chronic 
SP 167,168,188,192,209,233 (Table 3.18). The percentage of arthritis ranged from 1.5% to 71%, 
whereas other types of musculoskeletal pain ranged from 5.9% to 64.9%. Having chronic SP 
increased the odds of having arthritis by 3.0 – 7.9 times and other types of musculoskeletal pain 
by 2.62 to 7.12 times. The publications did not make a clear differentiation between chronic SP 
and arthritis. The comorbid arthritis may well overlap with spinal joint regions. 
Table 3.18 Musculoskeletal pain as comorbidity of chronic SP 
Studies Percentage of 
comorbidity/accompanying symptoms 
OR and 95% CI 
Gureje et al. 192 No data Compared to general public 
without chronic SP: 
Arthritis: 7.9 (5.5-11.3) 
Ijzelenberg et al. 168 Compared to hard labour 
workers without LBP: 
Chronic neck pain: 4.81 
(1.48-15.57), 
Chronic shoulder pain: 2.62 
(0.89-7.73) 
Chronic complains of 
elbow-wrist-hand pain: 7.12 
(1.48-34.39) 
Chronic upper extremity 
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Studies Percentage of 
comorbidity/accompanying symptoms 
OR and 95% CI 
complaint: 3.59 (1.47-8.80)
Von Korff et al. 167 Arthritis: 51.0 (1.5%) Compared with general 
public without chronic SP: 
Arthritis: 3.0 (3.2-4.7) 
Whitson et al. 209 Symptoms in previous month:  
Pain (64.9%) 
Muscle cramps: 44.6% 
Arthritis: 71% 
Osteoporosis: 61% 
Broken bone(s): 61.1% 
Chronic pain syndrome: 6.6% 
No data 
Schofield et al. 233 Prevalence of comorbidity: 
Arthritis: 21.7% 
Other diseases of the musculoskeletal 
system: 5.9% 
Cakit et al. 188 Fibromyalgia: 23.6% 
Comorbidities/accompanying symptoms of no association were italicised 
CI: Confidence interval 
OR: Odds ratio 
 
3.3.3.4 Diseases/symptom of the digestive system as comorbidities or 
accompanying symptoms of chronic SP 
Five studies reported digestive disorders as chronic SP comorbidities 167,188,192,209,233. Their 
findings are listed in Table 3.19. Accompanying Irritable bowel syndrome percentage ranged 
from 1.9% to 30.1%. Apart from irritable bowel syndrome, the most common 
comorbidity/accompanying symptom was nausea (13.7%), and the comorbidity with the 
highest OR was ulcer in the digestive system (4.0). Except for irritable bowel syndrome, each 
accompanying symptom/comorbidity was only investigated by one study.  
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Table 3.19 Digestive comorbidity as accompanying symptom of chronic SP 
Studies Percentage of comorbidity accompanying 
symptoms 
OR and 95% CI 
Gureje et al. 192 No data Compared with 
general public 
without chronic SP: 
Peptic ulcer: 3.1 
(1.6-6.0) 
Von Korff et al. 167 Irritable bowel syndrome: 1.9% (SE:0.4) 
Ulcer: 6.6% (SE:0.8) 
Compared with 
general public 
without chronic SP: 
Irritable bowel 
syndrome: 2.4 
(1.1-5.3) 
Ulcer: 4.0 (2.6-5.9) 
Whitson et al. 209 Nausea: 13.7% No data 
Schofield et al. 233 Diseases of the digestive system: 3.4% 
Cakit et al. 188 Irritable bowel syndrome: 30.1% 
CI: Confidence interval 
OR: Odds ratio 
SE: Standard error 
 
3.3.3.5 Diseases/symptoms of the circulatory system as comorbidities or 
accompanying symptoms of chronic SP  
Four studies reported data on circulatory system related comorbidities/accompanying 
symptoms with their results listed in Table 3.20 167,192,209,233. Three studies provided percentage 
data and two provided OR for circulatory system related conditions. Stroke, heart diseases, and 
high blood pressure ranged from 4.3% - 26.6% respectively. Other 
comorbidities/accompanying symptoms were investigated by single studies and ranged from 
4.0% for heart attack to 53.6% for shortness of breath with exertion. Two studies found chronic 
SP was not associated with heart attack.  
Having chronic SP was associated with a 1.5-2.9 times greater likelihood of having high 
blood pressure. There was a conflict finding in the association between heart attack, stroke 
and chronic SP.  
 76 
 
Table 3.20 Circulatory system related comorbidities and accompanying symptoms of chronic 
SP 
Studies Percentage of comorbidity/accompanying 
symptoms 
OR and 95% CI 
Gureje et al. 192 No data Compared with general 
public without chronic SP: 
Heart disease: 11.4 
(2.2-58.7) 
High blood pressure: 2.9 
(1.5-5.8).  
Stroke: 1.7 (0.4–6.9) 
Heart attack: 2.7 (0.6–
12.0) 
Von Korff et al. 
167 
Stroke: 4.3% (SE:0.5),  
High blood pressure: 26.6% (SE:2.0) 
Heart disease: 6.9% (SE:0.8), 
Heart attack: 4.0% (SE:0.6), 
Compared with general 
public without chronic SP: 
Stroke: 1.5 (1.1-2.1) 
High blood pressure: 1.5 
(1.2-2.0) 
Heart disease: 1.3 (1.0-1.7)
Heart attack: 0.9 (0.6-1.4) 
Whitson et al. 
209 
Chest pain or pressure with exertion:10.9% 
Shortness of breath at rest:10.4% 
Shortness of breath with exertion 53.6% 
Angina pectoris:11.4% 
Congestive heart failure:4.7% 
Heart attack:5.7% 
Stroke:6.7% 
No data 
Schofield et al. 
233 
Heart disease: 3.6% 
Hypertension: 19.3%,  
Other diseases of the circulatory system (other 
than Heart disease and hypertension): 4.9% 
Comorbidities/accompanying symptoms of no association were italicised 
CI: Confidence interval 
OR: Odds ratio 
SE: Standard error 
 
3.3.3.6 Endocrine, nutritional and metabolic diseases/symptoms as 
comorbidities or accompanying symptoms of chronic SP 
Four studies reported findings on endocrine conditions 167,192,209,233, including diabetes, thyroid 
disease, and high cholesterol (Table 3.21). All four reported findings on diabetes with two 
finding no associations between chronic SP and diabetes 167,192 and three reporting that the 
percentages of diabetes ranged from 0.5% to 8.2% 167,209,233. Thyroid disease was reported by 
one study as not associated with chronic SP 192. High cholesterol was reported to occur in 
6.8% of chronic SP 233. 
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Table 3.21 Endocrine, nutritional and metabolic diseases/symptoms as comorbidity or 
accompanying symptoms of chronic SP 
Studies Percentage of 
comorbidity/accompanying 
symptoms 
OR and 95% CI 
Gureje et al. 192 No data Compared with general public 
without chronic SP: 
Diabetes: 0.8 (0.1-4.0) 
Thyroid disease: 0.4 (0.08–2.6)
Von Korff et al. 167 Diabetes: 8.2% (SE:1.0) Compared with general public 
without chronic SP: 
Diabetes: 1.2 (0.8-1.7) 
Whitson et al. 209 Diabetes mellitus: 0.5% 
No data 
Schofield et al. 233 Other endocrine/nutritional 
and metabolic disorders: 
3.0% 
Diabetes: 6.8% 
High cholesterol: 6.8% 
Comorbidities/accompanying symptoms of no association were italicised 
CI: Confidence interval 
OR: Odds ratio 
SE: Standard error 
 
3.3.3.7 Diseases/symptoms of the respiratory system as comorbidities or 
accompanying symptoms of chronic SP 
Four studies reported findings of respiratory conditions (Table 3.22) 167,192,209,233. The 
percentage of asthma ranged from 7.2% to 16.9%. And the OR for lung diseases, apart from 
asthma and tuberculosis, ranged from 1.7 to 2.9. There was a conflicting finding for asthma 
where one study 167 found an association but the other study 192 found chronic SP did not 
increase the chance of having asthma. The finding for tuberculosis was either no association or 
no data available. 
Table 3.22 Respiratory comorbidities and accompanying symptom of chronic SP 
Studies Percentage of 
comorbidity/accompanying 
symptoms 
OR and 95% CI 
Gureje et al. 
192 
No data Compared with general public without 
chronic SP: 
Other lung disease (lung diseases apart 
from asthma, and tuberculosis): 2.9 
(1.1-7.4) 
Asthma: 1.2 (0.2–6.9) 
Tuberculosis: 7.1 (0.6–82.2) 
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Studies Percentage of 
comorbidity/accompanying 
symptoms 
OR and 95% CI 
Von Korff et 
al. 167 
Asthma: 16.9% (SE:1.3) 
Tuberculosis: 0.1% (SE:0.1) 
Other lung disease: 4.1% (SE:0.8) 
Compared with general public without 
chronic SP: 
Asthma: 1.8 (1.4-2.1) 
Tuberculosis: no data, 
Other lung disease (lung diseases 
apart from asthma, and tuberculosis): 
1.7 (1.0-2.7) 
Whitson et 
al. 209 
Symptoms in previous month: lung 
disease: 15.2% 
No data 
Schofield et 
al. 233 
Asthma: 7.2% 
Diseases of the respiratory system: 
3.3% 
Comorbidities/accompanying symptoms of no association were italicised 
CI: Confidence interval 
OR: Odds ratio 
SE: Standard error 
 
3.3.3.8 Other kinds of pain 
Four studies reported findings on other kinds of pain 167,186,192,231 (Table 3.23). Percentage of 
chronic pain ranged from 18.9% to 68.6% within chronic SP 167,231. Chronic SP was 3.4 to 4.8 
times more likely to have one other chronic pain and up to 9.1 times more likely to have any 
other pain. 
Table 3.23 Other kinds of pain conditions as comorbidities and accompanying symptom of 
chronic SP 
Studies Percentage of comorbidity/accompanying 
symptoms 
OR and 95% CI 
Braden et al. 
186 More than one lifetime pain condition: 39.1% No data 
Gureje et al. 
192 
The prevalence of chronic SP amongst 
respondents with at least one other chronic 
pain condition (54.2% SE:2.6) is 
approximately three times higher than among 
those with no other chronic pain (14.8% 
SE:1.0). 
Compared with general 
public without chronic SP: 
Other pain (chest pains, joint 
pains, frequent headaches): 
4.5 (2.6-7.5) 
Any pain (persistent pain in 
any other body parts): 9.1 
(6.3-13.1) 
Von Korff et 
al. 167 
Other chronic pain: 18.9% (SE:1.4) 
Any chronic pain: 68.6% (SE:1.5) 
Compared with general 
public without chronic SP: 
Other chronic pain (other 
than chronic SP, arthritis, or 
headache): 3.7 (2.9-4.7) 
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Studies Percentage of comorbidity/accompanying 
symptoms 
OR and 95% CI 
Any chronic pain: 4.8 
(3.9-5.8) 
Dominick et 
al. 231 
Percentage of chronic pain within CMP: 
Chronic neck/back disorder: 36.8% 
Compared with general 
public without chronic SP: 
The OR for chronic pain 
after adjusted for 
sociodemographic variables 
and the physical and mental 
conditions: 
Chronic neck/back disorder: 
3.4 (95% CI 2.9-3.9) 
 
Chronic pain is defined as 
pain lasted more than six 
months and may be in any 
parts of the body ranging 
from head to toes and 
including chest, stomach, 
and pelvic pain. 
CI: Confidence interval 
CMP: Chronic musculoskeletal pain 
OR: Odds ratio 
SE: Standard error 
 
3.3.3.9 Diseases/symptoms of the eye and adnexa and disease/symptoms of 
the ear and mastoid process as comorbidities or accompanying 
symptoms of CMP 
Three studies reported findings for eye and adnexa diseases/symptoms 167,209,233 and two 
studies reported findings for ear and mastoid process conditions (Table 3.24) 167,209. Percentage 
of comorbidities/accompanying symptoms in the eye diseases category ranged from 1.7% to 
74.9%. All of the specific eye diseases were reported by a single study. The comorbidity with 
the highest percentage was cataract. Vision impairment was 2.6 times more likely to occur in 
chronic SP.  
The percentage of ear and mastoid process diseases/symptoms amongst chronic SP was 
between 6%-8.3%. Hearing impairment was consistently reported at approximately 6% by 
both studies 167,209. Hearing impairment was not significantly associated with chronic SP 
(OR:1.5, 95% CI 1.0-2.2) 167. 
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Table 3.24 “Eye and adnexa” and “ear and mastoid process” conditions as comorbidities and 
accompanying symptom of chronic SP 
Studies Percentage of comorbidity/accompanying 
symptoms 
OR and 95% CI 
Eye and adnexa diseases/symptoms 
Von Korff 
et al. 167 
Vision impairment: 7.1% (SE:0.8)  
Compared with general public 
without chronic SP: 
Vision impairment: 2.6 (1.8-3.9)
Whitson et 
al. 209 
Symptoms in previous month:  
problems with eyesight: 43.1% 
glaucoma: 15.2% 
cataract: 74.9% 
No data 
Schofield et 
al. 233 Diseases of the eye and adnexa: 1.7% 
Ear and mastoid process diseases/symptoms 
Von Korff 
et al. 167 
Hearing impaired: 6.0% (SE:0.7) 
Compared with general public 
without chronic SP: 
Hearing impaired: 1.5 (1.0-2.2) 
Schofield et 
al. 233 
Deafness/hearing loss: 6.6% 
Diseases of the ear and mastoid process: 8.3% No data 
Comorbidities/accompanying symptoms of no association were italicised 
CI: Confidence interval 
OR: Odds ratio 
SE: Standard error 
3.3.3.10 Symptoms, signs and abnormal clinical and laboratory findings, 
not elsewhere classified as accompanying symptoms of chronic SP 
Two studies reported findings on headache as an accompanying symptom of chronic SP 167,192. 
The prevalence within the sample ranged from 14.6-31.9% (Table 3.25). Having chronic SP 
increased the odds of having headache by 4-7 times.  
Table 3.25 Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere 
classified as accompanying symptoms of chronic SP 
Studies Percentage of 
comorbidity/accompanying 
symptoms 
OR and 95% CI 
Von Korff 
et al. 167 
Other headache: 14.6% (SE: 1.4) Compared with general public without 
chronic SP: 
Other headache: 4.0 (2.9-5.3) 
Gureje et 
al. 192 
Headache: 31.9% (SE:2.2) Compared with general public without 
chronic SP: 
Headache: 7.0 (4.9-10.1) 
CI: Confidence interval 
OR: Odds ratio 
SE: Standard error 
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3.3.3.11 Diseases/symptoms of the remaining disease systems as 
comorbidities or accompanying symptoms or other findings of 
chronic SP 
Three studies reported findings for the genitourinary system category (Appendix 10) 193,209,233. 
One reported 35.6% of chronic SP had incontinence 209 whereas the other study found the 
percentage for diseases of genitourinary system was 2% 233. Another study (n=572) included 
294 chronic LBP participants and 278 age and gender matched general population 193. The 
study found the chronic LBP population more likely to report back pain during pregnancy 
(OR=2.3, 95% CI 1.1-4.5), back pain during menstruation (OR=2.7, 95% CI 1.5-5.1), and an 
increased number of deliveries (OR=1.6, 95% CI 1.1-2.1) in comparison with general 
population without back pain. 
Four studies reported individual data for other comorbidities/accompanying symptoms 
167,193,209,233 (Appendix 11). The percentage of other comorbidity/accompanying symptoms 
ranged from 0.3% to 87.1%. HIV and neoplasms were both 0.3% with chronic SP and “all 
mental, pain or physical disorder” was 87.1% within chronic SP. Von Korff et al. reported 
cancer was not associated with chronic SP. Chronic SP was five times more likely to be 
accompanied with HIV and 2.3 times more likely to be associated with smoking comparaed to 
those without chronic SP. 
3.3.4 Arthritis and its comorbidities 
Thirty-seven studies provided comorbidity and accompanying symptoms data for arthritic pain 
166,176,177,179-181,185-187,190,194,200,202,206,207,210,212,213,217,219,220,222-224,227-232,234-240. One study provided 
p value for the association with OR or percentage data 240. This study was included but not 
described in the following comorbidity and accompanying symptom categories. Lee et al. 
reported separate comorbidity data for Beijing and Shanghai 166. These two data were 
considered as two data, although they came from the same article. Arthritis was defined as 
having pain in the joints and included both OA and RA. The majority of the included studies 
reported findings for comorbid mental and behavioural disorders (21 studies), whereas one 
study reported findings for “blood and blood-forming organs and certain disorders involving 
the immune mechanism”. 
The main comorbidities/accompanying symptoms for arthritic pain included frequent or 
 82 
 
severe headache, chronic back/neck problems, depression, panic attacks, PTSD, heart attack, 
heart disease, hypertension, asthma, any chronic pain, any physical diseases, and “any mental 
or physical disorders or pain”. 
The characteristics of the 37 included arthritic pain studies are presented in Table 3.26. Of the 
included studies, two recruited participants under 18 years 217,234, five did not describe the age 
of participants 177,187,231,232,234, and the remainder recruited adults. Eighteen studies recruited 
from the general public 166,176,177,185-187,190,202,206,217,222,224,229,231,232,234,238,240, 18 studies recruited 
arthritic patients 179-181,194,200,207,210,212,219,220,223,227,228,230,235-237,239. Nineteen studies recruited 
participants from USA 176,177,181,185,186,200,202,210,212,217,219,223,224,227,228,232,234,237,239, four recruited 
from the Netherlands 187,220,230,240, two recruited from China 166,229, one study was a 
collaborative work of several countries 206, and the remaining studies recruited participants 
from other countries. 
Table 3.26 Characteristics of included arthritic pain studies 
Study Sample size/types 
of participant 
Method of CMP 
identification 
Country of 
study 
Age of participants 
Ayers et al. 
237 
n=180, arthritis, 
from a university 
medical centre 
Patients were 
scheduled for total 
knee replacement 
USA 65.1 years 
Ayoubi et 
al.238 
 
n=177, G (33% 
arthritis and 67% 
controls who has 
never had 
musculoskeletal 
problems) 
Patient’s response to 
survey question of 
joints or 
musculoskeletal soft 
tissue problems 
Lebanon For the OA group: 
< 44 years: 15 (25.4%) 
45-64 years: 34 (57.6%)
≥65 years: 10 (16.9%) 
 
For the control group: 
< 44 years: 30 (25.4%) 
45-64 years: 68 (57.6%)
≥65 years: 20 (16.9%) 
Baruth et al. 
239 
n=152, arthritis, 
from a clinical trial
Patient’s self report to 
survey questions 
which were 
comprehensive and 
may include lupus, 
infectious arthritis, 
and carpal tunnel 
syndrome 
USA 57.0 ± 9.9 years 
Bischoff-Fe
rrari et al. 
181 
n=922, medicare 
beneficiaries 
 
Patient’s medicare 
claim of total hip 
replacement. 
USA 73.1 ± 5.6 years 
Black et al. 
185 
n=3050, G (40.8% 
arthritis) 
Patient’s response to a 
checklist of chronic 
physical conditions 
USA Depressed group: 
57.2±13.0 years. 
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Study Sample size/types 
of participant 
Method of CMP 
identification 
Country of 
study 
Age of participants 
including arthritis Not depressed group: 
61.6±13.5 years. 
Blackman et 
al. 2011 217 
n=40465, G, 
children with 
chronic health 
conditions 
Survey question 
asking presence of 
arthritis 
USA Age for the total 
population was not 
provided. The total 
population age provided 
was for a previous 
survey as an estimate of 
prevalence. For the 
Arthritis/other joint 
problems, the age 
category break down 
was as follows: 
0-5 years old: 12.9±2.4 
6-11 years old: 23.9±3.5
12-17 years old: 
63.1±3.9 
Blackman et 
al. 2013 234 
n=91642, G with 
1824 having 
arthritis.  
Based on parental 
report of bone, joint, or 
muscle problems  
USA Did not describe 
Braden et al. 
186 
n=5689, G (27.9% 
arthritis, 33.5% 
chronic back/neck 
problems) 
Patient’s response to a 
checklist of arthritis/ 
rheumatism, chronic 
back or neck problems
USA With lifetime 
self-reported pain:  
18-44 years: 42.7% 
45-64 years: 36.1% 
65 years and older: 
21.2% 
 
Without lifetime 
self-reported pain: 
18-44 years: 63.3% 
45-64 years: 25.0% 
65 years and older: 
11.4% 
Buist-Bouw
man et al. 
187 
n=7076, G (9% 
chronic back 
trouble, 8.3% 
rheumatism) 
Survey question 
asking presence of 
chronic back trouble 
or rheumatism 
Netherland Not described 
Dominick et 
al. 231 
n=12488, G (24.2% 
neck/back disorder, 
14.7% arthritis, 
2.9% osteoporosis)
Patient’s response to a 
checklist of CMP sites 
(via a list of pain 
regions) 
New 
Zealand 
Not described 
Fernandez-d
e-Las-Penas 
et al. 190 
n=29478, G (7616 
arthritis (25.8%), 
6654 cervical pain 
(22.6%), 6793 LBP 
(23%), 1945 
osteoporosis 
(6.6%)) 
Uncertain, authors 
only mention 
analysing presence of 
chronic 
diseases/symptoms 
Spain 16-30 years: 4536 
31-50 years: 11170  
51-70 years: 8198  
>70 years: 5574 
Fitzgerald et n=183, arthritis, Based on 1986 USA For the standard 
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Study Sample size/types 
of participant 
Method of CMP 
identification 
Country of 
study 
Age of participants 
al. 219 from a university 
medical centre 
American College of 
Rheumatology clinical 
criteria for knee OA 
and grade II Kellgren 
and Lawrence 
radiograph changes 
exercise group (n=92): 
64.6±8.4 years 
For agility and 
perturbation group 
(n=91): 63.3±8.9 years 
Hoogeboom 
et al. 220 
n=401, arthritis, 
from a specialized 
hospital for 
orthopedics, 
rheumatology and 
rehabilitation 
Inclusion criteria is not 
described, radiographs 
are taken for index 
joint of complaint and 
number of painful 
joint sites are recorded
Netherland For OA without joint 
pain comorbidity 
(n=170): 57.7±13.7 
years 
For OA with joint pain 
comorbidity (n=231): 
58.4±12.2 years 
Kauppila et 
al. 194 
n=88, arthritis, 
from surgical 
waiting list 
Pre-defined criteria 
requiring the presence 
of OA 
Finland. 70.7 (5.5) years 
Klemenc-K
etiš et al. 222 
n=712, G who 
visits GP (15.7% 
osteoarthritis/ 
rheumatic diseases)
Questionnaire 
containing question 
asking presence of OA 
and rheumatic diseases
Slovenia 51.8 ±15.9 years 
Lee et al. 166 n=5201, G (8.6% 
arthritis from 
Beijing area, 15.3% 
arthritis from 
Shanghai area. 
Sample size not 
divided into 
Beijing/Shanghai 
areas) 
Patient’s response to a 
question on arthritis 
China Beijing: 
18-29 years: 12.6% 
30-44 years: 39.8% 
45-59 years: 29.5% 
60+ years: 18.1% 
 
Shanghai: 
18-29 years: 19.3% 
30-44 years: 33.9% 
45-59 years: 32.4% 60+ 
years: 14.4% 
Lee et al. 
2012 223 
n=176, arthritis, 
source of 
participants unclear
Inclusion criteria 
includes satisfying 
American College of 
Rheumatology criteria 
for RA 
USA 21<45 years: 21.0% 
45<65 years: 55.1% 
≥65 years: 23.3% 
Mean age: 55 years 
Ligthart et 
al. 240 
n=11948, twins and 
relatives of twins. 
Participants must 
have participated in 
the previous survey 
in order to be in the 
current survey 
(9.6% had chronic 
joints pain) 
Survey question 
asking the location and 
frequency of pain. 
Netherland All participants: 
44.5±15.7 years  
No pain: 43.4±16.3 
years 
Occasional pain: 
44.3±15.4 years 
Frequent pain: 
45.7±16.2 years 
Mangani et 
al. 200 
n=435, arthritis, 
within community 
dwelling persons 
Knee pain and 
radiograph evidence of 
knee OA 
USA 68.7±5.6 years 
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Study Sample size/types 
of participant 
Method of CMP 
identification 
Country of 
study 
Age of participants 
L. A. 
McWilliams 
& Higgins 
et al. 224 
n=5692, G (27.3% 
arthritis, 29.3% 
chronic SP) 
Questionnaire 
containing question 
asking presence of 
arthritis, chronic 
neck/back problems 
USA 52.1±11.2 years 
Lachlan A. 
McWilliams 
& Bailey et 
al. 232 
n=5645, G (27.1% 
arthritis, 29.2% 
chronic back/neck 
problem) 
Survey question 
asking presence of 
chronic back/neck 
problems or and 
arthritis 
USA Not described 
McWilliams 
et al. 2003 
176 
n=5877, G (6.5% 
arthritis) 
Survey question 
asking presence of 
“severe arthritis, 
rheumatism, or 
another bone or joint 
disease” 
USA Chronic pain group: 
mean 40.44±10.08 years
 
General population 
group: mean 
32.66±10.58 years 
McWilliams 
et al. 2004 
177  
n=3032, G (19.4% 
arthritis, 20.3% 
back pain) 
Survey question 
asking presence of 
chronic back pain and 
arthritis 
USA Not stated 
Nilsdotter et 
al. 180 
n=281, arthritis 
(70%), and control 
group (30%) 
without hip 
complaints. 
Patients had primary 
unilateral total hip 
replacement due to 
primary OA. 
Sweden OA group: 71 (50-92) 
years 
 
Reference group: 72 
(50-90) years 
Raab et al. 
235 
n=344, arthritis, 
from an 
observational 
cohort study – adult 
juvenile idiopathic 
arthritis JuMBO 
Patients were recruited 
if they fulfill 
International League 
of Associations for 
Rheumatology criteria 
for juvenile idiopathic 
arthritis 
Germany 19.7±2.8 years 
Rat et al. 236 n=284, arthritis, 
from two 
multicentre cohorts 
of total hip/knee 
arthroplasty 
patients 
OA according to 
American College of 
Rheumatology criteria 
and patients were 
scheduled for hip/knee 
arthroplasty. 
France For the 3 year follow up 
cohort (n=195): 72.4 ± 
8.3 years 
 
For the 10 year follow 
up cohort (n=89): 73.3 ± 
11.9 years  
 
Sareen et al. 
202 
n=5877, G (6.5% 
arthritis, 
rheumatism, or 
other bone/joint 
disease) 
Patient’s response to a 
checklist of question 
including arthritis 
USA Ranged from 15 - 54 
years 
Singh et al. 
(hip OA) 227 
n=13310, arthritis, 
from Mayo clinic, 
Rochester 
Patients who have 
undergone total hip 
arthroplasty 
USA Mean age was 65 years.
 
For the four groups, 
their mean age were as 
 86 
 
Study Sample size/types 
of participant 
Method of CMP 
identification 
Country of 
study 
Age of participants 
following: 
 
Primary total hip 
arthroplasty: 
Two year follow up: 
65.0±13.3 years 
Five year follow up: 
64.7±12.9 years 
 
Revision total hip 
arthroplasty: 
Two year follow up: 
65.7±13.1 years 
Five year follow up: 
64.6±13 years 
Singh et al. 
(knee OA) 
228 
n=13787, arthritis, 
from Mayo clinic 
total joint registry 
Patients who had 
undergone total knee 
arthroplasty 
USA Mean age was 68 years.
 
For the four groups, 
their mean age were as 
following: 
 
Primary total knee 
arthroplasty: 
Two year follow up: 
68.0±10 years 
Five year follow up: 
68.0±10 years 
 
Revision total knee 
arthroplasty: 
Two year follow up: 
69.0±10 years 
Five year follow up: 
69.0±10 years 
Siu et al. 229 n=1518, H Uncertain, method of 
CMP identification not 
described in the 
publication 
SAR, China 11-13 years: 34.7% 
14-16 years: 49.1% 
17-19 years: 16.2% 
Stupar et al. 
179 
n=1692, arthritis, 
from a population 
based cohort study 
in Southern 
Ontario, Canada 
Pre-defined criteria 
requiring the patients 
to have significant 
pain and functional 
disabilities related to 
hip/knee joints. 
Canada 71.7 years 
Tamber et 
al. 213 
n=17,638, G born 
in 1970, 1960, 
1955, 1940/41 and 
1924/25 (3.9% 
have osteoporosis) 
Survey question 
asking presence of 
osteoporosis 
Norway 30 years: 34.5% 
40 and 45 years:42.6% 
59/60 years:50.9% 
75/76 years:49.8% 
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Study Sample size/types 
of participant 
Method of CMP 
identification 
Country of 
study 
Age of participants 
Tsang et al. 
206 
n=85,052, G (20% 
chronic SP, 16.5% 
arthritis) 
Survey question 
asking presence of 
chronic back/neck 
problems, arthritis, 
and rheumatism 
IntS Mean age (overall): 
42.9 years  
 
Mean age (developing 
countries): 38.2 years  
 
Mean age (developed 
countries): 45.5 years 
Van Dijk et 
al. 207 
 
n=288, arthritis, 
from 3 
rehabilitation 
centres and 2 
hospitals 
Diagnosis of hip or 
knee OA by MD based 
on radiograph findings 
or America College of 
Rheumatology clinical 
criteria 
Did not 
specify. But 
authors 
were from 
Netherland. 
66±8.7 years 
Wesseling 
et al. 230 
n=979, arthritis, 
from a multicentre 
trial (Cohort Hip 
and Cohort Knee). 
Participants 
referred by GP and 
advertisement 
Having pain or 
stiffness of the knee or 
hip 
Netherland 56±5 years 
Williams 
Russo et al. 
212 
 
n=51, arthritis, 
undergoing total 
knee replacement 
from hospital 
Participants have to be 
scheduled for knee 
replacement 
USA 68±7.3 years (range: 48 
- 84 years with 75% 
above 65 years) 
Wolfe et al. 
210 
n=22131, from 
national databank 
for rheumatic 
diseases, 
participants are 
recruited from 
rheumatologists, 
7597 had RA. 
Participants are 
diagnosed by US 
rheumatologists 
USA For RA, the 
participants’ age are as 
following: 
Depressed: 57.2±13.0 
years. 
Not depressed: 
61.6±13.5 years. 
IntS: International study including Colombia, Mexico, USA, Belgium, France, Germany, Italy, 
Netherlands, Spain, Ukraine, Israel, Lebanon, Nigeria, South Africa, Japan, PRC (Beijing and 
Shanghai),and New Zealand. 
Six studies also provided data for chronic SP and had been included in the chronic SP section 
186,187,190,206,229,231 
G: General population 
GP: General practitioner 
H: High school student 
LBP: Low back pain 
MD: Medical doctor 
OA: Osteoarthritis 
RA: Rheumatoid arthritis 
SD: Standard deviation 
USA: United state of America 
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3.3.4.1 Mental and behavioural disorders/symptoms as 
comorbidity/accompanying symptoms of arthritis 
Twenty-one studies reported findings in this category 
166,176,177,180,185-187,202,206,207,210,212,217,219,220,222,224,228,232,234,235 (Appendix 9). Of the 21 studies, 
two of them recruited children as participants 217,234 and one of them recruited teenager as 
participant 235. The range of reported mental and behavioural disorder percentage was between 
0% to 28.1% amongst adult participants (Table 3.28). One study reported the “incidence rate” 
and “cumulative risk” in nine years for depression to be 5.5 (95% CI 5.3-5.7) per 100 patient 
years, and 38.3% (95% CI 36.6-40.1%) respectively 210.  
Amongst the children with arthritis, the percentage of comorbid mental and behavioural 
disorders/accompanying symptoms ranged from 10.8% to 38% (Table 3.27). Association wise, 
the overall results were conflicting among studies. For mental disorders, there were conflicting 
findings for dysthymia, major depressive disorder, GAD, any anxiety, panic disorder, simple 
phobia, social phobia, specific phobia, agoraphobia without panic, any mood disorders, and 
substance use (Table 3.28). The only certain findings were depression (OR ranged from 
1.48-2.82), panic attacks (OR ranged from 2.00-2.09), and PTSD (OR ranged from 2.52-3.69) 
(Table 3.28). One study reported separate data for two surveyed sites and indicated no 
significant association between arthritis and alcohol dependence/abuse, and any substance use 
disorder 166 (Table 3.28). One study reported no association between arthritis and all mental 
disorders 166, drug abuse or dependence 166 (Table 3.28). Another study reported OR for 
depression-anxiety disorder was 1.6 206, and a third study 186 reported the ORs for arthritis and 
suicidal ideation, plan, and attempt were between 1.4-2.0 (Table 3.28). 
For children with arthritis, only one study reported the association with comorbid mental and 
behavioural disorders/accompanying symptoms 234. Children with arthritis were at least three 
times more likely to have ADHD and at maximum of 5.1 times more likely to have depression. 
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Table 3.27 Summary of percentage data of comorbid mental and behavioural conditions or 
accompanying symptoms of children with arthritis 
Mental and behavioural disorders/symptoms of children Percentage 
among arthritis
Learning disability 38% 
Difficulty with feeling anxious or depressed 33.4% 
ADD/ADHD 22.1% and 29% 
Behaviour problem at least 12 months 27.1% 
Difficulty with behaviour problems, such as acting out, fighting, bullying or 
arguing 
27.1% 
Difficulties in learning, understanding or paying attention 26.0% 
Long-term emotional, developmental or behavioural problem 25.9% 
Depression 20.9% 
Anxiety 20.3% 
Difficulties in speaking, communicating or being understood 12.5% 
Feels worthless or inferior: 10.8% 
Unhappy, sad, or depressed 10.8% 
Information extracted from 217,234 
ADD: Attention deficit disorder 
ADHD: Attention deficit hyperactive disorder
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Table 3.28 Summary of ORs range and percentage data of mental and behavioural disorders as comorbidities or accompanying symptoms of 
arthritis 
Mental and behavioural 
disorders/symptoms of 
children 
Study 
provided 
OR 
ORs Comparison group Study provided 
percentage data 
Percentage 
Significant association 
PTSD 176,202 2.52 and 3.69 General public without arthritis 166 0% and 0.8% 
Panic attacks 177,202 2.00 and 2.09 General public without arthritis ND 
Depression  176,177 1.48 and 2.82 General public without arthritis 210,219,220,222,228,235 4.9-24% 
Agoraphobia with or without 
panic  
176 3.19 General public without arthritis 
ND 
Anxiety based on Zung anxiety 
score ≥50 
222 2.59 
Compared to GP-visiting general 
public without osteoarthritis and 
rheumatic diseases 
Suicidal plan 186 2 General public without arthritis 
Depressive symptoms 185 1.87 General public without arthritis 
Substance use 187 1.8 Compared with general public without rheumatism 
Suicidal ideation  186 1.7 Compared with general public without arthritis 
Depression-anxiety disorder 202 1.6 General public without arthritis 
Suicide attempt  186 1.4 General public without arthritis 
No association 
Agoraphobia without panic 2.23 (0.97–5.11) 
(Sareen et al.) 202 
General public without arthritis 166 0% 
Depression based on Zung depression score 
≥50 
1.23 (0.62-2.41) 
(Klemenc-Ketiš et al.) 
222 
Compared to GP-visiting general 
public without osteoarthritis and 
rheumatic diseases 
ND 
Alcohol abuse or dependence No association  
1.9 (0.9-4.1) (Beijing) 
166 
General public without arthritis 166 0.5% and 
4.3% 
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Mental and behavioural 
disorders/symptoms of 
children 
Study 
provided 
OR 
ORs Comparison group Study provided 
percentage data 
Percentage 
1.0 (0.2-5.6) 
(Shanghai) 166 
Alcohol dependence No association  
2.4 (0.4-15.9) (Beijing) 
166 
1.9 (0.3-13.2) 
(Shanghai) 166 
General public without arthritis 166 0.5% and 
1.7% 
Drug abuse or dependence No association  
2.6 (0.2-42.7) (Beijing) 
166 
General public without arthritis 166 0% and 
0.2% 
Any substance use disorder No association  
1.9 (0.9-4.0) (Beijing) 
166 
1.0 (0.2-5.4) 
(Shanghai) 166 
General public without arthritis  166 0.5% and 
4.5% 
Conflict results 
Any mood disorder Conflicting result  
1.7 (0.5-6.2) (Beijing) 
166 
5.7 (1.3-26.1) 
(Shanghai) 166 
2.78 (2.06-3.75) 176 
1.5 (1.1-2.0) 187 
General public without 
arthritis/rheumatism  
166 3.9% and 
5.7% 
All mental disorders Conflicting result  
1.6 (0.8-3.1) (Beijing) 
166 
3.7 (1.2-11.4) 
(Shanghai) 166 
General public without arthritis  166,187 10% to 
28.1% 
Social phobia Conflicting result  
0.96 (0.66–1.39) 
General public without arthritis  166 0% 
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Mental and behavioural 
disorders/symptoms of 
children 
Study 
provided 
OR 
ORs Comparison group Study provided 
percentage data 
Percentage 
(Sareen et al.) 202 
1.92 (1.31-2.82) 176 
Simple phobia Conflicting result  
1.22 (0.78–1.93 ) 
(Sareen et al.) 202 
2.20 (1.43-3.38) 176 
General public without arthritis ND 
Specific phobia Conflicting result  
2.3 (0.5-10.5) (Beijing) 
166 
6.9 (1.3-37.0) 
(Shanghai) 166 
General public without arthritis  166 3.5% and 
7.5% 
Major depression disorder alone or with 
hierarchy 
Conflicting result  
1.8 (0.5-6.6) (Beijng) 
166 
8.0 (1.7-38.4) 
(Shanghai) 166 
General public without arthritis  166 3.9% and 
5.7% 
Dysthymia:  Conflicting result  
4.0 (1.1-14.4) (Beijing) 
166 
0.8 (0.1-8.0) 
(Shanghai) 166 
2.07 (1.26-3.42) 176 
General public without arthritis  166 0.3% and 
1.1% 
GAD:  Conflicting result  
2.4 (1.3-4.5) (Beijing) 
166 
15.4 (2.9-83.3) 
(Shanghai) 166 
1.13 (0.60–2.13) 
(Sareen et al.) 202 
2.17 (1.42-3.33) 177 
General public without arthritis 166 2.3% and 
3.6% 
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Mental and behavioural 
disorders/symptoms of 
children 
Study 
provided 
OR 
ORs Comparison group Study provided 
percentage data 
Percentage 
2.30 (1.45-3.67) 176 
Any anxiety Conflicting result  
1.8 (0.7-4.5) (Beijing) 
166 
5.9 (1.3-25.9) 
(Shanghai) 166 
2.86 (2.06-3.97) 176 
1.4 (1.1-1.8) 187 
2.28 (1.58-3.29) 202 
General public without 
arthritis/rheumatism 
166,222,228,235 2% to 
22.3% 
Panic disorder with or without agoraphobia Conflicting result  
4.27 (2.39-7.61) 176 
1.0 (0.1-10.1) (Beijing) 
166 
General public without arthritis  166 0% and 
0.4% 
Borderline personality disorder ND ND 224 27.3% 
Psychiatric diseases/disorder 180,207,212,235 2.6% to 
26.3% 
Memory problems 219 8.2% 
GAD: Generalized anxiety disorder 
GP: General practitioner 
ND: No data 
PTSD: Post traumatic stress disorder 
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3.3.4.2 Diseases/symptoms of the circulatory system as 
comorbidities/accompanying symptoms of arthritis 
Cardiovascular comorbidities 
Sixteen studies reported findings for cardiovascular comorbidities/accompanying symptoms 
166,176,180,194,200,207,212,219,220,227,228,230,235-237,239 (Table 3.29). The prevalence of cardiovascular 
diseases ranged from 0.3% to 79.5%. More specifically, the prevalence of cardiac insufficiency, 
hypertension, stroke, heart attack, and heart disease (not specified) ranged from 0.3% to 
29.6%, 7.3% to 50.7%, 0.7% to 4.2%, 11.8% to 17.1%, and 4% to 54% respectively. One 
study reported the ORs for heart attack, heart disease, and high blood pressure ranged from 
5.8-8.7, 3.1-4.0, and 2.0-2.7 respectively 166. This study did not specify what heart disease 
referred to. 
Table 3.29 Cardiovascular disorders comorbidity of arthritis 
Studies Percentage of 
comorbidity/accompanying 
symptoms 
OR and 95% CI 
Kauppila et al. 194 Cardiovascular disease: 70 (79.5%) No data 
Lee et al. 166 Beijing participants: 
 Stroke: 4.2% (SE: 2.1) 
 Heart attack: 11.8% (SE: 2.4) 
 Heart disease: 25.2% (SE: 6.0) 
 High blood pressure: 25.5% (SE: 3.4)
 
Shanghai participants: 
 Stroke: 2.3% (SE: 1.9) 
 Heart attack: 17.1% (SE: 5.1) 
 Heart disease: 22.5% (SE: 4.8) 
 High blood pressure: 24.6% (SE: 4.2)
Compared with general 
public without arthritis: 
 
Beijing: 
Stroke: 11.5 (2.9-45.5) 
Heart attack: 5.8 
(3.5-9.7) 
Heart disease: 4.0 
(2.1-7.6) 
High blood pressure: 2.7 
(1.6-4.8) 
 
Shanghai: 
Heart attack: 8.7 
(2.9-25.7) 
Heart disease: 3.1 
(1.7-5.7) 
High blood pressure: 2.0 
(1.3-3.0) 
Van Dijk et al. 207 Cardiac diseases: 54% 
No data 
Mangani et al. 200 Hypertension: 44.1% 
Angina: 5.7% 
Myocardial infarction: 1.8% 
Other heart disease:13.8% 
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Studies Percentage of 
comorbidity/accompanying 
symptoms 
OR and 95% CI 
Stroke: 0.7% 
McWilliam et al. 2003 176 High blood pressure: 24.6% 
Williams Russo et al. 212 Hypertension: 43% 
Coronary artery disease (myocardial 
infarction or angina): 14% 
Cerebrovascular accident: 2% 
Fitzgerald et al. 219 The percentage listed below are the 
combined results of both groups: 
 
High blood pressure: 86 (47.0%) 
Congestive heart failure: 1 (0.5%) 
Heart disease: 15 (8.2%) 
Stroke: 3 (1.6%) 
Hoogeboom et al. 220 For hip and/or knee OA (n=401): 
 47 (12%) have cardiovascular disease
Singh et al. (hip OA) 227 Primary total hip arthroplasty: 
Two year follow up: 
Heart disease: 7% 
 
Five year follow up:  
Heart disease: 6% 
 
Revision total hip arthroplasty: 
Two year follow up:  
Heart disease: 6% 
 
Five year follow up:  
Heart disease: 4% 
Singh et al. (knee OA) 228 Primary total knee arthroplasty: 
Two year follow up: 
Heart disease: 8% 
 
Five year follow up:  
Heart disease: 7% 
 
Revision total knee arthroplasty: 
Two year follow up:  
Heart disease: 7% 
 
Five year follow up:  
Heart disease: 5% 
Wesseling et al. 230 For self-reported comorbidity of >1% 
prevalence: 
Hypertension: 198 (19.8%) 
Severe heart disease or myocardial 
infarction/stroke: 14 (1.4%) 
Raab et al. 235 Cardiovascular diseases: 34 (9.9%) 
 Hypertension: 25 (7.3%) 
 96 
 
Studies Percentage of 
comorbidity/accompanying 
symptoms 
OR and 95% CI 
 Cardiac insufficiency: 1 (0.3%) 
Rat et al. 236 For the 3 year follow up cohort: 
Cardiac insufficiency: 29 (17.9%) 
 
For the 10 year follow up cohort:  
Cardiac insufficiency: 21 (29.6%) 
Ayers et al. 237 Cardiac disease: 8.8% 
Baruth et al. 239 hypertension: 50.7% 
stroke: 2.0% 
Nilsdotter et al. 180 Heart: 9.2% 
Hypertension: 27.8% 
CI: Confidence interval 
OA: Osteoarthritis 
OR: Odds ratio 
SE: Standard error 
 
 
Vascular comorbidities 
Five studies reported prevalence of vascular diseases 180,200,207,227,228. The percentage of 
vascular comorbidities ranged from 2% to 25.6% (Table 3.30). The studies did not specify 
what kind of vascular diseases they were. 
Table 3.30 Vascular disorder comorbidity of arthritis as comorbidity of arthritis 
Studies Percentage of comorbidity/accompanying 
symptoms 
OR and 95% 
CI 
Van Dijk et al. 207 Vascular diseases: 25.6% 
No data 
Mangani et al. 200 Vascular disease: 12.6% 
Singh et al. (hip OA) 
227 
Primary total hip arthroplasty: 
Two year follow up: 
Peripheral vascular disease: 4% 
 
Five year follow up:  
Peripheral vascular disease: 3% 
 
Revision total hip arthroplasty: 
Two year follow up:  
Peripheral vascular disease: 4% 
 
Five year follow up:  
Peripheral vascular disease: 3% 
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Singh et al. (knee OA) 
228 
Primary total knee arthroplasty: 
Two year follow up: 
Peripheral vascular disease: 5% 
 
Five year follow up:  
Peripheral vascular disease: 4% 
 
Revision total knee arthroplasty: 
Two year follow up:  
Peripheral vascular disease: 4% 
 
Five year follow up:  
Peripheral vascular disease: 2% 
Nilsdotter et al. 180 Peripheral arteries: 12.7% 
CI: Confidence interval 
OA: Osteoarthritis 
OR: Odds ratio 
 
3.3.4.3 Diseases/symptoms of the respiratory system as 
comorbiditie/accompanying symptoms of arthritis 
There were 14 studies that reported data on respiratory disorders 
166,176,180,194,200,207,212,219,220,227,228,230,235,237 (Table 3.31). The prevalence of respiratory disorders 
ranged from 0.5% to 28.8%. Asthma ranged from 7.6% to 12.6%, tuberculosis ranged from 
0.5% to 3.2%, and chronic obstructive pulmonary disease ranged from 7% to 14%. The ORs 
for asthma ranged from 3.8 to 5.0 according to the report of Beijing and Shanghai from Lee et al. 
166. This report also showed conflict results for tuberculosis and “lung disease other than asthma 
and tuberculosis”. 
Table 3.31 Respiratory disorders comorbidity of arthritis 
Studies Percentage of 
comorbidity/accompanying 
symptoms 
OR and 95% CI 
Kauppila et al. 194 Pulmonary disease: 18 (20.5%) No data 
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Studies Percentage of 
comorbidity/accompanying 
symptoms 
OR and 95% CI 
Lee et al. 166 
Beijing participants: 
 Asthma: 8.2% (SE: 2.4) 
 Tuberculosis: 3.2% (SE: 2.4) 
Seasonal allergies: 7.8% (SE: 2.2) 
 Other lung disease: 2.2% (SE: 1.0)
 
Shanghai participants: 
 Asthma: 12.6% (SE: 5.2) 
 Tuberculosis: 0.5% (SE: 0.4) 
Seasonal allergies: 12.4% (SE: 4.8)
 Other lung disease: 2.2% (SE: 1.6)
Compared with general public 
without arthritis: 
 
Beijing: 
Asthma: 5.0 (2.2-11.2) 
Tuberculosis: 8.9 (1.1-71.4) 
Other lung disease: 5.0 (1.0-24.8) 
 
Non-significant difference: 
Seasonal allergies: 0.9 (0.5-1.8) 
 
Shanghai:  
Asthma: 3.8 (1.0-13.7) 
 
Non-significant difference:  
tuberculosis: 0.4 (0.0-3.1) 
Other lung disease: 5.7 (0.7-44.8) 
Seasonal allergies: 2.1 (0.8-5.1) 
Van Dijk et al. 207 Respiratory diseases: 28.8% 
No data 
Mangani et al. 200 Pulmonary disease: 8.3% 
McWilliam et al. 
2003 176 
Severe asthma, bronchitis, 
emphysema, tuberculosis, or other 
lung problems: 15.7% 
Williams Russo 
et al. 212 
Chronic obstructive pulmonary 
disease: 7 (14%) 
Fitzgerald et al. 
219 
The percentage listed below are the 
combined results of both groups: 
Lung disease: 11 (6.0%) 
Hoogeboom et al. 
220 
For hip and/or knee OA (n=401): 
 27 (7%) have respiratory disease 
Singh et al. (hip 
OA) 227 
Primary total hip arthroplasty: 
Two year follow up: 
Chronic obstructive pulmonary 
disease: 9% 
 
Five year follow up:  
Chronic obstructive pulmonary 
disease: 9% 
 
Revision total hip arthroplasty: 
Two year follow up:  
Chronic obstructive pulmonary 
disease: 7% 
 
Five year follow up:  
Chronic obstructive pulmonary 
disease: 7% 
Singh et al. (knee Primary total knee arthroplasty: 
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Studies Percentage of 
comorbidity/accompanying 
symptoms 
OR and 95% CI 
OA) 228 Two year follow up: 
Chronic obstructive pulmonary 
disease: 11% 
 
Five year follow up:  
Chronic obstructive pulmonary 
disease: 10% 
 
Revision total knee arthroplasty: 
Two year follow up:  
Chronic obstructive pulmonary 
disease: 9% 
 
Five year follow up:  
Chronic obstructive pulmonary 
disease: 9% 
Wesseling et al. 
230 
For self-reported comorbidity 
of >1% prevalence: 
Asthma, chronic bronchitis, 
pulmonary emphysema or chronic 
non-specific lung disease: 90 
(9.1%) 
Pharyngitis, sinusitis: 91 (9.0%) 
Raab et al. 235 Pulmonary diseases: 28 (8.1%) 
Asthma: 26 (7.6%) 
Allergic diseases: 84 (24.4%) 
Allergic rhinitis: 50 (14.5%) 
House dust mite allergy: 16 (4.7%)
Ayers et al. 237 Pulmonary disease: 6.3% 
Nilsdotter et al. 
180 Lung: 0.5% 
Comorbidities/accompanying symptoms of no association were italicised 
CI: Confidence interval 
OA: Osteoarthritis 
OR: Odds ratio 
SE: Standard error 
 
3.3.4.4 Endocrine, nutritional and metabolic diseases/symptoms as 
comorbidities/accompanying symptoms of arthritis 
Fifteen studies reported data in this category 166,176,180,181,194,200,207,219,220,223,227,228,230,235,238 
(Table 3.32). For prevalence, endocrinological diseases were reported to be between 0.4% to 
69%, diabetes between 0.9% to 22.7%, thyroid diseases between 0.4% to 6.7% 
(hypothyroidism is reported as 2% 235), obesity/overweight between 16.1% to 54.2%. The ORs, 
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according to Lee et al. 166, for diabetes and thyroid disease were conflicting. The Beijing data 
showed an association between arthritis and diabetes and thyroid disease whereas the Shanghai 
data showed no association. 
Table 3.32 Endocrine disorders as comorbidities of arthritis 
Studies Percentage of comorbidity/accompanying 
symptoms 
OR and 95% CI 
Kauppila et al. 
194 
Diabetes: 20 (22.7%) 
Endocrine disease: 20 (22.7%) 
No data 
Lee et al. 166 
Beijing participants: 
 Diabetes or high blood sugar: 16.5% (SE: 
5.9) 
 Thyroid disease: 4.0% (SE: 1.6) 
 
Shanghai participants: 
 Diabetes or high blood sugar: 7.4% (SE: 
4.1) 
 Thyroid disease: 0.4% (SE: 0.4) 
Compared with general 
public without arthritis: 
 
Beijing: 
Diabetes or high blood 
sugar: 5.3 (1.9-14.8) 
Thyroid disease: 5.1 
(1.6-15.1) 
 
Shanghai: 
Diabetes or high blood 
sugar: 2.2 (0.6-7.7) 
Thyroid disease:0.4 
(0.0-6.0) 
Van Dijk et al. 
207 
Endocrine and metabolic disease: 46% 
Overweight (body mass index 25-30): 51.7%
Obesity: 23.6%. 
No data 
Mangani et al. 
200 
Obesity: 52.9% 
Diabetes: 9.2% 
McWilliam et 
al. 2003 176 Diabetes: 5.5% 
Fitzgerald et al. 
219 
The percentage listed below are the 
combined results of both groups: 
 
Diabetes: 11 (6.0%) 
Hoogeboom et 
al. 220 
For hip and/or knee OA (n=401): 
 28 (7%) have diabetes 
Lee et al. 223 31% of participants were obese 
Singh et al. (hip 
OA) 227 
Primary total hip arthroplasty: 
Two year follow up: 
Diabetes (with or without organ damage): 
6% 
 
Five year follow up:  
Diabetes (with or without organ damage): 
5% 
 
Revision total hip arthroplasty: 
Two year follow up:  
Diabetes (with or without organ damage): 
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Studies Percentage of comorbidity/accompanying 
symptoms 
OR and 95% CI 
7% 
 
Five year follow up:  
Diabetes (with or without organ damage): 
7% 
Singh et al. 
(knee OA) 228 
Primary total knee arthroplasty: 
Two year follow up: 
Diabetes (with or without organ damage): 
9% 
 
Five year follow up:  
Diabetes (with or without organ damage): 
8% 
 
Revision total knee arthroplasty: 
Two year follow up:  
Diabetes (with or without organ damage): 
10% 
 
Five year follow up:  
Diabetes (with or without organ damage): 
7% 
Wesseling et al. 
230 
For self-reported comorbidity of >1%: 
Obesity:161 (16.1%) 
Diabetes mellitus: 35 (3.5%) 
Thyroid disease: 53 (5.3%) 
Raab et al. 235 Thyroid/endocrine diseases: 23 (6.7%) 
 Hypothyroidism: 7 (2%) 
 Hashimoto thyroiditis: 4 (1.2%) 
 Diabetes mellitus: 3 (0.9%) 
Amyloidosis: 3 (0.9%) 
Ayoubi et al.238 Obesity (body mass index ≥30): 
32 (54.2%) in OA 
19 (16.1%) in controls (p=0.008) 
Nilsdotter et al. 
180 Diabetes: 7.1% 
Bischoff-Ferrari 
et al. 181 Body mass index > 30: 25% 
Baruth et al. 239 High cholesterol: 42.4% 
Comorbidities/accompanying symptoms of no association were italicised 
CI: Confidence interval 
OA: Osteoarthritis 
OR: Odds ratio 
SE: Standard error 
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3.3.4.5 Diseases/symptoms of the musculoskeletal system and connective 
tissue as comorbidities/accompanying symptoms of arthritis 
Sixteen studies reported data on musculoskeletal pain comorbidities (Table 3.33) 
166,179-181,190,194,207,219,220,227,228,230,235-237,239. Only one study reported OR for chronic back/neck 
problems 166, the other studies all reported percentage data. Percentage of back/neck pain 
ranged from 6% to 69%, osteoporosis ranged from 3.2% to 13.9%, whereas other 
musculoskeletal comorbidities/accompanying symptoms ranged from 6.6% to 100%. Arthritic 
patients were 6.5 to 7.9 times more likely to have chronic back/neck problems 166. Lee et al. did 
not make a clear differentiation between arthritis and chronic SP 166. The comorbid chronic SP 
may well overlap with spinal joints regions. Other studies recruited OA of knee and/or hip 
179-181,194,207,219,220,227,228,230,237 and some did not specify the location or included all the possible 
arthritic joints 166,190,235,236,239. 
Table 3.33 Musculoskeletal pain as comorbidities/accompanying symptoms of arthritis 
Studies Percentage of 
comorbidity/accompanying symptoms
OR and 95% CI 
Kauppila et al. 194 Osteoarthritis of other joints: 80 (90.9%) 
Osteoporosis: 9 (10.2%) 
No data 
Lee et al. 166 
Beijing participants: 
Chronic back/neck pain: 69.1% (SE: 5.4) 
 
Shanghai participants: 
Chronic back/neck pain: 61.0% (SE: 5.0) 
Compared with general 
public without arthritis: 
 
Beijing: 
Chronic back/neck 
problems: 6.5 (3.4-12.4) 
 
Shanghai:  
Chronic back/neck 
problems: 7.9 (4.5-13.9) 
Van Dijk et al. 207 Diseases of bones, joints, muscle and skin: 
100% 
No data 
Stupar et al. 179 Prevalence of back pain amongst different 
OA: 
Hip only: 121 (62%) 
Knee only: 295 (45%) 
Both hip and knee: 514 (71%) 
Fernandez-de-Las
-Penas et al. 190 
Prevalence of neck pain within arthrosis: 
47.5% (46.0-49.1) 
Prevalence of LBP within arthrosis: 
46.3% (44.8-47.8) 
Fitzgerald et al. 219 The prevalence listed below are the 
combined results of both groups: 
 
Back pain: 88 (48.1%) 
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Studies Percentage of 
comorbidity/accompanying symptoms
OR and 95% CI 
Previous hip fracture: 2 (1.1%) 
Hoogeboom et al. 
220 
 
For knee OA group (n=284):  
Spine pain:  
 Lumbar: 66 (23%) 
 Thoracic: 18 (6%) 
 Neck: 49 (17%) 
 
Extremity pain (single and both sides are 
reported together): 
 Shoulder: 47 (17%) 
 Elbow: 20 (7%) 
 Wrist: 26 (9%) 
 Hand: 39 (14%) 
 Hip: 41 (14%) 
 Knee: 241 (85%) 
 Ankle: 31 (11%) 
 Foot: 39 (14%) 
 
For hip OA group (n=117): 
Spine pain:  
 Lumbar: 43 (37%) 
 Thoracic: 12 (10%) 
 Neck: 18 (15%) 
Extremity pain (single and both sides are 
reported together): 
 Shoulder: 17 (16%) 
 Elbow: 5 (5%) 
 Wrist: 9 (9%) 
 Hand: 10 (10%) 
 Hip: 95 (81%) 
 Knee: 36 (33%) 
 Ankle: 12 (12%) 
 Foot: 13 (13%) 
Singh et al. (hip 
OA) 227 
Primary total hip arthroplasty : 
Two year follow up: 
Connective tissue disease: 6% 
 
Five year follow up:  
Connective tissue disease: 6% 
 
Revision total hip arthroplasty: 
Two year follow up:  
Connective tissue disease: 8% 
 
Five year follow up:  
Connective tissue disease: 8% 
Singh et al. (knee 
OA) 228 
Primary total knee arthroplasty: 
Two year follow up: 
Connective tissue disease: 7% 
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Studies Percentage of 
comorbidity/accompanying symptoms
OR and 95% CI 
 
Five year follow up:  
Connective tissue disease: 8% 
 
Revision total knee arthroplasty: 
Two year follow up:  
Connective tissue disease: 8% 
 
Five year follow up:  
Connective tissue disease: 8% 
Wesseling et al. 
230 
For self-reported comorbidity of >1% 
prevalence: 
Disorders of neck, shoulder, elbow, wrist 
or hand: 222 (22.2%) 
Back disorders (including slipped disc): 
172 (17.2%) 
Chronic inflammation of joints (such as 
RA): 37 (3.7%) 
Other chronic rheumatic diseases, longer 
than 3 months: 29 (2.9%) 
Raab et al. 235 Osteoporosis: 11 (3.2%) 
Rat et al. 236 For the 3 year follow up cohort: 
Back pain: 91 (54.2%) 
 
For the 10 year follow up cohort:  
Back pain: 46 (59.0%) 
Ayers et al. 237 Moderate to severe pain in the following 
areas: 
Non-operatively treated knee : 41 (23%) 
Ipsilateral hip: 36 (20%) 
Contralateral hip: 16 (9%) 
Low back: 46 (26%) 
Baruth et al. 239 Osteoporosis: 13.9% 
Nilsdotter et al. 180 Low back pain: 21.5% 
Unilateral hip pain: 20.2% 
Regional pain: 59.1% 
Widespread pain: 6.6% 
Bischoff-Ferrari 
et al. 181 
Other joint replacement or other revision: 
39% (out of 828) 
Pain in back of lower extremity: 60% (out 
of 795) 
CI: Confidence interval 
LBP: low back pain 
OA: Osteoarthritis 
OR: Odds ratio 
RA: Rheumatoid arthritis 
SE: Standard error 
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3.3.4.6 Diseases/symptoms of the nervous system as 
comorbidities/accompanying symptoms of arthritis 
Eight studies reported findings for neurological comorbidities 166,180,194,207,220,229,230,235 (Table 
3.34). The percentage of neurological conditions ranged from 0% to 76.2%. Specifically, 
epilepsy or seizures ranged from 0% to 1.5%. Siu et al. reported percentages of sleep 
disturbances amongst teenagers suffering from arthritis 229. The percentage of sleep 
disturbances ranged from 64.2% for arthritis in arm to 76.2% for arthritis in shoulder. There 
was one study provided data for fatigue 220. Of the participants, 44% of them scored more than 
35 on the Checklist Individual Strength 969 which indicated severe fatigue. 
There were conflicting results from Lee et al. 166 for neurological conditions. The Beijing data 
showed an association whereas the data from Shanghai showed no association between 
arthritis and neurological conditions. Epilepsy or seizures was shown to have no association 
with arthritis and was reported by the Beijing site but no data was available from Shanghai 
site 166. 
Table 3.34 Neurological disorders as comorbidity/accompanying symptom of arthritis 
Studies Percentage of 
comorbidity/accompanying 
symptoms 
OR and 95% CI 
Kauppila et 
al. 194 Neurologic disease: 15 (17%) 
No data 
Lee et al. 166 
Beijing participants: 
 Neurological problems: 1.7% (SE:1.6)
 Epilepsy or seizures: 1.3% (SE:1.2) 
 
Shanghai participants: 
 Neurological problems: 0.3% (SE:0.3)
 Epilepsy or seizures: 0% 
Compared with general public 
without arthritis: 
 
Beijing: 
Neurological problems: 19.2 
(1.8-208.2) 
 
Shanghai: 
Neurological problems: 0.6 (0.0-6.4) 
 
Beijing participants reported 
non-significant difference between 
arthritic and non-arthritic participants 
for the following physical disorders: 
epilepsy or seizures: 4.8 (0.3-79.8). 
Van Dijk et 
al. 207 Neurological disease: 31.9% No data 
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Siu et al. 229 Percentage of sleep disturbance 
amongst teenagers with a particular 
type of chronic pain are listed below: 
 
Shoulder (n=115): 76.2% 
Arm (n=70): 64.2% 
Muscle (n=118): 70.0% 
Foot (n=87): 65.3% 
Limb (n=5): 74.6% 
Wesseling 
et al. 230 
For self-reported comorbidity of >1% 
prevalence: 
Dizziness with falls: 17 (1.7%) 
Raab et al. 
235 
Neurologic diseases: 41 (11.9%) 
 Epilepsy: 5 (1.5%) 
Hoogeboom 
et al. 220 
 
44% of them scored more than 35 on 
the Checklist Individual Strength which 
indicated severely fatigue 
Nilsdotter et 
al. 180 Neurological disease: 2.0% 
Comorbidities/accompanying symptoms of no association were italicised 
CI: Confidence interval 
OR: Odds ratio 
SE: Standard error 
 
3.3.4.7 Diseases/symptoms of the digestive system as 
comorbidities/accompanying symptoms of arthritis 
Gastrointestinal comorbidity 
Eight studies reported findings on the digestive system 166,176,180,207,219,220,230,235 (Table 3.35). 
The prevalence of digestive issues ranged from 0.3% to 34.7%. More specifically, ulcers in the 
digestive system, including “peptic ulcer” “duodenal ulcer” and/or “ulcerative colitis”, ranged 
from 0.3% to 11%. There was no association between arthritis and ulcer in stomach or 
intestine. 
Liver and gallbladder comorbidity 
Five studies provided data for comorbid liver and gallbladder diseases 176,207,219,230,235. The 
percentage of liver diseases was 0.9% to 7.4% (the exact liver diseases were not specified) 
whereas the percentage of stomach or gall bladder disorders was between 0.9% to 9.7% (the 
exact gall bladder or stomach disorders were not specified). The percentage of cholelithiasis 
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was 1.8% 230. Hoogeboom et al. (n=401) also described the prevalence of kidney/liver diseases 
was 1% 220. 
Table 3.35 Diseases/symptoms of the digestive system as comorbidities/accompanying 
symptoms of arthritis 
Studies Percentage of 
comorbidity/accompanying symptoms
OR and 95% CI 
Lee et al. 166 Beijing participants: 
Ulcer in stomach or intestine: 5.4% (SE: 
3.5) 
 
Shanghai participants: 
Ulcer in stomach or intestine: 11.0% 
(SE: 2.7) 
Compared with general 
public without arthritis: 
 
Beijing: 
Ulcer in stomach or 
intestine:1.6 (0.5-5.9) 
 
Shanghai: 
Ulcer in stomach or intestine: 
1.3 (0.7-2.4) 
Van Dijk et 
al. 207 
Upper gastrointestinal disease: 34.7% 
Lower gastrointestinal disease: 30.5% 
Liver diseases: 7.4% 
No data 
McWilliams 
et al. 2003 176 
Chronic stomach or gall bladder trouble: 
9.7% 
Fitzgerald et 
al. 219 
The prevalence listed below are the 
combined results of both groups: 
 
Stomach ulcer: 14 (7.7%) 
Liver disease: 2 (1.1%) 
Hoogeboom 
et al. 220 
 Gastrointestinal complaints: 32 (8%) 
Wesseling et 
al. 230 
Cholelithiasis: 18 (1.8%) 
Peptic ulcer or duodenal ulcer: 14 (1.4%)
Raab et al. 235 Gastrointestinal diseases: 14 (4.1%) 
Crohn's disease: 4 (1.2%) 
Ulcerative colitis: 3 (0.9%) 
Gastrointestinal ulcer: 1 (0.3%) 
 
Liver and gallbladder disease: 3 (0.9%) 
Nilsdotter et 
al. 180 Peptic ulcer: 1.5% 
Comorbidities/accompanying symptoms of no association were italicised 
CI: Confidence interval 
OA: Osteoarthritis 
OR: Odds ratio 
SE: Standard error 
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3.3.4.8 Diseases/symptoms of the eye and adnexa as 
comorbidities/accompanying symptoms of arthritis 
Six studies reported findings on eye and adnexa disorders 166,176,180,207,235,236 (Table 3.36). The 
prevalence of eye and adnexa diseases/symptoms ranged from 0.9% to 96.1%. Apart from 
seasonal allergies where the percentage ranged from 7.8% to 12.4%, there was no specific eye 
and adnexa disease reported by more than one study. One study reported no association 
between seasonal allergies and arthritis 166. 
Table 3.36 Diseases/symptoms of the eye and adnexa as comorbidities of arthritis 
Studies Percentage of comorbidity/accompanying 
symptoms 
OR and 95% CI 
Lee et al. 166 
Beijing participants: 
 Seasonal allergies: 7.8% (SE: 2.2) 
 
Shanghai participants: 
 Seasonal allergies: 12.4% (SE: 4.8) 
Compared with general 
public without arthritis: 
 
Beijing: 
Seasonal allergies: 0.9 
(0.5-1.8) 
 
Shanghai: 
Seasonal allergies: 2.1 
(0.8-5.1) 
Van Dijk et al. 207 Eye, ear, nose, throat and larynx disease: 
96.1% 
No data 
McWilliam et al. 
2003 176 
Blindness, deafness, or severe visual or 
hearing impairment: 9.9% 
Raab et al. 235 Eye diseases: 80 (23.3%) 
 Uveitis: 59 (17.7%) 
 Cataract: 3 (0.9%) 
 Glaucoma: 9 (2.6%) 
 Other eye diseases: 8 (1.6%) 
Rat et al. 236 For the 3 year follow up cohort: 
Visual impairment: 51 (31.1%) 
 
For the 10 year follow up cohort:  
Visual impairment: 23 (31.9%) 
Nilsdotter et al. 
180 Vision problems: 1.5% 
Comorbidities/accompanying symptoms of no association were italicised 
CI: Confidence interval 
OR: Odds ratio 
SE: Standard error 
 
 
 
 
 109 
 
3.3.4.9 Symptoms, signs and abnormal clinical and laboratory findings, 
not elsewhere classified and migraine as accompanying symptom of 
arthritis 
Four studies reported data on headache/migraine 166,190,230,235 and one study reported data on 
dizziness/faintness 213 as an accompanying symptom of arthritis. Those who had arthritis were 
two to five times more likely to also have headache, 2.35 times to have migraine, and 2.38 
times to have dizziness/faintness during the last week (Table 3.37). The chance of 
accompanying headache or migraine ranged from 8.7% to approximately 20%, and the chance 
of having dizziness/faintness during the last week was 47.2%.  
Table 3.37 Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere 
classified and migraine as comorbidity/accompanying symptoms of arthritis 
Studies Percentage of 
comorbidity/accompanying 
symptoms 
OR and 95% CI 
Lee et al. 166 
Beijing participants: 
Frequent or severe headaches: 
14.0% (SE: 2.7) 
 
Shanghai participants: 
Frequent or severe headaches: 
19.8% (SE: 5.8) 
Compared with general 
public without arthritis: 
 
Beijing: 
Frequent or severe 
headache: 2.1 (1.2-3.7) 
 
Shanghai:  
Frequent or severe 
headache : 4.8 (2.2-10.7) 
Fernandez-de-Las-Penas 
et al. 190 
Migraine: 18.89% 
Compared with general 
public without arthritis: 
Migraine: 2.35 (2.13 - 2.60)
Wesseling et al. 230 Migraine or chronic headache: 124 
(12.4%) 
No data Raab et al. 235 Migraine: 30 (8.7%) 
Tamber et al. 213 
Dizziness/faintness during the last 
week: 47.2% 
Compared with general 
public without arthritis: 
Dizziness/faintness during 
the last week: 2.38 
(2.03-2.78) 
CI: Confidence interval 
OR: Odds ratio 
SE: Standard error 
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3.3.4.10 Diseases of the blood and blood-forming organs and certain 
disorders involving the immune mechanism as comorbidities of 
arthritis 
One study reported data for blood diseases 235. Raab et al. included 344 adults who had 
previously been diagnosed with juvenile idiopathic arthritis recruited from a biological 
register “JuMBO”. Of them, 6.7% had haematological diseases, the study did not specify the 
kind of haematological diseases, 3.2% had anaemia, and 1.7% had iron deficiency. 
3.3.4.11 Other findings 
Eleven studies reported findings for the other category 166,176,179,180,186,194,200,219,231,234,239 (Table 
3.38). The percentage for any physical or mental diseases ranged from 0% to 85.2%. The 
percentage of one other chronic pain ranged from 45.2% to 73.4%. The percentage of cancer 
ranged from 0% to 14.8%. Lee et al. 166 reported findings from both Beijing and Shanghai and 
found the percentage for “malaria or other parasitic diseases”, or HIV ranged from 0.4% to 
1.3%, and 0% to 0% respectively. The percentage of comorbidity/accompanying symptom 
reported by single studies included other chronic diseases (44.3%) 194, more than one lifetime 
pain conditions (39.1%) 186, and “ulcer, lupus, thyroid disease, or other autoimmune disorders” 
(5.5%) 176. Blackman et al. reported data on functioning of behaviour, social, school, and 
home, of children 234. For behavioural, social, and school functioning of arthritic children, at 
least 40% of the children showed positive functioning and less than 37% of them showed 
negative functioning. For home functioning, only 27.2% of children exercised everyday, at 
least 40% of children have enough sleep, and read for pleasure less than 30 mins/day. 
The OR reported by Lee et al. 166 for any physical disease, and “any mental or physical 
disorders, pain”, ranged between 2.3-3.1, and 4.0-6.2 respectively. The OR for chronic pain in 
arthritic pain was between 2.1 and 6.3. And there was no association between arthritis and 
“malaria or other parasitic diseases”, or cancer. 
Table 3.38 Other findings of arthritis 
Studies Percentage of 
comorbidity/accompanying 
symptoms 
OR and 95% CI or other findings
Kauppila et 
al. 194 Other chronic disease: 39 (44.3%)
No data 
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Studies Percentage of 
comorbidity/accompanying 
symptoms 
OR and 95% CI or other findings
Lee et al. 166 Beijing participants: 
Any chronic pain: 73.4% (SE: 5.3)
Any physical diseases: 54.7% (SE: 
7.4) 
Any mental or physical disorders, 
pain: 85.2% (SE: 5.7) 
Malaria or other parasitic diseases: 
0.4% (SE: 0.4) 
Cancer: 0% 
HIV: 0% 
 
Shanghai participants: 
Any chronic pain: 64.8% (SE: 5.1)
Any physical diseases: 57.2% (SE: 
7.4) 
Any mental or physical disorders, 
pain: 79.9% (SE: 4.2) 
Malaria or other parasitic diseases: 
1.3% (SE: 0.2) 
Cancer: 0.6% SE: (0.6) 
HIV: 0% 
Compared with general public 
without arthritis: 
 
Beijing: 
Any chronic pain (chronic pain 
anywhere): 6.1 (3.0-12.5) 
Any physical diseases: 3.1 (1.6-6.0)
Any mental or physical disorders, 
pain: 6.2 (2.2-17.7) 
Malaria or other parasitic diseases: 
0.5 (0.0-5.7) 
 
Shanghai:  
Any chronic pain (chronic pain 
anywhere): 6.3 (3.4-11.6) 
Any physical diseases: 2.3 (1.2-4.3)
Any mental or physical disorders, 
pain: 4.0 (2.3-7.0) 
Malaria or other parasitic diseases: 
3.3 (0.2-57.5) 
Cancer: 3.1 (0.3-35.4) 
Braden et al. 
186 
More than one lifetime pain 
condition: 39.1% 
No data 
Mangani et 
al. 200 Cancer: 4.6% 
Stupar et al. 
179 
No data 
Compared to arthritic patients 
without LBP: 
 
Low back pain group included more 
females, had more comorbidities, 
had a greater number of 
troublesome joints, and reported 
more pain and disability. 
 
Low back pain was associated with 
worse pain and function at 
follow-up (3-5 years) (β=6.59; 95% 
CI, 4.36-8.81; P<0.001) 
McWilliam 
et al. 2003 176 
Ulcer, lupus, thyroid disease, or 
other autoimmune disorders: 5.5%
No data 
Fitzgerald et 
al. 219 
The prevalence listed below are 
the combined results of both the 
standard exercise group and 
“agility and perturbation” group: 
 
Cancer: 27 (14.8%) 
Dominick et 
al. 231 
Percentage of chronic pain within 
CMP: 
Compared with general public 
without arthritis: 
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Studies Percentage of 
comorbidity/accompanying 
symptoms 
OR and 95% CI or other findings
Arthritis: 45.2% 
Osteoporosis: 49.2% 
The OR for chronic pain after 
adjusted for sociodemographic 
variables and the physical and 
mental conditions: 
Arthritis: 3.9 (3.3-4.6) 
Osteoporosis: 2.1 (1.5-2.8) 
 
Chronic pain is defined as pain 
lasted more than six months and 
may be in any parts of the body 
ranging from head to toes and 
including chest, stomach, and 
pelvic pain. 
Blackman et 
al. 2013 234 
Of the chronic bone, joint, muscle 
problem children, their percentage 
for the following emotional and 
behavioural problems are listed 
below: 
Behavioural functioning: 
 Positive: 
 Shows respect for teachers and 
neighbors: 86.9% (SE: 2.6) 
 Gets along well with other 
children: 80.1% (SE: 3.1) 
 Negative: 
 Argues too much: 33.5% (SE: 
3.4) 
 Is disobedient: 9.6% (SE: 2.1) 
 Is stubborn, sullen, or irritable: 
21.8% (SE: 3.1) 
 
Social functioning: 
 Positive: 
 Tries to understand other people's 
feelings: 68.5% (SE: 3.3) 
 Tries to resolve conflicts with 
classmates, family, or friends: 
60.8% (SE: 3.3) 
 Play sports: 44.3% (SE: 3.2) 
 Participate in clubs: 56.6% (SE: 
3.1) 
 Negative:  
 Bullies or is cruel or mean to 
others: 6.8% (SE: 2.0) 
 Is withdrawn, and does not get 
involved with others: 3.2% (SE: 
0.5) 
No data School functioning: 
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Studies Percentage of 
comorbidity/accompanying 
symptoms 
OR and 95% CI or other findings
 Positive: 
 Cares about doing well in school: 
87.5% (SE: 0.3) 
 Does all required homework: 
79.1% (SE: 2.6) 
 Negative: 
 Missed ≥ 10 days of school: 31% 
(SE: 3.2) 
 School contacted >1 time: 36.7% 
(SE: 3.4) 
 Repeat grade: 23.9% (SE: 3.3) 
 
Home functioning: 
 Get enough sleep 7 days per 
week: 53% (SE: 3.2) 
 Exercise every day: 27.2% (SE: 
3) 
 Read for pleasure ≤ 30 minutes 
per day: 43.7% (SE: 3.1) 
Baruth et al. 
239 Cancer: 12.7% 
Nilsdotter et 
al. 180 Cancer: 5.6% 
Comorbidities/accompanying symptoms of no association were italicised 
CI: Confidence interval 
CMP: Chronic musculoskeletal pain 
LBP: Low back pain 
OR: Odds ratio 
SE: Standard error 
3.3.4.12 Diseases/symptoms of the genitourinary system or ear and mastoid 
process as comorbidities or accompanying symptoms of arthritis 
Ten studies reported percentage data for renal disorders 180,200,207,219,220,227,228,230,235,237 
(Appendix 12). The prevalence of renal disease ranged from 0% to 11.2% and the percentage 
for urogenital disease was 44.4%. For gynaecological diseases, the percentage ranged between 
4.2% to 5%. There was no specific genitourinary disease reported by more than one study. 
Two studies reported the percentage of ear, nose, throat, and eye disorders ranged from 7.8% to 
96.1% without reporting OR data 176,207 (Appendix 13).  
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3.3.5 Widespread pain and its comorbidities 
Fourteen studies provided data for fibromyalgia/widespread pain 
182,184,189,196,201,203,204,210,214,216,218,225,226,241. The main comorbidities/accompanying symptoms 
for widespread pain included depression, anxiety, fatigue, irritable bowel syndrome, and 
irritable bladder. 
The characteristics of the 14 included widespread pain studies are presented in Table 3.39. 
Except for one study that recruited participants from a national databank for rheumatic 
diseases 210, and three other studies that recruited adult women, twins, or from the general 
population 201,203,204, the remaining studies recruited fibromyalgia patients and these studies 
identified fibromyalgia either by meeting American College of Rheumatology criteria 1990 for 
fibromyalgia diagnosis or diagnosed by doctors. Most of the included studies recruited 
participants from USA and/or Canada 184,201,203,210,216,226, three recruited participants from Italy 
189,214,241, and the remaining studies recruited from other countries or did not describe the 
country. All of the studies recruited adult participants with one study recruited twins 203, three 
recruited adult women 182,201,241, and one study recruited participants aged 31 years old and 
born on 1966 204. 
Table 3.39 Characteristics of included widespread pain/fibromyalgia studies 
Study Sample 
size/types of 
participant 
Method of CMP 
identification 
Country of 
study 
Age of participants 
Aguglia et al. 214 n=30, 
fibromyalgia, 
from 
rheumatology 
unit in hospital 
Meeting American 
College of 
Rheumatology 
criteria 1990 for 
fibromyalgia 
diagnosis 
Italy 58.33±13.43 years 
Arnold et al. 216 n=1025, 
fibromyalgia, 
source of 
participants not 
described 
Meeting American 
College of 
Rheumatology 
criteria 1990 for 
fibromyalgia 
diagnosis 
USA and 
Canada 
Placebo group: 48.7±10.6 
years 
 
Milnacipran group: 
49.1±10.8 
Bernatsky et al. 
184 
n=99, 
fibromyalgia, 
from 
rheumatology 
clinics and from 
the community 
Primary 
fibromyalgia 
fulfilling American 
College of 
Rheumatology 
criteria 1990 
Canada 50.8±10.2 years 
Carbonell-Baeza n=118, Meeting American Spain 51.9±7.3 years 
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Study Sample 
size/types of 
participant 
Method of CMP 
identification 
Country of 
study 
Age of participants 
et al. 218 fibromyalgia, 
from local 
association of 
fibromyalgia 
College of 
Rheumatology 
criteria 1990 for 
fibromyalgia 
diagnosis 
 
Ciapparelli et al. 
189 
n=117, 
fibromyalgia, 
from 
rheumatology 
clinic 
Meeting American 
College of 
Rheumatology 
criteria 1990 for 
fibromyalgia 
diagnosis 
Italy 52.0± 12.5 years 
Kurtze et al. 196 n=1816, 
fibromyalgia 
Self-reported 
fibromyalgia that is 
informed by a doctor
Norway The mean age of 
fibromyalgia patients 
without comorbidity was 
48.63±11.02 years whereas 
the fibromyalgia patients 
with comorbidity were 
56.36±12.40 years.  
 
The mean age of the other 
general population not 
having fibromyalgia was 
not listed. 
Raphael et al. 201 n=1312, AW Questions on  
1) pain lasting at 
least 1 week 2) axial 
skeletal pain  
3) limb pain on the 
right and left side. 
 
Participants fulfilling 
the above 3 criteria 
are considered to 
have 
fibromyalgia-like 
symptoms 
USA Not mentioned. 
Rehm et al. 225 n=3035, 
fibromyalgia, 
from GP, 
orthopaedist, 
rheumatologist, 
and pain 
specialists clinics 
American College of 
Rheumatology 
criteria 
Germany 52.1±11.2 years 
Schur et al. 203 n=3982, T (2% 
fibromyalgia) 
Self-reported 
fibromyalgia that is 
informed by a doctor
USA 32.4 ±14.7 years 
Shillam et al. 226 n=171, 
fibromyalgia, 
Patients diagnosed 
with fibromyalgia 
USA and 
Canada 
60.7 ± 6.2 (range: 50-76) 
years 
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Study Sample 
size/types of 
participant 
Method of CMP 
identification 
Country of 
study 
Age of participants 
from 
fibromyalgia 
database of 
community 
living 
fibromyalgia 
patients 
who was diagnosed 
clinically or 
participated in 
previous 
fibromyalgia clinical 
trials 
(Pacific 
Northwest 
region) 
Sipila et al. 204 n=5969, G 
(32.6% 
widespread pain) 
Widespread pain 
defined as pain 
involving at least 1 
upper extremity, 1 
lower extremity, and 
either neck, back , or 
chest 
Finland Not mentioned. But sounds 
like 31 years old as 
authors, in 1997, contacted 
cohort who were born in 
1966. 
Wolfe et al. 210  n=22131, from 
national databank 
for rheumatic 
diseases, 
participants are 
recruited from 
rheumatologists. 
2674 had 
fibromyalgia 
Participants are 
diagnosed by USA 
rheumatologists 
USA For RA, the participants’ 
age are as following: 
Depressed: 57.2±13.0 
years. 
Not depressed: 61.6±13.5 
years. 
 
Age of fibromyalgia 
participants was not 
provided. 
Bazzichi et al.241 n=140, 
fibromyalgia, 
from 
rheumatology 
division of Pisa 
university 
Clinically classified 
by a rheumatologist 
based on 1990 
American College of 
Rheumatology 
criteria 
Italy 47.8 ± 8.8 years 
Tikiz et al. 182 n=100, 
fibromyalgia, 
source of 
participants not 
described 
Based on criteria of 
American College of 
Rheumatology 
Not 
described, 
but 
participants 
completed 
questionnaire 
in Turkey 
Healthy control: 37.2 ± 
10.3 years 
 
Only fibromyalgia: 42.9 ± 
9.1 years 
 
Fibromyalgia plus major 
depression: 39.6 ± 10.1 
years 
AW: Adult women in the general population 
G: General population 
GP: General practitioner 
RA: Rheumatoid arthritis 
T: Twins 
USA: United states of America 
Two studies also provided data for chronic SP and had been included in the chronic SP section 
188,197 
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3.3.5.1 Mental and behavioural disorders/symptoms as 
comorbidities/accompanying symptoms of widespread pain 
Twelve studies reported finding in this category 182,184,189,196,201,203,204,210,214,216,225,226,241 (Table 
3.40).  
They reported the percentage range of depression/depressiveness was between 5% to 90.9%, 
anxiety between 1% to 77.7%. Based on BDI, Patient Health Questionnaire, and Hamilton 
rating scale for depression, at the very least more than 11% of fibromyalgia patients had 
moderate depression. The percentages of other reported conditions/accompanying mental 
symptoms ranged from 2.6% to 67%. The ORs for PTSD, PTSD associated symptom clusters, 
panic attacks, or major depression ranged from 2.22 to 9.0. 
Table 3.40 Mental disorders as comorbidities of fibromyalgia 
Studies Percentage of 
comorbidity/accompanying symptoms
OR and 95% CI or other findings 
Raphael et al. 
201 
Approximately 6 months after the WTC 
terrorist attacks, 4.8% (N = 64) of the 
sample reported current symptoms 
consistent with a diagnosis of PTSD. 
Female general public residing in 
New York/New Jersey metropolitan 
area, USA with fibromyalgia-like 
symptoms were compared to female 
general public without 
fibromyalgia-like symptom: 
 
Probable PTSD symptoms at 
follow-up: 3.39 (1.82-5.99). 
 
Among those with fibromyalgia-like 
symptoms at follow-up, PTSD was 
more likely among those reporting 
higher levels of pain interference (OR 
= 1.25 for a 10-point increase, 95% 
CI = 1.02–1.52, p < 0.05). 
 
Higher levels of pain severity: 1.26 
(for a 10-point increase) (0.99–1.62, 
p < 0.10) 
 
For PTSD symptom clusters: 
avoidance/numbing: 2.22 (1.45-3.40) 
Increased arousal (OR 2.85 95% CI 
1.98-4.09). 
But not “at a greater risk for event 
re-experiencing” 
Sipila et al. 204 Of the widespread pain patients, 30.4% 
(n=1477) of them have depression.  
Compared with general public: 
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Studies Percentage of 
comorbidity/accompanying symptoms
OR and 95% CI or other findings 
 
Of the patients with both facial and 
widespread pain (n=469), the depression 
prevalence becomes 27.3% (n=128). 
Depressiveness was associated with 
widespread pain (PPR 2.37, 95% CI 
2.09-2.69). 
Schur et al. 203 
No data 
Compared to twins within the Twin 
Registry without fibromyalgia: 
 
Major depression: 6.1 (6.3-6.9) 
Panic attacks: 4.2 (3.5-5.0) 
PTSD: 9.0 (7.6-10.8) 
Kurtze et al. 
196 
Anxiety: 1411 (77.7%) 
Depression: 1650 (90.9%) 
No data 
Bernatsky et 
al. 184 Depression: 9 (5%) 
Anxiety: 1 (1%) 
Ciapparelli et 
al. 189 
Of the 117 participants, they have life time 
prevalence of the following diseases: 
Psychiatric comorbidity: 86 (73.5%) 
Major depression: 59 (50.4%) 
Anxiety disorders: 26 (22.2%) 
 -Panic disorder: 16 (13.7%) 
 -GAD: 10 (8.5%) 
Eating disorder: 5 (4.3%) 
 
And the current prevalence of the 
following diseases: 
Psychiatric comorbidity: 50 (42.7%) 
Major depression: 39 (33.3%) 
Anxiety disorders: 14 (12%) 
 -Panic disorder: 9 (7.7%) 
 -GAD: 5 (4.3%) 
Eating disorder: 3 (2.6%) 
Aguglia et al. 
214 
83.3% of patients had clinically 
significant depressive symptoms, 
corresponding to a Hamilton rating scale 
for depression total score>7. 
Arnold et al. 
216 
Based on BDI score where below 10 is 
no/minimal depression, 10 to 18 is mild 
depression, and 19 to 25 is moderate 
depression. 
 
There were  
599 (58%) with no/minimal depression,  
317 (31%) with mild depression,  
109 (11%) with moderate depression. 
Rehm et al. 225 Based on the PHQ-9 score, 208 (6.8%) of 
the were not diagnosed with depression 
(PHQ-9 score: 0-4), 828 (27.3%) of them 
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Studies Percentage of 
comorbidity/accompanying symptoms
OR and 95% CI or other findings 
were diagnosed with mild depression 
(PHQ-9 score: 5-9), 1556 (51.3%) of them 
were diagnosed with moderate depression 
(PHQ-9 score: 10-19), and 443 (14.6%) of 
them were diagnosed with moderately 
severe depression (PHQ-9 score: 20-27). 
 
Based on PHQ-9 score, 545 (18%) of 
participants have panic/anxiety disorder. 
Shillam et al. 
226 
Anxious: 123 (72%) 
Sad: 114 (67%) 
Easily angered: 94 (55%) 
Fear of symptoms worsening: 93 (54%) 
Feel like a burden to others: 66 (39%) 
Wolfe et al. 210  There were 2674 fibromyalgia 
participants, 37.9% (95% CI 36.1-39.8%) 
have self-reported depression. 
Bazzichi et 
al.241 
There were 100 fibromyalgia patients 
Lifetime psychiatric comorbidity: 
 Major depression: 20% 
 Bipolar disorder: 2% 
 Panic disorder: 12% 
 
Current psychiatric comorbidity: 
 Major depression: 8% 
 Bipolar disorder: 9% 
 Panic disorder: 7% 
Tikiz et al. 182 Of the fibromyalgia patients (n=67), 27 
(40.2%) had major depression. 
Comorbidities/accompanying symptoms of no association were italicised 
CI: Confidence interval 
GAD: Generalized anxiety disorder 
OR: Odds ratio 
PHQ: Patient health questionnaire 
PPR: Prevalence proportion ratio. Interpretation of PPR is similar to relative risk where >1 means increased 
risk and <1 means decreased risk. 
PTSD: Post traumatic stress disorder 
 
3.3.5.2 Diseases/symptoms of the musculoskeletal system and connective 
tissue as comorbidities/accompanying symptom of widespread pain 
Six studies reported findings for comorbid musculoskeletal pain 184,196,203,204,225,226 (Table 3.41). 
For the comorbidity, one study reported the percentage of osteoarthritis to be 40% and 
osteoporosis to be 2.2% 184. Other studies reported the percentage of 
neck/shoulder/back/arms/legs pain to be 100% 196, and facial pain to be 26% 204. One study 
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assessed the types of pain with painDETECT questionnaire where approximately 1/3 or more 
of patients describe their pain as burning, prickling, spontaneous pain attack, or pressure, and 
approximately 1/5 of patients described their pain as allodynia, pain evoked by thermal 
stimuli, or numbness 225. Shillam et al. on the other hand reported fibromyalgia patients 
described their pain as pain and stiffness (100% and 99% respectively) 226. 
The study by Sipila et al. used prevalence proportion ratio, which was similar to relative risk 
where >1 means increased risk and <1 means decreased risk. They found that widespread pain 
increased the risk of getting facial pain by 1.51 204. The other study by Schur et al. found 
fibromyalgia was 5.2 and 10.4 times more likely to have LBP or temporal mandibular joint 
disorder (TMD) respectively 203 (OR for LBP: 5.2 (4.4-5.9), OR for TMD: 10.4 (5.4-20.1)). 
Table 3.41 Musculoskeletal pain comorbidity of fibromyalgia 
Studies Percentage of comorbidity/accompanying 
symptoms 
OR and 95% CI or 
other findings 
Sipila et 
al. 204 
Facial pain within widespread pain: 469 (26%) 
Compared with general 
public: 
 
Facial pain: PPR 2.51 
(2.22-2.83). 
Schur et 
al. 203 
No data 
Compared to twins within 
the Twin Registry without 
fibromyalgia: 
 
Low back pain: 5.2 
(4.4-5.9) 
TMD: 10.4 (5.4-20.1) 
Kurtze et 
al. 196 
Pain in neck/shoulder: 1816 (100%) 
Back pain: 1816 (100%) 
Arms/legs pain: 1816 (100%) 
No data 
Bernatsky 
et al. 184 
Osteoarthritis: 72 (40%) 
Osteoporosis: 4 (2.2%) 
Rehm et 
al. 225 
For painDETECT questionnaire, 29.8% described as 
burning, 32.6% described as prickling, 20.4% 
described as allodynia, 39.9% described as 
spontaneous pain attacks, 24% described as pain 
evoked by thermal stimuli, 19.8% described as 
numbness, and 58.3% described as pressure. 
Shillam et 
al. 226 
Pain: 171 (100%) 
Stiffness: 170 (99%) 
CI: Confidence interval 
OR: Odds ratio 
PPR: Prevalence proportion ratio. Interpretation of PPR is similar to relative risk where >1 means increased 
risk and <1 means decreased risk. 
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3.3.5.3 Diseases/symptoms of the neurological system as 
comorbidities/accompanying symptoms of widespread pain 
Four studies reported findings for comorbid neurological disorders. Bernatsky et al. included 
99 Canadian fibromyalgia participants 184. Schur et al. included 3982 USA twin participants 203. 
Kurtze et al. included 65220 general public and 1816 of them had fibromyalgia 196. And 
Shillam et al. included 171 US/Canada fibromyalgia patients 226) (Table 3.42). They all 
reported findings on fatigue. The percentage of fatigue ranged from 2.2% to 95%. 
Fibromyalgia patients are 29.1 times more likely to have chronic fatigue syndrome (OR 29.1 
95% CI 26.9-31.5) 203. This chronic fatigue was based on patients’ self-report of doctor’s 
diagnosis. 
Shillam et al. 226 reported fibromyalgia patients had sleep related problems ranging from 75% 
to 93%, memory and concentration problems ranging from 76% to 87%, and other neurological 
conditions ranged from 53% to 81%. 
Schur et al. 203 reported finding for chronic tension type headache. It is found that people who 
have fibromyalgia was five times more likely to also have tension type headache  
Table 3.42 Neurological diseases/symptoms as comorbidities/accompanying symptoms of 
fibromyalgia 
Studies Percentage of 
comorbidity/accompanying 
symptoms 
OR and 95% CI or other 
findings 
Bernatsky et al. 184 Chronic fatigue syndrome: 4 (2.2%) No data 
Schur et al. 203 
No data 
Compared to twins within the 
Twin Registry without 
fibromyalgia: 
 
The OR and 95% CI after 
adjusted for age and sex is as 
following: 
Chronic fatigue syndrome: 29.1 
(26.9-31.5)  
Chronic tension type headache: 
5.0 (4.3-5.7)  
Kurtze et al. 196 Fatigue: 1359 (74.8%) 
No data 
Shillam et al. 226 Restless legs: 98 (57%) 
Difficulty falling asleep: 128 (75%) 
Difficulty staying asleep: 146 (85%)
Muscle spasms: 138 (81%) 
Fatigue: 163 (95%) 
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Studies Percentage of 
comorbidity/accompanying 
symptoms 
OR and 95% CI or other 
findings 
Nonrefreshing sleep: 159 (93%) 
Forgetfulness: 149 (87%) 
Difficulty concentrating: 130 (76%) 
Falling easily: 99 (58%) 
Feeling dizzy: 90 (53%) 
CI: Confidence interval 
OR: Odds ratio 
 
3.3.5.4 Diseases/symptoms of the digestive system as 
comorbiditis/accompanying symptoms of widespread pain 
Three studies reported findings for comorbid digestive disorders 184,203,226 (Table 3.43). The 
percentage of irritable bowel syndrome in fibromyalgia patients ranged from 36.1% to 62%. 
The association between fibromyalgia and irritable bowel syndrome was not significant (OR 
1.7 95% CI 0.8-3.9) 203. 
Table 3.43 Digestive diseases/symptoms as comorbidity/accompanying symptoms of 
fibromyalgia 
Studies Percentage of 
comorbidity/accompanying 
symptoms 
OR and 95% CI or other 
findings 
Schur et al. 203 
No data 
Compared to twins within the 
Twin Registry without 
fibromyalgia: 
 
IBS: 1.7 (0.8-3.9) 
Bernatsky et al. 
184 Irritable bowel: 65 (36.1%) 
No data Shillam et al. 226 Irritable bowel: 106 (62%) 
Comorbidities/accompanying symptoms of no association were italicised 
CI: Confidence interval 
OR: Odds ratio 
 
3.3.5.5 Diseases/symptoms of the genitourinary system as 
comorbidities/accompanying symptoms of widespread pain 
Three studies reported data for comorbid genitourinary disease/symptoms (Table 3.44) 
184,226,241. The percentage of irritable bladder ranged from 1% to 58%. 
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Table 3.44 Genitourinary diseases/symptoms as comorbidity/accompanying symptoms of 
fibromyalgia 
Studies Percentage of comorbidity/accompanying symptoms OR and 95% CI 
or other findings 
Bernatsky 
et al. 184 
The comorbidities of the 180 participants are as following: 
Irritable bladder 1 (1%) 
No data 
Shillam et 
al. 226 Irritable bladder: 99 (58%) 
Bazzichi 
et al.241 
Fibromyalgia only (FM1),  
Fibromyalgia with lifetime psychiatric comorbidity (FM2) 
Fibromyalgia with current comorbidity (FM3)  
 
ISS score > 30 - indicates sexual dysfunction. 76% of FM3, 
64% of FM2, and 43% of FM1 have sexual dysfunction. In 
total 57% of fibromyalgia have sexual dysfunction. In 
comparison with healthy controls, there is statistical 
significant difference between FM patients and health 
control (p<0.05). 
CI: Confidence interval 
ISS: Index of sexual satisfaction 
OR: Odds ratio 
 
3.3.5.6 Diseases/symptoms of circulatory, endocrine systems as 
comorbidity/accompanying symptoms of widespread pain or other 
findings 
There were two studies reported data for comorbid circulatory disease/symptoms (Appendix 
14) 184,226. The percentage for hypertension/vascular diseases were 10% 184 and for cold hands 
or bruising easily was 66% each 226. 
Only one study, included 99 fibromyalgia participants, reported the percentages for thyroid 
disease was 5%, for diabetes was 3.3%, and for anaemia/haematological disorders was 3.3% 
184. 
One study (n=171, USA fibromyalgia participants) reported the percentage of headache 
amongst fibromyalgia patients was 56% 226 
Two studies reported other findings (Appendix 15) 218,226. Carbonelle et al. 218 used 
Fibromyalgia Impact Questionnaire to assess the impact of fibromyalgia on those patients. 
The author found more than 50% of fibromyalgia patients with symptoms, including pain, 
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fatigue, stiffness, and did not have a well-rested sleep, rated the impact as severe (50th 
percentile VAS more than 7/10), and more than 50% of fibromyalgia patients with anxiety and 
depression rated the impact as moderately severe (50th percentile VAS at least 6.5/10). Shillam 
et al. 226 used another questionnaire (modified from Memorial Symptom Assessment Scale) 
and found at least 73% of fibromyalgia patients reported “sensitivity to light or 
sound”, ”profuse sweating or feeling hot”, and “skin tenderness”. Approximately 60% of 
fibromyalgia patients had “accident prone”, “swelling”, and “Inability to enjoy life”; and 35% 
of fibromyalgia patients had pelvic pain. 
3.3.6 Summaries for comorbidities/accompanying symptoms of CMP 
Summing up the types of comorbidities/accompanying symptoms. This SR included most data 
on comorbid mental and behavioural disorders (42 studies) and least data on comorbid “Eye 
and adnexa” and “ear and mastoid process” disorders (9 studies) (Table 3.45). Summaries of the 
comorbidities of CMP are listed from Table 3.46 to Table 3.48. These three tables only 
included data if more than one study reported percentage data or ORs on the same 
comorbidities/accompanying symptoms. There was no reporting of ORs of the same 
comorbidities/accompanying symptoms for fibromyalgia/widespread pain by more than one 
study.  
Percentage wise, the comorbidity/accompanying symptoms are listed below if the maximal 
percentage is more than 30%. For chronic SP, the comorbidity/accompanying symptoms 
included: somatoform disorder (97%), sleeping problem (76%), arthritis (71%), chronic pain 
(68.6%), GAD (65.7%), alcohol related disorders (64.9%), all kinds of anxiety disorders 
(45.7%), abuse or dependence of substance (36%), headache (31.9%), and irritable bowel 
syndrome (30.1%). For arthritis, the comorbidity/accompanying symptoms included: any 
physical or mental diseases (85.2%), chronic pain (73.4%), back/neck pain (69%), heart 
disease (54%), obesity/overweight (52.9%), and hypertension (47%). And for widespread pain, 
the comorbidity/accompanying symptoms included: fatigue (95%), depression/depressiveness 
(90.9%), anxiety (77.7%), irritable bowel syndrome (62%), and irritable bladder (58%). 
For chronic SP and arthritis, they were both associated with headache/migraine, depression, 
and panic attacks/disorder, hypertension, and heart diseases. Chronic SP and arthritis were both 
associated with each other. Chronic SP had also been shown to associate with GAD, mood 
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disorder, alcohol use disorder, digestive ulcer, and other lung diseases (apart from asthma, and 
tuberculosis); whereas arthritis was associated with PTSD, heart attack, asthma, any chronic 
pain, any physical disease, and "any mental or physical disorders, pain". 
Table 3.45 Number of studies reporting comorbidities and accompanying symptoms 
Types of comorbidities Study 
Mental and behavioural 
disorders/symptoms 
42 studies 
166,167,175-178,180,182,184-187,189,192,193,196,197,201-204,206-210,212,214,216,
217,219,220,222,224-226,228,232-235,241 
Musculoskeletal system and 
connective tissue disorders 
29 studies 
166-168,179-181,184,188,190,192,194,196,203,204,207,209,219,220,225-228,230,233,
235-237,239,240 
Circulatory disorders 22 studies 
166,167,176,180,184,192,194,200,207,209,212,219,220,226-228,230,233,235-237,239 
Endocrine, nutritional and 
metabolic disorders 
20 studies 
166,167,176,180,181,184,192,194,200,207,209,219,220,223,227,228,230,233,235,238 
Respiratory disorder 18 studies 
166,167,176,180,192,194,200,207,209,212,219,220,227,228,230,233,235,237 
Neurological disorders 18 studies 
166,167,180,184,188,190,194,196,203,207,209,220,226,229,230,233,235,240 
Digestive disorder 17 studies 
166,167,176,180,184,188,192,203,207,209,219,220,226,230,233,235,240 
Genitourinary disorders 16 studies 180,184,193,200,207,209,219,220,226-228,230,233,235,237,241. 
“Signs and abnormal clinical and 
laboratory findings, not 
elsewhere classified” (including 
headache) 
9 studies 166,167,190,192,213,226,230,235,240 
“Eye and adnexa” and “ear and 
mastoid process” disorders 
9 studies 166,167,176,180,207,209,233,235,236 
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Table 3.46 OR and percentage data of mental and behavioural, digestive, and circulatory, comorbidities/accompanying symptoms of CMP 
  Mental and behavioural disorders Diseases/symptom of the digestive system Diseases/symptoms of circulatory system 
CMP type   OR Percentage   OR Percentage   OR Percentage 
Chronic SP 
Major depression/depression 2.5 - 6.2 11.4% - 64% 
Digestive 
ulcer 3.1-4.0 ND 
Heart 
disease  CF  3.6% - 6.9%  
GAD 2.54 to 2.6 2% - 65.7%
Panic disorder 2.0 to 2.69 2.8% - 8.2%
Mood disorder 1.7 - 2.5 ND 
All anxiety disorders CF 21.6% - 45.7% 
Abuse or dependence on 
substances other than 
alcohol 
CF 4.1% -36% 
Irritable 
bowel 
syndrome 
ND 1.9% - 30.1% 
Hypertension 1.5-2.9 19.3% - 26.6% 
Somatoform disorder 
ND 
1% - 97% Stroke CF 4.3% - 6.7% 
Alcohol related disorders 2.1% - 64.9% 
Heart attack NA ND 
Phobias (including simple 
phobia, social phobia, and 
Specific phobia  
0% - 25.7%
Dysthymia 2% - 23.7%
Digestive 
ulcer 3.1-4.0 ND 
Obsessive compulsive 
disorder 0% - 13.4%
PTSD 1% - 7.3%  
Bipolar I or II  2% - 4.4% 
Arthritis 
Depression 1.48-2.82 4.9-24%  
Digestive 
ulcer / 
ulcer in 
stomach or 
intestine 
NA 0.3% – 11% 
Heart attack 5.8-8.7 11.8% - 17.1% 
Panic attacks/disorders 2.00-2.09 0% - 0.4% Heart disease 3.1-4.0 4% - 54% 
PTSD 2.52-3.69 0% - 0.8% 
High blood 
pressure 2.0-2.7 7.3% - 47% 
Dysthymia 
CF 
0.3% - 1.1%
Major depression disorder 
with/without hierarchy 3.9% - 5.7%
GAD 2.3% - 3.6% Stroke ND 0.7% - 4.2% 
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  Mental and behavioural disorders Diseases/symptom of the digestive system Diseases/symptoms of circulatory system 
CMP type   OR Percentage   OR Percentage   OR Percentage 
Any anxiety 2% - 22.3%
Panic disorder with or 
without agoraphobia ND 
Liver 
diseases ND  0.9% - 7.4% 
Vascular 
diseases ND 2% - 25.6% 
Simple phobia ND 
Social phobia ND 
Specific phobia 3.5% - 7.5%
Agoraphobia without 
panic ND 
Any mood disorders 3.9% - 5.7%
All mental disorder 10% - 10.5% 
Substance use 0.5% - 4.5%
Psychiatric diseases/disorder ND 7.84% - 26.3% 
Alcohol abuse or 
dependence NA 0.5% - 4.3%
Drug abuse or dependence 0% - 0.2% 
ADD/ADHD ND 22.1% - 29% 
Widespread pain 
Depression/depressiveness ND 5% - 90.9% Irritable 
bowel 
syndrome 
ND 36.1% - 62% ND Anxiety ND 1% - 77.7%
ADD: Attention deficit disorder 
ADHD: Attention deficit hyperactive disorder  
CF: Conflicting finding, indicated by bold font 
GAD: Generalized anxiety disorder 
ND: No data 
NA: No association, indicated by italicised font 
PTSD: Post traumatic stress disorder 
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Table 3.47 OR and percentage data of respiratory, “endocrine, nutritional, and metabolic”, “musculoskeletal and connective tissue” 
comorbidities/accompanying symptoms of CMP 
  Diseases/symptoms of the respiratory system 
Endocrine, nutritional and 
metabolic diseases/symptoms 
Diseases/symptom of the nervous 
system 
Diseases/symptoms of the 
musculoskeletal system and 
connective tissue 
CMP type   OR Percentage   OR Percentage   OR Percentage   OR Percentage 
Chronic SP 
Other lung 
disease (lung 
diseases apart 
from asthma, 
and 
tuberculosis) 
1.7-
2.9 ND Diabetes NA 0.5% - 8.2%
Migraine 1.33-5.2 
12.5% - 
25.39% Arthritis 3.0-7.9 1.5%-71% 
Asthma CF 7.2% - 16.9% 
Sleeping 
problem ND 
12.8% - 
76% 
Arthritis 
Asthma 3.8-5.0 
7.6% - 
12.6% 
Diabetes or 
high blood 
sugar 
CF 0.9% - 22.7% 
Neurological 
disorders CF ND 
Chronic back 
/ neck 
problem 
6.5-7.
9 6% - 69% 
Tuberculosis CF 0.5 - 3.2% 
Thyroid 
disease CF 0.4% - 6.7% 
Epilepsy or 
seizures ND 0% - 1.5% Osteoporosis ND 
3.2% - 
13.9% 
Other lung 
disease 
(apart from 
asthma and 
tuberculosis)
CF ND 
Chronic 
obstructive 
pulmonary 
disease 
ND 7% - 14% Obesity / overweight ND 
16.1% - 
54.2% 
Widespread 
pain ND Fatigue ND 2.2% - 95% ND 
CF: Conflicting finding, indicated by bold font 
ND: No data 
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NA: No association, indicated by italicised font 
 
 
Table 3.48 OR and percentage data of “abnormal clinical and laboratory findings, not elsewhere classified”, “eye, adnexa, ear and mastoid process”, 
and other comorbidities/accompanying symptoms of CMP 
  Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified 
Diseases/symptoms of the eye and 
adnexa and disease/symptom of the 
ear and mastoid process 
Other 
CMP type   OR Percentage   OR Percentage   OR Percentage 
Chronic SP Headache 4.0-7.0 14.6% - 31.9% Hearing impairment ND 6.0% - 6.6% Chronic pain* 3.4-4.8 18.9% - 68.6% 
Arthritis 
Headache 
(including 
frequent/severe 
headache/migraine) 
2.1-4.8 8.7% - 19.8% Seasonal allergies NA 7.8% - 12.4% 
Any chronic pain 6.1-6.3 45.2% -73.4% 
Any physical disease 2.3-3.1 ND 
Any mental or 
physical disorders, 
pain 
4.0-6.2 0% - 85.2% 
Malaria or other 
parasitic diseases NA ND 
Renal diseases: ND 0% - 11.2% 
Cancer ND 0% - 14.8% 
Widespread 
pain ND Irritable bladder ND 1% - 58% 
CF: Conflicting finding, indicated by bold font 
ND: No data 
NA: No association, indicated by italicised font 
*Chronic pain is defined as pain lasted more than six months and may be in any parts of the body ranging from head to toes and including chest, stomach, and pelvic 
pain.
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3.4 Discussion 
3.4.1 Summary 
The aims of the SR were to identify 1) the types of comorbidities/accompanying symptoms of 
CMP; 2) the percentages of comorbidities/accompanying symptoms in CMP; and 3) the 
association between CMP and comorbidity/accompanying symptoms of CMP.  
The SR identified that the types of comorbidities/accompanying symptoms of CMP included 
the mental and behavioural disorders, digestive diseases/symptoms, circulatory 
disorder/symptoms, respiratory diseases/symptoms, endocrine and metabolic 
diseases/disorders, nervous system disorders/symptoms, musculoskeletal diseases/disorders, 
headache, ear and nose symptoms, and other symptoms. The percentage of 
comorbidities/accompanying symptoms had been summarised in Chapter 3.3.6 Summaries for 
comorbidities/accompanying symptoms of CMP (p. 124). The most frequently occurred 
comorbidity/accompanying symptom for chronic SP was somatoform disorder (97%), for 
arthritis was any mental/physical disorders or pain (85.2%), and for widespread pain was 
fatigue (95%). Association between CMP and comorbidity/accompanying symptoms was also 
summarised in Chapter 3.3.6 Summaries for comorbidities/accompanying symptoms of CMP 
(p. 124). The highly associated comorbidity/accompanying symptoms with chronic SP was 
arthritis (OR 7.9), with arthritis was heart attack (OR 8.7), and no firm association for 
widespread pain was found. 
The association between CMP and its comorbidities does not reflect any cause-effect 
relationship. The cause of association included direct/indirect associations between the 
diseases 110, genetic susceptibility and family history 112, chance alone 110 or unknown of cause 
113. See details in Chapter 2.5.2 What are the causes of comorbidity? (p. 27). The discussion 
here is limited to the association without speculating on the cause-effect relationship. In this 
section, the discussion is focused on 1) comparison with other SRs, 2) complexity of CMP 
comorbidities and its relevance to diagnosis, 3) assessing comorbidities and accompanying 
symptoms, 4) assessing quality of case control and cohort studies, and 5) the need for urgent 
attention for CMP management. 
3.4.2 Strengths and limitations of this systematic review 
The strengths of the SR include: 
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1) Comprehensiveness. This review searched all conditions of OM and studied all reported 
comorbidities as well as symptoms.  
2) Both the epidemiological and the CMP-specific data were included and the sample sizes 
were large (total 358559 with a median of 590 and 635); 
3) Multiple studies reported findings on the same comorbidity/accompanying symptoms of 
the same type of CMP were found; 
4) Some of the comorbidity assessments, e.g. WHO CIDI, BDI, symptom checklist 90, body 
mass index, were used by multiple studies which further strengthens the evidence of the 
comorbidities; 
Limitations of this SR include: 
1) Only English data were available for analysis. No suitable study was selected from Chinese 
databases. Key Chinese databases, including CQVIP and Wanfang Data, were searched. Due 
to the differences in the database interface, the search results came up as either no results from 
CQVIP, or thousands of non-specific studies from Wangfang Data. This SR did not include 
studies in Chinese language nor included Chinese databases as part of the search strategy. 
Data in other languages were excluded;  
2) only data from a few countries were reported and available;  
3) the outcome measures of the comorbidities were not consistent. This can also affect the 
consistency of the results; For instance, self reported mental/psychiatric illnesses, BDI, and 
WHO CIDI. 
3.4.3 Comparison with other systematic review on comorbidity and 
accompanying symptom 
There were a few SRs published related to comorbidity and accompanying symptoms of 
musculoskeletal disorders. Kelly et al. found chronic LBP was associated with greater sleep 
disturbance, reduced sleep duration and sleep quality, increased time taken to fall asleep, poor 
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day-time function, and greater sleep dissatisfaction and distress. Inconsistent evidence was 
found that sleep efficiency and activity were adversely associated with chronic LBP 970.  
Shiri et al. substantiated the associations between overweight, long smoking history, high 
physical activity and a high serum C-reactive protein level with lumbar radicular pain or 
sciatica 971. Leboeuf-Yde et al. did not find any study evaluating the dose effect of alcohol on 
LBP and none of the included studies were prospective in design 972. Shiri et al. and 
Leboeur-Yde et al. only focused on Medline searches 971,972 whereas Kelly et al. focused on 
multi-databases searches 970. All of those SRs focused on either LBP 970, lumbar radicular pain 
or sciatica 971, or muscle diseases 973 with their searches up to end of January 2009 (Table 3.49). 
In comparison, the current review included the latest evidence, with database searches up to 
13/05/2015, comprehensive, included both comorbidities and accompanying symptoms and 
had identified the association between CMP and various disorders, most notably the comorbid 
mental and behavioural disorders/symptoms (Table 3.45). This SR included none of the 
studies included in the SRs of Kelly et al. 970 Shiri et al. 971 and Leboeuf-Yde et al 972 since to 
Kelly et al. specifically searched for and included only chronic LBP reporting sleep problems. 
Shiri et al. on the other hand searched for back pain including sciatica, radicular pain, and 
focused on cardiovascular or lifestyle risk factors, including hypertension, without including 
studies that reported data for hypertension. Furthermore Leboeuf-Yde et al. specifically 
focused and searched for “alcohol”, “substance abuse”, “life style”, “risk factor”, 
“epidemiology” and “low back pain”. Their search terms and selection criteria were different 
from the current SR. 
Table 3.49 Comparison with other CMP SRs 
Study Database Population Outcome 
Kelly et al. 970 Pubmed, CINAHL 
Plus, PsychInfo, 
Pedro, and the 
Cochrane database of 
SRs up to January 
2009 
Chronic LBP Sleep outcome 
measures 
Shiri et al. 971 Medline to August 
2006 
Lumbar radicular 
pain or sciatica 
patients 
Cardiovascular or 
lifestyle risk factors 
and lumbar radicular 
pain or clinically 
defined sciatica 
Leboeuf-Yde et al. 
972 
Medline from 1992 to 
June 1999 
LBP Consumption of 
alcohol and LBP. 
LBP: Low back pain 
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3.4.4 The complexity of CMP comorbidities and its relevance to diagnosis  
For the associations amongst CMP and comorbidities, it is certain that chronic SP and arthritic 
pain were associated with other types of pain (OR ranged from 1.33-7.9), including headache, 
other types of musculoskeletal pain, chronic pain, and other types of diseases (OR ranged 
from 1.48 – 6.2), including depression, panic disorder, and hypertension. Individually chronic 
SP and arthritic pain have their own associated comorbidities/accompanying symptoms. Such 
that alcohol use disorder, digestive ulcer, other lung disease (lung diseases apart from asthma, 
and tuberculosis) were associated with chronic SP, but not arthritic pain, and heart attack and 
asthma were associated with arthritic pain, but not chronic SP. Such association show arthritic 
pain and chronic SP had some similarities and differences. Although the strength of the 
association might not be as strong as the data informed due to the included studies mainly being 
reports from USA, and therefore not representing the world population. However, since the 
confidence intervals of ORs were larger than one, for such association to happen by chance was 
rare.  
These findings also ascertain the associations between CMP and the various comorbidities and 
add complexity to the understanding of CMP. Those comorbidities could be part of the 
presentation of CMP, but could also be the results of the treatment. Also, they could interact 
with each other. In an osteoporosis review, the author used osteoporosis as an example and 
discussed the depressive comorbidity and how depression and hip fracture increased the risk 
of each other 974. The findings were that 14-16% of hip fracture patients developed clinical 
significant depressive symptoms within six months after hospitalisation from no active 
depression history and 27% reported depressive reactions amongst the older adults 975. The 
daily use of serum serotonin reuptake inhibitor (SSRI) for depression was associated with a 
4.0% (95% CI, 1.4-6.6) lower bone mineral density at the hip compared to non-SSRI user 976. 
Moreover, the presence of two diseases could relate to a third independent disease, for 
example psoriasis, cardiovascular disease, and erectile dysfunction 977, bipolar, substance 
abuse, and psoriasis 977. Such complex relationship between diseases make diagnosis difficult 
978. 
Overall, the associations indicated chronic SP and arthritic pain occur together with other 
diseases/symptoms. It is necessary to look at these CMPs as a syndrome of 
diseases/symptoms cluster. For example, instead of looking at arthritic pain by itself, the 
arthritic pain syndrome will encompass arthritic pain, other chronic pain, headache, 
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depression, panic disorder, heart disease, and asthma. These symptoms and diseases should be 
viewed together and such approach had been proposed by Hartvigsen et al. 39.  
For the included studies on chronic SP and arthritis, there were four studies that reported OR 
for comorbid arthritis or chronic SP 166-168,192. Apart from Ijzelenberg et al. 168 who specified 
the comorbid symptoms as chronic neck pain, chronic shoulder pain, chronic complaints of 
elbow-wrist-hand pain, and chronic upper extremity complaint, none of the other three studies 
specified whether or not the arthritis was in the four extremities. Participants of these three 
studies may have overlapped arthritis and chronic SP where arthritic joint pain could occur 
within the spine, e.g. hyperplastic vertebrae, or chronic SP may also be considered as arthritis. 
Subsequently participants selected both the arthritis and chronic SP together and resulted in 
higher than normal ORs of their association. 
For widespread pain, the available data are limited. Multiple studies reported the percentage 
data for a wide range of accompanying symptoms associated with fibromyalgia and not OR. 
The accompanying symptoms included depression/depressiveness, anxiety, irritable bowel 
syndrome, fatigue, and irritable bladder. Those studies have helped the redevelopment of the 
diagnostic criteria of fibromyalgia. The recently published preliminary new diagnostic criteria 
for fibromyalgia 979 have included all the above mentioned conditions as well as sleep and 
cognitive problems. Only the percentage of sleep issues were reported by some of the 
included studies without OR data. This may be due to the search strategy did not search for 
fibromyalgia or widespread pain. The new criteria was established due to that the clinical 
trials reported symptoms in addition to the 1990 American College of Rheumatology criteria 
for fibromyalgia 980, such as sleep and cognitive problems. Based on the reference list of 
Wolfe et al. 979, although 10 RCTs were mentioned, their references were not listed 981,982. And 
such discrepancy between the current review and the new criteria maybe the current review 
did not specifically target fibromyalgia but instead focused on CMP. 
3.4.5 Assessing comorbidities and accompanying symptoms 
Several comorbidity/accompanying symptoms outcome measures were used in the included 
studies (Table 3.9 to Table 3.11). The most frequently used outcome measures were WHO 
CIDI, self-reported physical illness, and author -made comorbidity/accompanying symptoms 
list. For mental disorders, WHO CIDI was consistently used; but for physical illnesses there 
was heterogeneity in the tools used. Majority of the authors used self-reported physical illnesses 
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179,185,190,203,204,210,217,231 including Schur et al. who reported fibromyalgia patients was 29.1 
times more likely to develop chronic fatigue where the author obtained the data by asking 
participants “Has your doctor ever told you that you have chronic fatigue syndrome?” 203, or 
author made comorbidity/accompanying list 180,213,221,224,232,239,240. The other different 
comorbidity questionnaires were each used by single study 
187,188,198,202,205,207,211,212,215,218-220,225,229,230,236,241. Such heterogeneity can lead to problems in 
integrating findings 983. As shown in the results section, some authors reported the lumped 
together results of both liver/kidney diseases 220 and stomach/gall bladder conditions 176. This 
made it impossible to separate the data of liver diseases from those of kidney diseases.  
3.4.6 Inconsistent results in the included studies  
Of the reviewed studies, there were several conflict findings as shown from Table 3.46 to Table 
3.48. The possible reasons for such conflict were evaluated and listed in Table 3.50. It was clear 
that when data were collected from different countries, the results could be different. For 
example, all anxiety disorders had a conflicting finding between studies where Gureje et al. 
(Nigeria) reported no association (OR 1.5 (0.9-2.5)) 192, whereas Buist-Bouwman et al. 187 
(Netherlands) (OR 1.6 (1.3-2.0)), Tsang et al. 206 (Internationally collaborated study including 
Colombia, Mexico, USA, Belgium, France, Germany, Italy, Netherlands, Spain, Ukraine, 
Israel, Lebanon, Nigeria, South Africa, Japan, PRC (Beijing and Shanghai), and New Zealand.) 
(OR 2.0 (1.8-2.1)), and Von Korff et al. 167 (USA) (OR 2.3 (1.9-2.7)) all showed a positive 
association between chronic SP and all anxiety disorders. Another possibility is how data were 
analysed. Two studies presented the same set of data, but data were adjusted differently, 
resulting in different OR (Appendix 9) 176,202. This is a concern for SRs as there is no gold 
standard for the adjustment of ORs. 
Table 3.50 Possible explanations for conflicting findings 
Possible 
explanations 
of conflict 
finding 
Country difference Same set of data 
with different 
kind of 
adjustment for 
ORs 
Uncertain 
chronic SP All anxiety disorders, stroke, asthma No conflicting 
findings 
Abuse or 
dependence on 
other substances 
Arthritis Dysthymia, major depression disorder 
alone or with hierarchy, any anxiety, 
panic disorder with or without 
agoraphobia, specific phobia, any 
mood disorders, all mental disorder, 
GAD, simple 
phobia, social 
phobia, 
agoraphobia 
without panic 
No conflicting 
findings 
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Possible 
explanations 
of conflict 
finding 
Country difference Same set of data 
with different 
kind of 
adjustment for 
ORs 
Uncertain 
substance use, diabetes or high blood 
sugar, thyroid disease, tuberculosis, 
other lung disease (apart from asthma 
and tuberculosis), neurological 
disorders 
GAD: Generalized anxiety disorder 
3.4.7 Assessing quality of case control and cohort studies  
NOS was recommended by the Cochrane library and subsequently used in the SR to evaluate 
the methodological rigour 172. Currently there are other scales for quality assessment 984,985, but 
many of their validities and reliabilities have not been established or were designed for 
interventional studies (e.g. Checklist for Measuring Quality- Downs and Black) and are not 
suitable for the current SR 985. The content validity and inter rater reliability of NOS has been 
established and is valid and a reliable quality appraisal 41. 
For the included studies, the NOS scores were graded as unsatisfactory for most of the studies 
(58 studies). Only14 studies achieved five out of nine on NOS, reaching a satisfactory level. 
However some authors made the cut off NOS score for low quality studies to be equal to or less 
than five 986, and this would have graded all the included studies of low quality. Such a low 
score was due to NOS requiring the control group to be present for five items and requiring the 
reporting of follow up rate of each group. Many of the included studies did not have a control 
group and only reported the follow up rate of the whole sample, but not of each individual 
group. The requirement made some studies unable to score for five items (six scores lost), 
resulting a low score for many studies.  
Another point is the requirement of primary record. Studies described confirmation of 
diagnosis by specialists (e.g. rheumatologist), without referencing to the primary record (e.g. 
x-ray, medical/hospital records). Again four studies lost scores on this item 198,199,238,241. There 
is no gold standard to evaluate the quality of observational studies 987. NOS is among the most 
suitable ones. There is a need to develop a gold standard methodological appraisal instrument 
for evaluating the quality of observational studies. 
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Based on the NOS results, the heterogeneity amongst the studies and the lack of suitable scale, 
caution is advised when interpreting the results. 
3.4.8 The need for urgent attention for CMP management 
Bair et al. reviewed literatures on depression and pain and found depression and painful 
conditions frequently coexist 640. Often patients were referred to a specialist who has expertise 
in either depression or pain but not to a specialist who was good at both. Primary care 
practitioners who often encountered the combination of these two conditions often lacked 
knowledge or expertise to tackle this combination of conditions 640. A multidisciplinary and 
personalised pain management is essential to tackle both CMP and comorbidities, and 
improve both function and QoL 126,988. Researchers have proposed to have a guideline for 
each patient, who presents with multi comorbidities, rather than a guideline for each disease 
989, but the applicability of current evidence based guidelines for comorbidities is limited as 
most of them do not provide explicit guidance on treatment for patients with comorbidities 990. 
There are so far guidelines for treating comorbidities, but are limited to substance misuse 
comorbid with mental disorders in Australia 991(p5)992(p1). 
Based on the results of the current SR as well as the literature review on comorbidity (Chapter 
2.5 Comorbidities and symptomatology of chronic pain – a new direction of pain management 
(p. 27)), healthcare practitioners should pay closer attention to the comorbidities when treating 
CMP. Especially the comorbidities and accompanying symptoms listed from Table 3.46 to 
Table 3.48 as supported with ORs and prevalence/percentage data. These closer attentions will 
help health care practitioners to better diagnose, understand the patients’ complaints and 
intervene early in the course of disease progress before the diseases and comorbidities 
aggravate each other further. 
3.5 Conclusion 
3.5.1 Implications for practice 
Evidence indicates there is a need to view CMPs as CMP syndromes. Chronic musculoskeletal 
pain syndromes include other bodily pain, mental disorders, and non-pain physical 
disorders/diseases. When treating CMP syndromes, health care practitioners should be aware of 
the diseases and accompanying symptoms such syndromes include, and intervene as soon as 
possible before such patients present with increased numbers of comorbidities and 
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accompanying symptoms. 
3.5.2 Implications for future research 
More research is needed into the comorbidities and accompanying symptoms of CMP to better 
understand their potential cause-result relationship or interaction. Future research should focus 
on designing high quality studies based on the current methodology quality appraisal (NOS) 
and may need to focus on updating the diagnostic criteria for CMP including musculoskeletal 
diseases to reflect the realistic symptom presentation of CMP. Valid tools for observational 
studies are needed for quality control purpose.   
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4. Methods of initial CMPQ development 
4.1 Introduction 
This chapter describes the development and validation process of CMPQ. To develop a 
questionnaire, a series of steps are involved, including item generation, consultation with 
experts in the field for face and content validities of the questionnaires, and statistical analysis 
of validity and reliability. In addition, CMPQ also needed additional statistics such as 
frequency analysis, chi square tests, factor analysis, cluster analysis, Cochran’s Q test, and 
correlation tests. 
There were four stages in the the development and testing of the CMPQ. Figure 4.1 shows the 
four stages and the work involved. This chapter outlines the method and further details and 
results are presented in the subsequent four chapters as follows.  
Chapter five, item generation: This chapter detailed the process of how the items were 
generated for this CMPQ. Relevant literatures were searched and symptoms related to CMP 
were extracted. The extracted symptoms were grouped into pain regions, pain quality, pain 
rhythm, pain aggravators, pain alleviators, and accompanying symptoms. 
Chapter six, the initial development of CMPQ: This chapter involved experts’ discussion on 
the content and face validities of CMPQ. In addition, CMPQ was tested among EAOM trial 
participants 1 to evaluate internal consistency, test-retest reliability, and responsiveness which 
are essential components of questionnaire development. 
Chapter seven, the sub grouping of CMP: This chapter included using factor analysis and 
cluster analysis to sub group the CMP participants. Factor analysis was repeated with different 
commands in Statistical Package for Social Science (SPSS) several times to identify the 
factors that were meaningful in CM. Cluster analysis was also repeated with different 
commands in SPSS to identify the clusters interpretable in CM. Chinese medicine pattern 
diagnosis was used to interpret the two major clusters. Differences between clusters were also 
evaluated based on OM consumption, non OM analgesics consumption, average pain intensity, 
Roland Morris Disability Questionnaire (RMDQ), BDI, and SF36.  
Chapter eight, effect of treatments and association with other outcome measures: This chapter 
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included using CMPQ to evaluate the treatment effect of REA on the symptom presentation. 
This part also utilised SF36, BDI, and pain diary, which documented pain intensity and OM 
consumption, to compare the differences in these questionnaires between the two major 
subgroups of CMP. Results of SF36, BDI, and pain diary were used to identify the differences 
amongst the two major CMP clusters and the three treatment groups. 
 
BDI: Beck Depression Inventory 
CM: Chinese medicine 
CMP: Chronic musculoskeletal pain 
CMPQ: Chinese medicine pain questionnaire 
MANOVA: Multivariate analysis of variance 
OM: Opioid medication 
SF36: Medical outcome short form health survey 36 items 
Figure 4.1 Flow chart of the CMPQ development 
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Within this chapter, section 4.1 is the introduction which briefly describes the process involved 
in the CMPQ development and the roadmap of the work completed, section 4.2 outlines the 
participants involved, the inclusion and exclusion criteria, and the procedures of the EAOM 
trial in relation to questionnaire completion; section 4.3 describes the assessment of reliability 
and various forms of validity for questionnaire development; section 4.4 lists the outcome 
measures used in this developmental stage; section 4.5 describes data collection, and finally 
section 4.6 outlines the statistical analysis methods used during this developmental stage.  
4.2 Initial development of CMPQ 
This project was embedded within the EAOM trial 1. This trial aimed at inducing the release 
of endorphin, enhancing the opioid binding potential, but did not aim to target the CMP 
directly 1. The EAOM trial was approved by Human Research Ethics Committees (HRECs) of 
Melbourne Health (HREC number: 2009.033), Alfred Health (HREC number: 80.09) and 
RMIT University (HREC number: 06/09). The EAOM trial participant recruitment and 
inclusion/exclusion criteria are listed below. 
4.2.1 Participant identification 
There were several pathways of participant identification and recruitment: 
1) patient case records from Pain Services clinic, Royal Melbourne Hospital, Royal Park 
Campus, and Caulfield Pain Management and Research Centre, Caulfield Hospital, 
Caulfield were screened,  
2) newspaper advertisements for the EAOM trial identified respondents who were screened 
for the EAOM trial criteria, 
3) referrals from general practitioners (GPs) and specialists within Victoria, Australia. 
These pathways identified participants for the EAOM trial and CMPQ development. 
4.2.2 Inclusion and exclusion criteria 
The inclusion criteria for the EAOM trial were as follows:  
1) presence of CMP;  
2) regularly taking OM for more than three months;  
3) willing to reduce their OM usage;  
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4) 18 years and older;  
5) understanding written and spoken English.  
The exclusion criteria were:  
1) addicted to OM as judged by Pain Medication Questionnaire (PMQ);  
2) severely depressed with suicidal tendency as judged by medical doctors and BDI;  
3) abusing drugs, alcohol or having a history of abuse;  
4) severe arrhythmia or heart failure, pregnancy or intend to get pregnant, breast feeding 
women, epilepsy, brain tumour, cancer, haemophilia or wearing cardiac pacemakers. 
 
4.2.3 Procedure of the EAOM trial 
Participants were recruited for the EAOM trial if they fulfilled all selection criteria. They were 
given the participation information consent form and the other questionnaires to complete. 
Chinese medicine pain questionnaire was one of the questionnaires. Participants completed 
the questionnaires at one of the following trial centres: either at the Royal Melbourne or 
Caulfield hospital sites, National Ageing and Research Institute, the Geelong site, the 
participating CM clinics, or at the Discipline of Chinese medicine, RMIT University, 
Bundoora, Victoria. Chinese medicine pain questionnaire was handed to participants by the 
research personnel or by post. The trial procedure is illustrated in Figure 4.2 with details of the 
questionnaires completed. Treatment phases were divided into four phases – pre-baseline 
(week one), baseline (week five), mid treatment (week ten), and end of treatment (week 14) 
weeks. When participants entered baseline week, they were randomised into either real EA 
(REA), sham EA (SEA), or PMM alone, and completed CMPQ along with BDI, RMDQ, and 
SF36. Participants completed the same set of questionnaires in mid treatment week and at end 
of the treatment weeks. In addition, participants also completed daily pain and medication 
diaries which documented participants’ pain intensity and medication usage from pre-baseline 
week to end of treatment week. For pain diaries, the baseline weeks were defined as from 
week one to week four and end of treatment weeks was defined as from week 11 to week 14. 
This was due to participants with CMP having consumed OM for long term. It was necessary 
to observe their normal OM usage and normal pain level. The average pain and OM 
consumption over four weeks reflects better the participants’ pain and OM consumption. 
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When comparing the side effects of OM recorded in the pain and medication diary, baseline 
week was defined as week four. 
 
GP: General practitioner 
EAOM trial: Electroacupuncture on opioid consumption by patients with chronic 
musculoskeletal pain: a randomised controlled trial 
BDI: Beck depression inventory 
RMDQ: Roland Morris Disability Questionnaire 
CMPQ: Chinese medicine pain questionnaire 
REA: Real electro acupuncture 
SEA: Sham electro acupuncture 
PMM: Pain and medication management 
SF36: Medical outcome short form health survey36 items 
PMM: Pain medication management 
PMD: Pain and medication diary 
Figure 4.2 Procedure of patient recruitment and administering of questionnaires 
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4.3 Criteria of questionnaire development 
Development of a valid and reliable questionnaire requires fulfilling the questionnaire criteria. 
These included item generation and reduction, validities and reliabilities, responsiveness, 
interpretability. They are described in the following sections.  
4.3.1 Item generation and reduction 
Item generation referrs to generating questionnaire questions that reflect the key concept of 
the research 993. Such questions needed to relate to and be accepted by the participants 993. The 
source of the items was from texts relevant to the key concept of the research and discussion 
with experts in the field 993,994. Item reduction referred to removing items that were redundant, 
ambiguous, or insensitive to disease progression 995. Items selected by less than 5% of 
participants were removed 995. Chinese medicine pain questionnaire items were generated 
based on reviewing literatures relevant to CMP from a CM perspective. Details of how the 
items were generated have been described in Chapter 5 CMPQ item generation (p. 152). 
4.3.2 Validities 
Validities refer to whether or not a questionnaire was measuring what it was supposed to be 
measuring 996(p184)993. Content and face validities were assessed in the CMPQ development.  
4.3.2.1 Content validity 
Content validity refers to whether the questionnaire items were appropriate and measure what 
they are supposed to measure 996(p186)997. Such validity could be achieved by having experts in 
the field discuss the items through the Delphi method to reach agreement on the included 
items 996(p186,187). The Delphi method is a method used to reach consensus amongst experts 998. 
It uses structured surveys to obtain data from the experts 998. After each round of survey, the 
data is collected and fed back to the experts 998. Experts’ new responses are influenced by 
other experts’ opinions 998. Such rounds of survey continue until consensus is reached 
amongst the experts and generally goes for two to three rounds 999.  
In the CMPQ development, content validity was evaluated by assessing if the measurement 
aim, target population, concept measured, item selection and reduction, and the 
interpretability of the items of the CMPQ fulfilled the requirement of content validity. 
Participants in the Delphi process were CM researchers from RMIT Chinese Medicine 
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Research Group (RCMRG), RMIT University. The requirements for the participating 
RCMRG researchers were 1) graduated with a minimum of a bachelor degree in CM, 2) 
having practiced and researched in the CM field for at least three years, 3) be registered with 
the Chinese medicine registration board, Victoria, and 4) currently working in an educational 
institution. The participating RCMRG researchers included Dr. Zheng, Zhen (15 years of 
clinical experience and 13 years of clinical experience), Dr. Wang, Yanyi (4 years clinical and 
research experience), and Dr. Dong, Lin (over 20 years clinical experience and over 10 years 
research experience) in 2008. See Chapter 6.3.1 Content validity and face validity (p. 191). 
4.3.2.2 Face validity 
Face validity refers to the questionnaire appearing to be measuring what it is meant to 
measure 1000(p82). For example, the Oswestry Disability questionnaire achieved face validity 
when other people looked at it and felt it was measuring the disabilities of LBP. Face validity 
was assessed by asking the RCMRG researchers whether or not they thought the CMPQ was 
assessing the symptoms that CMP patients usually have. See Chapter 6.3.1 Content validity and 
face validity (p.191) for detailed assessment. 
4.3.3 Internal consistency 
Internal consistency refers to how correlated are the items in the questionnaire 997. Internal 
consistency is measured using Cronbach’s α 997. A Cronbach’s α value between 0.7-0.95 is 
considered sufficient 997. For example, SF36 has questions on physical functioning such as the 
questions in section three of SF36 “Does your health limit you in these activities”. The 
activities included “vigorous activities”, “moderate activities”, “lifting or carrying groceries”, 
and “climbing several flights of stairs”. A study has shown that SF36 had a high internal 
consistency for physical functioning (Cronbach's α= 0.90) 1001. Such an α coefficient indicated 
the questions were highly correlated.  
Internal consistency was assessed in the CMPQ development among the CMP patients who 
used OM for pain control by using statistical software SPSS. See Chapter 6.3.2 Internal 
consistency (p. 192). 
4.3.4 Reproducibility 
Reproducibility is also referred to as test-retest reliability. Test-retest reliability refers to how 
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similarly a person answered a questionnaire when he/she had been given the test again when 
there was no change in the person’s situation 997. For example, when a person completed SF36 
and scored 70/100 at the first time and then repeated SF36 in three days, during which time 
there was no change to his health status or other factors relevant to QoL, and he scored 71/100 
this second time, the SF36 is said to have test-retest reliability.  
Test-retest reliability was assessed in the CMPQ development by comparing the results of 
CMPQ at pre-baseline week with those at baseline week during the four-week baseline when 
the participants were informed not to change their usual treatments. See Chapter 6.3.3.1 
Agreement (test-retest reliability) (p. 192) for results. 
4.3.5 Responsiveness 
Responsiveness refers to the ability of the questionnaire to identify clinically important 
changes before and after an intervention 997. An example of responsiveness is the changes in 
BDI. When the change in BDI is five marks, it demonstrates a minimally important clinical 
difference, a change of 10-19 marks demonstrates a moderate difference, and a change of 
more than 20 marks demonstrates a large difference 1002.  
Responsiveness was assessed in the CMPQ development by comparing the changes in CMPQ 
between baseline week, mid treatment week, and end of treatment week using the Cochran’s 
Q analysis. The responses of REA and PMM alone were compared. See Chapter 6.3.7 
Responsiveness (p. 204) for details. 
4.4 Outcome measures 
The outcome measures used in this initial CMPQ development included CMPQ, BDI, SF36, 
and RMDQ, and pain and medication diaries.  
Chinese medicine pain questionnaire (Appendix 16) was developed to collect patient data on 
the symptoms the patient presented with. It focused on musculoskeletal pain with the 
accompanying non-pain symptoms. It was scored in a dichotomous manner where the 
symptom either was present or absent. This is the type of data a CM practitioner collects 
during a patient consultation, either presence of a symptom or absence of a symptom. This 
questionnaire was divided into six parts, the pain regions, the nature of pain, the rhythm of 
pain, the aggravators of pain, the alleviators of pain, and the accompanying non-pain 
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symptoms. 
Beck depression inventory (Appendix 17) is a questionnaire used to assess the degree of 
depression in the patient 1003. It was developed in 19611004, and later developed into BDI I-A 
and now BDI II 1002,1005. The current BDI II has 21 questions in relation to the existence and 
severity of depression 1003. Each of the questions, except for question 16 and 18, has four 
choices of answers ranging from no impact of the symptom to severely affected by that 
symptom 1003,1006. The total scores were added and the results were interpreted as described in 
(Table 6.1, p. 185). The psychometric properties of BDI include high internal consistency 
(Cronbach’s α=0.92), high test-retest reliability (coefficient = 0.93), content, construct, and 
criterion validities, and sensitivity to change where a five point difference indicates a 
minimum important clinical difference 1006. 
Medical outcome short form health survey 36 items (Appendix 18) was developed to evaluate 
the burden of disease and evaluate the changes between various treatments 1007. It is a 36 item 
questionnaire and currently version two has been developed 1007. These 36 questions can be 
grouped into eight scales, physical functioning, role-physical, bodily pain, general health, 
vitality, social functioning, role-emotional, and mental health 1007. These eight scales can be 
further summarised into a physical health summary and a mental health summary 1007. Scoring 
of SF36 is by a dichotomous response to a six point likert scale. The total score is summed up 
and organised into the eight scales and further summarised into the two health summaries. 
The instrument itself has achieved reliability, both internal consistency and test-retest 
reliability 1007, as well as content, concurrent, criterion, construct, and predictive validities 
1007. 
Roland Morris disability questionnaire (Appendix 19) was developed in 1983 to assess 
disabilities associated with LBP 1008. It contains 24 questions related to the disabilities 1009. 
Each question is scored as one if a patient ticks it. The score ranges from 0 to 24 where 0 
means no disabilities and 24 means the worst disability. It has good internal consistency 
(Cronbach’s α: 0.84–0.96) 1009. The intraclass correlation coefﬁcients for test–retest reliability 
in acute/subacute LBP patients were between 0.86 to 0.93 for one to 42 days test-retest interval 
1009. Roland Morris disability questionnaire also has achieved content, face, and construct 
validities 1009. 
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Pain and medication diary (Appendix 20) documented the severity of pain and the use of 
medication. The questions related to pain were divided into average, highest, and current pain 
and assessed using VASs. Furthermore there were two questions on the strength/unpleasantness 
of average pain with a word description next to the numbers for patients to select the number. 
Lastly there was a question on pain which asked participants to indicate the time of the day 
participants experienced pain. The medication part included an open ended table asking 
patients to fill in the types of OM/analgesics they used during the day. Participants were asked 
to fill in the name of the medication and the dosage of the medication as well as the number of 
tablets they consumed each time. At the end, there were questions related to the side effects of 
OMs and pain killers. Participants were asked to rate the severity of the side effects as well as 
the side effects of acupuncture when they had received EA treatments. 
4.5 Data collection 
Participants were asked to complete the CMPQ, BDI, SF36, RMDQ, and pain and medication 
diary (Figure 4.2). These data were collected either at the Royal Melbourne/Caulfield hospitals, 
Discipline of Chinese medicine, RMIT University, at the participating CM clinics by the 
research personnel, or by post. The data were entered and double checked by research 
personnel. Missing data were treated as missing data and no other methods (e.g. intention to 
treat, or mean score of all participants) were used for CMPQ. Last value carried forward was 
used for SF36, BDI, and pain and medication diary. 
4.6 Statistical analysis 
The statistical analysis used for this project included frequency analysis, Chi square test, 
factor analysis (principal component analysis), cluster analysis (K-means), Cochran’s Q test, 
analysis of variance (ANOVA), and multivariate analysis of variance (MANOVA).  
The following is a brief explanation of these statistical methods. 
Frequency analysis: Frequency analysis was by summing up the frequency results of all the 
participants’ variables. It was used to provide percentage data on demographic variables and 
CMPQ items. 
Chi square test: Chi square test was used to assess if the distribution of categorical variables 
were different between the groups or if there was an association between the variables 1010. 
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Chi square test was used in the project to test if there was a difference between groups in the 
variables of CMPQ symptoms. 
Factor analysis: Factor analysis used statistical software to group variables together into a 
subset of variables called factors 1011(p628). Examples of factors are traits of psychoticism, 
extraversion and neuroticism where any of the three traits contains a list of psychological 
symptoms/traits associated with each of them 1012. Factor analysis and principal component 
analysis are very similar. Principal component analysis aims to identify the linear components 
of a set of variables, in other words, its goal is to use the least number of factors to explain the 
maximal amount of variance whereas factor analysis aims to identify the factors by 
estimations 1011(p792). When applying principal component analysis, it might be that most 
variables have high factor loadings on the most important factor and small factor loadings on 
the other variables 1011(p642). This would make interpretation of the factors difficult. One 
method to overcome such a problem is by using factor rotation. Factor rotation refers to 
rotating the axis of factors so the variables are loaded maximally to the factors 1011(p642). One 
of the factor rotation methods is varimax. Varimax is an orthogonal rotation which aims to 
maximise the dispersion of the factor loading within the factors 1011(p644). 
In factor analysis, after software groups the variables together, it produces Eigen values, 
Kaiser–Meyer–Olkin measures (KMOs), and factor loadings. The Eigen value is an indication 
of the variance of variables in a given factor. KMO is used to assess the sampling adequacy 
1011(p647). The value of KMO ranges from zero to one where zero means the pattern of 
correlation in the factors was diffuse and one means the factors were distinct and reliable 
1011(p647). The interpretation for KMO is: 0.5-0.7 is mediocre, 0.7-0.8 is good, 0.8-0.9 is great 
and above 0.9 is superb 1011(p647). Factor loading is a regression coefficient of a variable to the 
factor 1011(p786). It indicates the relative contribution a variable contributed to a factor. Stevens et 
al. proposed the following significant factor loading critical values based on sample size (Table 
4. 1) 1013. 
 Table 4. 1 Critical value for correlation coefficient at α=0.01 for a two tailed test. 
N Critical 
value 
50 0.722 
80 0.572 
100 0.512 
140 0.434 
180 0.384 
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N Critical 
value 
200 0.364 
250 0.326 
300 0.298 
400 0.258 
600 0.21 
800 0.182 
1000 0.162 
 
For each of the resulting factors, it must be interpretable. Otherwise the resulting factors are 
not meaningful. 
Cluster analysis: Cluster analysis refers to using statistical methods to produce meaningful 
subgroups of individuals 1014(p18). Studies have been done using cluster analysis to sub group 
patients in conditions such as LBP, SP 1015, and upper extremity musculoskeletal disorders 1016. 
These three studies used K-means cluster analysis. K-means cluster analysis sub groups 
observations by reassigning the observations iteratively into a pre-specified number of 
clusters. It does so until distinctive clusters are found and until the maximum iteration 
numbers are met 1014(p478). K-means cluster analysis can only be used on scaled data but not 
ordinal data. That is to say when the data is a continuous scale, e.g. zero to ten on VAS, this is 
suitable for K-means cluster analysis. Whereas if the data is an ordinal scale or a dichotomous 
data, e.g. zero to five on the pain intensity scale where zero meant no pain, one meant slight 
pain, two meant just pain, three meant more pain, four meant strong pain, and five meant 
agonising pain, or a yes/no response where yes meant there was pain and no meant there was 
no pain, then K-means cluster analysis is not suitable.  
After deriving the clusters, these clusters were reviewed by the CM cluster analysis group to 
diagnose the CM patterns based on the CM eight guiding principles. This group included Dr. 
Zhen, Zheng; Dr. Yanyi, Wang; Dr. Xinyu (Alan), Hao; Dr. Dawn Lit Wong, and the author. 
Cochran’s Q test: Cochran’s Q test is a test for identifying if there are differences in the 
change of dichotomous response in groups. That is to say if participants were divided into 
three groups A, B, and C and they answered yes or no for if they liked to have an X-ray test as 
part of a routine health check-up. Then, half a year later, they were asked the same question 
and the results were compared to determine if there were any significant changes in their 
response. 
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Association with other outcome measures: Both ANOVA and MANOVA were used to 
evaluate if there were differences associated with CM patterns and SF36, BDI, OM 
consumptions, and average pain as well as CM patterns, treatment groups, and the four 
outcome measures. 
ANOVA: Analysis of variance is a statistical test used to find out if there is a difference 
between three or more groups in the dependent variable 1017. That is to say if there were three 
groups A, B, and C and you want to find out if the participant’s weights in these three groups 
differed significantly, you could use ANOVA to find out. 
MANOVA: This is ANOVA with several dependent variables. That is to say for the above 
example, if you were interested in knowing if weight, height, and number of work hours 
differed significantly amongst the three groups. Then you can use MANOVA for all three 
variables instead of separate ANOVAs for each individual variable. 
4.7 Summary 
This chapter listed the key steps in this initial CMPQ development, the roadmap of the project, 
and the relevant statistical analysis. Next chapter focuses on item generation of CMPQ.
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5. CMPQ item generation 
5.1 Introduction 
In the previous chapter, the methods used for CMPQ development were described. This chapter 
reports on the first step which was generating the items for a CM questionnaire for application 
in CMP.  
The development of the CM questionnaire incorporated reviewing the literature to generate the 
items and a delphi expert consultation process for the addition and retention of the items 1018. In 
a clinical situation, CM practitioners gather data about the characteristics of pain including pain 
location, pain rhythm, pain quality, the pain aggravators, the pain alleviators, and the 
accompanying symptoms. As explained in Chapter 2.6 Chinese medicine (p. 32), these data are 
used to diagnose a CM pattern. One of the methods of pattern identification is called “CM 
eight guiding principles”. The CM eight guiding principles identify a pattern based on the 
combination of four categories. These four categories include Yin and Yang, interior and 
exterior, cold and heat, and deficiency and excess depending on the symptom presentation. For 
example, the presence of fatigue indicates a deficient pattern whereas the presence of severe 
pain indicates an excess pattern 1019(p307,531) and the absence of the symptom may indicate a 
particular pattern (e.g. excess/deficiency) is not present.  
This chapter explains the procedure involved in generating CMPQ items as part of the initial 
CMPQ development and reports the results for item generation. 
5.2 Methods 
5.2.1 Literature search 
In order to generate the CMPQ items to assess the clinical presentation of CMP from a CM 
perspective, literature search and experts’ opinion were applied. Standard textbooks used in 
tertiary education and specialised CMP texts in CM were used and searched.  
5.2.2 Restriction of language 
Languages were limited to Chinese and English. 
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5.2.3 Search strategies and extracting literature information 
Descriptions of all types of CMP were considered. Examples of CMP included LBP (腰痛), 
Bi syndrome (痹症), arthritis (关节炎), and cervico-spondylopathy (颈椎病). Information 
related to CMP description, CMP clinical presentation, aggravating and alleviating factors as 
well as other accompanying non-pain symptoms were extracted.  
The criteria for the included textbooks were 1) prescribed textbooks in CM courses offered by 
tertiary education institutions, or 2) specialised CM book on pain. Exclusion criteria for the 
items were those items describing acute musculoskeletal pain disease/conditions, such as 
muscle aches related to influenza. 
Symptoms associated with CMP in the included textbooks were extracted. The symptoms may 
be directly associated with CMP or related to one of the CM patterns of CMP. These 
symptoms may be related to the location of pain, rhythm of pain, pain quality, 
alleviating/aggravating factors of pain, accompanying symptoms other than CMP, and 
gynaecological symptoms. Repetitive items were deleted; and the descriptions of symptoms 
were rephrased when necessary to avoid medical jargon and make them understandable by a 
lay person. The resulting items were then categorised into pain regions, pain quality, pain 
rhythm, pain aggravators, pain alleviators, accompanying non-pain symptoms, and 
gynaecological symptoms. 
5.3 Results 
The CMPQ items were generated based on reviewing CMP related conditions/diseases from 
four texts: 1) the practice of Chinese medicine 1020(p981-1047,1059-1118), 2) clinical handbook of 
internal medicine 1021(p308-335), 3) Chinese internal medicine 132(p706-708,890-895), 4) Traumatology 
of Chinese medicine 
1022(p963,973,976,984,987,995,996,1002,1005,1007,1012,1014,1017,1019,1023,1032,1034,1042,1045,1047,1051,1054,1062,1069,1078,10
94,1097,1107,1108,1116,1131,1136,1158,1168,1171,1172,1176,1177,1306,1325,1536,1538,1541-1548,1554-1557,1567-1570,1574-1576,157
9-1581,1583,1584,1586-1588,1631-1635,1642-1644,1650-1651,1652-1653,1654-1656), and discussion with expert in the 
field. The expert identified was A/Prof. Zhen Zheng who had a bachelor degree in CM, a PhD 
degree, and 15 years of CM clinical experience.  
Some additional symptoms were added upon discussion with A/Prof. Zhen Zheng. Minor 
changes were made to the draft questionnaires as a result of discussion. The items “burning 
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pain”, “not known”, and an open ended question on “other” pain quality were added in the 
pain quality domain. Some terms were rephrased e.g. “worse at night” was rephrased as 
“Worse at night, better during the day”. The resultant CMPQ included 187 items. Dichotomous 
data format was used, which meant the symptom was either present/absent to be consistent 
with clinical practice. 
5.3.1 Composition of the questionnaire  
CMPQ items were grouped into the six domains. These six domains were pain regions, pain 
quality, pain rhythm, pain aggravator, pain alleviator, and accompanying symptoms. 
1) Pain regions were arranged and categorised according to the anatomical body regions 
modified based on International Association for the Study of Pain coding for chronic pain 
1023(p3). These categories included a) head, neck & shoulder (seven items), b) upper limbs 
(six items), c) lower limbs (nine items), d) front of the body trunk (five items)), and e) back 
of the body trunk (five items). There were a total of 32 items. The exact items are listed in 
Table 5.1. 
Table 5.1 Pain region items generated from literature search 
Pain regions Item 
Head, Neck & Shoulder Frontal head 
Sides of the head 
Back of the head 
Vertex  
Neck 
Shoulder 
Shoulder blades 
Upper limbs  Upper arm  
Elbow 
Forearm 
Wrist 
Hand 
Fingers 
Lower limbs Hip 
Thigh 
Knee  
Front of the leg  
Calf 
Ankle 
Heel 
Sole 
Toes 
Front of the body trunk Chest 
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Pain regions Item 
Stomach 
Abdomen  
Groin 
Side of the body 
Back of the body trunk Between shoulder blades 
Middle Back  
Lower back  
Sacrum 
Buttocks  
 
2) Pain quality and pain rhythm items are listed in Table 5.2. There are 14 items for pain 
quality with the last item being an open ended question for participants to describe if they 
could not find a suitable description. There are12 items for pain rhythm with the last item 
being an open ended question for participants to describe if they could not find a suitable 
description. 
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Table 5.2 Pain quality and pain rhythm items generated from literature review 
Item category Items 
Pain quality Cold 
Pulling 
Distending 
Fixed location 
Moving from one spot to another 
Sharp 
Pricking 
Numbness 
Dull 
Dull pain with weakness 
Hot 
Burning 
Not known 
Other (please specify) 
Pain rhythm All the time 
Recurrent 
Fluctuate 
Worse during the day, better at night 
Worse at night, better during the day 
Worse when first get up 
Worse at the end of the day 
Worse in the morning 
Worse at lunch time 
Worse in the afternoon 
Not known 
Other (please specify) 
Italicised items mean additional items upon discussion with A/Prof. Zhen Zheng. 
 
3) Pain aggravators were arranged according to the types of aggravators (Table 5.3): a) 
environmental changes (five items); b) exercise or sports (10 items); c) physiological and 
psychological changes (five items), d) others (four items), and e) female menstrual cycle 
(three items). There were two additional items not belonging to the above groups. One 
was “not known” and the other one was “others (please specify)”. “Others (please specify)” 
was an open ended question for participants to describe the aggravators if they were not 
listed in this section. In total there were 29 items. 
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Table 5.3 Pain aggravators items generated from literature review 
Types of aggravators Item 
Environmental changes Cold weather  
Wet weather 
Windy days 
Weather change 
Hot weather  
Exercise of sports Standing 
Walking
Lying-down 
Physical work 
Sitting  
Lifting 
Bending 
Any movement 
Going up/down stairs 
Driving  
Physiological and 
psychological changes 
After eating 
Being hungry 
Bad night sleep 
Stress 
Being emotional 
Others Pressure on the area 
Sex 
Everything 
Household chores 
 
 Not known 
 
 Others (Please specify) 
 
Female menstrual cycle Before period 
During period 
After period 
Italicised items mean additional items upon discussion with A/Prof. Zhen Zheng. 
 
4) Pain alleviators items were arranged similarly to pain aggravators. They were also 
grouped into a) environmental changes (eight items); b) exercise or sports (nine items); c) 
physiological and psychological changes (five items); d) others (14 items), and e) female 
menstrual cycle (three items). There were two additional items not belonging to the above 
groups. One was “not known”, and the other one was “others (please specify)”. “Others 
(please specify)” was an open ended question for participants to describe the alleviators if 
they were not listed in this section. The items are slightly different from the pain 
aggravators and are listed in Table 5.4. In total, there were 41 pain alleviator items. 
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Table 5.4 Pain alleviators items generated from literature review 
Types of alleviators Items 
Environmental changes Cold weather  
Wet weather 
Windy days 
Hot packs 
Cold packs 
Hot weather 
Warm/hot bath
Warm/hot shower 
Exercise or sport Standing 
Walking 
Lying-down 
Sitting 
Gentle massage 
Gentle exercise 
Any movement 
Resting 
Driving  
Physiological and 
psychological changes 
Eating 
Being hungry 
Deep breathing  
Belching 
Bowel movement 
Others Pain killer 
Pressure on the pain area 
Keeping my mind off pain 
Being with other people 
Alcohol  
Reading 
Sleep 
Working 
Watching TV  
Keeping busy 
Sex 
Everything  
Household chores 
Nothing  
 
 Not known 
 
 Other (please specify) 
 
Female menstrual cycle Before period 
During period 
After period 
Italicised items mean additional items upon discussion with A/Prof. Zhen Zheng. 
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5) The accompanying symptoms (Table 5.5). The accompanying symptoms were divided into 
two groups. They were the accompanying symptoms (46 items) and gynaecological 
related symptoms (13 items). In both categories, the last item “Others (please specify)” 
was an open ended question for participants to describe other accompanying 
symptoms/gynaecological symptoms if they were not listed in this section. In total there 
were 59 items in this category. 
Table 5.5 Accompanying symptom items generated from literature review 
Item category Items 
Accompanying symptoms Swollen joints 
Red and hot joints 
Cold joints 
Limited movement 
Distention sensation in the abdomen  
Indigestion 
Heavy sensation in the body 
Cold hands and feet 
Cold lower back or knees 
Feeling cold easily  
Feeling hot easily 
Insomnia 
Night sweating 
Irritable 
Dry or sore throat 
Flushed face 
Hot palms 
Thirsty  
Watery diarrhoea 
Mushy stools 
Dry stools 
Constipation 
Dry skin 
Leak when sneezing or cough 
Frequent urination at night  
Frequent urination 
Poor concentration 
Poor memory  
Low libido 
Poor appetite  
Feeling tired easily 
Sigh often 
Need deep breath 
Short of breath 
Sweat upon mild activities 
Catch cold easily  
Abdominal distention 
Stuffiness in the chest 
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Feeling nervous easily  
Feeling depressed 
Reflux 
Belching  
Nausea 
Dizziness 
Skin itch 
Others (please specify) 
Gynaecological symptoms Abdominal pain during or before periods 
Low back pain during or before periods 
Dark blood 
Light blood (pink) 
Bleeding with clots 
Excessive bleeding 
Light bleeding 
Delayed periods 
Early periods 
Irregular periods 
Excessive watery discharge 
Yellow discharge 
Other (please specify) 
Italicised items mean additional items upon discussion with Dr. Zhen Zheng. 
 
Overall there were 187 items in CMPQ. Table 5.6 lists the number of items in each of the 
CMPQ categories. The accompanying symptoms category has the highest number of items 
and pain rhythm category has the least number of items. 
Table 5.6 Number of items in the CMPQ 
Category Main items Open ended 
question 
Female related 
questions 
Total 
Pain region 32 0 0 32 
Pain quality 13 1 0 14 
Pain rhythm 11 1 0 12 
Pain aggravators 25 1 3 29 
Pain alleviators 37 1 3 41 
Accompanying 
symptoms 
45 2 12 59 
Total 163 6 18 187 
 
5.4  Discussion 
This chapter listed the steps and results of how CMPQ items were generated. The generated 
items were grouped into pain regions, pain quality, pain rhythm, pain aggravators, pain 
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alleviators, and accompanying symptoms. The included accompanying symptoms covered a 
wide range of symptoms necessary for CM pattern identification. This feature was distinctive 
to CM in comparison to Western medicine. 
The anatomical region was incorporated into the CMPQ and coding of chronic pain from 
IASP was used. In CM, apart from the lower back region, which indicated a CM kidney 
involvement; other regions of the body were not relevant in CM pattern diagnosis.  
For pain quality, the McGill pain questionnaire 1024 is available. It lists many types of pain 
sensations such as boring, drilling, scalding, and smarting. Some of these pain sensations 
could be understood from CM perspective, e.g. sharp, and pricking (Table 5.7), whereas some 
were not explainable in CM point of view, e.g. smarting, boring, and drilling. Consequently 
McGill pain questionnaire was not incorporated within CMPQ.  
Different kinds of pain rhythm could mean different patterns such as pain worse in the 
morning means dampness retention and pain that fluctuates means Qi stagnation. So these 
were included in the CMPQ (Table 5.7). 
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Table 5.7 Pain quality and rhythm and their CM eight guiding principles explanation 
Item 
category
Items CM eight guiding principles 
 Yin Yang Exterior Interior Cold Heat Deficient Excess Comments 
Pain 
quality 
Cold    x x     
Pulling    x x   x  
Distending    x    x Qi stagnation 
Fixed 
location 
   x    x Blood stagnation 
Moving 
from one 
spot to 
another 
  x x    x This symptom can indicate interior 
pattern, if it accompanies with dull ache; 
or exterior pattern if accompanies with 
numbness, stiffness, or spasm. 
Sharp    x    x Blood stagnation 
Pricking    x    x Blood stagnation 
Numbness    x   x x This symptom can indicate deficiency 
pattern if there is accompanying weakness 
in the extremity, withered and lustreless 
complexion, shortness of breath, 
palpitation, dizziness and vertigo, pale 
nails and lips; or excess pattern if there is 
accompanying symptom aggravation by 
cold weather, aversion to cold, cold 
extremities, sore and heaviness in the 
lumbar or knee, pins and needles 
sensation, dull and distending sensation, 
dark complexion, purple lips, tremor of 
the extremities, dizziness, irritability, 
short temper, insomnia with excessive 
dreams, itchiness, vertigo, heaviness in 
the shoulder and back, or nausea, copious 
phlegm, heaviness and pain in the limbs, 
not very thirsty, both feet prefers to step 
on cool area, heaviness sensation, nausea, 
dizziness, or chest stuffiness. 
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Item 
category
Items CM eight guiding principles 
 Yin Yang Exterior Interior Cold Heat Deficient Excess Comments 
Dull    x    x Qi stagnation 
Dull pain 
with 
weakness 
   x   x  Qi stagnation 
Hot    x  x    
Burning    x  x    
Not known          
Pain 
rhythm 
All the time          
Recurrent    x    x Dampness retention 
Fluctuate    x    x Qi stagnation 
Worse 
during the 
day, better at 
night 
 x  x   x   
Worse at 
night, better 
during the 
day 
x   x   x   
Worse when 
first get up 
   x    x Dampness retention 
Worse at the 
end of the 
day 
   x   x  Qi deficiency 
Worse in the 
morning 
   x    x Dampness retention 
Worse at 
lunch time 
         
Worse in the 
afternoon 
         
Not known          
*Pain character in italicised font indicates no possible CM explanation. 
Information extracted from Chinese medicine diagnosis 38(p50-53), and Differential diagnosis of symptom in Chinese medicine 1025(p223-225). 
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Pain aggravators and alleviators could have a close link to the CM pattern such as worse in wet weather means dampness retention and worse in 
the cold weather means cold retention (Table 5.8 and Table 5.9). For pain aggravated by physical work such as lifting, bending, going up/down 
stairs, these indicate Qi deficiency as Qi is considered a source of nutrients that nourishes the muscle, tendon, bone and skin 130 whereas pain 
aggravated by lying down and sitting are a symptom related to dampness retention 38(p179) pain aggravated by stress/being emotional is due to 
stagnation of Qi, and pain aggravated by pressure on the area indicated excess. For pain alleviators, they were opposite to the pain aggravators in 
many aspects such as pain alleviated by hot weather indicates cold retention, pain alleviated by walking indicated dampness retention (excess as 
oppose to Qi deficiency in the pain aggravators), and pain alleviated by pressure on the area indicated deficiency. 
Table 5.8 Pain aggravators and their CM eight guiding principles explanation 
Pain aggravator 
categories 
Items CM eight guiding principles 
Yin Yang Exterior Interior Cold Heat Deficient Excess Comments 
Environmental 
changes 
 
Cold weather      x   x  
Wet weather    x    x Dampness retention 
Windy days   x       
Weather change    x    x Dampness retention 
Hot weather     x  x  x  
Exercise of sports 
 
 
Standing          
Walking    x   x  Qi deficiency 
Lying-down    x    x Dampness retention 
Physical work    x   x  Qi deficiency 
Sitting     x    x Dampness retention 
Lifting    x   x  Qi deficiency 
Bending    x   x  Qi deficiency 
Any movement    x   x  Qi deficiency 
Going up/down stairs    x   x  Qi deficiency 
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Pain aggravator 
categories 
Items CM eight guiding principles 
Yin Yang Exterior Interior Cold Heat Deficient Excess Comments 
Driving           
Physiological and 
psychological 
changes 
After eating    x    x Food retention 
Being hungry          
Bad night sleep x   x   x   
Stress    x    x CM liver Qi stagnation 
Being emotional    x    x Qi stagnation 
Others Pressure on the area    x    x  
Sex    x   x   
Everything          
Household chores    x   x  Qi deficiency 
           
 Not known          
           
Female menstrual 
cycle 
Before period          
 During period          
 After period          
*Pain character in italicised font indicates no possible CM explanation. 
Information extracted from Chinese medicine diagnosis 38(p50-53,81-100) Chinese medicine internal medicine 134(p135)Principle of Chinese 
medicine133(p37,95,96) 
Table 5.9 Pain alleviators and their CM eight guiding principles explanation 
Pain alleviator 
categories 
Items CM eight guiding principles 
Yin Yang Exterior Interior Cold Heat Deficient Excess Comments 
Environmental 
changes 
Cold weather           
Wet weather          
Windy days          
Hot packs    x x  x x This symptom may 
indicate excess pattern if 
there is accompanying 
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Pain alleviator 
categories 
Items CM eight guiding principles 
Yin Yang Exterior Interior Cold Heat Deficient Excess Comments 
cold limbs, abdominal 
pain and refused to be 
touched; or deficiency 
pattern if there is 
accompanying cold limbs, 
abdominal pain preferring 
to be touched, loose stool.  
Cold packs    x  x x x This symptom may 
indicate excess pattern if 
there is accompanying 
fever with preference of 
cold temperature, thirst 
with preference of cold 
drinks, red face and eyes, 
irritability; or deficiency 
pattern if there is 
accompanying malar 
flush, emaciation, tidal 
fever, night sweating, heat 
in the chest/palm/soles, 
dry mouth and thirst. 
Hot weather    x x  x x Same as hot packs 
Warm/hot bath    x x  x x 
Warm/hot shower    x x  x x 
Exercise or sport Standing          
Walking    x    x Dampness retention 
Lying-down    x   x   
Sitting    x   x   
Gentle massage       x   
Gentle exercise        x Dampness retention 
Any movement        x Dampness retention 
Resting       x  Qi deficiency 
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Pain alleviator 
categories 
Items CM eight guiding principles 
Yin Yang Exterior Interior Cold Heat Deficient Excess Comments 
Driving           
Physiological 
and 
psychological 
changes 
Eating          
Being hungry        x Food retention 
Deep breathing           
Belching          
Bowel movement    x    x  
Others Pain killer          
Pressure on the pain 
area 
   x   x   
Keeping my mind off 
pain 
         
Being with other people          
Alcohol     x x    Interior cold retention 
Reading          
Sleep x   x   x   
Working    x    x Dampness retention 
Watching TV           
Keeping busy          
Sex          
Everything           
Household chores    x    x Dampness retention 
Nothing           
           
 Not known          
           
Female 
menstrual cycle 
Before period          
 During period          
 After period          
*Pain character in italicised font indicates no possible CM explanation. 
Information extracted from Chinese medicine diagnosis 38(p50-53,81-100) 
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For other symptoms (Table 5.10), they also have CM interpretations such as “red and hot joints” as well as “swollen joints” indicate heat 
retention, whereas "leaking urine when sneezing or coughing", "frequent urination at night", "frequent urination", "feeling tired easily", "need a 
deep breath", "short of breath", and "sweat upon mild activities" all indicate Qi deficiency. 
Table 5.10 Accompanying symptoms and their CM eight guiding principles explanation 
Item category Items CM eight guiding principles 
Yin Yang Exterior Interior Cold Heat Deficient Excess Comments 
Accompanying 
symptoms 
Swollen 
joints 
   x  x  x  
Red and hot 
joints 
   x  x  x  
Cold joints  x  x   x   
Limited 
movement 
         
Distention 
sensation in 
the abdomen  
   x    x Dampness retention 
Indigestion    x   x  CM spleen Qi deficiency 
Heavy 
sensation in 
the body 
   x    x Dampness retention 
Cold hands 
and feet 
 x  x   x  CM spleen Yang deficiency 
Cold lower 
back or knees 
 x  x   x  CM kidney Yang deficiency 
Feeling cold 
easily  
 x  x   x   
Feeling hot x   x   x   
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Item category Items CM eight guiding principles 
Yin Yang Exterior Interior Cold Heat Deficient Excess Comments 
easily 
Insomnia x   x  x x x This symptom may indicate Yin deficiency 
pattern if there is accompanying night sweating, 
emaciation, feverish sensation in 
chest/palm/soles; or excessive heat pattern if 
there is accompanying constipation, red eyes 
and/or face, thirst with preference of cold drink, 
and irritability.  
Night 
sweating 
x   x   x   
Irritable    x  x  x  
Dry or sore 
throat 
x  x x  x x x This symptom may indicate 
exterior/interior/Yin deficiency/excessive 
heat patterns. 
 
If this is exterior heat pattern, patient may also 
have fever, slight chill, and cough with yellow 
phlegm. 
 
If this is interior excessive heat pattern, patient 
may also have coarse breathing, high grade 
fever, thirst, irritability, and cough with thick 
yellow phlegm. 
 
If this is Yin deficiency/deficient heat pattern, 
patient may accompany with steaming bone 
sensation, night sweating, heat in 
chest/palms/soles, dizziness and vertigo. 
Flushed face x   x   x   
Hot palms x   x   x   
Thirsty     x  x x x This symptom may indicate 
deficient/excessive heat pattern depending on 
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Item category Items CM eight guiding principles 
Yin Yang Exterior Interior Cold Heat Deficient Excess Comments 
if patient present with symptoms of interior 
excessive heat pattern or Yin deficient pattern 
as described in “Dry or sore throat”. 
Watery 
diarrhoea 
 x  x   x   
Mushy stools    x   x   
Dry stools x   x  x x x This symptom may indicate interior 
deficient/excessive/cold/heat pattern. 
 
The interior excess pattern includes excessive 
heat pattern, Qi stagnation pattern, and cold 
retention pattern. Their symptoms include dry 
stool, scanty and red urine, red face with 
feverish sensation, abdominal distention/pain, 
dry mouth, foul breath; frequent hiccup, 
fullness and distention sensation in the chest 
and hypochondriac region, distending pain in 
the abdomen, poor appetite; clear profuse 
urine, pale complexion, cold extremity, prefers 
warmth and dislike scold, cold pain in the 
abdomen, cold and ache in the lumbar spine. 
 
The interior deficiency pattern includes Qi 
deficiency pattern and blood deficiency 
pattern. Their symptoms include shortness of 
breath after cleaning bowel, fatigue after 
cleaning bowel, stool not dry/hard, pale 
complexion, lassitude; pale complexion, 
dizziness and vertigo, palpitation. 
Constipation x   x  x x x 
Dry skin x   x   x   
Leak when 
sneezing or 
   x   x  Qi deficiency 
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Item category Items CM eight guiding principles 
Yin Yang Exterior Interior Cold Heat Deficient Excess Comments 
cough 
Frequent 
urination at 
night  
   x   x  Qi deficiency 
Frequent 
urination 
   x   x  Qi deficiency 
Poor 
concentration 
   x   x   
Poor memory  x   x   x   
Low libido  x  x   x   
Poor appetite     x   x   
Feeling tired 
easily 
   x   x  Qi deficiency 
Sigh often    x   x  Deficiency of CM lung 
Need deep 
breath 
   x   x  Qi deficiency 
Short of 
breath 
   x   x  Qi deficiency 
Sweat upon 
mild 
activities 
   x   x  Qi deficiency 
Catch cold 
easily  
   x   x  Qi deficiency 
Abdominal 
Distention 
   x x x x x This symptom may indicate 
interior/cold/heat/deficient/heat pattern. 
 
Interior cold excess/deficient patterns may 
include cold dampness obstruction in middle 
Jiao pattern, CM spleen and CM stomach 
deficient cold pattern. Their symptoms include 
abdominal distention, pressing does not 
alleviate the distention, poor appetite, nausea 
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Item category Items CM eight guiding principles 
Yin Yang Exterior Interior Cold Heat Deficient Excess Comments 
and vomiting, heaviness in the head and body, 
diarrhoea, or pain in the epigastrium and 
abdomen, thirsty without preference to drink, 
or yellowing in the body and eyes, females 
may have excessive vaginal discharge; 
intermittent abdominal distention with varying 
severity, prefers heat and being pressed, 
symptom alleviated by hot drinks/food, fatigue, 
poor appetite. 
 
Interior heat excess patterns may include 
damp heat retention pattern, excessive heat 
accumulation in CM stomach and CM 
intestine. Their symptoms include abdominal 
distention, nausea and vomiting, chest 
stuffiness, thirst without preference to drink, 
sweats often, watery diarrhoea, scanty and red 
urine; abdominal pain may be hard or occurs 
around the navel, constipation, streaming 
sweating, tidal fever, manic speech. 
 
Interior excess pattern includes food retention 
in the CM spleen and CM stomach. Its 
symptoms includes abdominal distention, 
hiccup, acid regurgitation, or dislikes the smell 
of food, or diarrhoea with a foul smell like a 
rotten egg. 
Stuffiness in 
the chest 
   x x   x  
Feeling 
nervous 
easily  
   x   x  Deficiency of CM kidney 
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Item category Items CM eight guiding principles 
Yin Yang Exterior Interior Cold Heat Deficient Excess Comments 
Feeling 
depressed 
x x  x  x x  This symptom may indicate 
Yang/Yin/interior/excess/deficient/heat 
pattern. 
Excess patterns may have Qi stagnation 
pattern, Qi stagnation turning into fire pattern, 
and Qi stagnation with phlegm retention 
pattern. Their symptoms include depression, 
emotional restlessness, sigh often, distension 
pain at chest and hypochondriac region, pain 
that moves around, stuffiness in epigastrium, 
hiccup, abdominal distension with poor 
appetite, vomiting, females may have irregular 
menstruation; irritability and easy to get angry, 
stuffy chest with distension sensation at the 
hypochondriac region, acid regurgitation, dry 
mouth, bitter taste in the tongue, constipation, 
or headache, red eyes, tinnitus; globus 
sensation, stuffiness in the chest, or 
accompanied with pain at the hypochondriac 
region. 
Deficient patterns may include depression that 
damages the spirit, deficiency of both CM 
heart and CM spleen, Yin deficiency with 
excessive fire. Their symptoms include absent 
minded, distraught, grievous and cry often, 
yawn often; over thinking and over worrying, 
palpitation and timidity, poor sleep and 
forgetful, lustreless complexion, dizziness and 
fatigue, poor appetite; vertigo, palpitation, poor 
sleep, irritability, or nocturnal emission with 
low back soreness, females may have irregular 
menstruation. 
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Item category Items CM eight guiding principles 
Yin Yang Exterior Interior Cold Heat Deficient Excess Comments 
Reflux    x x  x  Deficient cold in CM spleen and CM stomach. 
Belching  x x  x x x x x This symptom may indicate 
Yang/Yin/interior/excess/deficient/heat/cold 
pattern. 
 
Excessive cold pattern may have belching 
aggravated by cold property food/environment 
and alleviated by hot/warm property 
food/environment, and poor appetite. 
 
Excessive heat pattern may have symptoms of 
loud belching, foul breath, irritability, prefers 
cold drinks, scanty red urine, and constipation. 
 
Interior Yang deficiency pattern may have 
feeble hiccup sound, shortness of breath, pale 
complexion, cold limbs, poor appetite, and 
fatigue. 
 
Interior Yin deficiency pattern may have rapid 
discrete hiccup sound, dry mouth or throat, 
irritable, and restless. 
Nausea x   x x  x x This symptom maybe indicate interior 
excess/interior deficiency pattern. 
 
Food retention (interior excess) pattern may 
have vomiting with acid regurgitation, 
abdominal distention, hiccup, poor appetite, 
nausea aggravated by food consumption and 
alleviated by vomiting, foul smell stool or 
diarrhoea, or constipation. 
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Item category Items CM eight guiding principles 
Yin Yang Exterior Interior Cold Heat Deficient Excess Comments 
Phlegm retention (interior excess) pattern may 
have vomiting out water and saliva, epigastrium 
distention, poor appetite, vertigo, and 
palpitation. 
 
CM liver Qi attacks CM stomach (interior 
excess) pattern may have vomiting, acid 
regurgitation, frequent hiccup, distending pain 
in the chest and hypochondriac region. 
 
Deficient cold in CM spleen and CM stomach 
(interior deficiency) pattern may have easily 
vomiting, pale complexion, fatigue, weakness, 
dry mouth and does not wish to drink, cold 
extremities, and loose stools. 
 
Deficient CM stomach Yin (interior 
deficiency) pattern may have recurrent nausea 
and vomiting, dry retching, dry mouth and 
throat, poor appetite. 
Dizziness x x  x   x x This symptom may indicate 
Yin/Yang/deficient/excess patterns. 
 
Excess pattern may have CM liver Yang 
upsurge pattern, and phlegm turbidity obstruct 
the middle Jiao pattern. The accompanying 
symptoms may have tinnitus, headache with a 
distending sensation, aggravated by irritation 
and anger, malar flush, easily irritated and 
grumpy, poor sleep with dreams, bitter taste in 
the mouth; headache with mental cloudiness, 
chest stuffiness, nausea, poor appetite, 
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Item category Items CM eight guiding principles 
Yin Yang Exterior Interior Cold Heat Deficient Excess Comments 
somnolence. 
 
Deficiency pattern may have Qi and blood 
deficiency pattern, and CM kidney essence 
deficiency pattern. The accompanying 
symptoms include dizziness aggravated by 
movement, physical labour, and fatigue. Pale 
complexion/lips/nails, lustreless hair, 
palpitation, somnolence, fatigue, poor appetite; 
fatigue, somnolence with dreaminess, 
forgetful, sore and weak knee and low back, 
nocturnal emission, tinnitus, feverish sensation 
in the chest/palms/soles, cold extremities, cold 
body. 
Skin itch   x x  x x x This symptom may indicate 
exterior/interior/heat/deficient/excess 
patterns. 
 
The excess patterns include both the exterior 
and interior patterns. These patterns include 
wind pattern, dampness pattern, and heat 
pattern. The wind pattern symptoms include 
itchiness that moves around, whole body feels 
itch, patient may scratch to bleed, the skin is 
normally dry. 
The dampness pattern symptoms include 
blisters, erosions, pustules, ulceration, or is 
infectious. 
The heat pattern symptoms include papules, 
erythema with feverish sensation, blisters, 
scabs, and are often not infectious. 
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Item category Items CM eight guiding principles 
Yin Yang Exterior Interior Cold Heat Deficient Excess Comments 
The deficiency pattern includes the interior 
deficiency pattern which is blood deficiency 
pattern. The symptoms include thickened skin, 
dry, itch, skin scales off, oozes out fluid, rarely 
there is erosion. 
Gynaecological 
symptoms 
Abdominal 
pain during 
or before 
period 
periods 
   x    x  
Low back 
pain during 
or before 
periods 
      x x This symptom may indicate excess or deficient 
pattern.  
 
The excess pattern includes patterns of Qi and 
blood stagnation, cold dampness retention, and 
downpour of damp heat. Their symptoms 
include distending abdominal pain before 
period and refused to be touched, distending 
breast pain, scanty menstrual blood, purple 
dark blood with spots, period pain that is 
alleviated after the excretion of menstrual 
blood clots and is relieved when the 
menstruation finishes; cold abdominal pain 
before or during period, pain alleviated by heat 
and aggravated by pressing, scanty menstrual 
blood with dark black colour and clots, 
aversion to cold and body ache; abdominal 
pain before period with feverish sensation, or 
accompanies with low back distending pain, or 
abdominal pain aggravated by period, low 
grade fever, dark red thick menstrual blood 
with clots, thick yellow vaginal discharge, 
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Item category Items CM eight guiding principles 
Yin Yang Exterior Interior Cold Heat Deficient Excess Comments 
short yellow urine;  
 
The deficiency pattern includes pattern of 
Yang deficiency with cold retention, deficiency 
of Qi and blood, CM liver and CM kidney 
deficiency. The accompanying symptoms 
include cold abdominal pain during or after 
menstruation with preference to be pressed, 
pain is alleviated by heat, scanty menstrual 
blood, dark pale in colour, sore low back and 
legs, clear profuse urine; dull abdominal pain 
during or after period, or empty and falling 
sensation of abdomen and genitalia, prefers to 
be touched and rubbed in the abdomen, scanty 
menstruation with pale colour and thin in 
quality, lassitude, weakness, or pale 
complexion, poor appetite, diarrhoea; 
continuous dull ache in abdomen 1 or 2 days 
after menstruation, sore loin, scanty and thin 
dark pale menstrual blood, tidal fever, tinnitus. 
Dark blood    x x   x  
Light blood 
(pink) 
   x   x  Qi deficiency 
Bleeding 
with clots 
   x x   x  
Excessive 
bleeding 
   x  x x x This symptom may indicate interior excess or 
interior deficiency patterns. 
 
Interior excess pattern includes the patterns of 
heat in the blood, and blood stasis. Their 
symptoms include excessive bright/deep red 
thick menstrual blood, or accompanies with 
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Item category Items CM eight guiding principles 
Yin Yang Exterior Interior Cold Heat Deficient Excess Comments 
small blood clots, irritability, thirst, yellow 
urine, constipation; excessive purple black 
menstrual blood that is difficult to clear/stop, 
blood clots, abdominal pain refused to be 
pressed. 
 
Interior deficiency pattern includes Qi 
deficiency pattern. The accompanying 
symptoms include excessive amount of thin 
pale red menstrual blood, pale complexion, 
shortness of breath, and reluctant to talk, weak 
limbs, or empty falling sensation in the tummy, 
or heart palpitation. 
Light 
bleeding 
   x   x x This symptom may indicate interior excess or 
interior deficiency patterns. 
 
The pattern of interior excess includes patterns 
of blood stasis, and phlegm dampness. Their 
accompanying symptoms include dark purple 
scanty menstrual blood with clots, distending 
abdominal pain and refused to be touched, the 
distending pain is alleviated after the excretion 
of menstrual blood clots; or scanty pale red 
thick and greasy like phlegm menstrual blood, 
overweight, chest stuffiness, nausea, vomiting, 
greasy and sticky vaginal discharge. 
 
The pattern of interior deficiency includes 
patterns of blood deficiency, and CM kidney 
deficiency. Their symptoms include scanty 
pale menstrual blood to as little as a few drops, 
accompanies with dizziness and vertigo, 
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Item category Items CM eight guiding principles 
Yin Yang Exterior Interior Cold Heat Deficient Excess Comments 
palpitation, withering complexion, empty 
dropping sensation of abdomen; scanty thin 
pale/dark red menstrual blood, low back ache, 
heel pain, dizziness, tinnitus, cold abdomen, 
profuse nocturnal urination. 
Delayed 
periods 
   x   x x This symptom may indicate interior excess 
and interior deficiency patterns. 
 
Interior excess pattern includes patterns of 
cold in blood, and Qi stagnation. Their 
symptoms include delayed period with scanty 
amount and dark colour with clots, cold 
abdominal pain alleviated by heat, aversion to 
cold, cold limbs; distending pain in 
abdomen/chest/hypochondriac regions/breast. 
 
Interior deficiency pattern includes patterns of 
deficient cold, and blood deficiency. Their 
symptoms include delayed period with pale red 
thin scanty blood, no clots, dull abdominal 
pain, prefers heat and being pressed, low back 
ache with weakness, clear profuse urination, 
loose stool or diarrhoea, dizziness, vertigo, 
palpitation, somnolence. 
Early periods    x  x x x This symptom may indicate patterns of 
interior deficiency or interior excess. 
 
The interior deficiency pattern includes 
patterns of Qi deficiency, and deficient heat. 
Their symptoms include early menstruation 
with increased pale thin blood volume, fatigue, 
empty dropping feeling in abdomen, poor 
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Item category Items CM eight guiding principles 
Yin Yang Exterior Interior Cold Heat Deficient Excess Comments 
appetite, loose stool, the early menstruation 
may accompany with scanty/excess amount of 
red thick blood, malar flush, feverish sensation 
in the palms/soles. 
 
The interior excess pattern includes patterns of 
excessive Yang with heat in the blood, and CM 
liver Qi stagnation with heat in the blood. 
Their symptoms include large amount of early 
menstruation with large amount thick deep 
red/purple colour blood, chest stuffiness, red 
face, dry mouth, short yellow urination, dry 
stool, distending abdominal pain, distending 
sensation in the breast, irritability, grumpiness, 
dry mouth, bitter taste in the mouth. 
Irregular 
periods 
   x   x x This symptom may indicate interior excess or 
interior deficiency patterns. 
 
Interior excess pattern includes CM liver Qi 
stagnation pattern. The accompanying 
symptoms include irregular period with either 
scanty/large amount of purple red blood and 
clots, the menstrual blood flow is unsmooth, 
distending pain in chest/breast/hypochondriac 
region/abdomen, stuffiness in epigastric area, 
sigh often, hiccup, poor appetite. 
 
Interior deficient pattern includes CM kidney 
deficiency pattern. The accompanied 
symptoms include irregular period with scanty 
dark thin blood, LBP, dizziness, tinnitus. 
Excessive    x x   x  
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Item category Items CM eight guiding principles 
Yin Yang Exterior Interior Cold Heat Deficient Excess Comments 
watery 
discharge 
Yellow 
discharge 
   x  x  x Damp heat retention 
*Pain character in italicised font indicates no possible CM explanation. 
Information extracted from CM diagnosis 38 (p99), CM internal medicine 134(p108,114,115,121-123,144,145,152-154,171, 172, 205, 206), CM gynaecology 
1026(p23,37-42,44-5,47-51,55-7), Differential diagnosis of symptom in CM 1025(p330), and Chinese medicine surgery1027(p20-21) 
CM: Chinese medicine 
LBP: low back pain
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Of all of the categories, there are some symptoms that maybe excess/deficiency/heat or cold. 
To determine the pattern, the other symptoms are taken into consideration. For example, 
constipation accompanied with swollen, red, and hot joints is due to excessive heat whereas 
constipation accompanied with pain worse at night and night sweating is due to Yin deficiency. 
There are some symptoms not explainable from a CM perspective, such as pain worse at 
lunch time and pain worse in the afternoon. The purpose of these symptoms is to identify if 
there are new symptoms related to the current CM understanding and not currently understood 
by CM; and to identify the essential CM information needed to understand CMP.  
This first version of CMPQ has the following strengths.  
1) Standard textbooks and specialised books on pain in CM were searched to identify items. 
This ensured CM relevant information was used rather than non-CM relevant information 
such as in RMDQ. 
2) Items were categorised enabling easy comprehension. 
3) The questionnaire was designed from the CM perspective instead of the Western medicine 
perspective as is the McGill pain Questionnaire. This made the CMPQ suitable to assist 
CM pattern identification. 
The following chapters describe the next stages in the development of CMPQ and how these 
accompanying symptoms and other symptoms were used to derive CM patterns in a statistical 
manner. 
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6. Initial development of CMPQ 
6.1 Introduction 
Chinese medicine views CMP different from Western medicine, in which it uses four diagnostic 
techniques to collect data on pain and non-pain symptoms and signs of patients then groups 
those signs and symptoms into different types or pattern 1020(p981-1047,1059-1118). The main part of 
the consultation is enquiry, which refers to obtaining data from patients through an interview. 
Other methods are palpating, smelling/listening and observing. Chinese medicine 
questionnaires can be used to collect data relevant to CM diagnosis, however this method is 
limited to gathering answers from the inquiry part of consultation 1028. Relying on 
questionnaires alone has been found to be sufficient to make initial pattern identification 1029.  
A standardized CM questionnaire documents the symptoms and signs of a patient, aids the 
consistency of the questions asked each time and assist in assessment of the changes or 
treatment outcomes 1028. It is necessary for the CM questionnaire to achieve responsiveness 
which refers to the ability to detect significant important changes over time 997. A CM pain 
questionnaire should also contain questions on location of pain, quality of pain, pattern of 
pain occurrence (rhythm), aggravating and alleviating factors of pain, and accompanying 
non-pain symptoms. From the data gathered, the CM practitioner is able to differentiate the 
patients’ symptom presentation into a CM pattern. Such pattern can then be used to guide 
setting up treatment principle and the appropriate treatment.  
In Chapters four and five, methods of questionnaire development and item generation of 
CMPQ were described. This chapter aimed to evaluate the properties of CMPQ, including 
various forms of validity, internal consistency, reproducibility, responsiveness, interpretability, 
and avoid “floor and ceiling effect”. These criteria are listed in Table 6.1. A good 
questionnaire should achieve most of these aspects in its development. 
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Table 6.1 Essential properties of a questionnaire 
Property Definition How to achieve it 
Item generation Generating questionnaire items that are 
relevant to the questionnaire itself 
The items can be generated through 1) focus groups 1000(p18-23), 2) key informant interviews 
1000(p18-23), 3) clinical observation 1000(p18-23), 4) theory 1000(p18-23), 5) research 1000(p18-23), and 
6) expert opinion 1000(p18-23). 
Content validity The questionnaire items are representative to 
the concept of interest 997. 
Describe the measurement aim of the questionnaire (e.g. discriminative, evaluative, or 
predictive) 997, the population targeted, the concept the questionnaire is trying to measure 
997, and make sure the interpretability of the questionnaire items can be achieved by a 12 
year old 997. 
Construct 
validity 
“a framework of hypothesis testing based on 
the knowledge of the underlying 
construct”1000(p257-261) 
Comparing the score with another questionnaire that measures the same concept 997. 
Criterion 
validity 
How the score of the questionnaire relates to a 
gold standard 997. 
Compared the questionnaire results with another validated questionnaire and see if the 
results are similar. 
Face validity The questionnaire looks like measuring what it 
is supposed to measure 1000(p82). 
Give the questionnaire to someone in the field and ask them if they think this 
questionnaire is assessing what it appears to measure. 
Internal 
consistency 
The items measuring the same concept in the 
questionnaire are correlated 997. 
By using statistical software to analyse the data and achieve Cronbach’s α ≥ 0.70. 
Agreement 
(test-retest 
reliability) 
The similarity between a person answering the 
questionnaire and repeat the questionnaire 
again in a short time when there is no change 
in this person’s condition 997. 
By using statistical software to analyse the data with the correlation coefficient ≥ 0.70. 
Inter observer 
reliability 
The degree of agreement between observers 
1000(p92). 
By using Cochran’s Q test and achieve kappa > 0.41. 
Reliability The ability of the questionnaire to distinguish 
one patient from another 997. 
By using intra-class correlation coefficient and achieve at least 0.70 for continuous data or 
using weighted Cohen’s Kappa coefficient and achieve at least 0.70 for ordinal data 997. 
Responsiveness The ability to detect clinical important 
changes over time 997. 
By using statistical analysis to find out if longitudinally, the questionnaire can detect 
clinical important changes. 
Interpretability Defining the qualitative meaning of the 
quantitative score from the questionnaire 1030. 
Defining the meaning of the scores, if it is a numerical scale, such as Beck et al. assigned 
0-13 as minimal range, 14-19 as mild depression, 20-28 as moderate depression, and 29-63 
as severe depression for BDI-II 1006. 
Floor and ceiling 
effect 
The number of participants who achieve the 
best or the worst possible scores 1031. 
Looking at the results of the survey, if there are more than 15% of participants who 
achieved either the best or the worst scores, then there are ceiling/floor effect. 
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For responsiveness, as the EA protocol (described in Chapter 8.2.1 Participants (p. 260)) aimed 
at enhancing the release of endorphin, reducing OM use and the side effects of OM, it was 
necessary to evaluate if the participants responded to EA in terms of reducing the side effects of 
OM. 
The aims of this chapter were to  
1) Test the initial version of CMPQ on the CMP patients who used OM for pain control; 
2) Evaluate its content validity, face validity, internal consistency, reproducibility(test-retest 
reliability), and responsiveness; 
3) identify common pain and non-pain symptoms of those patients. 
6.2 Methods 
6.2.1 Participant recruitment 
As outlined in Chapter 4.2.1 Participant identification (p. 141) and Chapter 0  
Inclusion and exclusion criteria (p. 141), participants were identified from patient case records 
of Caulfield Hospital, Royal Melbourne Hospital, local GP/specialist referral, and 
advertisements. Participants who fulfilled the inclusion and had none of the exclusion criteria 
were recruited into the EAOM trial. Of the participants, 101 completed the CMPQ at both 
pre-baseline and baseline weeks, and were included for initial CMPQ development. 
6.2.2 Item generation and item reduction 
The CMPQ items were generated in Chapter five. The questionnaire items were of 
dichotomous nature as CM diagnosis depends on the presence of a symptom/sign. Items 
selected by less than 5% of participants were removed 995. 
6.2.3 Validity 
6.2.3.1 Content validity and face validity 
Content validity was evaluated by asking the RCMRG researchers (composition described in 
 187 
Chapter 4.3.2 Validities (p. 144)) if the measurement aim, target population, concept measured, 
item selection and reduction, and the interpretability of the items of CMPQ fulfilled the 
content validity. 
Both content and face validities were evaluated by asking the RCMRG researchers if they 
agreed with 1) CMPQ measured CMP and other symptoms, 2) CMPQ was appropriate for 
such measurement, 3) would the CMPQ be appropriate for assisting CM pattern identification 
based on the CM eight guiding principles, and 4) did CMPQ appear to be measuring the 
symptoms of CMP and other symptoms?  
6.2.3.2 Criterion validity 
Criterion validity refers to comparison with another gold standard 997. If the results are 
similar/same, then such criterion validity is achieved. E.g. developing a new QoL measurement 
and comparing it with SF36. If testing this newly developed QoL measurement on a person 
resulting in high QoL and this person also scores high on SF36. Such newly developed QoL 
questionnaire has achieved criterion validity. As there was no gold standard for CM pain 
diagnosis. The diagnosis of the CM pattern relied on the CM practitioner to identify. Criterion 
validity was not tested. 
6.2.4 Internal consistency 
Internal consistency was assessed by using SPSS version 22 on the pre-baseline week data. 
Reliability analysis was used to assess the internal consistency of pre-baseline week data. Such 
analysis would produce Cronbach’s α. Cronbach’s α ≥ 0.7 indicated a good internal consistency 
997. 
6.2.5 Reproducibility (agreement) 
Statistical Package for Social Science was used to assess agreement (test-retest reliability). The 
interval between the test and retest assessments was four weeks between pre-baseline and 
baseline weeks. During the four weeks, the participants were told not to change any of their 
medication intake, life style, or receiving new treatment for their pain. 
6.2.6 Responsiveness 
Chi square test was first carried out to assess if there were significant differences between REA 
 188 
and PMM alone groups in symptoms related to side effects of OM during baseline week (Table 
6.2). The comparison of REA and no-EA groups provides the opportunity to assess which of the 
side effects of OM, including fatigue, constipation, drowsiness, dizziness, nausea, night 
sweating, insomnia, nightmare, skin itch, dry mouth, anxiety, blurred vision, vomiting, and 
profuse sweating, responded to REA treatment. This responsiveness section only assessed REA 
and PMM alone but not SEA due to it was not intended to assess the placebo effect. 
Table 6.2 CMPQ symptoms related to side effect of OM 
Domain Symptom 
Pain aggravator bad night sleep, stress, being emotional, sex 
Pain alleviator bowel movement, sleep 
Other 
symptoms 
insomnia, night sweating, irritable, dry stools, constipation, 
dry skin, feeling tired easily, sigh often, sweat upon mild 
activities, feeling depressed, reflux, nausea, dizziness, skin 
itch 
 
Cochran’s Q test was then used to test if there were significant changes in these symptoms from 
baseline, mid treatment, to end of treatment weeks. Only items with a p value <0.1 were 
considered significant. Such approach had been used for studies with small sample sizes 1032. 
Only REA and PMM alone groups’ participants who provided data for all the three time points 
(baseline, mid treatment, and end of treatment weeks) were included for responsiveness 
assessment. Both groups received OM reduction schedule which aimed to have participants to 
reduce their OM usage from baseline week onwards and either use the least amount of OM or 
no OM by the end of treatment week. Electro acupuncture treatment was designed to help 
reducing pain, increasing endogenous opioid release and reducing side effects of OM (Please 
see Chapter 2.7.1 Mechanisms of acupuncture (p. 45) for details). Real EA group received its 
respective treatment twice per week from baseline week to week eight, once per week for week 
nine and ten (mid treatment week), and once every second week for a further two treatments 
from week 11 to end of treatment week for a total of 12 treatments. It was expected side effects 
of OM addressed would respond to the REA treatment. The responsiveness test was assessing if 
the symptom/item had significant changes but not whether the change was improvement or 
deterioration.  
Comparison with the side effects of OM, as recorded in the pain and medication diary 
(Appendix 20), was carried out to compare the responsiveness of CMPQ and participant’s self 
reported side effects of OM. 
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6.2.7 Interpretability 
Due to the nature of the CMPQ, there was no score used. The interpretability relied on the 
practitioners to do CM pattern identification based on the symptoms checked by the 
participants and the CM eight guiding principles. If practitioners diagnosed CM pattern based 
on the CM eight guiding principles differently for the same CMPQ, this indicated the 
subjectivity of CM pattern identification diagnosis. And the interpretability was left to the 
discretion of the CM practitioner. This initial CMPQ development did not assess the 
interpretability. 
6.2.8 Floor and ceiling effect 
Due to there is no score used for this CMPQ. Floor and ceiling effect was not assessed. 
6.2.9 Data collection 
Participants were asked to complete the demographic questionnaire, CMPQ, BDI, SF36, 
RMDQ, and pain medication diary. Pain medications were divided into OM and non-OM. 
Opioid medications were converted into morphine equivalent dose based on the conversion 
ratio 1033 whereas non-OMs were converted based on Medication Quantification Scale version 
(MQS) III 1034. The non-OMs used by each participant were given a summed score derived 
from the multiplication of the detriment weight and the relative dosage scores 1034. The score 
derived from MQS III was used to evaluate the class and dosage of medication usage in order to 
minimize toxicity, drug-drug interactions and adverse events 1034. Except for pain medication 
diary was completed daily, other questionnaires were completed when participants commenced 
their participation (pre-baseline week, except for SF36, and RMDQ which was not completed 
in pre-baseline week), four weeks later (baseline week), mid treatment week, and end of 
treatment week (Table 6.3). These data were collected either at Caulfield Hospital, Royal 
Melbourne Hospital, Discipline of Chinese medicine, RMIT University, or at the participating 
CM clinics by the personnel involved in this research project, or by post. Chinese medicine 
pain questionnaire data were entered and double checked by research personnel. Missing data 
were reported and removed from analysis. No other methods (e.g. intention to treat, or mean 
score of all participants) were used for CMPQ missing data. For other questionnaires, last 
value carried forward was used. 
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Table 6.3 Trial procedure and outcome assessments 
EAOM trial periods* Procedures Outcome assessment 
Initial screening for 
eligibility assessment 
All potential participants 
with CMP were assessed for 
eligibility by MDs  
 
Baseline period 
W1-W4 
All potential eligible 
participants 
Demographic data, Pain and Medication 
Diaries W1-W4 Daily and Patient 
Information Questionnaire, BDI, CMPQ, 
Pain Medication Questionnaire 
 Randomisation of eligible 
participants 
 
Treatment period 
W5-W8  
2 EA treatments/week 
 
W9-W10  
1 EA treatment/week 
 
W11-W14  
1 EA treatment/2 
weeks 
REA SEA PMM 
alone 
Pain and Medication Diaries was 
completed daily from baseline to end of 
treatment weeks and other measures for 
baseline, mid treatment and end of 
treatment weeks, including CMPQ, BDI, 
SF36, and RMDQ. 
Information extracted from 1 
*The EAOM trial periods are different from the CMPQ time points (Figure 1.2, p. 5).  
CMP: Chronic musculoskeletal pain 
MD: Medical doctor 
W: week 
BDI: Beck Depression Inventory 
CMPQ: Chinese medicine pain questionnaire 
SF36: Medical outcome short form health survey 36 items 
RMDQ: Roland Morris Disability Questionnaire 
 
6.2.10 Statistical analysis 
Data were entered into SPSS version 22 for analysis. Frequency analysis was used to assess 
the frequency of occurrence of each questionnaire items as well as item reduction (items 
selected by less than 5% of participants). Reliability analysis, in the scale command, was used 
for test-retest reliability. Split half model was chosen and in the statistics button, scale was 
chosen for “descriptive for”, correlation was chosen for “summaries”, all other options were 
not checked/selected. Items that might contribute to discrepancies in the total number of items 
between pre-baseline and baseline weeks were removed from the analysis in both pre-baseline 
and baseline weeks.  
For internal consistency, the reliability analysis was also used. This time “alpha” was chosen for 
the model and in statistics, “item”, “scale”, and “scale if item deleted” were checked for 
“Descriptives for”. “Correlation” was checked for “inter item”. All the other boxes were 
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unchecked. 
For responsiveness, Chi square test was first used to compare if there was significant 
difference between REA and PMM alone groups. Crosstabs in “Descriptive statistics” was 
used. In the statistics option, observed was checked in “counts”, row, column, and total were 
checked in “percentages”. In format option, ascending was selected for “row order”. 
Treatment group was put into “row” box and all other symptoms related to side effects of OM 
were put in “column” box. 
Subsequently Cochran’s Q test was used to assess changes amongst baseline, mid treatment, 
and end of treatment weeks for responsiveness. Syntax was used in SPSS for all the 
symptoms listed in Table 6.2. Example of the syntax was as following: 
NPAR TESTS 
  /COCHRAN=ITEMA@W5 ITEMA@W10 ITEMA@W14 
  /MISSING LISTWISE. 
Repeated MANOVA was carried out to evaluate the change of side effects of OM severity 
according to pain and medication diary between baseline and end of treatment weeks. Only 
participants who provided data for both baseline and end of treatment weeks were included for 
the analysis. 
6.3 Results 
6.3.1 Content validity and face validity 
The first draft of CMPQ was presented to the RCMRG researchers and they agreed that 
CMPQ assessed CMP and the accompanying symptoms of CMP and CMPQ was appropriate 
for such assessment, data from CMPQ could be used to assist CM pattern identification. Based 
on these, the content validity was achieved. 
For face validity, CMPQ had been presented to the RCMRG researchers as of content validity. 
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The researchers agreed this questionnaire appeared to measure the symptoms and signs of 
patients who had CMP which was essential in the clinical diagnosis process. 
6.3.2 Internal consistency 
The results from the analysis showed the Cronbach’s α to be 0.919 or 0.935, depending on if 
pain regions were included. This indicated a high level of internal consistency (Table 6.4). If 
each section was analysed separately, then pain quality, pain rhythm, and some of the individual 
pain regions were of a lower level of Cronbach’s α (Cronbach’s α<0.70) 1035.  
Table 6.4 Internal consistency as assessed using Cronbach’s α (n=101) 
Domains Cronbach's α
Cronbach's α 
based on 
standardized items 
Number 
of items 
All domains, except for pain 
regions 0.919 0.914 127 
All domains, including pain 
regions 0.935 0.931 159 
Pain region – head 0.742 0.728 7 
Pain region – upper limb 0.763 0.760 6 
Pain region – lower limb 0.793 0.800 9 
Pain region – front of the body 0.384 0.409 5 
Pain region – back of the body 0.603 0.604 5 
Pain region – all 0.862 0.855 32 
Pain quality 0.327 0.390 12 
Pain rhythm 0.344 0.436 11 
Pain aggravators 0.817 0.783 25 
Pain alleviators 0.725 0.692 34 
Accompanied symptoms 0.883 0.884 45 
 
6.3.3 Reproducibility 
6.3.3.1 Agreement (test-retest reliability) 
For test-retest reliability, there were 27 items not scored by any participants in pre-baseline 
week and/or baseline week assessments and caused the item numbers uneven in the analysis. 
These items were listed in Appendix 21 and removed from test-retest reliability analysis. 
Test-retest reliability have been shown to have a high reliability for the overall questionnaire 
(correlation coefficient=0.846) (Table 6.5). When individual domains were compared, they 
were all showing a high level of reliability (correlation coefficient >0.7) (Table 6.5) except for 
pain quality and pain rhythm domains where the domains showed correlation coefficient ranged 
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between 0.49 – 0.556 (Table 6.5). This indicated overall, the entire questionnaire was reliable 
but the pain quality and pain rhythm domains were not that reliable (e.g. patients did not choose 
the similar description on the repeated test). When pain regions were assessed altogether 
(Table 6.5) and when they were individually assessed (Table 6.6) all showed similar results to 
the entire questionnaire and subgroup assessments where the more items in the domain, the 
stronger the correlation between the two assessment times and vice versa.
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Table 6.5 Test-retest reliability - Overall 
Domains Overall Pain aggravators
Pain 
alleviators 
Other 
symptoms
Pain 
regions
Pain 
rhythm
Pain 
quality
Cronbach's 
Alpha 
Pre-baseline 
week 
Value 0.934 0.82 0.725 0.883 0.862 0.328 0.327 
N of 
Items 155
a 23a 34a 44a 32a 10a 12a 
Baseline week 
Value 0.941 0.815 0.739 0.877 0.878 0.369 0.505 
N of 
Items 155
b 23b 34b 44b 32b 10b 12b 
Total N of Items 310 46 68 88 64 20 24 
Correlation Between Forms 0.846 0.721 0.73 0.822 0.808 0.49 0.556 
Spearman-Brown 
Coefficient 
Equal Length 0.916 0.838 0.844 0.902 0.894 0.657 0.714 
Unequal 
Length 0.916 0.838 0.844 0.902 0.894 0.657 0.714 
Guttman Split-Half Coefficient 0.916 0.838 0.844 0.902 0.893 0.657 0.707 
a denotes pre-baseline week items 
b denotes baseline week items 
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Table 6.6 Test-retest reliability - subdivided pain regions 
Domains within pain regions Head Upper limbs Lower limbs Front of the body Back of the body 
Cronbach's Alpha 
Pre-baseline week Value 0.742 0.763 0.793 0.384 0.603 N of Items 7a 6a 9a 5a 5a 
Baseline week Value 0.787 0.817 0.739 0.51 0.606 N of Items 7b 6b 9b 5b 5b 
Total N of Items 14 12 18 10 10 
Correlation Between Forms 0.735 0.686 0.729 0.621 0.674 
Spearman-Brown Coefficient Equal Length 0.847 0.813 0.843 0.766 0.805 
Unequal Length 0.847 0.813 0.843 0.766 0.805 
Guttman Split-Half Coefficient 0.845 0.811 0.841 0.765 0.805 
a denotes pre-baseline week items 
b denotes baseline week items 
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6.3.4 Demographic data of participants 
One hundred and eight participants consented to participate in the EAOM trial and 101 
provided CMPQ data for both pre-baseline and baseline weeks. Not all participants provided 
the complete demographic data. The majority of the sample is females (56%), middle aged, 
born in Australia (62.6%), married (46%), and with a tertiary education (University and TAFE 
education) (45.5%) (Table 6.7). For most of them, their pain was not related to worker’s 
compensation or a third party claim (75.8%). The average years of pain were 12.92 years. The 
types of pain the participants had are listed in Table 6.9. Forty two out of 56 females were at or 
above the age of 51 years, the average age for the onset of menopause 1036.  
Table 6.7 Demographic data 
Demographic variable Valid 
N 
Mean (SD) 
or N (%) 
Minimum Maximum
Age 100 55.62 
(12.41) 
24 83 
Gender Male 100 44 (44%) Not applicable 
Female 56 (56%) 
Female age ≤ 51 years 54 14 (25.9%) 
Female age > 51 years 40 (74.1%) 
Country of birth 
Australia 99 62 (62.6%) Not applicable 
England 8 (8.1%) 
Scotland 4 (4.0%) 
Holland 2 (2.0%) 
Poland 2 (2.0%) 
Greece 2 (2.0%) 
Egypt 2 (2.0%) 
Bosnia 2 (2.0%) 
The remaining other countries 15 (15.2%) 
In relation to pain 
A workers' compensation claim 99 18 (18.2%) Not applicable 
A third party accident 
compensation claim 
6 (6.1%) 
Not related to works' compensation 
claim/third party accident 
compensation/other legal case 
75 (75.8%) 
Marital status 
Married 100 46 (46%) Not applicable 
Single 19 (19%) 
Separated 7 (7%) 
Divorced 18 (18%) 
De facto 5 (5%) 
Widowed 5 (5%) 
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Demographic variable Valid 
N 
Mean (SD) 
or N (%) 
Minimum Maximum
Education level 
University 99 26 (26.3%) Not applicable 
TAFE 19 (19.2%) 
Adult education/CAE 2 (2.0%) 
Others 52 (52.5%) 
Duration of pain (years) 93 12.92 (10.7) 0 52 
SD: Standard deviation 
6.3.5 Medication 
For OMs, on average participants consumed 633 mg morphine equivalent dosage per week 
whereas the non-OMs, on average participants’ MQSII score was 10 per week (Table 6.8). 
Table 6.8 Baseline pain medication consumption 
Type of medication Valid 
N 
Mean SD 
Average OM usage of baseline (morphine equivalence, mg/week) 96 633.1 1081.1
Average non-OM pain medication of baseline (based on medication 
quantification scale, score/week) 
96 10.4 7.1 
 
6.3.6 Descriptive data  
For pre-baseline week data, the frequency of each item is listed from Table 6.9 to Table 6.15. 
Females related items are listed in Table 6.12, Table 6.13, and Table 6.15 (only females under 
the age of 51 years were counted for these items). For pain regions (Table 6.9), majority of the 
participants (>40%) had LBP, neck pain, hip pain, knee pain, shoulder pain, and middle back 
pain. Less than 5% of participants described pain at vertex. Most of the participants have seven 
or more pain regions (55.60%). 
Table 6.9 Frequency (percentage) of the regions of pain (n=101) 
Pain regions  Frequency Percentage
Head, neck and shoulder regions 
Neck 45 44.60% 
Shoulder 42 41.60% 
Shoulder blades 24 23.80% 
Back of the head 21 20.80% 
Sides of the head 14 13.90% 
Frontal head 13 12.90% 
Vertex 1 1.00% 
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Pain regions  Frequency Percentage
Upper limbs 
Upper arm 29 28.70% 
Fingers 27 26.70% 
Wrist 22 21.80% 
Hand 19 18.80% 
Elbow 14 13.90% 
Forearm 11 11.00% 
Lower limbs 
Knee 49 48.50% 
Hip 48 47.50% 
Thigh 41 40.60% 
Ankle 31 30.70% 
Calf 29 28.70% 
Front of the leg 25 24.80% 
Sole 24 23.80% 
Toes 23 22.80% 
Heel 18 17.80% 
Front of the body trunk 
Groin 17 17.00% 
Chest 12 11.90% 
Side of the body 12 11.90% 
Stomach 10 9.90% 
Abdomen 8 7.90% 
Back of the body trunk 
Lower back 79 78.20% 
Middle back 42 41.60% 
buttocks 36 35.60% 
Between shoulder blades 35 34.70% 
Sacrum 28 27.70% 
Total number of pain regions 
1 10 9.90% 
2 8 7.90% 
3 3 3.00% 
4 11 10.90% 
5 8 7.90% 
6 7 6.90% 
7-10 20 19.90% 
11-15 22 21.80% 
16-20 11 10.90% 
21-29 3 3.00% 
Items greater than 40% were bolded and items less than 5% were italicised. 
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For pain quality (Table 6.10), majority of participants (>40%) described their pain as sharp, in a 
fixed location. Participants rarely described their pain quality as “not known”. 
Table 6.10 Frequency percentage of pain quality (n=101) 
Pain quality Frequency Percentage
Sharp 59 58.40% 
Fixed location 43 42.60% 
Dull pain with weakness 38 37.60% 
Numbness 32 31.70% 
Burning 28 27.70% 
Dull 24 23.80% 
Moving from one spot to another 18 17.80% 
Hot 17 16.80% 
Pulling 17 16.80% 
Pricking 13 12.90% 
Cold 11 10.90% 
Distending 8 7.90% 
Not known 0 0% 
Items greater than 40% were bolded and items less than 5% were italicised. 
 
For pain rhythm (Table 6.11), majority of participants described their pain was there “all the 
time”, “worse when first get up”. Rarely participants feel their pain rhythm was recurrent, 
worse at lunch time, or not known. 
Table 6.11 Frequency percentage of pain rhythm (n=101) 
Pain rhythm Frequency Percentage 
All the time 64 63.40% 
Wore when first get up 43 42.60% 
Worse at the end of the day 38 37.60% 
Fluctuate 28 27.70% 
Worse in the afternoon 26 25.70% 
Worse during the day, better at night 16 16.00% 
Worse at night, better during the day 13 12.90% 
Worse in the morning 11 10.90% 
Worse at lunch time 4 4.00% 
Recurrent 3 3.00% 
Not known 2 2.00% 
Items greater than 40% were bolded and items less than 5% were italicised. 
 
For pain aggravator (Table 6.12), majority of participants found cold weather, standing, 
walking, physical work, sitting, lifting, bending, going up/down stairs, bad night sleep, stress, 
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and household chores aggravated their pain. And their pain rarely was aggravated by “after 
eating”, “being hungry”, or the “not known” factors. The three items relate to menstrual period 
were assessed in females under 51 years of age as per the National Institute of Health’s 
definition of menopausal age 1036. And the menstruation was neither a frequent, nor a rare factor 
that aggravated pain. 
Table 6.12 Frequency and percentage of pain aggravator (n=101) 
Pain aggravators Frequency Percentage
Environmental changes 
Cold weather 54 53.50% 
Weather change 27 26.70% 
Hot weather 19 18.80% 
Wet weather 14 13.90% 
Windy days 6 5.90% 
Exercises of sporting 
Standing 69 68.30% 
Physical work 64 63.40% 
Walking 64 63.40% 
Lifting 55 54.50% 
Sitting 54 53.50% 
Bending 53 52.50% 
Going up/down stairs 45 44.60% 
Driving 35 34.70% 
Lying down 25 24.80% 
Any movement 22 21.80% 
Physiological and psychological changes 
Bad night sleep 52 51.50% 
Stress 49 48.50% 
Being emotional 34 33.70% 
Being hungry  4 4.00% 
After eating 1 1.00% 
Others 
Household chores 47 46.50% 
Pressure on the area 28 27.70% 
Everything 23 22.80% 
Sex 20 19.80% 
Not known 1 1.00% 
For female patients (n=14) 
Before period 5 35.7%  
During period 4 28.6% 
After period 2 14.3% 
Items greater than 40% were bolded and items less than 5% were italicised. 
 
For pain alleviator (Table 6.13), majority of participants found hot packs, warm/hot shower, 
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pain killer, resting, and gentle massage alleviated their pain. Cold weather, wet weather, windy 
days, standing, driving, eating, being hungry, belching, working, sex, everything, or “not 
known” rarely alleviated their pain. 
Table 6.13 Frequency and percentage of pain alleviator (n=101) 
Pain alleviators Frequency Percentage
Environmental changes 
Hot packs 58 57.40% 
Warm/hot shower 50 49.50% 
Warm/hot bath 31 30.70% 
Hot weather 12 11.9 
Cold packs 6 5.90% 
Cold weather 2 2.00% 
Wet weather 1 1.00% 
Windy days 0 0% 
Exercises of sporting 
Resting 49 48.50% 
Gentle massage 41 40.60% 
Lying down 34 33.70% 
Gentle exercise 24 23.80% 
Walking 16 15.80% 
Sitting 13 12.90% 
Any movement 7 6.70% 
Driving 5 5.00% 
Standing 4 4.00% 
Physiological and psychic changes 
Pain killer 80 79.20% 
Sleep 34 33.70% 
Keeping my mind off pain 31 30.70% 
Watching TV 24 23.80% 
Being with other people 23 22.80% 
Deep breathing 21 20.80% 
Pressure on the pain area 20 19.80% 
Reading 17 16.80% 
Bowel movement 13 12.90% 
Alcohol 7 6.70% 
Working 5 5.00% 
Eating 3 3.00% 
Being hungry 1 1.00% 
Belching 1 1.00% 
Others 
Keeping busy 35 34.70% 
Nothing 11 10.90% 
Household chores 6 5.90% 
Sex 3 3.00% 
Everything 0 0% 
Not known 0 0% 
For female patients 
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Pain alleviators Frequency Percentage
Before period 1 7.10% 
During period 1 7.10% 
After period 1 7.10% 
Items greater than 40% were bolded and items less than 5% were italicised. 
 
For other symptoms (Table 6.14), participants often had “feeling tired easily”, insomnia, 
limited movements, poor concentration, poor memory, feeling depressed, irritable, constipation, 
and low libido. Participants rarely had mushy stools or belching. 
Table 6.14 Frequency and percentage of non-pain symptoms (n=101) 
Item Frequency Percentage
Feeling tired easily 70 69.20% 
Insomnia 60 59.40% 
Limited movement 57 56.40% 
Poor concentration 56 55.40% 
Poor memory 49 48.50% 
Feeling depressed 48 47.50% 
Irritable 46 45.50% 
Constipation 45 44.50% 
Low libido 42 41.60% 
Night sweating 39 38.60% 
Feeling cold easily 39 38.60% 
Sweat upon mild activities 35 34.70% 
Swollen joints 33 32.70% 
Feeling nervous easily 33 32.70% 
Feeling hot easily 30 29.70% 
Cold hands and feet 30 29.70% 
Thirsty 28 27.70% 
Need deep breathing 26 25.70% 
Reflux 26 25.70% 
Frequent urination at night 25 24.80% 
Skin itch 24 23.80% 
Short of breath 24 23.80% 
Frequent urination 24 23.80% 
Dizziness 24 23.80% 
Poor appetite 23 22.80% 
Dry or sore throat 22 21.80% 
Dry skin 22 21.80% 
Nausea 21 20.80% 
Indigestion 19 18.80% 
Heavy sensation in the body 18 17.80% 
Sigh often 14 13.90% 
Red and hot joints 14 13.90% 
Cold lower back or knees 14 13.90% 
Flushed face 13 12.90% 
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Item Frequency Percentage
Leak when sneezing or cough 13 12.90% 
Distention sensation in the abdomen 11 10.90% 
Abdominal distention 10 9.90% 
Dry stools 10 9.90% 
Cold joints 9 8.90% 
Stuffiness in the chest 9 8.90% 
Catch cold easily 8 7.90% 
Hot palms 8 7.90% 
Watery diarrhoea 6 5.90% 
Mushy stools 5 5.00% 
Belching 4 4.00% 
Items greater than 40% were bolded and items less than 5% were italicised. 
 
For other symptoms related to gynaecological issues (Table 6.15), only “low back pain during 
or before period” was frequently experienced by those non-menopausal participants. Excessive 
watery discharge, yellow discharge, light menstrual blood, and early periods were not 
experienced by any of the non-menopausal female participants. 
Table 6.15 Frequency percentage of other symptoms for female patients (n=14) 
Item Frequency Percentage 
Low back pain during or before periods 6 42.90% 
Abdominal pain during or before periods 5 35.70% 
Dark blood 4 28.60% 
Excessive bleeding 3 21.40% 
Light bleeding 3 21.40% 
Irregular periods 2 14.30% 
Bleeding with clots 2 14.30% 
Delayed periods 2 14.30% 
Excessive watery discharge 0 0% 
Yellow discharge 0 0% 
Light blood (pink) 0 0% 
Early periods 0 0% 
Items greater than 40% were bolded and items less than 5% were italicised. 
 
Summing up, the rarely selected items included pain at vertex; pain worse at lunch time, 
recurrent pain; pain aggravated when hungry and after eating; pain alleviated by cold weather, 
wet weather, windy weather, driving, standing, working, eating, being hungry, belching, sex, 
everything; accompanying mushy stools and belching. Participants rarely describe their pain 
quality/rhythm/aggravator/alleviator as “not known”. 
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6.3.7 Responsiveness 
As described in the methods section (Chapter 6.2.6 Data collection (p. 187)), only participants 
who had completed set of data, that was having completed CMPQ at baseline, mid treatment, 
and end of treatment weeks, could be included in the responsiveness analysis. In total, 39 
were included. The difference between 73 (only REA and PMM alone were counted here) at 
baseline week to 39 at the end of treatment week was due to drop out (n=12), not able to 
complete the CMPQ (n=12 for REA and n=10 for PMM alone). Due to there was insufficient 
number of females in each group, items about the gynaecological symptoms were excluded 
from the analysis. 
Chi square test was carried out to identify group differences at baseline week. Of those 
symptoms listed in Table 6.2 (p. 188), only other symptom – reflux was showing a significant 
difference (p=0.025) amongst REA and PMM alone. There were 37.5% in REA (n=23) and 
only 6.3% in PMM alone (n=16) having reflux symptom. All the other symptoms were not 
different between REA and PMM alone. 
Cochran’s Q test was used to analyse these 39 sets of data. Cochran’s Q test showed the 
symptoms responded to the REA and PMM alone interventions but not the direction of changes, 
e.g. improvement/deterioration. The results were as following:  
6.3.7.1 Summary for responsiveness 
The results of responsiveness are summarised in Table 6.16. Only REA was showing symptoms 
responding to REA. There were no symptoms responding to PMM alone intervention. 
Table 6.16 Summary of baseline, mid treatment, and end of treatment weeks responsiveness 
comparison for the two groups 
Domain Items show significant responsiveness 
REA 
Pain alleviator bowel movement 
Other symptoms  skin itch 
PMM alone 
 No symptoms responded to PMM alone. 
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6.3.7.2 Responsiveness as determined by CMPQ among those in the REA 
group (n=23) 
Table 6.18 shows the p values for the Cochran’s Q test for REA in baseline, mid treatment, and 
end of treatment weeks. Of these, the significant changes are listed in Table 6.17. Only bowel 
movement in pain alleviator and skin itch in other symptom responded to REA over time.  
Table 6.17 Summary of baseline, mid treatment, and end of treatment weeks responsiveness 
comparison for REA group (n=23) 
Domain Items show significant responsiveness 
Pain alleviator bowel movement 
Other symptoms skin itch 
 
Table 6.18 P values for Cochran’s Q test – REA - baseline, mid treatment, and end of treatment 
weeks (n=23) 
Symptoms p value 
Pain aggravators 
Physiological and psychological changes 
Bad night sleep 0.717 
Being emotional 0.819 
Stress 0.867 
Others 
Sex 0.368 
Pain alleviators 
Physiological and psychological changes 
Bowel movement 0.074 
Sleep 0.779 
Others 
Sex 0.368 
Other symptoms 
Skin itch 0.097 
Nausea 0.115 
Reflux 0.135 
Feeling depressed 0.18 
Constipation 0.247 
Irritable 0.319 
Dry stools 0.368 
Night sweating 0.549 
Sweat upon mild activities 0.549 
Dizziness 0.549 
Feeling tired easily 0.607 
Feeling nervous easily 0.717 
Dry skin 0.779 
Insomnia 1 
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Bond indicate significant responsiveness (p value <0.10) 
6.3.7.3 Responsiveness as determined by CMPQ among those in the PMM 
alone group (n=16) 
Table 6.19 shows the p values for the responsiveness changes for PMM alone in baseline, mid 
treatment, and end of treatment weeks. Of them, there was no significant change in any of the 
symptoms over time.  
Table 6.19 P values for Cochran’s Q test – PMM alone – baseline, mid treatment, and end of 
treatment weeks (n=16) 
Symptoms p value 
Pain aggravators 
Physiological and psychic changes 
Bad night sleep 0.276 
Stress 0.156 
Being emotional 0.247 
Others 
Sex 0.223 
Pain alleviators 
Physiological and psychic changes 
Bowel movement 0.223 
Sleep 0.867 
Others 
Sex 0.368 
Other symptoms 
Feeling depressed 0.223 
Skin itch 0.247 
Constipation 0.264 
Night sweating 0.368 
Dry skin 0.368 
Sigh often 0.549 
Feeling hot easily 0.607 
Irritable 0.607 
Sweat upon mild activities 0.607 
Reflux 0.607 
Nausea 0.607 
Dizziness 0.607 
Feeling tired easily 0.867 
Feeling nervous easily 0.867 
Insomnia 0.882 
Dry stools 1 
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6.3.7.4 Comparison with side effect of OM as recorded in pain and 
medication diaries 
Table 6.20, Figure 6.2 to Figure 6.5 show the repeated MANOVA results and the graphical 
illustration of changes in side effects of OM severity between baseline week and end of 
treatment week amongst the REA and PMM alone groups. Apart from dizziness (Figure 6.1), 
fatigue (Figure 6.2), drowsiness (Figure 6.3), blurred vision (Figure 6.4), and lethargy (Figure 
6.5), none of the other OM side effects were showing significant changes over time. And only 
lethargy reached statistical significant changes over time amongst the two treatment groups 
where PMM alone reduced more than REA (p=0.080). Not all the participants within the two 
treatment groups reported experiencing side effects of OM (Table 6.20). 
Table 6.20 Repeated MANOVA for side effects of OM amongst the two treatment groups 
between week 4 and end of treatment week (n=39) 
OM side 
effect 
N 
(total) 
(n=39) 
N 
(REA) 
(n=24) 
N (PMM 
alone) 
(n=16) 
Wilk’s 
Λ F 
Hypothesis 
df 
Error 
df 
P 
value
partial 
η2 
Repeated MANOVA over time 
Nausea 3 2 1 0.949 0.053 1.000 1.000 0.856 0.051 
Vomiting 0 0 0 No data 
Dizziness 3 1 2 0.024 40.333 1.000 1.000 0.099 0.976 
Fatigue 13 6 7 0.659 5.679 1.000 11.000 0.036 0.341 
Drowsiness 10 4 6 0.465 9.199 1.000 8.000 0.016 0.535 
Blurred 
vision 4 2 2 0.169 9.846 1.000 2.000 0.088 0.831 
Sedation 6 3 3 1.000 0.002 1.000 4.000 0.968 0.000 
Lethargy 10 5 5 0.520 7.398 1.000 8.000 0.026 0.480 
Anxiety 8 3 5 0.702 2.545 1.000 6.000 0.162 0.298 
Nightmares 4 2 2 0.569 1.514 1.000 2.000 0.344 0.431 
Constipation 9 6 3 0.999 0.007 1.000 7.000 0.937 0.001 
Repeated MANOVA over time and the two treatment group 
Nausea 3 2 1 0.500 1.001 1.000 1.000 0.500 0.500 
Vomiting 0 0 0 No data 
Dizziness 3 1 2 0.036 27.000 1.000 1.000 0.121 0.964 
Fatigue 13 6 7 1.000 0.001 1.000 11.000 0.975 0.000 
Drowsiness 10 4 6 0.946 0.459 1.000 8.000 0.517 0.054 
Blurred 
vision 4 2 2 0.591 1.385 1.000 2.000 0.360 0.409 
Sedation 6 3 3 0.770 1.196 1.000 4.000 0.336 0.230 
Lethargy 10 5 5 0.666 4.006 1.000 8.000 0.080 0.334 
Anxiety 8 3 5 0.974 0.158 1.000 6.000 0.705 0.026 
Nightmares 4 2 2 0.709 0.822 1.000 2.000 0.460 0.291 
Constipation 9 6 3 0.950 0.371 1.000 7.000 0.561 0.050 
Bold font indicates significant difference (p 0.1)≦  
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 OM: Opioid medication 
VAS: Visual analogue scale 
Baseline week: Mean: 2.625. Standard error: 0.650 
End of treatment week: Mean: 2.075. Standard error: 0.736 
Figure 6.1 Changes of side effect of OM - dizziness - between baseline and end of treatment 
weeks (p=0.099) (n=3) 
 OM: Opioid medication 
VAS: Visual analogue scale 
Baseline week: Mean: 5.662. Standard error: 0.479 
End of treatment week: Mean: 3.956. Standard error: 0.819 
Figure 6.2 Changes of side effect of OM - fatigue - between baseline and end of treatment 
weeks (p=0.036) (n=13) 
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  OM: Opioid medication 
VAS: Visual analogue scale 
Baseline week: Mean: 5.658. Standard error: 0.651 
End of treatment week: Mean: 2.729. Standard error: 0.823 
Figure 6.3 Changes of side effect of OM – drowsiness - between baseline and end of treatment 
weeks (p=0.016) (n=10) 
 OM: Opioid medication 
VAS: Visual analogue scale 
Baseline week: Mean: 3.325. Standard error: 0.825 
End of treatment week: Mean: 4.125. Standard error: 0.910 
Figure 6.4 Changes of side effect of OM – blurred vision - between baseline and end of 
treatment weeks (p=0.088) (n=4) 
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 OM: Opioid medication 
VAS: Visual analogue scale 
Baseline week: Mean: 5.440. Standard error: 0.650 
End of treatment week: Mean: 3.850. Standard error: 0.874 
Figure 6.5 Changes of side effect of OM – lethargy - between baseline and end of treatment 
weeks (p=0.026) (n=10) 
  OM: Opioid medication 
VAS: Visual analogue scale 
Blue bars belong to real EA 
Red bars belong to PMM alone 
REA: Baseline week: Mean: 4.020. Standard error: 0.927. End of treatment week: Mean: 3.600. 
Standard error: 1.317. 
PMM alone: Baseline week: Mean: 6.860. Standard error: 0.927. End of treatment week: Mean: 
4.100. Standard error: 1.317. 
Figure 6.6 Changes of side effect of OM – lethargy - between baseline and end of treatment 
weeks amongst the two treatment groups (p=0.080) 
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6.4 Discussion 
6.4.1 Summary of findings  
The aim of this chapter was to test the initial version of CMPQ on the CMP patients who used 
OM for pain control, including 1) evaluating content validity, face validity, internal consistency, 
reproducibility(test-retest reliability), and responsiveness; 2) collect data on the pain and 
non-pain symptoms of the patients. The recruited participants were mainly middle aged 
Australian female who were married and well educated. They consumed OM with morphine 
equivalence of 633mg/week or 90mg/day on average, which is equivalent to 20 panadeine forte 
per day. The majority of the participants had an average history of pain 12.92 years and the 
mean intensity of average pain of 5.5 on a VAS scale. Content and face validities were achieved, 
internal consistency was high (Cronbach’s α = 0.919 to 0.935), reproducibility was high 
(correlation coefficient = 0.846), and bowel movement as pain alleviator and the accompanying 
skin itch symptom showed responsiveness to REA whereas PMM alone did not have any 
symptom responding to it. The only side effect of OM, as recorded in the pain and medication 
diary, showing statistical significant changes over time between REA and PMM alone groups 
was lethargy. The discrepancy between the side effects of OM recorded in the pain and 
medication diary and CMPQ (Table 6.17 and Table 6.20) may be due to the pain and 
medication diary specifically asked patients the side effects of OM whereas CMPQ only 
asked the presence of symptom. Participant may consider the symptoms they experienced 
were not side effects of OM. 
The recruited participants mainly had sharp pain in their spine, shoulder, lower limb, and 
mainly at a fixed location. More than 55% of participants had more than seven pain regions. 
This is similar to widespread pain according to the updated diagnosis of fibromyalgia 979. To be 
consistent with the commonly used questionnaire, the future version of CMPQ will incorporate 
a pain diagram.  
The participants had pain all the time or the pain was worse when first got up. Their pains were 
often aggravated by cold weather, movement (walking, bending, going up/down stair), being 
static (standing, sitting), physical work (lifting, physical work, household chore), bad night 
sleep and stress. Their pains were mainly relieved by hot packs/shower, resting, gentle massage, 
and pain killer. Majority of them experienced multiple non-pain symptoms, including fatigue, 
insomnia, limited movement, cognitive (concentration and memory) and emotional (depression 
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and irritability) issues, constipation, and libido issues 
6.4.2 Comparing with other CM questionnaires  
In this chapter, the CMPQ was developed specifically for CMP patients and tested on CMP 
patients who use OM for pain relief. A few CM questionnaires have been developed for other 
health conditions. Park et al. developed a phlegm pattern questionnaire 1037, Zhao et al. 
developed a sub-optimal health status questionnaire (SHSQ-50) 1038, Lee et al. developed a Yin 
deficiency questionnaire 1039. This CMPQ differs from them as more items are included, and it 
is focusing on CMP patients who use OM for pain relief whereas Park et al. recruited healthy 
college students who went for a health consultation, Zhao et al. recruited sub-healthy 
participants who had fatigue for more than three months and healthy participants who did not 
have fatigue for more than three months. This CMPQ is developed to assist CM clinical 
consultation for CMP patients whereas Park et al. 1037 and Lee et al. 1039 developed their 
questionnaires for the CM diagnosis of phlegm pattern and Yin deficiency respectively. And 
generally questionnaires were specific to one disease/condition, CMPQ aimed to collect 
broader data from participants to assist CM practitioner with pattern identification about CMP 
using the CM eight guiding principles.  
The CM eight guiding principles (briefly described in Chapter 2.6.2 CM syndrome 
differentiation (p. 32)) is unique to CM. Briefly the CM eight guiding principles sub groups 
the patient’s symptom presentation into the combination of the eight categories e.g. 
interior/exterior, cold/heat, deficiency/excess, and Yin/Yang. If a patient presents with lower 
back pain aggravated by cold weather, alleviated by hot pack, and accompanied with 
diarrhoea, abdominal distension, and fatigue, such patient has interior cold with deficiency 
pattern according to the CM eight guiding principles. For the purpose of the CM eight guiding 
principles, it is necessary to capture sufficiently broader information to cover symptoms for 
differentiation of different patterns. In this project, the majority participants with SP, lower 
limb pain, and shoulder pain were included. And according to the search on PubMed on 
05/11/2016, there is no other questionnaire developed and utilising the CM eight guiding 
principles for CM syndrome differentiation. 
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6.4.3 Comparison with Chapter 3 Systematic review on comorbidity and 
accompanying symptom associated with CMP conditions 
Of the SR chapter, the accompanying symptoms are listed from Table 3.46 to Table 3.48 (p. 126 
- 129). The current project included mainly SP, widespread pain, and knee and hip pain which 
are similar to the three types of pain described from Table 3.46 to Table 3.48. Both the SR and 
the current project have identified the accompanying fatigue and depression symptoms. In 
addition, the current CMPQ has identified accompanying symptoms that are frequently 
occurring but not listed in Table 3.46 to Table 3.48 (p. 126 - 129). The included participants 
would fall into the three types of CMP based on their pain region presentation. The 
accompanying symptoms not listed from Table 3.46 to Table 3.48 included poor concentration, 
poor memory, limited movement, irritable, constipation, and low libido. The possible reason for 
such information was not found in the SR may be the researchers did not assess them and 
should include these symptoms for the future research. Although the use of OM may influence 
the symptom presentation, the CM view on the symptom presentation, as seen in this 
comparison, would enhance the understanding of the broader picture of the accompanying 
symptoms of CMP. 
6.4.4 The questionnaire properties of CMPQ 
The CMPQ results demonstrated good content validity, face validity, a high level of internal 
consistency (Cronbach’s α: 0.912), and test-retest reliability except for domains of individual 
pain region, pain quality, and pain rhythm due to small item numbers in these domains 1040. If 
pain regions were assessed together, then the test-retest reliability was adequate (correlation 
coefficient = 0.808).  
Although two (pain rhythm and pain quality) out of six domains (pain region, pain quality, 
pain rhythm, pain aggravators, pain alleviators, and other symptoms) did not meet Cronbach’s 
α ≥ 0.70 for internal consistency, the overall CMPQ had a high level of internal consistency. 
This is considered to be acceptable in questionnaire development as not all domains of a 
questionnaire needs to have a high level of internal consistency as long as the overall 
consistency is high 1041. Apart from that, the Cochran’s Q test showed only REA was showing 
significant change. This indicated symptoms were responding to REA intervention but not 
PMM alone intervention. On the other hand, it may also mean due to the dichotomous format 
of the questionnaire CMPQ was not able to detect small changes, e.g. it was not able to detect 
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small portion of changes, the symptom had to be from presence to absence or vice versa in 
order to show responsiveness. It is necessary to change the format of question from 
dichotomous to a likert scale (e.g. 0 – 4) or a VAS like scale (e.g. 0-100) to reflect the degree 
of variance over time 1042.  
The interpretability was not assessed in the development process due to there is no gold 
standard to compare with for the CM pattern identification. Literature has suggested the 
medical experiences of the CM practitioners and other factors can influence the CM pattern 
identification diagnosis 1043. Expert’s CM pattern identification diagnosis is imperfect and can 
lead to imperfect gold standard bias which gives rise to falsely high sensitivity 1044. The 
interpretability of CMPQ requires further research to standardize it. 
6.4.5 Item reduction 
Within item reduction, there were items rarely selected by participants (Table 6.21). There are 
symptoms ambiguous to participants, unrelated to pain, contradictory to CM theory, and 
insufficient participants, or others. The term vertex was rarely selected may be due to the trial 
recruited CMP patients but not headache patients or maybe this technical term was not 
understood by participants. The term “not known” in pain quality, pain rhythm, pain 
aggravator, and pain alleviator was rarely selected. It may be participants all knew what their 
pain was like or this term was ambiguous to them. Cold weather, wet weather, and windy days 
all related to a combination type of pathogen in CM understanding – cold, dampness, and 
wind 1045,1046. These pathogens cause pain (cold pathogen), make the symptoms to linger 
(dampness pathogen), or are the guiding pathogen to bring other pathogens to the body or 
changing frequently such as pain that moves around (wind pathogen) 133(p94-96). And due to 
insufficient participants, gynaecological symptoms were rarely selected by participants. 
Standing, driving, and working are factors known not to alleviate pain. Belching-related 
symptoms were rarely selected, and this may be due to the participants did not have belching. 
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Table 6.21 Possible reasons for rarely selected items 
Domain Symptom Reasons 
Not understood 
or ambiguous 
Maybe pain has 
nothing to do 
with appetite 
Contradictory to 
CM theory 
Insufficient 
female 
participants 
Other reasons 
Pain region Vertex x    Not target group, this item 
is suitable for a Headache 
population  
Pain quality Not known x     
Pain rhythm Recurrent     Similar to “all the time” 
Worse at 
lunch time 
 x    
Not known x     
Pain aggravator After eating  x    
Being hungry  x    
Not known x     
Pain alleviator Cold weather   x   
Wet weather   x   
Windy days   x   
Standing     Commonly not an alleviator 
Driving     Commonly not an alleviator 
Eating  x    
Being hungry  x    
Belching     Not many participants have 
belching 
Working     Commonly not an alleviator 
Sex   x   
Everything x     
Not known x     
Other symptoms Mushy stools     Side effect of OM is 
constipation 
Belching     Maybe not related to CMP 
Other Excessive    x This is perhaps more 
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Domain Symptom Reasons 
Not understood 
or ambiguous 
Maybe pain has 
nothing to do 
with appetite 
Contradictory to 
CM theory 
Insufficient 
female 
participants 
Other reasons 
gynaecological 
symptom 
Watery 
discharge 
suitable for pain due to 
gynaecological conditions,  
Yellow 
discharge 
   x 
Light blood    x 
Early periods    x 
Total  6 5 4 4  
OM: Opioid medication
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6.4.6 Sample size calculation 
For sample size, there is no gold rule for a minimum sample size 1047. Some authors have 
suggested to have the participant number as five times the total number of items in the 
questionnaire whereas other authors suggested to have minimum of 100 subjects 1047. This 
project followed the minimum of 100 subjects suggestion. Apart for responsiveness where the 
participants were divided into two groups, the sample size was sufficient for agreement 
(test-retest reliability) and internal consistency. 
The strengths of the project include: 
1) a very specific population was targeted, there is no other pain questionnaire developed and 
recruited participants using OMs as a search in PubMed on 06/11/2016.  
2) the total number of participants was over 100. 
3) Chinese medicine pain questionnaire contains a broad range of symptoms which is 
different from other types of outcome measures and it provides clinical data for CM 
practitioners to differentiate the CM patterns. 
4) multiple assessment times allowing for test of responsiveness and test-retest reliability. 
The limitations of this project are: 
1) there was no other questionnaire or gold standard to compare for construct and criterion 
validities. 
2) most of the females recruited were at the postmenopausal age and items related to 
gynaecological conditions could not be assessed for reliabilities and validities. 
3) the dichotomous format of the questionnaire limited the type of statistical analysis that can 
be performed. 
4) the participants were limited to Victoria region of Australia. The main participants are 
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Australians. Very few participants from other ethnic background were included in the 
project. 
5) the recruited participants were a small subset of CMP who consumed OM for pain relief. 
The limitations of this project affect the validity of the CMPQ to some extend such as most of 
the females are over the age of menopause. However, researches have shown the prevalence 
of chronic pain, such as joint pain, widespread pain, and fibromyalgia, increases with age in 
females and either peaks around or increases further from menopausal age 1048. The included 
females are representative of the female population of chronic pain. Furthermore, this 
limitation should not affect the validity for the non-female related items. The dichotomous 
format of the data, although limits the assessment of changes, is the basis of how CM doctor 
diagnoses a patient – whether or not a symptom is present 1019(p873) rather than giving a score 
as in most western medical diagnosis.  
Implication for future research 
The first stage of the CMPQ development demonstrated face validity, content validity, 
test-retest reliability, and internal consistency. Future development should focus on fulfilling 
other questionnaire properties that were not assessed in this current project for CMPQ, turning 
the format into likert scale to reflect the changes after intervention. 
The next chapter (Chapter 7 Pre treatment data: pattern identification (all participants) , p. 219) 
is on CM pattern for the participants where it details the process of sub grouping the 
symptoms participants presented and the CM patterns, according to the CM eight guiding 
principles, for the subgroups.  
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7. Pre treatment data: pattern identification (all 
participants) 
7.1 Introduction 
In the last chapter, CMPQ was shown to be reliable, valid, internally consistent, and with some 
items responded to REA. This chapter will assess if data collected from the CMPQ can be used 
to help CM pattern identification.  
In CM, one disorder or condition may have several clinical patterns or subgroups. For example, 
the diagnosis of LBP can be subcategorised into five patterns, including LBP due to cold 
dampness Bi (painful) blockage (寒湿痹阻), LBP due to damp heat retention (湿热阻滞), 
LBP due to blood stasis (瘀血腰痛), LBP due to Qi stagnation (气滞腰痛), LBP due to CM 
spleen deficiency (脾虚腰痛), LBP due to CM kidney deficiency (肾虚腰痛) based on a CM 
textbook 132(p706-708). Those patterns are also called CM syndromes. The process of diagnosing 
a pattern is called CM pattern identification, which heavily relies on data gathered from 
inspection, auscultation and olfaction, enquiry, and palpation (Table 7.1). For example, if a 
patient has LBP and accompanied with heaviness of the limbs and the LBP is aggravated by 
humid or wet weather, such LBP is considered to be the pattern of cold dampness; whereas if 
the LBP is sharp in nature and the pain is fixed at one location, then such LBP is likely to be a 
pattern of blood stasis (Table 7.1). Currently the types of patterns of many health conditions 
outlined in textbooks are established by the experts in the fields. Different textbooks may 
provide slightly different CM patterns for the same condition 
132(p706-708)1022(p1131,1158,1168,1171,1172,1176,1177,1306,1325,1554-1557)1020(p1059-1118) 1021(p308-335). For instance, 
LBP patterns include stagnation of Qi and blood, CM kidney deficiency, CM liver Qi stagnation, 
invasion of cold and dampness as listed in The Practice of Chinese Medicine 1020(p1059-1118), and 
CM kidney deficiency, CM kidney Qi deficiency, CM kidney Yang deficiency, CM kidney Yin 
deficiency, cold dampness, blood stagnation, CM liver stagnation, CM spleen deficiency as 
listed in Clinical Handbook of Internal Medicine 1021(p308-335). None of the textbooks have 
applied evidence-based approaches to analyse the clinical data from the patients to develop CM 
patterns. Does the textbook information reflect the reality is unknown and requires 
examination. 
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Table 7.1 Signs and symptoms of different LBP patterns 
Low back pain CM 
patterns 
CM eight 
guiding 
principles 
diagnosis 
Signs and symptoms 
Cold dampness Bi 
(painful) blockage (寒
湿痹阻) 
Interior excess 
cold 
Cold LBP with heaviness, difficult to turn 
around, slowly getting worse, resting does not 
relieve the pain, pain alleviated by 
exercise/movement, pain worsened during rainy 
and cloudy day, greasy white tongue coating, 
slow and deep pulse 
Damp heat retention 
(湿热阻滞) 
Interior excess 
heat 
Low back pain being heavy and hot, pain 
aggravated by hot days or rainy days, pain 
alleviated by exercise/movement, dry mouth and 
thirsty, greasy yellow coating, soft and rapid 
pulse 
Blood stasis (瘀血腰
痛) 
Interior excess Sharp LBP at fixed location, worse at night and 
better during the day, those with mild pain cannot 
bend easily, those with severe pain cannot turn 
their body to the side, patient refused to be 
touched in the tender area, purple dark tongue 
body, may accompany with ecchymosis in the 
tongue, unsmooth pulse. Some patients may have 
a history of trauma. 
Qi stagnation (气滞腰
痛) 
Interior excess Low back pain comes with pain in hypochondriac 
region, accompanied with abdominal pain, sigh 
often, pain aggravated by emotional upset, pain 
radiates to abdomen, dark tongue body with thin 
white coating, taut pulse. 
CM spleen deficiency 
(脾虚腰痛) 
Interior 
deficiency 
Chronic LBP, heaviness in the body and limbs, 
lustreless complexion, poor appetite with 
diarrhoea, white greasy tongue coating, slippery 
or soft pulse. 
CM kidney deficiency 
(肾虚腰痛) 
Interior 
deficiency 
Low back pain manifested as sore and weakness, 
prefers rubbing, weakness in the lumbar and knee 
regions, worse after work out, alleviated by bed 
resting, recurrent in nature. For Yang deficiency, 
there will be tightness in the lateral abdomen, 
pale complexion, cold limbs, lassitude and 
weakness, pale tongue body, and thready deep 
pulse. For Yin deficiency, there will be vexation 
and insomnia, dry mouth and throat, malar flush, 
feverish sensation in the palms and soles, red 
tongue body with little coating, thready and rapid 
pulse. 
Signs and symptoms extracted from “Chinese medicine internal medicine” 132(p706-708) 
CM: Chinese medicine 
LBP: low back pain 
 
For pattern identification, there is an increasing application of scientific methods to sub-group 
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the diseases/conditions including CM pattern identification in the recent years 1049,1050. In 
Western medicine, advanced statistical methods are used. Table 7.2 lists two examples of 
factor and cluster analyses having been used for sub-group identification for LBP and 
repetitive strain injury. Cluster analysis is used to sub group LBP into two clusters and 
repetitive strain injury into eight clusters 1016 based on their clinical presentation and/or other 
questionnaire outcomes. 
Table 7.2 Other pattern identification studies 
Study Participants Sub grouping 
methods 
Results 
Billis 
et al. 
1051 
106 non 
specific LBP 
K-means cluster 
analysis on a 
consensus list of 
potentially 
discriminatory 
examination items
2-4 clusters groups were found with 2 clusters 
being clinical meaningful. One small group 
(n=24) with more severe clinical presentation 
whereas the larger group (n=80) were of a less 
dysfunctional group. The items used for 
clustering included pain symptom presentation, 
limitation in range of motion, VAS for pain, 
RMDQ, Oswestry Disability Index, Fear 
Avoidance Belief Questionnaire, Hospital 
Anxiety Depression Scale, and Pain 
Catastrophizing Scale. 
Gold et 
al. 1016 
700 
repetitive 
strain injury 
patients 
Principal 
component 
analysis then K 
means cluster 
analysis 
Questionnaire contained 118 variables which 
were grouped into 3 attributes. The 3 attributes 
included 1) current symptom quality intensity, 2) 
duration of symptoms in the last week by body 
region, 3) severity of symptoms in the last week. 
8 Clusters were found, 1) mild diffuse 
musculoskeletal disorder (37.86%) 2) mild 
bilateral aching stiff neck and shoulder 
(25.43%), 3) moderate bilateral arm and 
wrist/hand/finger musculoskeletal disorder 
(15.56%), 4) severe diffuse musculoskeletal 
disorder (4.57%), 5) moderate musculoskeletal 
disorder with highlighted bilateral elbow 
shooting stabbing pain (11.00%), 6) severe 
diffuse musculoskeletal disorder with 
highlighted CNP (2.86%), 7) extreme diffuse 
musculoskeletal disorder with highlighted pain 
(1.86%), 8) extreme diffuse musculoskeletal 
disorder with highlighted CNP (0.86%). 
Mild diffuse musculoskeletal disorder: this cluster has mild symptoms without any 
predominant anatomical area in the upper extremity 1016. 
CNP: Coldness, numbness, and paraesthesias 
LBP: Low back pain 
RMDQ: Roland morris disability questionnaire 
VAS: Visual analogue scale 
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For CM, some authors applied factor analysis and clusters to categorise osteoporosis 1050, 
hypertension 1052, and non-alcoholic fatty liver disease 1053 (Table 7.3). The authors collected 
the clinical data from patients instead of simply relying on experts opinions as described in 
the textbooks132(in “the guide to use this book”)1054. The resulted sub-groups were meaningful in CM. 
Table 7.3 Modern CM pattern identification 
Study Participants Sub grouping 
methods 
Questionnaire 
/ interview 
based data 
collection 
Results 
Huang et 
al. 1050 
236 
osteoporosis 
patients 
Hierarchical 
cluster 
analysis 
Questionnaire 
based 
Patients were grouped into four 
patterns for a better distribution of 
the data gathered from the four 
diagnostic methods. The 4 patterns 
included CM liver and CM kidney 
Yin deficiency (n=82), CM spleen 
and CM kidney Yang deficiency 
(n=71), Qi and blood deficiency 
(n=46), Qi stagnation and blood 
stasis (n=37). 
Gu et al. 
1052 
477 
hypertension 
patients 
Two steps 
cluster 
analysis 
Questionnaire 
based 
Patients were grouped into one of 
the seven patterns. 1) CM heart and 
CM kidney Qi deficiency (10.1%); 
2) hyperactivity of CM liver Yang 
(24.1%); 3) deficiency of Yin and 
Yang (8.4%); 4) stagnation of 
phlegm dampness (27.1%); 5) 
phlegm heat (percentage not 
provided); 6) blood stasis 
obstructing collaterals (9%); 7) 
other pattern (not specified) 
(21.4%);  
Fan et al. 
1053 
928 
non-alcoholic 
fatty liver 
disease 
patients 
Factors 
analysis and 
cluster 
analysis 
Questionnaire 
based 
The resultant patterns included 1) 
dampness heat accumulation, 2) 
CM spleen deficiency with 
dampness and phlegm, 3) CM liver 
Qi stagnation and CM spleen 
deficiency, 4) phlegm stasis 
accumulation, and 5) CM liver and 
CM kidney insufficiency 
CM: Chinese medicine 
 
 
In the above mentioned examples, factor analysis and cluster analysis were used. Both are 
described in Chapter 4.6 Statistical analysis (p.148). Briefly factor analysis is a method used 
to reduce the items into factors and cluster analysis is a statistical method that is used to group 
similar items together, named as clusters. When using factor analysis, criteria of KMO, eigen 
 223 
value, and total factors explained needed to be fulfilled and the factors needed to be 
interpretable. Currently, sub-categorising CMP patients who use OM for pain control based on 
CM pattern identification was not found in a PubMed search on 06/11/2016. Such data for 
CMP patients who use OM for pain control is in need to fill the knowledge gap between the 
textbook information and the clinical situation.  
The aims of this chapter were to  
1) establish the CM pattern(s) for CMP patients who use OM for pain control with an 
evidence-based approach by using the clinical data gathered with CMPQ at the baseline stage 
of the clinical trial.  
2) identifying the differences in demography and pain data among the CM patterns. 
7.2 Methods 
Inclusion and exclusion criteria 
As described in Chapter 4.2.2 Inclusion and exclusion criteria (p. 141), CMP patients who 
used OM for pain control were included. In addition, only participants who provided baseline 
week CMPQ data were included. 
Outcome measure 
Outcome measure included CMPQ completed in baseline week, expression of interest and 
initial pain questionnaire, which documented patient’s pain and demographic data. 
Statistical analysis 
Baseline week CMPQ data was used. SPSS version 23 was used for statistical analysis. The 
statistical analysis methods used included frequency analysis, factor analysis, cluster analysis, 
ANOVA, Chi square, and MANOVA.  
Frequency analysis: Frequency analysis was used to evaluate the rarely selected symptoms. 
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Factor analysis was used to reduce the number of symptoms by principal component analysis.  
Factor analysis: Principle component analysis in factor analysis was applied on the items apart 
from the pain regions. Pain regions were excluded from factor analysis. In CM, apart from low 
back regions which was associated with the function of CM kidney, pain regions were of no 
value in CM pattern identification. Varimax rotation was used to rotate the factors. Items that 
were removed (<5% occurrence in both pre-baseline and baseline weeks) were not used in the 
factor analysis to prevent distortion to the factors. Factor items with less than 0.5 absolute 
coefficient values were suppressed. The minimum eigen value depended on the number of 
factors produced. It was determined the minimum eigen value should explain 60% of the 
variance 1014(p109) and at the same time produced adequate factors so the sample size to factor 
ratio was at least 2:1 1055. KMO was used to assess the sampling adequacy 1011(p647). The value of 
KMO ranged from zero to one where zero meant the pattern of correlation in the factors were 
diffuse and one meant the factors were distinct and reliable 1011(p647). The interpretations for 
KMO were: 0.5-0.7 was mediocre, 0.7-0.8 was good, 0.8-0.9 was great and above 0.9 was 
superb 1011(p647). In factor analysis, the resulted factors may be not interpretable with CM theory. 
When this occurred, options in factor analysis were manipulated to identify the factors 
interpretable in CM and fitted into the CM theoretical framework. Factors and factor domains 
were different. Factors here referred to the individual factors derived from principle 
component analysis whereas factor domains referred to the characteristics of pain described in 
Chapter 5.1 Introduction (p. 152). 
Cluster analysis: The resulted factors were saved and used in K-means cluster analysis. 
K-means cluster analysis could only take up scale data but not ordinal data. Scale data referred 
to data such as VAS for pain where patients can rate from 0 to 10 even to decimals. Ordinal data 
referred to data rated with a hierarchy in the data. That is to say three is always better/worse 
than two depending on the question. But there is nothing in between the numbers e.g. no 
decimals. The resulted factors from factor analysis were scale data - suitable for K means 
cluster analysis. This referred to the dichotomous data in the CMPQ had been turned into a 
scale data where there is decimal numbers by factor analysis. This is illustrated in Figure 7.1 
and Figure 7.2 where Figure 7.1 shows the original dichotomous data where only zero and one 
are used and Figure 7.2 shows the resulted scale data showing decimals after factor analysis. 
Further information about how factors were generated is provided in Chapter 4.6 Statistical 
analysis (p. 148). Again, different options in K-means clusters were manipulated to identify the 
interpretable clusters. In the method of K means cluster analysis in SPSS, “classify only” was 
 225 
selected instead of “iterate and classify” in the end to derive interpretable clusters (Figure 
7.3).  
 Figure 7.1 Original dichotomous data for factor analysis 
 
 Figure 7.2 Factor analysis turned dichotomous data into scale data with decimals 
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 Figure 7.3 The method of K means cluster analysis 
To determine the number of clusters, the elbow method described by Gelasakis et al. was used 
1056. The elbow method used Wards method within hierarchical cluster analysis. Within the 
agglomeration schedule, one needed to find the two stages where the biggest change in 
distance coefficient occurred. The stage before the biggest change in distance coefficient was 
subtracted from the sample size. This gave the ideal number of clusters for the K-means 
cluster analysis. For example, the biggest change occurred in step 12 as shown in Figure 7.4. 
Then number of cluster was 16-12 = 4. 
 227 
 Figure 7.4 Example of the elbow method 
Chi square, ANOVA, and MANOVA were used to find out if the identified clusters were of 
any differences in age, gender, pain history and other data. Specifically ANOVA was used on 
age, Chi square was used on demographic data and MANOVA was used on pain history, and 
baseline week data of total pain regions, current work status, average of OM consumption, 
average of NonOM analgesics, average of average pain intensity, unpleasantness of average 
pain, RMDQ, total score of BDI, physical health total of SF36, mental health total of SF36, 
and total SF36 score. 
Chinese medicine cluster analysis group researchers of the Discipline of Chinese Medicine 
within RMIT University reviewed the clusters and related data and provided the CM pattern 
for them. 
7.3 Result 
7.3.1 Baseline week frequency analysis 
For baseline week, data were available for 106 participants. Frequency of each item was 
presented from Appendix 22 to Appendix 27. For pain region, the frequently (≥ 40%) occurred 
pain regions were lower back (77.4%), neck (45.3%), hip (43.4%), knee (40.6%). There was no 
pain region selected by less than 5% of participants. 
Participants often felt the qualities of their pains were sharp (58.5%) and in a fixed location 
(47.2%) (Appendix 23) and described they had pain all the time (74.5%), and worse when 
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first got up (40.6%).  
Standing (65.1%), physical work (64.2%), walking (62.3%), stress (55.7%), cold weather 
(54.7%), lifting (53.8%), bad night sleep (52.8%), sitting (51.9%), bending (50.0%), going 
up/down stairs (50.9%), household chores (50.0%) often aggravated participants’ pain. For 
females (n=15 for females aged under 51), before and during period often aggravated their 
pain (40% each) whereas after period (6.7%) generally did not aggravate participant’s pain 
(Appendix 24). 
Pain killer (80.2%), hot packs (53.8%), resting (44.3%), warm/hot shower (42.5%) often 
alleviated participants’ pain (Appendix 25). 
For females (n=15 for females aged under 51), only 26.7% of participants described after 
period alleviated their pain whereas before and during period did not alleviate their pain 
(Appendix 25). 
For other symptoms, participants’ often had feeling tired easily (66.0%), insomnia (53.8%), 
limited movement (51.9%), poor concentration (50%), poor memory (50%), feeling depressed 
(45.3%), low libido (43.4%) and constipation (41.5%) (Appendix 26).  
For females’ other symptoms, none of them were frequently experienced by female 
participants and no participants had light menstrual blood (pink) (0%), early periods (0%), 
excessive watery discharge (0%), and yellow discharge (0%) (Appendix 27). 
7.3.2 Factor analysis 
Items that had a low frequency of less or equal to five percent were removed prior to 
conducting factor analysis (Table 7.4). All the female related items were removed as only 15 
female participants were under the age of menopause. 
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Table 7.4 Removed items prior to factor analysis  
Domain Items 
Pain quality Not known 
Pain rhythm Recurrent, worse at lunch time, not known 
Pain aggravator Environmental changes - windy days 
Physiological and psychic changes - after eating 
Others - not known 
For female patient - before period, during period, after period 
Pain alleviator Environmental changes - cold weather, wet weather, windy days, 
Exercises of sporting - standing, driving, 
Physiological and psychic changes - eating, being hungry, belching, working
Others - sex, everything, not known 
For female patient - before period, during period, after period 
Other 
symptoms 
Belching, watery diarrhoea 
For female patients - abdominal pain during or before period periods, low 
back pain during or before periods, dark blood, light blood (pink), bleeding 
with clots, excessive bleeding, light bleeding, delayed periods, early periods, 
irregular periods, excessive watery discharge, yellow discharge 
 
The KMO values are listed in Table 7.5. All factor domains were of acceptable KMO values 
(KMO>0.5). The aggravating factor domain was well sampled (KMO>0.7). The total variance 
explained were all acceptable except for pain rhythm which was close to acceptable. 
Table 7.5 Eigen values, total variance explained and KMO 
Factor domains Eigen values Total variance explained KMO 
Pain quality 1.061 59.84% 0.628 
Pain rhythm 1.27 56.76% 0.538 
Aggravating factors 1.108 60.77% 0.725 
Alleviating factors 1.134 61.80% 0.553 
Other symptoms 1.163 62.40% 0.633 
KMO: Kaiser–Meyer–Olkin measure 
 
Table 7.6 to Table 7.10 show the results of the factor analysis. There were five pain quality 
factors (Table 7.6), three pain rhythm factors (Table 7.7), seven pain aggravating factors (Table 
7.8), nine pain alleviating factors (Table 7.9), and 12 other symptoms factors (Table 7.10). In 
total there were 36 factors, resulting in the ratio of the number of participants to the number of 
factors ratio to almost 3:1. Interpretation of those factors is provided in Table 7.11.  
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Table 7.6 Pain quality factor analysis (factor unrotated) 
Component Matrixa 
 
Component 
1 2 3 4 5 
Pain quality-cold-wk5      
Pain quality-pulling-wk5      
Pain quality-distending-wk5      
Pain quality-fixed location-wk5  .619    
Pain quality-moving from one spot to another-wk5     .540 
Pain quality-sharp-wk5   .534  .510 
Pain quality-pricking-wk5    -.547  
Pain quality-numbness-wk5 .724     
Pain quality-dull-wk5  .594  .514  
Pain quality-dull pain with weakness-wk5   -.587   
Pain quality-hot-wk5 .507     
Pain quality-burning-wk5 .684     
Extraction Method: Principal Component Analysis. 
a. 5 components extracted. 
Empty cells means < 0.5 and are suppressed 
 
Table 7.7 Pain rhythm factor analysis 
Rotated Component Matrixa 
 Component 1 2 3 
pain rhythm-all the time-wk5 -.772   
pain rhythm-fluctuate-wk5 .826   
pain rhythm-worse during the day, better at night-wk5  .719  
pain rhythm-worse at night, better during the day-wk5  -.540 .528 
pain rhythm-worse when first get up-wk5   .510 
pain rhythm-worse at the end of the day-wk5   .794 
pain rhythm-worse in the morning-wk5  .676  
pain rhythm-worse in the afternoon-wk5   .510 
Extraction Method: Principal Component Analysis.  
 Rotation Method: Varimax with Kaiser Normalization.a 
a. Rotation converged in 5 iterations. 
Empty cells means < 0.5 and are suppressed 
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Table 7.8 Pain aggravator factor analysis 
Rotated Component Matrixa 
 Component 
1 2 3 4 5 6 7 
Pain aggravator-environmental changes-wet 
weather-wk5 
  .833     
Pain aggravator-environmental 
changes-weather change-wk5 
  .717     
Pain aggravator-environmental changes-hot 
weather-wk5 
    .851   
Pain aggravator-exercises of 
sporting-standing-wk5 
       
Pain aggravator-exercises of 
sporting-walking-wk5 
.631       
Pain aggravator-exercises of sporting-lying 
down-wk5 
   .618    
Pain aggravator-exercises of sporting-physical 
work-wk5 
.658       
Pain aggravator-exercises of 
sporting-sitting-wk5 
   .785    
Pain aggravator-exercises of 
sporting-lifting-wk5 
.675       
Pain aggravator-exercises of 
sporting-bending-wk5 
.741       
Pain aggravator-exercises of sporting-any 
movement-wk5 
     .682  
Pain aggravator-exercises of sporting-going 
up/down stairs-wk5 
.627       
Pain aggravator-exercises of 
sporting-driving-wk5 
   .625    
Pain aggravator-Physiological and psychic 
changes-after eating-wk5 
      -.722
Pain aggravator-Physiological and psychic 
changes-being hungry-wk5 
       
Pain aggravator-Physiological and psychic 
changes-bad night sleep-wk5 
       
Pain aggravator-Physiological and psychic 
changes-stress-wk5 
 .778      
Pain aggravator-Physiological and psychic 
changes-being emotional-wk5 
 .766      
Pain aggravator-others-pressure on the 
area-wk5 
    .753   
Pain aggravator-others-sex-wk5        
Pain aggravator-others-everything-wk5      .663  
Pain aggravator-others-household chores-wk5 .655       
Extraction Method: Principal Component Analysis.  
 Rotation Method: Varimax with Kaiser Normalization.a 
a. Rotation converged in 8 iterations. 
Empty cells means < 0.5 and are suppressed 
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Table 7.9 Pain alleviator factor analysis 
Rotated Component Matrixa 
 Component 1 2 3 4 5 6 7 8 9 
pain alleviator-environmental changes-hot packs-wk5          
pain alleviator-environmental changes-cold packs-wk5  .580       
pain alleviator-environmental changes-hot weather-wk5   .672      
pain alleviator-environmental changes-warm/hot 
bath-wk5 
  .595      
pain alleviator-environmental changes-warm/hot 
shower-wk5 
         
pain alleviator-exercises of sporting-walking-wk5      .815   
pain alleviator-exercises of sporting-lying down-wk5    .788     
pain alleviator-exercises of sporting-sitting-wk5     .634    
pain alleviator-exercises of sporting-gentle massage-wk5          
pain alleviator-exercises of sporting-gentle exercise-wk5      .566   
pain alleviator-exercises of sporting-any movement-wk5        -.518  
pain alleviator-exercises of sporting-resting-wk5          
pain alleviator-Physiological and psychic changes-deep 
breathing-wk5 
 .751       
pain alleviator-Physiological and psychic changes-bowel 
movement-wk5 
        .890
pain alleviator-Physiological and psychic changes-pain 
killer-wk5 
       .700  
pain alleviator-Physiological and psychic 
changes-pressure on the pain area-wk5 
    .689    
pain alleviator-Physiological and psychic 
changes-keeping my mind off pain-wk5 
         
pain alleviator-Physiological and psychic changes-being 
with other people-wk5 
         
pain alleviator-Physiological and psychic 
changes-alcohol-wk5 
      .561   
pain alleviator-Physiological and psychic 
changes-reading-wk5 
.590         
pain alleviator-Physiological and psychic 
changes-sleep-wk5 
   .712     
pain alleviator-Physiological and psychic 
changes-watching TV-wk5 
.778         
pain alleviator-others-keeping busy-wk5  .541       
pain alleviator-others-household chores-wk5          
pain alleviator-others-nothing-wk5       -.701   
Extraction Method: Principal Component Analysis.  
 Rotation Method: Varimax with Kaiser Normalization.a 
a. Rotation converged in 23 iterations. 
Empty cells means < 0.5 and are suppressed 
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Table 7.10 Other symptoms factor analysis 
Rotated Component Matrixa 
 Component 
1 2 3 4 5 6 7 8 9 10 11 12 
other symptoms-swollen joints-wk5             
other symptoms-red and hot joints-wk5        .549     
other symptoms-cold joints-wk5    .653         
other symptoms-limited movement-wk5            .722 
other symptoms-distention sensation in the abdomen-wk5  .764           
other symptoms-indigestion-wk5          .646   
other symptoms-heavy sensation in the body-wk5  .576           
other symptoms-cold hands and feet-wk5   .518          
other symptoms-cold lower back or knees-wk5    .789         
other symptoms-feeling cold easily-wk5       .559      
other symptoms-feeling hot easily-wk5             
other symptoms-insomnia-wk5     .553        
other symptoms-night sweating-wk5         .715    
other symptoms-irritable-wk5 .689            
other symptoms-dry or sore throat-wk5             
other symptoms-flushed face-wk5        .681     
other symptoms-hot palms-wk5        .642     
other symptoms-thirsty-wk5   .605          
other symptoms-mushy stools-wk5  .664           
other symptoms-dry stools-wk5             
other symptoms-constipation-wk5 .558            
other symptoms-dry skin-wk5   .624          
other symptoms-leak when sneezing of cough-wk5             
other symptoms-frequent urination at night-wk5     .701        
other symptoms-frequent urination-wk5             
other symptoms-poor concentration-wk5 .660            
other symptoms-poor memory-wk5 .746            
other symptoms-low libido-wk5 .560            
other symptoms-poor appetite-wk5       .756      
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other symptoms-feeling tired easily-wk5         .605    
other symptoms-sigh often-wk5             
other symptoms-need deep breath-wk5             
other symptoms-short of breath-wk5      .744       
other symptoms-sweat upon mild activities-wk5             
other symptoms-catch cold easily-wk5           .773  
other symptoms-abdominal distention-wk5  .834           
other symptoms-stuffiness in the chest-wk5      .545       
other symptoms-feeling nervous easily-wk5             
other symptoms-feeling depressed-wk5             
other symptoms-reflux-wk5          .810   
other symptoms-nausea-wk5             
other symptoms-dizziness-wk5   .553          
other symptoms-skin itch-wk5            .512 
Extraction Method: Principal Component Analysis.  
 Rotation Method: Varimax with Kaiser Normalization.a 
a. Rotation converged in 27 iterations. 
Empty cells means < 0.5 and are suppressed 
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For the factors extracted above, they were discussed and named based on CM theories about 
pain by the CM cluster analysis group researchers. Those factors became units enabling 
cluster analysis and interpretation of the clusters (Table 7.11). Some of the factors were too 
complicated or too simple there was no name/interpretation given for them.  
Table 7.11 Factor names 
Domain Factors Factor names Explanation  
Pain quality Numbness, hot, burning Hot and numb pain Heat  
Fixed location, dull Dull pain at fixed 
location 
Possibly 
Deficiency 
Sharp, dull pain with weakness 
(-)* 
Sharp pain not dull with 
weakness 
Excess, possible 
blood stasis  
Pricking (-)*, dull Dull pain Qi deficiency 
Moving from one spot to 
another, sharp 
Sharp moving pain Excess, possible 
Qi and Blood 
stagnation  
Pain rhythm All the time (-)*, fluctuate Pain fluctuates Deficiency 
"Worse during the day, better at 
night", "worse at night, better 
during the day"(-)*, worse in 
the morning 
Pain worse from 
morning to day time 
and better at night. 
Yang deficiency 
"Worse at night, better during 
the day", worse when first get 
up, worse at the end of the day, 
worse in the afternoon 
Pain better during the 
day and worse at all 
other times. 
Yin deficiency 
Pain 
aggravating 
factor 
Walking, physical work, 
lifting, bending, going up/down 
stairs, household chores 
Worse by exertion Deficiency, 
possibly Qi 
deficiency 
Stress, being emotional Worse by mental strain Qi stagnation 
Wet weather, weather change Worse by wet weather 
and weather change 
Excess, possible 
dampness  
Lying down, sitting, driving Worse by static 
activities 
Excess, possible 
blood stagnation 
Hot weather, pressure on the 
area 
Worse by hot weather 
and pressure on the area 
Heat, excess  
Any movement, everything Non-specific Excess 
After eating (-)*  Not able to 
classify 
Pain 
alleviating 
factor 
Reading, watching TV Better by being 
distracted. 
Not able to 
classify  
Cold packs, deep breathing, 
keeping busy 
Better by cold packs, 
deep breathing, and 
keeping busy 
Heat 
Hot weather, warm/hot bath Better with heat Cold 
Lying down, sleep Better by rest Deficient  
Sitting, pressure on the pain 
area 
Better by sitting and 
applying pressure on the 
pain area 
Deficiency 
Walking, gentle exercise Better by gentle Excess, possible 
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Domain Factors Factor names Explanation  
movement dampness 
Alcohol, nothing(-)* Better with alcohol Possibly Cold 
Any movement (-), pain killer Better with pain killer Not able to 
classify  
Bowel movement Better with bowel 
movement 
Excess 
Other 
symptoms 
Irritable, constipation, poor 
concentration, poor memory, 
low libido 
Irritability, constipation, 
poor concentration, 
poor memory, and low 
libido 
Deficiency, heat 
Distention sensation in the 
abdomen, heavy sensation in 
the body, mushy stools, 
abdominal distention 
Abdominal distention 
and heavy sensation in 
the body. 
Excess, possible 
dampness 
Cold hands and feet, thirsty, dry 
skin, dizziness 
Cold extremity, thirsty, 
dry skin, and dizziness 
Yin and Yang 
deficiency  
Cold joints, cold lower back or 
knees 
Cold joints and back Deficiency, cold 
Insomnia, frequent urination at 
night 
Insomnia and frequent 
urination at night 
Deficiency 
Short of breath, stuffiness in the 
chest 
short of breath and 
stuffiness in chest 
Excess or 
deficiency 
Feeling cold easily, poor 
appetite 
Feeling cold easily and 
poor appetite 
Deficiency, cold 
Red and hot joints, flushed 
face, hot palms 
(Red and hot joints, 
palms, and face) 
Excess, heat 
Night sweating, feeling tired 
easily 
Night sweating and 
feeling tired easily 
Deficiency, heat 
Indigestion, reflux Upper digestive track 
issues 
Excess 
Catch cold easily Catch cold easily Deficiency 
Limited movement, skin itch Limited movement and 
skin itch 
Heat 
*(-) indicates a negative value. Symptoms with negative values mean the symptoms are related 
to the factor in the opposite way e.g. after eating (-) in pain aggravator means “after eating” 
does not aggravate pain. 
7.3.3 Cluster analysis 
The extracted factors were used for cluster analysis. The purpose for clustering the extracted 
factors is that factor analysis had reduced the 110 items into 36 factors and turned the 
dichotomous data into scale data, suitable for K-means cluster analysis. The ideal number of 
clusters was worked out from the hierarchical cluster analysis. Figure 7.5 shows the scree 
diagram derived from hierarchical cluster analysis. Figure 7.6 shows the enlargement of the 
elbow in the scree diagram to indicate the biggest change occurred in between stage 100 and 
101. This left the ideal number of cluster to be six. 
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Figure 7.5 The scree diagram 
 
 
Figure 7.6 Enlargement of the elbow in the screen diagram  
For K-means cluster analysis, the results are shown in Table 7.12. The numerical values shown 
in the table called “mean component values”, indicated how close the factor was to the centre of 
the cluster. A higher positive value meant a closer distance to the centre whereas a negative 
value meant being further away from that centre. For the purpose of the cluster analysis, only 
factors with positive mean component values are shown in Table 7.12 and are used for CM 
pattern identification as negative values mean the factors are away from the cluster and not 
relevant to that cluster. 
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Table 7.12 K-means cluster analysis 
Final Cluster Centers 
 Cluster 
1 2 3 4 5 6 
Factor analysis - wk5 - pain quality – (hot and 
numb pain) 
.29829 1.04774.80616   .69329
Factor analysis - wk5 - pain quality – (dull pain 
at fixed location) 
.01751 2.72487 .20410 
Factor analysis - wk5 - pain quality – (Sharp 
pain not dull with weakness) 
 .37981 1.99424.17099 .13659
Factor analysis - wk5 - pain quality – (Dull 
pain) 
1.67641   .08177.44818
Factor analysis - wk5 - pain quality – (Sharp 
moving pain) 
2.65148   .45325 
Factor analysis - wk5 - pain rhythm – (Pain 
fluctuates) 
.72065 .52885   .03370 
Factor analysis - wk5 - pain rhythm - (Pain 
worse from morning to day time and better at 
night) 
 .80418 3.42520 .39928 
Factor analysis - wk5 - pain rhythm - (Pain 
better during the day and worse at all other 
times) 
1.76002.77478 1.55660  .66467
Factor analysis - wk5 - pain aggravating factor -
(worse by exertion) 
.27440 .43277   .48314 
Factor analysis - wk5 - pain aggravating factor -
(worse by mental strain) 
1.47145 1.79819 .38195.22826
Factor analysis - wk5 - pain aggravating factor –
(Worse by both changing and wet weather) 
 1.130163.32095  .57361
Factor analysis - wk5 - pain aggravating factor -
(worse by static activities) 
1.45090 .35313  .09333 
Factor analysis - wk5 - pain aggravating factor –
(Worse by hot weather and pressure on the area)
 .65804    .96215
Factor analysis - wk5 - pain aggravating factor –
(Non-specific) 
     .81479
Factor analysis - wk5 - pain aggravating factor -
after eating (-) 
 .17352 .36801  .30087 
Factor analysis - wk5 - pain alleviating factor - 
(better by being distracted) 
.91158 1.23911.12683  .07232.33069
Factor analysis - wk5 - pain alleviating factor –
(Better by cold packs, deep breathing, and 
keeping busy) 
.67441 .56013 1.13481  .63301
Factor analysis - wk5 - pain alleviating factor - 
(Better with heat) 
.80873 1.035151.15941  .29660
Factor analysis - wk5 - pain alleviating factor - 
(Better by rest) 
1.79373.91922   .11952.39746
Factor analysis - wk5 - pain alleviating factor –
(Better by sitting and applying pressure on the 
pain area) 
  2.99475 .47626.21762
Factor analysis - wk5 - pain alleviating factor - 
(Better by gentle movement) 
1.31444  .11914 .16567
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Final Cluster Centers 
 Cluster 
1 2 3 4 5 6 
Factor analysis - wk5 - pain alleviating factor –
(Better with alcohol) 
2.02484 .45418   .20925
Factor analysis - wk5 - pain alleviating factor –
(Better with pain killer) 
 .02765   .26053 
Factor analysis - wk5 - pain alleviating factor –
(Better with bowel movement) 
     1.74922
Factor analysis - wk5 - other symptoms - 
Irritability, constipation, poor concentration, 
poor memory, and low libido 
.28826 .47026   .31340.75921
Factor analysis - wk5 - other symptoms – 
(Abdominal distention and heavy sensation in 
the body) 
3.269471.196122.94489   
Factor analysis - wk5 - other symptoms – (Cold 
extremity, thirsty, dry skin, and dizziness) 
.49332   .21849.16771
Factor analysis - wk5 - other symptoms – (Cold
joints and back) 
 .01928 2.75338  .99611
Factor analysis - wk5 - other symptoms – 
(Insomnia and frequent urination at night) 
 .95164 2.48416  .23998
Factor analysis - wk5 - other symptoms – (short 
of breath and stuffiness in chest) 
 .41105  .05529.55190
Factor analysis - wk5 - other symptoms – 
(Feeling cold easily and poor appetite) 
  .29106  .41435 
Factor analysis - wk5 - other symptoms – (Red 
and hot joints, face, and palms) 
1.93445.72705 .29451 .11181  .14420
Factor analysis - wk5 - other symptoms – (Night
sweating and feeling tired easily) 
1.75066   .16956 
Factor analysis - wk5 - other symptoms – 
(Upper digestive track issues) 
2.61226 .39657   1.52161
Factor analysis - wk5 - other symptoms - catch 
cold easily 
.42231    .22612 
Factor analysis - wk5 - other symptoms – 
(Limited movement and skin itch) 
.30522 .54268  .08474 .42915
*To assist reading, negative values have been removed from the table. 
Cells without any value means negative mean component value and is irrelevant to the cluster. 
 
For CM patterns mentioned below, they were described from the CM perspective not western 
medicine perspective. Of the six clusters, cluster four (n=48) and cluster five (n=41) were the 
two largest groups whereas cluster one and three contained only one participant each, and 
cluster two (n=7) and cluster six (n=8) were also of a small number. Clusters one, two, three, 
and six were excluded from CM pattern identification here. Table 7.13 lists the contrast of 
cluster four and five. Cluster four contained less factors than cluster five. Cluster four 
presented with more of a heat related symptoms and cluster five presented with a more cold 
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related symptoms. The symptoms of these two presentations were opposite to each other such 
as hot joints and cold extremities. After reviewing cluster four and five, CM cluster analysis 
group researchers agreed that cluster four was of a CM heat pattern and cluster five was of a 
CM cold with deficiency pattern. It was agree by the CM cluster analysis group researchers 
that these two clusters are of opposite nature and cluster four presents with heat symptoms 
and cluster five presents with cold with deficiency symptoms. 
Table 7.13 Contrast of cluster 4 and 5 
Clusters Factors Pain quality Pain rhythm Pain aggravator Pain alleviator Other symptoms 
Cluster 4 
Sharp pain 
not dull with 
weakness 
No symptom No symptom 
Better by 
gentle 
movement 
Red and hot joints, 
palms, and face; 
Limited movement 
and skin itch 
Cluster 5 
Dull pain at 
fixed 
location; 
Dull pain; 
Sharp 
moving pain 
Pain 
fluctuates; 
Worse during 
day time 
Worse by 
exertion; Worse 
by mental strain; 
Worse by static 
activities; After 
eating (-) 
Better by being 
distracted; 
better by rest; 
Better by 
sitting and 
applying 
pressure on the 
pain area; 
Better with 
pain killer 
Irritability, 
constipation, poor 
concentration, poor 
memory, and low 
libido; Cold 
extremity, thirsty, dry 
skin, and dizziness; 
Short of breath and 
stuffiness in chest; 
Feeling cold easily 
and poor appetite; 
Night sweating and 
feeling tired easily; 
Catch cold easily 
Each factor is separated by ; 
 
For cluster four, the factors with positive mean component values are listed in Table 7.14. 
This cluster showed a heat type CM pattern with red and hot joints, flushed face, hot palms, 
and skin itch (Table 7.15).  
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Table 7.14 Cluster four with its factors (n=48) 
 Factors Mean component value
Factor analysis - wk5 - pain quality - (Sharp pain not dull with 
weakness) 0.17099 
Factor analysis - wk5 - pain alleviating factor - (Better by gentle 
movement) 0.11914 
Factor analysis - wk5 - other symptoms – (Red and hot joints, 
palms, and face) 0.11181 
Factor analysis - wk5 - other symptoms - (Limited movement and 
skin itch) 0.08474 
 
Table 7.15 CM pattern and evidence for cluster four 
CM pattern Evidence 
Heat other symptoms – Red and hot joints, palms, and face, skin itch
 
For cluster five, the factors with positive mean component values are listed in Table 7.16 and 
the key signs and symptoms are listed in Table 7.17. This cluster of patients showed more of a 
cold with deficiency type CM pattern. 
Table 7.16 Cluster five with its factors (n=41) 
Factors Mean component value
Factor analysis - wk5 - pain quality - (Dull pain at fixed location) 0.20410 
Factor analysis - wk5 - pain quality – (Dull pain) 0.08177 
Factor analysis - wk5 - pain quality - (Sharp moving pain) 0.45325 
Factor analysis - wk5 - pain rhythm - (Pain fluctuates) 0.03370 
Factor analysis - wk5 - pain rhythm - (Pain worse from morning to 
day time and better at night.) 0.39928 
Factor analysis - wk5 - pain aggravating factor - (worse by 
exertion) 0.48314 
Factor analysis - wk5 - pain aggravating factor - (worse by mental 
strain) 0.38195 
Factor analysis - wk5 - pain aggravating factor - (Worse by static 
activities) 0.09333 
Factor analysis - wk5 - pain aggravating factor - after eating (-) 0.30087 
Factor analysis - wk5 - pain alleviating factor - (Better by being 
distracted) 0.07232 
Factor analysis - wk5 - pain alleviating factor - (better by rest) 0.11952 
Factor analysis - wk5 - pain alleviating factor – (Better by sitting 
and applying pressure on the pain area) 0.47626 
Factor analysis - wk5 - pain alleviating factor – (Better with pain 
killer) 0.26053 
Factor analysis - wk5 - other symptoms – (Irritability, constipation, 
poor concentration, poor memory, and low libido) 0.31340 
Factor analysis - wk5 - other symptoms – (Cold extremity, thirsty, 0.21849 
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Factors Mean component value
dry skin, and dizziness) 
Factor analysis - wk5 - other symptoms – (short of breath and 
stuffiness in chest) 0.05529 
Factor analysis - wk5 - other symptoms – (Feeling cold easily and 
poor appetite) 0.41435 
Factor analysis - wk5 - other symptoms – (Night sweating and 
feeling tired easily) 0.16956 
Factor analysis - wk5 - other symptoms - catch cold easily 0.22612 
 
Table 7.17 CM pattern and evidence for cluster five 
CM pattern Evidence 
Cold Other symptoms - short of breath, stuffiness in the chest, low 
libido, cold hands and feet, feeling cold easily, poor appetite. 
Deficiency Pain rhythm - "worse during the day, better at night" 
Pain aggravating factor - (worse by exertion) 
Pain alleviating factor - (better by rest), (Better by sitting and 
applying pressure on the pain area) 
Other symptoms - poor concentration, poor memory, low 
libido, cold hands and feet, dizziness, (Feeling cold easily and 
poor appetite), (Night sweating and feeling tired easily), catch 
cold easily 
 
7.3.4 CMP clusters, their demographic difference(s), and their pain related 
data 
7.3.4.1 CMP clusters and their demographic data 
For clusters with more than one participants (cluster two, four, five, and six), they were 
compared for their age using ANOVA. There was no statistically significant difference between 
groups in age distribution (Table 7.18). 
Table 7.18 Comparison of demographic group data (ANOVA) (n=103) 
Dependent 
Variable Cluster n Mean 
Std. 
Error 
95% Confidence 
Interval ANOVA 
Lower 
Bound 
Upper 
Bound F df Sig 
Age 
2 7 46.1429 8.05170 26.4410 65.8447 
1.424 3 0.2404 48 55.6042 1.89314 51.7957 59.4127 5 41 55.7805 2.07468 51.5874 59.9736 
6 7 60.4286 2.75903 53.6775 67.1797 
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For the Chi square test on other demographic data, including gender, country of birth, marital 
status, education background, and current work status, there was no significant difference 
between the four clusters after taking Bonferroni correction and set α level at 0.0083 (Table 
7.19). 
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Table 7.19 Comparison of cluster demographic data 
Demographic variable CMP clusters Missing male female Total N Pearson Chi square value df Asymp sig (2-sided) 
Gender 
2 0 2 5 7
2.706 3 0.439 4 0 25 23 485 0 17 24 41
6 0 2 5 7
Marital Status 
CMP clusters Missing Married/de facto Single/separated/divorced/widow         
2 0 1 6 7
4.847 3 0.183 4 1 27 20 485 1 19 21 41
6 0 3 4 7
Education 
CMP clusters Missing
year 12 and above (include 
university, adult education CAE, 
TAFE, and HSC) 
Under year 12 Other         
2 1 2 4 0 7
4.939 6 0.552 4 1 31 16 0 485 2 22 16 1 41
6 0 3 4 0 7
Current work status 
CMP clusters Missing
employed (including 
full/part time working, and 
voluntary work) 
unemployed (including home duties, student, unemployed 
due to pain, retraining, and unemployed due to other 
reasons) 
retired         
2 1 2 3 1 7
4.778 6 0.573 4 1 5 27 15 485 2 5 26 8 41
6 0 1 3 3 7
Country of birth 
CMP clusters Missing North Africa and Middle East 
North 
West 
Europe 
Oceania 
South 
East 
Asia 
Southern and Eastern 
Europe 
Sub-Sahara 
Africa          
2 0 0 0 5 0 2 0 7
13.627 18 0.753 4 1 1 10 31 0 3 2 485 2 2 4 27 1 4 1 41
6 0 0 2 3 0 2 0 7
HSC: High School Certificate 
CMP: Chronic musculoskeletal pain 
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7.3.4.2 CMP clusters and their pain related data 
Pain related data were compared among clusters. They included 1) Years in pain, 2) Total pain 
regions at baseline week, 3) average of OM consumption of baseline weeks, 4) average of 
NonOM analgesics of baseline weeks, 5) average of highest pain of baseline weeks, 6) average 
of average intensity of baseline weeks, 7) unpleasantness of pain of average of baseline weeks, 
8) RMDQ, 9) total score of BDI at baseline week, 10) physical health total of SF36 at baseline 
week, 11) mental health total of SF36 at baseline week, and 12) total SF36 score at baseline 
week. MANOVA showed statistical differences between them (Wilk’s Λ=0.540, F(36, 231.187) 
= 1.489, p=0.044, partial η2=0.186). Separate ANOVA showed statistical significant difference 
in years in pain (F(3,89) = 4.730, p=0.004, partial η2=0.138) after adjusted for Bonferroni’s 
correction and taking α level at 0.05/12=0.00417) (Table 7.20). Cluster four had the shortest 
years in pain (M: 10.140) whereas cluster six had the longest years in pain (M: 24.714) 
Table 7.20 MANOVA of clusters and pain related data at baseline week(s) (n=104) 
Multivariate Testsa 
Effect Value F 
Hypothesi
s df Error df Sig. 
Partial Eta 
Squared 
Intercept Pillai's Trace 0.974 241.434b 12.000 78.000 0.000 0.974 
Wilks' Lambda 0.026 241.434b 12.000 78.000 0.000 0.974 
Hotelling's 
Trace 37.144 241.434
b 12.000 78.000 0.000 0.974 
Roy's Largest 
Root 37.144 241.434
b 12.000 78.000 0.000 0.974 
Clusters Pillai's Trace 0.531 1.432 36.000 240.000 0.061 0.177 
Wilks' Lambda 0.540 1.489 36.000 231.187 0.044 0.186 
Hotelling's 
Trace 0.727 1.548 36.000 230.000 0.031 0.195 
Roy's Largest 
Root 0.512 3.414
c 12.000 80.000 0.000 0.339 
a. Design: Intercept + Clusters 
b. Exact statistic 
c. The statistic is an upper bound on F that yields a lower bound on the significance level. 
Tests of Between-Subjects Effects 
Source 
Type III Sum of 
Squares df 
Mean 
Square F Sig. 
Partial Eta 
Squared 
Clusters Years in pain 1517.352 3 505.784 4.730 0.004* 0.138 
Total pain region 97.334 3 32.445 0.953 0.419 0.031 
Average of OM 
consumption  554606.154 3 
184868.7
18 0.657 0.581 0.022 
Average of 
NonOM 56.194 3 18.731 0.386 0.763 0.013 
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analgesics 
Average of 
highest pain 
intensity 
10.113 3 3.371 1.208 0.312 0.039 
Average of 
average pain 
intensity 
19.916 3 6.639 1.905 0.134 0.060 
RMDQ 177.231 3 59.077 1.766 0.159 0.056 
Average 
unpleasantness 
of pain 
53.260 3 17.753 2.457 0.068 0.076 
Total score of 
BDI 1063.787 3 354.596 2.867 0.041 0.088 
Physical health 
total of SF36 2241.621 3 747.207 3.324 0.023 0.101 
Mental health 
total of SF36 4682.483 3 1560.828 4.052 0.009 0.120 
Total SF36 score 3407.135 3 1135.712 3.914 0.011 0.117 
Final 6 clusters using K means 
Dependent Variable Cluster n Mean 
Std. 
Error 
95% Confidence Interval 
Lower Bound
Upper 
Bound 
Years in pain 2 7 18.800 4.625 9.611 27.989 
4 48 10.140 1.577 7.006 13.273 
5 41 14.105 1.678 10.772 17.438 
6 8 24.714 3.908 16.948 32.480 
Total pain region 2 7 10.200 2.610 5.014 15.386 
4 48 7.791 0.890 6.022 9.559 
5 41 7.895 0.947 6.014 9.776 
6 8 11.286 2.206 6.903 15.668 
Average of OM 
consumption  
2 7 511.013 237.241 39.621 982.405 
4 48 414.761 80.898 254.017 575.504 
5 41 544.185 86.056 373.193 715.177 
6 8 657.983 200.505 259.584 1056.383 
Average of NonOM 
analgesics 
2 7 13.035 3.115 6.846 19.224 
4 48 10.124 1.062 8.014 12.235 
5 41 9.919 1.130 7.674 12.164 
6 8 11.607 2.633 6.376 16.838 
Average of highest pain 
intensity 
2 7 5.466 0.747 3.981 6.950 
4 48 6.604 0.255 6.098 7.111 
5 41 6.058 0.271 5.519 6.596 
6 8 6.552 0.631 5.297 7.807 
Average of average pain 
intensity 
2 7 3.949 0.835 2.290 5.607 
4 48 5.669 0.285 5.104 6.235 
5 41 4.969 0.303 4.367 5.570 
6 8 5.630 0.706 4.228 7.031 
RMDQ 
 
2 7 14.000 2.586 8.861 19.139 
4 48 10.698 0.882 8.945 12.450 
5 41 12.632 0.938 10.767 14.496 
6 8 15.143 2.186 10.800 19.486 
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Average unpleasantness of 
pain 
2 7 10.343 1.202 7.954 12.732 
4 48 12.537 0.410 11.722 13.351 
5 41 11.216 0.436 10.350 12.083 
6 8 12.821 1.016 10.803 14.840 
Total score of BDI 2 7 23.200 4.974 13.317 33.083 
4 48 16.465 1.696 13.095 19.835 
5 41 23.474 1.804 19.889 27.059 
6 8 21.571 4.204 13.219 29.924 
Physical health total of SF36 2 7 29.240 6.705 15.917 42.563 
4 48 37.172 2.286 32.629 41.715 
5 41 27.168 2.432 22.336 32.001 
6 8 27.114 5.667 15.854 38.374 
Mental health total of SF36 2 7 38.187 8.777 20.746 55.627 
4 48 52.310 2.993 46.363 58.257 
5 41 37.609 3.184 31.282 43.935 
6 8 41.552 7.418 26.812 56.292 
Total SF36 score 2 7 32.142 7.618 17.005 47.278 
4 48 44.880 2.598 39.718 50.041 
5 41 32.598 2.763 27.107 38.088 
6 8 34.149 6.438 21.356 46.942 
* significant difference 
BDI: Beck Depression Inventory 
OM: Opioid medication 
RMDQ: Roland Morris Disability Questionnaire 
SF36: Medical Outcome Short Form Health Survey 36 items. 
7.4 Discussion 
The aims of this chapter were to 1) establish the CM pattern(s) for CMP patients who use OM 
for pain control by using the clinical data gathered by CMPQ at the baseline stage of the 
clinical trial; and 2) identifying any possible differences in the demographic data and feature 
of pain among the clusters. 
Through factor and cluster analysis, the current study identified two key patterns of CMP 
sufferers who consumed OM for pain control and provided their CM pattern diagnosis. The 
two patterns are a CM heat type pattern and a CM cold with deficiency type pattern. The CM 
heat type pattern presented with red and hot joints, face, and palms, and itchy skin. These 
symptoms in CM are due to heat in the body 1025(p658). And the CM cold with deficiency type 
pattern presented with short of breath, stuffiness in the chest, low libido, cold extremities, 
feeling cold easily and poor appetite as well as pain aggravated by exertion, better by rest, 
applying pressure on the area, poor concentration, poor memory, night sweating, feeling tired 
easily. These are due to cold and deficiency in CM understanding 38. 
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7.4.1 Factor analysis 
The purpose of using factor analysis was to reduce variables into small subset of factors based 
on their variance 1057. The purpose of cluster analysis was to group similar symptoms in a 
large multivariate data set 1016,1058. Using factor analysis to reduce variables and then using 
cluster analysis to group the factors had been used before 1059,1060. This study is an exploratory 
study where there is no predefined number of clusters or factors and utilised the factor 
analysis then cluster analysis approach. This study utilised SPSS to reduce the 110 variables 
down to 36 factors and further clustered them into six clusters 
During the process, the factors extracted met the minimum KMO value (0.5) and the 
aggravating factors reached good KMO value (>0.7). Except for the domain of pain rhythm, 
other domains were all meeting the minimum of or almost 60% total variance explained for 
the factor analysis. And for the cluster analysis, K-means, which was appropriate for scale 
data only, was used as factor analysis had turned the dichotomous data into scale data factors 
which was suitable for K-means cluster analysis. Of the factors, they have all been rotated 
with varimax method except for pain quality. The statistician (A/Prof Da Costa) advised to 
attempt different ways in SPSS for a meaningful data output. This approach, not to rotate the 
pain quality, was then adopted as when pain quality symptoms were extracted and rotated, the 
symptoms of cold and heat were grouped in the same factor. Such result would make the 
interpretation of clusters difficult if not impossible. It was necessary to separate the heat and 
cold symptoms in order to derive interpretable CM patterns. 
7.4.2 CM patterns: heat and cold patterns  
Of the clusters, the case distribution was not even amongst the different clusters. Only the CM 
patterns of the two biggest clusters were identified based on the CM eight guiding principles. 
Most of the participants had a “heat pattern” (cluster four, n=48), followed by a “cold with 
deficiency pattern” (cluster five, n=41). This indicates there are two distinctive CMP sub 
types. The heat pattern is “Yang, interior, heat, with uncertainty in deficiency/excess”, the 
uncertainty in deficiency/excess comes from no other signs and symptoms to further support 
deficiency/excess. The cold with deficiency pattern is “Yin, interior, cold, and deficiency”, 
and is supported with signs and symptoms that reflect features of combined cold and 
deficiency patterns. 
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In CM, CMP may be due to blockages or deficiency. Blockages are considered to be an 
excessive patterns and deficiency a deficient pattern. The blockage due to excess may be by 
exterior pathogens (such as cold, heat, and dampness), Qi stagnation and blood stasis, phlegm 
stagnation. On the other hand Qi and blood deficiency, or Yin essence depletion, and 
malnourishment of the organs and meridians can also cause pain due to deficiency 1019(p305).  
Table 7.21 lists the comparison between the two patterns in their aetiology, pathogenesis, 
signs and symptoms, treatment principles and possible treatments in CM perspective. In CM, 
the heat pathogen is a Yang pathogen, it dries up the Yin essence and blood in the body 
whereas the cold pathogen is a Yin pathogen, cold pathogen obstructs the movement of Qi and 
blood and consumes Yang Qi of the body. Both pathogens cause pain to occur eventually 
(Figure 7.7). It is uncertain what the exact causes of heat patterns and cold with deficiency 
patterns are as this study did not specifically enquire into the onset of participants’ pain. It 
may have been CMP patients consumed hot/cold property substances, exposed to heat/cold 
pathogens/factors for long term which caused either heat or cold to form. Based on the side 
effects of OM, which include sedation 1061, dizziness 1061, nausea 1061, vomiting 1061, 
constipation 1061, physical dependence 1061, tolerance 1061, respiratory depression 1061, night 
sweating 1062, and excessive sweating 1063, some of them can be attributed to the heat 
symptoms 38, e.g. constipation; some of them can be attributed to the cold and/or deficiency 
symptoms 132(p64,67), e.g. dizziness, nausea, and vomiting; and sweating can be either heat or 
deficiency symptom depending on the accompanying symptoms 38. Traditionally, opium 
(“ying su ke” in Chinese pinyin), the raw plant where OM is derived from, is sour, neutral, 
astringent, and toxic, which is used to treat diarrhoea, long term cough, rectal prolapse, and 
alleviating pain 1064(p1045). According to the function of opium, it may be patients consumed 
OM which astringed the heat or cold pathogens inside the body and caused the accumulation 
of them. Subsequently patient presented with all these symptoms of cold or heat as opioids 
may aggravate the symptom that individual patient has. Hence when patients discontinued 
OM, their bowel movement is no longer astringed and their constipation then improved 1061. 
As illustrated in Figure 7.7, whether heat or cold pattern is developed, after consuming OM, 
depends on the pre-existing condition of individuals. And these two CM patterns inform of no 
cause of the cold or heat. Treatments for cold or heat pattern also differ significantly in their 
treatment principle and methods of treatment (Table 7.21). The use of moxibustion is often 
recommended for pain with a cold and deficient pattern, but discouraged for the heat pattern 
147(p56).  
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Figure 7.7 Diagram explaining how cold and heat patterns may have formed and how opioids 
might contributes to the process 
Table 7.21 Contrasting aspects of the two patterns 
 CM heat pattern CM cold with deficiency pattern 
Possible 
Aetiology 
Contracting heat pathogen, or 
cold and dampness pathogens 
which lingered and turned 
into heat. Chronic 
consumption of heat 
substance, including 
consuming medication which 
stimulates a person e.g. 
stimulants. 
Contracting cold pathogen, overuse, 
constitutional deficiency, physical 
exhaustion, old age, and chronic 
consumption of cold substance, including 
medication which calms the person e.g. 
sedatives. 
These aetiologies do not exclude injury, over use or other factors as causes. 
More information is required to ascertain the cause of pain. 
Pathogenesis The heat pathogen/substance 
caused heat to accumulate 
internally. 
The cold pathogen accumulates and 
damages Yang Qi of the body. 
Over use, physical exhaustion, 
constitutional deficiency, and old age lead 
to deficiency. 
Consumption of cold substance, causes the 
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 CM heat pattern CM cold with deficiency pattern 
cold pathogens to accumulate in the body 
and damages the Yang Qi. 
Signs and 
symptoms 
Red and hot joints, palms, 
and face, skin itch 
Cold - short of breath, stuffiness in the 
chest, low libido, cold hands and feet, 
feeling cold easily, poor appetite. 
 
Deficiency – Pain "worse during the day, 
better at night", (worse by exertion), (better 
by rest), (Better by sitting and applying 
pressure on the pain area) 
Other symptoms - poor concentration, poor 
memory, low libido, cold hands and feet, 
(Feeling cold easily and poor appetite), 
(Night sweating and feeling tired easily), 
catch cold easily 
Treatment 
principal 
Clear heat and stop pain Tonify Yang Qi, expel cold, and stop pain 
Treatments Acupuncture, Chinese herbal 
medicine, diet change, life 
style advices. 
Acupuncture, moxibustion, Chinese herbal 
medicine, diet change, life style advices, 
Tuina (Chinese therapeutic massage). 
 
In comparison with the textbook information on CM diagnosis, the current study found CMP 
mainly due to heat or “cold with deficiency” patterns but not the other patterns as listed in Table 
7.22. It may be due to the items generated were based on the CM eight guiding principles and 
not Zang Fu diagnosis, the complexity of CMP, and the lack of inspection and palpation data. 
Subsequently only simple diagnosis can be derived. It may also be the sample size was small 
and only allowed for two main patterns to manifest. 
Table 7.22 CMP CM patterns as listed in the CM textbooks 
Text Conditions CM patterns 
Chinese medicine 
orthopedics and 
traumatology 
textbook 1022 
(p963,973,976,984,987,995,99
6,1002,1005,1007,1012,1014,1
017,1019,1023,1032,1034,104
2,1045,1047,1051,1054,1062,1
069,1078,1094,1097,1107,110
8,1116,1131,1136,1158,1168,1
171,1172,1176,1177,1306,132
5,1536,1538,1541-1548,1554-
1557,1567-1570,1574-1576,15
79-1581,1583,1584,1586-1588
Various types 
of CMP 
Excessive type: cold dampness, cold damp Bi 
retention, wind cold, wind cold Bi stagnation, wind 
cold dampness, wind dampness blocking the vessel, 
damp heat retention inside, CM liver Yang upsurge, 
turbid phlegm stagnates in middle Jiao 
Static and stagnant type: Qi stagnation and blood 
stasis, Qi stagnant type, blood stasis type 
Deficient type: CM liver and CM kidney 
deficiency/insufficiency, Qi and blood deficiency, 
CM kidney deficiency type, CM kidney Qi 
deficiency, deficient cold 
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Text Conditions CM patterns 
,1631-1635,1642-1644,1650-1
651,1652-1653,1654-1656) 
Internal medicine of 
Chinese medicine 132 
(p706-708,890-895) 
Low back pain Excessive type: cold dampness Bi obstruction, damp 
heat obstruction 
Static and stagnant type: blood stasis, Qi stagnation 
Deficient type: CM spleen deficiency, and CM 
kidney deficiency 
Bi syndrome 
(blockages of 
Qi and blood 
flow in the 
muscles, 
joints, bones, 
and tendons) 
Excessive type: wind dampness Bi obstruction, cold 
dampness Bi obstruction, mixture of cold and heat, 
damp heat Bi obstruction, heat toxin Bi obstruction 
Static and stagnant type: blood stasis Bi obstruction, 
phlegm dirt Bi obstruction, phlegm stasis Bi 
obstruction 
Deficient type: Qi and Yin (blood) both deficient, 
CM liver and CM kidney both deficient 
* Bi means pain in CM 
 
During the course of differentiating the CM patterns of CMP patients, there were some 
symptoms that could not be explained by the two CM patterns (Table 7.23). Pain relieved by 
pain killer and limited movement are not explainable in CM. Other symptoms can be 
classified into Qi stagnation, blood stasis, dampness retention, Yin and/or Yang deficiency 
which can all be secondary to the consequences of cold and heat. In CM, dampness is a Yin 
pathogen that can slow down the movement of Qi and consumes Yang. It is not a surprise 
finding within the study that many participants present with the symptoms of Qi stagnation, 
blood stasis, dampness retention, Yin and/or Yang deficiency. It is normal in CM practice that 
not all symptoms are explained by the pattern. But it is important to identify the main 
symptoms which reflect the main pattern and not to focus on the irrelevant symptoms 1019(p818). 
Table 7.23 Symptoms not explainable by the two CM patterns 
Domains Heat pattern  Cold with deficiency pattern 
Symptoms 
Pain quality Sharp pain not dull with 
weakness 
Pain at fixed location; Sharp moving 
pain 
Pain rhythm No symptom Pain fluctuates 
Pain alleviating factor Better by gentle movement Better by being distracted; Better with 
pain killer 
Pain aggravating factor No symptom Worse by static activities 
Other symptoms Limited movement Irritability, constipation, thirsty, dry 
skin 
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In CM, there is also a diagnosis based on Zang Fu (脏腑) organs. Fu (腑) organs mean the 
hollow organs, e.g. large/small intestines (大/小肠), gallbladder (胆), urinary bladder (膀胱), 
stomach (胃), and San Jiao (三焦) which means the invisible water passage, and the Zang (脏) 
organs are solid organs, e.g. heart (心), lung (肺), spleen (脾), kidney (肾), pericardium (心包), 
and liver (肝). As list in Table 7.22, the organs involved with CMP are CM kidney, CM liver, 
and CM spleen 
1022(p963,973,976,984,987,995,996,1002,1005,1007,1012,1014,1017,1019,1023,1032,1034,1042,1045,1047,1051,1054,1062,1069,1078,10
94,1097,1107,1108,1116,1131,1136,1158,1168,1171,1172,1176,1177,1306,1325,1536,1538,1541-1548,1554-1557,1567-1570,1574-1576,157
9-1581,1583,1584,1586-1588,1631-1635,1642-1644,1650-1651,1652-1653,1654-1656)132(p706-708,890-895). In addition, there 
is a famous CM phrase “all kinds of pain, ulcers, pruritus all belong to heart” (诸痛疮痒皆属
于心) which indicates the involvement of CM heart organ. Chinese medicine lung and other 
hollow organs are not involved in CMP. Of these organs CM kidney has the direct connection 
with low back region and is most closely associated with LBP 130. According to another 
clinical study by MacPherson et al., of the 148 LBP patients, the only key Zang Fu organ 
diagnosis by the practitioners was CM kidney deficiency 1065. Another study looked at CM 
pattern diagnosis for osteoporosis 1050. Their Zang Fu organ diagnosis was different from 
MacPherson et al. 1065 and focused on CM kidney, CM liver, and CM spleen. In CM, apart 
from low back region, the other anatomical regions are not related to any organs. Although 
there is the involvement of CM liver and CM spleen, their involvements in anatomical regions 
are very limited. Chinese medicine liver and hypochondriac region (the lower rib area) are 
related. Chinese medicine spleen dominates the four limbs. The hypochondriac region is not 
commonly involved in CMP. In this sample, only 8.5% of participants had pain in side of the 
body and only 15.1% of participants have pain in the chest region. Although CM spleen 
dominates the four limbs, where in the four limbs was not clearly explained in CM theory. 
Thus it is not practical to use Zang Fu diagnosis in CMP and both textbooks and clinical 
studies did not involve CM lung organ in CMP. 
In comparison with other CM pattern identification studies (Table 7.24), Berle et al. 
researched in CM pattern by looking at how many symptoms a hepatitis C patient is suffering 
then divides the number of symptoms by the total number of symptoms of a specific CM 
pattern. Then a patient is given a percentage of a specific CM pattern 1066. For example, a 
patient experiences eight symptoms out of 11 symptoms of CM liver Yin deficiency and at the 
same time also experiences six symptoms out of nine symptoms of CM liver Qi stagnation. 
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Then this patient is diagnosed with 73% of CM liver Yin deficiency and 67% of CM liver Qi 
stagnation. Such approach is not utilized in the current study as the current study intends to 
find out the primary CM patterns using the CM eight guiding principles rather than the 
individualized types of CM pattern with a pre-defined list. MacPherson et al. looked into CM 
pattern of LBP and involved six practitioners to diagnose the patients 1065. The CM patterns 
for LBP are Qi and blood stagnation (70%), Bi syndrome (9%), and CM kidney deficiency 
(18%) based on the primary analysis. MacPherson’s approach is using practitioner to diagnose 
the patient and select the pre-defined patterns with pre-defined key symptoms for each pattern. 
This project differs from the two studies by utilizing questionnaire to collect the data without 
pre-defined pattern and without pre-defined key symptoms for CM patterns. And this project 
utilized statistical methods to group the symptoms together instead of the practitioners to 
collect and diagnose the patients, making the symptom grouping more objective 1067. 
Table 7.24 Comparison of different approach to pattern identification 
 Current 
project 
Berle et al. 1066 Macpherson et 
al. 1065 
Participants 106 CMP 
patients who 
use OM for 
pain control 
16 Hepatitis C participants 148 LBP patients
Method of 
pattern 
identification 
Using scientific 
sound factor 
analysis and 
cluster analysis 
List of symptoms extracted from 
literatures for the 17 identified CM 
patterns 
Pre-defined list 
of pattens with 
key symptoms 
Method of 
pattern 
interpretation 
By the CM 
cluster analysis 
group 
researchers  
Each of the 17 CM patterns had its 
own list of symptoms. By dividing the 
number of presenting symptoms by 
the total number of symptoms in the 
pattern. Patients are diagnosed as A% 
of B pattern and C% of D pattern 
depending on how many symptoms 
patients present with. 
By practitioners 
ticking on the 
pre-defined list 
of patterns. 
CM: Chinese medicine 
CMP: Chronic musculoskeletal pain 
LBP: low back pain 
 
7.4.3 Differences in pain measures among CM patterns 
For the different clusters, after taking Bonferroni correction into consideration (α = 0.00417), 
only duration of pain showed significant difference between the four clusters. Cluster four had 
the shortest duration of pain and cluster six had the longest duration of pain. Only cluster four 
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(n=48) had the significant larger sample size than cluster six (n=8). Comparing their 
symptoms, cluster six’s symptoms were more complicated than cluster four and actually had 
all of cluster four’s symptoms (Table 7.25). It may be cluster six is the advanced version of 
cluster four and is understandable to be having a longer pain history. 
Apart from symptom presentation, Zhou et al. and Lu et al. researched into the molecular 
signature and gene expression of the heat and cold pattern of RA patients 1068,1069. In one study, 
Zhou et al. recruited 33 female RA patients, of which 12 had heat pattern and 21 had cold 
pattern, and 12 healthy volunteers 1068. The author had found the genes related to the 
up-regulation of cell proliferation, the EIF4A2, CCNT1, and IL7R and the Jak-STAT cascade, 
were highly related to the CM cold pattern of RA. The genes related to the fatty acid 
metabolism, the PRKAA1, HSPA8, and LSM6, and the I-κB kinase/NF-κB cascade, were 
highly related to the CM heat pattern of RA. In another study 1069, Lu et al. recruited 10 RA 
patients with heat pattern and 10 RA patients with cold pattern and analysed their blood with 
microarray technology to reveal the gene expression profiles in CD4+ T cells. The author had 
found 29 genes important in differentiating cold and heat patterns. The cold pattern is closely 
associated with seven of them. This indicates the cold and the heat patterns not only differ in 
the symptom presentation, they also differ in the molecular signature and gene expression. 
This warrants further research into the subgroups of diseases. 
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Table 7.25 Comparison of signs and symptoms of cluster four and six 
Domain Cluster four Cluster six 
Pain quality Sharp pain not 
dull with 
weakness 
Sharp pain not dull with weakness;  
 
Dull pain; hot and numb pain; 
Pain rhythm No symptom Pain better during the day and worse at all other times 
Pain aggravator No symptom worse by mental strain; worse by both changing and 
wet weather; worse by hot weather and pressure on the 
area; non-specific 
Pain alleviator Better by gentle 
movement 
Better by gentle movement;  
 
Better by being distracted; better by cold packs, deep 
breathing, and keeping busy; better with heat; better 
by rest; better by sitting and applying pressure on the 
pain area; better with alcohol; better with bowel 
movement 
Accompanying 
symptoms 
Red and hot 
joints, palms, and 
face; limited 
movement and 
skin itch 
Red and hot joints, face, and palms; limited 
movement and skin itch;  
 
Irritability, constipation, poor concentration, poor 
memory, and low libido; cold extremity, thirsty, dry 
skin, and dizziness; cold joints and back; insomnia and 
frequent urination at night; short of breath and 
stuffiness in chest; upper digestive track issues;  
Each factor is separated by ; 
Bold indicates common symptoms amongst the two clusters and are place at the beginning of 
each cell. 
 
Limitations of the study: 
1) Not all types of CMP were included, mainly pain in the back, neck, hip, and knee. Other 
types of CMP may include tennis elbow, frozen shoulder, repetitive strain injury, arthritis 
of hands. 
2) Tongue and pulse data were not used in the diagnosis as they require a practitioner to 
obtain such data but the questionnaire is designed to be completed by patients themselves.  
3) Used a convenient sample of a subgroup of CMP who used OM for pain control. 
Although not all types of CMP were included, pain in the lower back (77.4%), neck (45.3%)), 
hip (43.4%), and knee (40.6%) are frequently occurring 1070,1071 and are considered as diseases 
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of priority according to WHO 1072. Although the study only focused on the subgroup of CMP 
who use OM for pain control, this particular group is a specific group of moderate to strong 
pain 1073, and 13% of chronic pain patient used OM 1074. Literature suggested the minimum of 
50 subjects for exploratory factor analysis 1075. Providing 106 subject data is more than 
needed for an exploratory factor analysis. 
Implication for clinical practice 
The current study has identified the two major types of CM pattern of CMP who use OM for 
pain control – heat type and cold with deficiency type. This could guide clinical practice. For 
instance for cold pattern, moxibustion should be added to provide warmth; while for the heat 
pattern, the application of moxibustion or a heat lamp should be minimal or not utilised. The 
current study provides a pattern identification reference for this particular subgroup of CMP. 
Caution is advised when extrapolating the CM pattern to CMP sufferers who have pain other 
than lower back, neck, hip, and knee areas as not many of them, especially upper limb regions, 
were included in the study. 
Implication for future research 
Factor analysis and cluster analysis can provide a statistical means to group symptoms and 
can be recommended for future CM pattern research. More CM pattern researches on CMP 
other than CMP who use OM are also recommended to further understand CMP. Chinese 
medicine eight guiding principles is easy to apply for pattern identification. It can be used for 
CM pattern identification research of other health conditions. 
Two main patterns of CMP who use OM for pain control had been identified in this chapter. 
Their differences had been examined and their CM patterns had been diagnosed. The next 
chapter will focus on effect of EA on the participants as well as the patterns. Differences 
amongst the two major patterns were also examined using BDI, SF36, OM consumption, and 
pain intensity. 
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8. EFFECT OF TREATMENT ON PATTERNS AND 
SYMPTOMS (SUB-GROUP) AND ASSOCIATION 
BETWEEN SUB-GROUP AND OTHER 
OUTCOME MEASURES 
8.1 Introduction 
The common questionnaires or outcome measures for acupuncture research in pain include 
VAS for pain, daily OM consumption, SF36 for QoL, BDI for depression, and RMDQ for pain 
related disability. These specific areas measured may not be exactly the most adequate ones to 
reflect the holistic effect of acupuncture. As described in Chapter 2.6 Chinese medicine (p. 32), 
CM views the body holistically, where body parts and medical conditions are related to one 
another via CM’s theories, and there are different patterns in the view of CM within one 
western medicine diagnosis, for instance osteoarthritis. When arthritis comes with fatigue and 
weakness, this is a deficient type pattern, and when arthritis comes with pain refused to be 
touched, this is an excess type pattern. 
Clinically, after acupuncture treatment, patients may have improvement in sensitivity to a 
stimulus (e.g. heat and/or cold), in the rhythm of the symptom (e.g. pain all the time, pain 
only occurs in the evening), pain quality (e.g. pain at a fixed location, sharp pain sensation, 
pain that moves around). Apart from pain, acupuncture had also been used to improve sexual 
functioning (e.g. libido) 1076, and digestion (e.g. abdominal distention) 1077. According to the 
text book of acupuncture Shu Xue Xue [腧穴学], the point LI4 (He Gu, 合谷) can be used for 
a wide range of symptoms including problems of head, eye, nose, teeth, jaw, ear, throat, cough, 
vertigo, sweating, epigastric and abdominal pain, constipation, dysentery, amenorrhoea, and 
difficult child labour, hypertension, skin itchiness, urticaria 144(p86). Such effects are not 
necessarily captured in acupuncture trials unless the authors specifically asked questions 
related to these aspects. Researchers have argued that when assessing the effectiveness of 
acupuncture in fibromyalgia patients, sleep and cognitive function should be assessed as those 
symptoms may be ameliorated in this group of patients due to the holistic effects of 
acupuncture 1078. And according to the findings from Chapter 3.3.6 Summaries for 
comorbidities/accompanying symptoms of CMP (p. 124), CMP is often accompanied with 
headache (OR 1.33-7.0), hypertension (OR 1.5-2.9), and digestive ulcer (OR 3.1-4.0). Unless 
the treating doctor specifically asks for questions related to headache, hypertension, or 
epigastric pain, it is likely the doctor is going to miss the changes in related symptoms or 
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signs when he/she treats the CMP patient by needling LI4. It is important to capture and 
evaluate the symptom presentation in CM way in order to evaluate the broader effect of 
acupuncture before and after acupuncture treatments. The current CMPQ can capture these 
changes before and after acupuncture treatment. For the CM heat pattern and CM cold with 
deficiency pattern identified in Chapter 7.3.3 Cluster analysis (p. 236), it was uncertain which 
one of them was associated with better/worse QoL, mild/severe depression/pain, or more/less 
OM consumption, and which one of the CM patterns responded better to REA for QoL, OM 
reduction, depression, and pain. 
The CMPQ developed in Chapter 6 Initial development of CMPQ (p. 184) was for both the 
diagnostic and outcome assessment purposes. It assesses the outcome by asking patients if 
they had experienced such symptoms. By repeated measurements, a CM doctor can know if 
there is a change in patients’ symptoms. Based on the symptoms patients ticked, the CM 
doctor can diagnose a CM pattern for the condition. By examining the changes in the number 
and types of symptoms, the CM doctor can make an estimate on if the patient is improving 
and on which aspect the improvement has happened. 
The four aims of this chapter were to test 
 Aim one: To identify the group difference between the CM “heat” and “cold with 
deficiency” patterns.  
o Objective one: If there are differences between CM “heat” and “cold with 
deficiency” patterns in “average pain intensity” and “average OM consumption” 
at baseline weeks, or BDI and SF36 at baseline week. 
 Aim two: If CMPQ could be used to assess changes after treatment and if the three 
treatment groups induced different changes in CMPQ. 
o Objective two: if CMPQ could capture changes in signs and symptoms on 
participants who use OM for CMP after REA, SEA, or PMM alone treatment. 
 Aim three: if the CM “heat” or “cold with deficiency” patterns differed in REA 
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treatment response 
o Objective three: If it is possible to identify the CM pattern with the best 
improvement after REA treatment based on the symptoms in CMPQ. 
 Aim four: if the CM “heat” or “cold with deficiency” patterns responded differently to 
treatments in pain, OM consumption, QoL, and depression.  
o Objective four: if there is any CM pattern responding to treatments better as 
assessed with “average pain intensity” and “average OM consumption” at the 
end of treatment weeks, QoL and depression at the end of treatment week. 
8.2 Methods 
8.2.1 Participants 
Participant identification and recruitment were described in Chapter 4.2 Initial development of 
CMPQ (p. 141). Briefly participants had to take OM and suffered from CMP. Participants 
were identified from hospital case record from both Caulfield pain management and research 
centre, Caulfield hospital, and Pain services, Royal Melbourne hospital, or referred by 
GP/pain specialists. The treatment protocol had been published 1. Participants were 
randomised into either REA, SEA, or PMM alone groups.  
The treatment of REA was using disposable acupuncture needle (Hwato, Suzhou Medical 
Instrument Factory, Suzhou, China) of 0.25mm in diameter and 30 – 40mm in length to needle 
one side of Hegu (LI4), and Shousanli (LI10) as well as Zusanli (ST36) and Fenglong (ST40) 
on the same side. LI4 and LI10 were linked up with one pair of connecting wire with alligator 
clip adaptor (Figure 8.1) and ST36 and ST40 were linked up with another pair of connecting 
wire with alligator clip adaptor (Figure 8.2). These two pairs of needles were stimulated using 
E600 HAN Multi-purpose Digital Electronic Acupunctoscope (manufactured by Tens Plus 
Industrial Company, Hong Kong). The intensity of the REA stimulation was strong but 
comfortable with an alternating frequency of 2 and 100 Hz every three seconds and stimulation 
duration of 20 minutes. The four REA points alternated between left and right hand sides from 
treatment to treatment. Up to eight additional needles were used to address side effects of OM 
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totalling to a maximum of 12 needles used during each treatment (Table 8.1). These points were 
modified based on previous EA trial to reduce OM consumption 1079. They included commonly 
used ST25, KI6, and SJ6 for constipation, CV4 and GV20 for fatigue. Deqi sensation, which 
was a numb, distending, or aching sensation, was achieved for all the points. Treatment 
frequency was two times per week from baseline week (commencement of randomisation) to 
week eight, once per week from week nine to week 10 (mid treatment week), and once every 
second week from week 11 to week 14 (end of treatment week). The total number of REA 
treatment sessions was 12. 
 
Figure 8.1 Needling LI4 and LI10 with connecting wire and alligator clip adaptor 
 
Figure 8.2 Needling ST36 and ST40 with connecting wire and alligator clip adaptor 
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Table 8.1 Additional acupuncture points for OM side effects 
Adverse effects of OM  Acupuncture point 
selection 
Recommended 
needle length  
Depth of 
needling  
Fatigue/General 
weakness/Lethargy 
CV4,  
GV20 
40mm 
30mm 
30-50mm 
13-24mm 
Constipation ST25, KI6, SJ6 40mm 13 – 30mm 
Drowsiness/sedation SP9 40mm 30mm 
Dizziness GV20 
LR3 
30mm  
30mm 
13-24mm  
13-24mm 
Nausea PC6 30mm 13-30mm 
Night sweat KI7, HT6 30-40mm 13-30mm 
Insomnia HT7, SP6 30-40mm 13-30mm 
Nightmare  HT7, Yin Tang  40mm 13-30mm 
Skin pruritus/skin itch  SP10 40mm 30mm 
Dry mouth  LI3 30mm 20mm 
Anxiety  Yin Tang, PC6 40mm 13-30mm 
Blurred vision  GB38 40mm 30mm 
Vomiting  BL17, PC6 30mm 20mm 
Profuse sweating KI7, LI4 40mm 13-30mm 
Others  As appropriate  As appropriate As appropriate
 
The same brand of needle was used for SEA. The needles were shallowly inserted onto points 
away from the REA points without manipulation or Deqi sensation. The locations of those sham 
points were standardised for the trial (Appendix 28). Each point used in REA all had a defined 
corresponding sham point. The sham LI4 and sham LI10 as well as sham ST36 and sham ST40 
were connected to the non-functioning E600 HAN Multi-purpose Digital Electronic 
Acupunctoscope. The non-functioning machine had been modified by the manufacturer to emit 
light and sound, as the real machine did, without any current passing through the machine. This 
non-functioning machine had also been checked by the engineer of Alfred Health and 
Melbourne Health. Additional sham points were selected for side effect of OM (Appendix 28). 
These sham points were modified based on previous EA trial 1079. The SEA treatment frequency 
and number of treatment was consistent with REA treatment. 
All the three treatment groups received OM reduction schedule which aimed to help 
participants to reduce their use of OM to minimum. The proposed OM reduction was 30% by 
week eight, 50% by week 11, and 75% to 100% by week 14, which was the end of treatment 
week. If participants found the reduced OM dosage made their pain worse, participants were 
advised to go back to previous week’s OM dosage and maintain at that level to the end of 
treatment week. 
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8.2.2 Outcome measures 
The CMPQ that was developed in this project (Chapter 6 Initial development of CMPQ (p. 
184)) was used to gather data for the symptoms of the participants. The items in the 
questionnaire included pain region, pain quality, pain rhythm, pain aggravator, pain alleviator, 
and other accompanying symptoms. The development of CMPQ had demonstrated content 
validity (Chapter 6.3.1 Content validity and face validity (p. 191)), internal consistency 
(Chapter 6.3.2 Internal consistency (p. 192)), and test-retest reliability (Chapter 6.3.3.1 
Agreement (test-retest reliability) (p. 192)). Beck depression inventory, SF36, VAS for pain 
intensity, and OM consumption were also used as outcome measurements. Time point for 
completing these questionnaires and reasons of drop out were outlined in Figure 8.3. 
 264 
 
 BDI: Beck Depression Inventory 
CMPQ: Chinese medicine pain questionnaire 
REA: Real electro acupuncture 
SEA: Sham electro acupuncture 
EA: Electro acupuncture 
PMM: Pain and medication management 
SF36: Medical Outcome Short Form 36 Health Survey 
*No data available for the sample size of each treatment group in mid treatment week. 
Figure 8.3 Flow chart of completing questionnaires 
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8.2.3 Statistical analysis 
Statistical Package for the Social Sciences version 22 was used for the statistical analysis. 
Frequency of each sign or symptoms was calculated for baseline and end of treatment weeks 
according to the treatment groups. Frequent symptoms were determined if their frequencies 
were more than 40%. To compare for baseline differences, one way ANOVA was used to 
assess the differences in total pain regions in baseline week amongst the three treatment 
groups. Two way ANOVA was used to assess the differences in the total pain region in 
baseline week sub grouped by the two CM patterns and the three treatment groups. Chi square 
analysis was used to assess if there was any statistically significant differences in the baseline 
week CMPQ items between the three treatment groups as well as when the CMPQ items were 
further sub grouped by the two CM patterns. Only participants who provided both baseline 
and end of treatment week’s data were included for statistical analysis. Chinese medicine pain 
questionnaire items with p<0.05 in Chi square test was considered significantly different. 
MANOVA was also carried out to evaluate differences between the three treatment groups in 
baseline BDI, SF36, average pain intensity and average OM consumption. 
Changes in signs and symptoms were based on changes between baseline and end of treatment 
weeks. The CMPQ items were all dichotomous (yes was represented by one and no was 
represented by zero). If a sign or symptom was present in any given week, the score “1” was 
given; if not present, the score “0” was given. Changes were calculated by subtracting the score 
of the previous week from the latter week (e.g. end of treatment week subtract baseline week). 
A value of zero meant no change, one meant new symptom arising and -1 meant symptom 
reduction. Table 8.2 provides three examples.  
Table 8.2 Work out of change in symptoms between baseline and end of treatment weeks 
Symptom Baseline 
week  
End of 
treatment 
week 
Changes between baseline 
and end of treatment 
weeks (overall treatment 
effect)  
Interpretation  
Constipation  1 0 -1  Constipation alleviated 
Fatigue  1 1 0 No change in fatigue in 
terms of its occurrence 
Thirst  0 1 1 Thirst as a new 
symptom  
 
To address aim number one, MANOVA was used to assess the association between the two 
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CM patterns and SF36, and BDI using baseline week data and average pain intensity and 
average OM consumption using the baseline weeks’ data.  
To address aim number two, Cochran’s Q test was carried out to evaluate the significant 
changes (p≤0.05) in signs and symptoms amongst the individuals within the three treatment 
groups. The assumptions for the use of Cochran’s Q test 1080 included 1) the response is 
dichotomous; 2) the subjects are independent of one another and randomly selected from a 
population; 3) the sample size is more than four and the number of subject (n) times the 
number of participants not showing the same results throughout the comparison (k) is more 
than 24 (nk>24). The results of Cochran’s Q test were interpreted as either symptom 
improvement or symptom deterioration. If the overall changes were symptom reduction, this 
was symptom improvement. If the overall changes were symptom increased except for pain 
alleviator, this was symptom deterioration. Pain alleviator was interpreted the opposite way to 
the other domains e.g. overall changes were increased in alleviator meant symptom improving 
as participants found more alleviators to improve their pain. For Cochran’s Q test, p value was 
maintained at 0.05 and not adjusted to 0.1 for significance level. 
To address aim number three, Cochran’s Q analysis was also carried out to evaluate which 
symptoms responded to the assigned treatment within CM heat pattern and CM cold with 
deficiency pattern (clusters four and five). Only the symptoms with p<0.05 in any of the 
treatment groups and CM patterns were presented in the results. 
To address aim number four, baseline and end of treatment weeks data of BDI and SF36 as 
well as baseline weeks’ and end of treatment weeks’ data of average pain intensity and 
average OM consumption were used to assess which of the CM patterns reported best to the 
three treatments by using repeated MANOVA. 
8.3 Result 
8.3.1 Differences of the two CM patterns 
At the baselines, MANOVA showed that there were significant differences between the two 
CM patterns in baseline average of OM consumption, average of pain intensity, BDI, and SF36 
total scores (Wilk’s Λ=0.814, F(4, 80) = 4.575, p=0.002, partial η2=0.186) (Appendix 29). 
Post-hoc one way ANOVAs were conducted for the four variables, with each evaluated at an α 
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level of 0.0125. There were statistically significant differences between the two patterns on 
SF36 (F(1,83)=12.181, p=0.001, partial η2=0.128) (Figure 8.6) and on BDI (F(1,83)=9.068, 
p=0.003, partial η2=0.098) (Figure 8.6). Heat pattern (cluster four) (M=45.461) scored higher 
on SF36 than cold with deficiency pattern (cluster five) (M=32.016), reflecting better QoL 
(Appendix 29). Heat pattern (cluster four) (M=16.64) (mild depression) scored lower than cold 
with deficiency pattern (cluster five) (M=23.775) (moderate depression) on BDI, reflecting 
being less depressed. There are no differences between the two patterns in the average pain and 
OM consumption (Figure 8.4 and Figure 8.5). 
 Heat pattern: Mean: 445.2681. Standard error: 97.51359 
Cold with deficiency pattern: Mean: 589.7261. Standard error: 105.1853 
p=0.233 
Figure 8.4 Average of OM consumption at baseline weeks of CM heat and “cold with 
deficiency” patterns 
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 Heat pattern: Mean: 5.4511. Standard error: .36783 
Cold with deficiency pattern: Mean: 5.1357. Standard error: 0.39459 
p=0.152 
Figure 8.5 Average pain intensity at baseline weeks of CM heat and “cold with deficiency” 
patterns 
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 BDI: 
Heat pattern: Mean: 16.1667. Standard error: 1.88526 
Cold with deficiency pattern: Mean: 24.4444. Standard error: 1.70664 
p=0.003 
Total SF36: 
Heat pattern: Mean: 45.9326. Standard error: 3.47133 
Cold with deficiency pattern: Mean: 31.2577. Standard error: 3.53 
p=0.001 
Figure 8.6 BDI and SF36 scores at baseline week of CM heat and CM “cold with deficiency” 
patterns 
8.3.2 CMPQ baseline comparison among three treatment groups  
Baseline week comparison Table 8.3 to Table 8.5 list the significant differences in CMPQ 
symptoms of participants’ baseline week data. Only those who had both baseline and end of 
treatment weeks data were included in the analysis. There were significant differences in the 
pain presentation amongst the three groups. Sham EA had more painful regions than REA and 
PMM alone (Table 8.3). And as shown in Table 8.4, when the three treatment groups were 
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further sub grouped into cluster 4 and cluster 5, the distribution of the symptoms differed more. 
Cluster four in SEA had more pain in wrist, front of the leg, and calf when compared with 
cluster five. Cluster five had more pain at fixed location than cluster four in REA and SEA. 
Cluster five’s pain was more affected by physical movements than cluster four in the PMM 
alone group. Overall, cluster five had more symptoms than cluster four apart from pain region 
which showed the opposite. And when looking at the symptom distribution amongst the three 
treatment groups within clusters four and five, cluster four had the most uneven distribution of 
symptoms within the three treatment groups (Table 8.5). 
Table 8.3 Significant difference for baseline week participants who also provide end of 
treatment week data and assessed by Chi square test (n=66) 
Domains Symptom/factor p value Number of participants or mean and 
standard error (SE) 
REA 
(n=27) 
SEA (n=22) PMM alone 
(n=17) 
Pain region Shoulder 0.031 6 13 7 
Upper arm 0.035 6 12 4 
Elbow 0.016 2 9 3 
Forearm 0.01 2 8 1 
Wrist 0.016 3 10 3 
Fingers 0.044 4 9 2 
Front of the leg 0.008 2 10 4 
Total pain regions 0.008 6.56 (0.86) 11.0 (1.32) 7.0 (1.06) 
Pain aggravator Lying down 0.006 4 10 1 
Other symptom Thirsty 0.034 8 7 0 
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Table 8.4 Significant difference in CMPQ symptoms for baseline week participants sub grouped by the treatment groups and the two clusters 
assessed by Chi square test (n=57) 
Domains Symptom/ factor 
Number of participants 
REA (n=21) SEA (n=21) PMM alone (n=15) Total (n=57) 
p 
value+ 
Cluster 
4 (n=13)
Cluster 
5 (n=8) 
p 
value++
Cluster 
4 (n=11)
Cluster 
5 (n=10) 
p 
value^
Cluster 
4 (n=6)
Cluster 
5 (n=9) p value
#
Cluster 
4 
(n=30)
Cluster 
5 
(n=27) 
Pain region 
Frontal head 0.142 3 0 0.593 2 1 0.063 2 0 0.033* 7 1 
Side of the 
head 
 No 
value 0 0 0.314 3 1 0.018* 3 0 0.061 6 1 
Wrist 0.243 2 0 0.044* 7 2 0.292 2 1 0.025* 11 3 
Front of the leg 0.191 0 1 0.044* 7 2 0.057 0 4 0.82 7 7 
Calf 0.091 1 3 0.006* 6 0 0.475 1 3 0.697 8 6 
Pain 
quality 
Fixed location 0.011* 4 7 0.044* 4 8 0.519 3 3 0.024* 11 18 
Moving from 
one spot to 
another 
0.091 1 3 0.223 1 3 0.057 0 4 0.005* 2 10 
Dull pain with 
weakness 0.854 2 1 0.049* 2 6 0.667 2 4 0.087 6 11 
Pain 
rhythm 
Worse during 
the day, better 
at night 
0.716 1 1 0.007* 0 5 0.114 0 3 0.003* 1 9 
Worse at night, 
better during 
the day 
0.854 2 1 0.031* 6 1 0.756 1 1 0.081 9 3 
Worse in the 
morning 0.058 0 2 0.05* 0 3 0.398 0 1 0.006* 0 6 
Worse in the 
afternoon 0.271 1 2 0.223 1 3 0.215 0 2 0.046* 2 7 
Pain 
aggravator 
Weather 
change 0.017* 0 3 0.097 1 4 0.114 0 3 0.001* 1 10 
Walking 0.027* 5 7 0.279 4 6 0.004* 2 9 0.001* 11 22 
Physical work 0.001* 3 8 0.256 5 7 0.004* 2 9 0* 10 24 
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Domains Symptom/ factor 
Number of participants 
REA (n=21) SEA (n=21) PMM alone (n=15) Total (n=57) 
p 
value+ 
Cluster 
4 (n=13)
Cluster 
5 (n=8) 
p 
value++
Cluster 
4 (n=11)
Cluster 
5 (n=10) 
p 
value^
Cluster 
4 (n=6)
Cluster 
5 (n=9) p value
#
Cluster 
4 
(n=30)
Cluster 
5 
(n=27) 
Lifting 0.204 3 4 0.123 4 7 0.025* 2 8 0.002* 9 19 
Bending 0.006* 2 6 0.05* 3 7 0.02* 1 7 0* 6 20 
Going 
up/down stair 0* 1 7 0.835 5 5 0.025* 2 8 0* 8 20 
Driving 0.378 4 4 0.89 3 3 0.025* 0 5 0.091 7 12 
Bad night sleep 0.071 3 5 0.256 5 7 0.833 3 5 0.47 11 17 
Stress 0.378 4 4 0.072 6 9 0.085 2 7 0.01* 12 20 
Being 
emotional 0.477 3 3 0.13 3 6 0.057 1 6 0.013* 7 15 
Sex 0.716 1 1 0.223 1 3 0.057 0 4 0.023* 2 8 
Everything 0.005* 0 4 0.593 2 1 0.114 0 3 0.023* 2 8 
Household 
chores 0.006* 2 6 0.017* 2 7 0.132 1 5 0* 5 18 
Pain 
alleviator 
Hot packs 0.071 3 5 0.031* 5 9 0.398 2 5 0.005* 10 19 
Warm/hot 
shower 0.027* 1 4 0.835 5 5 0.095 3 1 0.574 9 10 
Lying down 0.965 5 3 0.269 2 4 0.025* 0 5 0.091 7 12 
Sitting 0.057 0 2 0.223 1 3 0.215 0 2 0.014* 1 7 
Resting 0.154 4 5 0.525 2 3 0.132 1 5 0.05* 7 13 
Deep breathing 0.017* 0 3 0.593 2 1 0.018* 3 0 0.848 5 4 
Bowel 
movement 0.191 0 1 
no 
value 0 0 0.114 0 3 0.029* 0 4 
Pain killer 0.142 10 8 0.072 6 9 0.292 4 8 0.017* 20 25 
Other 
symptoms 
Heavy 
sensation in the 
body 
0.854 2 1 0.696 3 2 0.018* 3 0 0.137 8 3 
Dry or sore 0.005* 0 4 0.89 3 3 0.756 1 1 0.132 4 8 
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Domains Symptom/ factor 
Number of participants 
REA (n=21) SEA (n=21) PMM alone (n=15) Total (n=57) 
p 
value+ 
Cluster 
4 (n=13)
Cluster 
5 (n=8) 
p 
value++
Cluster 
4 (n=11)
Cluster 
5 (n=10) 
p 
value^
Cluster 
4 (n=6)
Cluster 
5 (n=9) p value
#
Cluster 
4 
(n=30)
Cluster 
5 
(n=27) 
throatp 
Dry stool No value 0 0 0.02* 0 4 0.398 0 1 0.014* 0 5 
Dry skin 0.027* 1 4 0.89 3 3 0.205 1 0 0.392 5 7 
Leak when 
sneezing or 
cough 
0.017* 0 3 0.943 1 1 0.063 2 0 0.58 3 4 
Poor 
concentration 0.071 3 5 0.757 7 7 0.264 3 7 0.04* 13 19 
Low libido 0.02* 3 6 0.89 3 3 0.205 2 6 0.026* 8 15 
Poor appetite 0.477 3 3 0.864 4 4 0.025* 0 5 0.091 7 12 
Feeling tired 
easily 0.027* 5 7 0.407 7 8 0.519 3 6 0.03* 15 21 
Sigh often 0.058 0 2 0.525 2 3 0.264 1 4 0.031* 3 9 
Sweat upon 
mild activities 0.017* 0 3 0.916 2 2 0.833 3 4 0.144 5 9 
Feeling 
nervous easily 0.248 2 3 0.05* 3 7 0.132 1 5 0.005* 6 15 
Feeling 
depressed 0.006* 2 6 0.017* 2 7 0.085 2 7 0* 6 20 
Dizziness 0.271 1 2 0.049* 2 6 0.264 1 4 0.009* 4 12 
 * indicates statistical significance 
For ease of reading, cell containing non-significant symptoms is shaded. 
+the p value for clusters 4 and 5 comparison in REA 
++ the p value for clusters 4 and 5 comparison in SEA 
^ the p value for clusters 4 and 5 comparison in PMM alone 
# the p value for clusters 4 and 5 comparison 
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Table 8.5 Significant difference in CMPQ symptoms for baseline week participants sub grouped by the two clusters and the treatment groups and 
assessed by Chi square test (n=57) 
Domains Symptom/factor 
Number of participants or mean and standard error 
Cluster 4 (n=30) Cluster 5 (n=27) Total (n=57) 
p 
value+ 
REA 
(n=13)
SEA 
(n=11)
PMM 
alone 
(n=6) 
p 
value++
REA 
(n=8) 
SEA 
(n=10)
PMM 
alone 
(n=9) 
p 
value^ 
REA 
(n=21)
SEA 
(n=21)
PMM 
alone 
(n=15) 
Pain region 
Side of the head 0.03* 0 3 3 0.414 0 1 0 0.097 0 4 3 
Back of the head 0.028* 1 5 0 0.414 0 1 0 0.015* 1 6 0 
Neck 0.011* 2 8 4 0.187 1 5 2 0.007* 3 13 6 
Shoulder 0.004* 1 8 3 0.53 2 5 3 0.007* 3 13 6 
Upper arm 0.015* 1 7 2 0.368 2 5 2 0.011* 3 12 4 
Elbow 0.211 1 4 1 0.074 0 4 1 0.019* 1 8 2 
Forearm 0.006* 0 5 0 0.842 1 2 1 0.021* 1 7 1 
Wrist 0.05* 2 7 2 0.407 0 2 1 0.038* 2 9 3 
Fingers 0.002* 0 7 1 0.754 2 2 1 0.022* 2 9 2 
Thigh 0.049* 3 6 0 0.914 4 4 4 0.401 7 10 4 
front of the leg 0* 0 7 0 0.281 1 2 4 0.016* 1 9 4 
Calf 0.029* 1 6 1 0.101 3 0 3 0.755 4 6 4 
Chest 0.028* 1 5 0 0.379 1 2 0 0.016* 2 7 0 
Total pain region 0.003* 4.69 (1.17) 
12.72 
(5.93) 
8.17 
(6.18) 0.534 
6.5 
(4.11) 
8.5 
(6.00) 
6.22 
(3.60) 0.004*
5.38 
(4.18) 
10.71 
(6.21) 
7.00  
(4.42) 
Pain quality Fixed location 0.721 4 4 3 0.032* 7 8 3 0.589 11 12 6 
Pain aggravator Lying down 0.028* 1 5 0 0.327 3 4 1 0.035* 4 9 1 
Pain alleviator Deep breathing 0.024* 0 2 3 0.082 3 1 0 0.873 3 3 3 
Other symptoms 
Cold hands and 
feet 0.438 2 4 1 0.024* 1 5 0 0.019* 3 9 1 
Irritable 0.511 3 5 2 0.027* 1 5 7 0.033* 4 10 9 
Thirsty 0.349 2 3 0 0.094 3 4 0 0.05* 5 7 0 
Poor memory 0.105 2 6 3 0.074 3 5 8 0.011* 5 11 11 
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Sweat upon mild 
activities 0.024* 0 2 3 0.506 3 2 4 0.064 3 4 7 
* indicates statistical significance 
For ease of reading, cell containing non-significant symptoms is shaded. 
+the p value for clusters 4 distribution in the three treatment groups 
++ the p value for clusters 5 distribution in the three treatment groups 
^ the p value for participant distribution in the three treatment groups for only clusters 4 and 5 
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Based on the Chi square tests (Table 8.3), the three treatment groups differed significantly in 
some of the symptoms in baseline week and the three treatment groups’ distribution over the 
two clusters (Table 8.4) as well as the two cluster distribution over the three treatment groups 
(Table 8.5) differed significantly in various symptoms. And due to the number of dropouts 
(n=35 or 33%), changes in percentages between baseline and end of treatment weeks were not 
analysed.  
Average OM consumption, average pain intensity, BDI and SF36 were compared amongst 
REA, SEA, and PMM alone groups using MANOVA. There was no difference between the 
three treatment groups (Wilk’s Λ=0.866, F(8, 120)=1.122, p=0.353, partial η2=0.070). Separate 
ANOVA showed there were no difference between groups in average OM consumption 
(p=0.42), average pain intensity (p=0.183), BDI (p=0.27), and SF36 (p=0.388) (Table 8.6). 
Comparison of these pain data and BDI, and SF36 between cluster four and five are presented 
in this chapter section 8.3 (p. 266). 
Table 8.6 Comparison of average OM dosage and pain over baseline weeks, and BDI and SF36 
data at baseline week (MANOVA) 
Treatment group 
Dependent 
Variable 
Treatment 
group n Mean 
Std. 
Error 
95% Confidence 
Interval ANOVA 
Lower 
Bound 
Upper 
Bound F df Sig. 
Average of OM 
consumption at 
baseline weeks 
REA 27 482.712 125.195 232.530 732.894 
0.880 2 0.420SEA 22 672.862 138.694 395.705 950.020 
PMM alone 17 412.182 157.777 96.889 727.475 
Average pain 
intensity at 
baseline weeks 
REA 27 4.741 0.388 3.965 5.516 
1.743 2 0.183SEA 22 5.815 0.430 4.956 6.675 
PMM alone 17 5.342 0.489 4.364 6.320 
Total score of 
BDI at baseline 
week 
REA 27 17.444 2.090 13.268 21.621 
1.336 2 0.270SEA 22 20.818 2.315 16.192 25.445 
PMM alone 17 22.706 2.634 17.443 27.969 
Total SF36 score 
at baseline week 
REA 27 41.538 3.706 34.132 48.943 
0.961 2 0.388SEA 22 38.781 4.105 30.577 46.985 
PMM alone 17 33.287 4.670 23.954 42.620 
 
Percentage of CMPQ symptoms of baseline and end of treatment weeks are summarised in 
Appendix 30. The raw frequency tables of baseline and end of treatment weeks are listed from 
Appendix 31 to Appendix 60. Due to the small number of female subjects (n=15 for females 
under 51 years old), CM items related to gynaecological problem were not analysed. 
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8.3.3 Changes in signs and symptoms between baseline week and end of 
treatment week 
For this section (Chapter 8.3.3) and the next section (Chapter 8.3.4) only symptoms with 
significant changes are presented. Symptoms not presented meant no significant changes (e.g. 
p>0.05). 
For the three assumptions of Cochran’s Q test described in Chapter 8.2.3 Statistical analysis (p. 
265). Criteria one and three were met. Chinese medicine pain questionnaire was designed 
with dichotomous outcome, and the n times k was greater than 24. N was at least six (CM 
heat pattern in PMM alone group) and k was 163 (Table 5.6p. 160). The only assumption that 
was partly met was the recruitment of the subjects were a convenient sample from the pain 
clinic or referred by specialists/GP rather than a randomly selected sample and participants 
were independent of one another.  
For REA (n=27), there were only two significant improvements between baseline and end of 
treatment weeks (Table 8.7). There were four fewer participants having nausea and five fewer 
participants feeling “nothing” alleviates their pain. Feeling nothing alleviated their pain 
indicated participants did not feel there was any pain alleviator, reflecting five more 
participants found their pain becoming responsive to interventions or strategies. 
Table 8.7 Significant changes between baseline and end of treatment weeks in REA group 
(n=27) 
Domain Sub-categories Item Overall changes* p-values
Pain alleviator Other nothing -5 0.025 
Other symptoms & nausea△ -4 0.046 
* Positive value means more participants experience such symptom/description and vice versa. 
Positive value indicates symptom worsening except for pain alleviator which is the opposite. 
And negative value in “nothing” as alleviator indicates improvement. 
△ Indicates related to OM side effects 
& no sub category for other symptoms 
 
For SEA (n=22), there was a mixture of improvement and deterioration between weeks five 
and 14 (Table 8.8). The improvements included four to five more participants having pain 
reduction in upper limb, or sacrum area. Seven fewer participants had pain in fixed location, 
four to six more participants found reading and “keeping their mind off pain” alleviated their 
pain. There were five to seven fewer participants suffering from nausea, dizziness, and poor 
appetite. Deterioration on the other hand included there were four more participants 
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experienced pain on the side of the body and seven more participants experienced pain 
aggravated by cold weather. 
Table 8.8 Significant changes between baseline and end of treatment weeks in SEA group 
(n=22) 
Domain Sub-categories Item Overall changes* p-values
Pain regions 
Upper limb upper arm -5 0.025forearm -4 0.046
Front of the body side of the body 4 0.046
Back of the body sacrum -4 0.046
Pain quality & fixed location -7 0.02
Pain aggravator Environmental changes cold weather 7 0.008
Pain alleviator Physiological and psychic changes 
reading 4 0.046
keeping my mind off 
pain 6 0.034
Other symptoms & 
nausea△ -7 0.008
dizziness -6 0.014
poor appetite -5 0.025
* Positive value means more participants experiences such symptom/description and vice versa. 
Positive value indicates symptom worsening except for pain alleviator which is the opposite.△ 
Indicates related to OM side effects 
& no sub category for pain quality and other symptoms 
 
For PMM alone (n=17), the changes between baseline and end of treatment weeks were also a 
mixture of improvements and deteriorations (Table 8.9). Improvements included four fewer 
participants felt their pain were numb, aggravated by “any movement”, suffered from poor 
memory and four more participants felt warm/hot shower alleviated their pain. On the other 
hand, the deterioration included four to five more participants had pain between shoulder blade 
or felt cold weather aggravated their pain. 
Table 8.9 Significant changes between baseline and end of treatment weeks in PMM alone 
group (n=17) 
Domain Sub-categories Item Overall changes* p-values
Pain regions Back of the body between shoulder blades 4 0.046 
Pain quality & numbness -4 0.046 
Pain 
aggravator 
Environmental changes cold weather 5 0.025 
Exercises or sporting any movement -4 0.046 
Pain alleviator Environmental changes warm/hot shower 4 0.046 
Other 
symptoms 
& poor memory -4 0.046 
* Positive value means more participants experiences such symptom/description and vice versa. 
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Positive value indicates symptom worsening except for pain alleviator which is the opposite. 
& no sub category for pain quality and other symptoms 
 
8.3.4 Changes in signs and symptoms according to treatment groups and 
clusters between baseline and end of treatment weeks 
The cluster distribution amongst different treatment group is listed in Table 8.10. Only 
participants who presented data for both baseline and end of treatment weeks were included. 
Most of the participants were from clusters four and five. 
Table 8.10 Distribution of clusters in the three treatment groups which provided both baseline 
and end of treatment weeks data 
Cluster REA SEA PMM alone 
1 0 0 0 
2 2 (7.4%) 0 1 (5.9%) 
3 0 1 (4.5%) 0 
4 13 (48.1%) 11 (50%) 6 (35.3%) 
5 8 (29.6%) 10 (45.5%) 9 (52.9%) 
6 4 (14.8%) 0 1 (5.9%) 
Percentage shown is the proportion of cluster in each treatment group 
 
REA (n=27) 
For REA group, in comparison of clusters four and five, cluster four reported four fewer 
participants experienced worse pain when first getting up and four more participants found hot 
packs alleviated their pain (Table 8.11). Cluster five on the other hand reported four fewer 
participants had pain at a fixed location. 
Table 8.11 Significant changes between baseline and end of treatment weeks in REA group with 
cluster information (n=21) 
Domain Sub-categories Item 
Cluster 4 (n=13) Cluster 5 (n=8) 
Overall 
changes* p-values
Overall 
changes* p-values
Pain 
quality & 
Fixed 
location 1 0.655 -4 0.046
Pain 
rhythm & 
Worse 
when first 
get up 
-4 0.046 -2 0.317
Pain Environmental Hot packs 4 0.046 -1 0.564
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Domain Sub-categories Item 
Cluster 4 (n=13) Cluster 5 (n=8) 
Overall 
changes* p-values
Overall 
changes* p-values
alleviator changes 
* Positive value means more participants experiences such symptom/description and vice versa. 
Positive value indicates symptom worsening except for pain alleviator which is the opposite. 
Bold font indicates significant difference at p<0.05 
& no sub category for pain quality and other symptoms 
 
SEA (n=22) 
In comparison of both clusters four and five, cluster four reported as four more participants 
experienced reductions in painful regions, four fewer participants experienced pain all the time, 
and four to five fewer participants experienced the digestive symptoms (poor appetite and 
nausea) (Table 8.12). Cluster five on the other hand showed improvements in six fewer 
participants feel pain at a fixed location, four more participants felt by “keeping busy” 
alleviated their pain, and four fewer participants had swollen joints, dizziness, and dry stools. In 
addition, cluster five also showed four more participants experienced pain aggravated by “cold 
weather” (Table 8.12). 
Table 8.12 Significant changes between baseline and end of treatment weeks in SEA group with 
cluster information (n=22) 
Domain Sub-categories Item 
Cluster 4 (n=11) Cluster 5 (n=10) 
Overall 
changes* p-values 
Overall 
changes* p-values
Pain 
regions Lower limb 
Calf -4 0.046 2 0.157 
Front of the leg -4 0.046 -1 0.317 
Pain 
quality & Fixed location -1 0.564 -6 0.014 
Pain 
rhythm & All the time -4 0.046 0 1 
Pain 
aggravator 
Environmental 
changes Cold weather 3 0.083 4 0.046 
Pain 
alleviator Other Keeping busy 0 1 4 0.046 
Other 
symptoms & 
Poor appetite -4 0.046 -1 0.317 
Nausea△ -5 0.025 -2 0.157 
Swollen joints -1 0.655 -4 0.046 
Dizziness -2 0.157 -4 0.046 
Dry stools△ 1 0.317 -4 0.046 
* Positive value means more participants experiences such symptom/description and vice versa. 
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Positive value indicates symptom worsening except for pain alleviator which is the opposite. 
Bold font indicates significant difference at p<0.05 
△ Indicates symptom related to OM side effects 
& no sub category for pain quality and other symptoms 
 
PMM alone (n=17) 
Only cluster five showed significant changes between baseline and end of treatment weeks in 
PMM alone group (Table 8.13). The only change was four fewer participants felt their pain as 
numbness. 
Table 8.13 Significant changes between baseline and end of treatment weeks in PMM alone 
group with cluster information (n=15) 
Domain Item Cluster 4 (n=6) Cluster 5 (n=9) Overall changes* p-values Overall changes* p-values
Pain quality Numbness 0 1 -4 0.046 
* Positive value means more participants experiences such symptom/description and vice versa. 
Positive value indicates symptom worsening except for pain alleviator which is the opposite. 
Bold font indicates significant difference at p<0.05 
 
Repeated MANOVA was used to assess the effects of the three treatments, and the treatment 
effects on the two CM patterns in the four outcome measures (average pain intensity, average 
OM consumption, total SF36 score, and BDI). Over time, only average OM consumption 
(Figure 8.7) and BDI (Figure 8.9) showed statistically significant improvements and not total 
SF36 score (Figure 8.9) and average pain intensity (Figure 8.8) (Table 8.14). Over time, there 
were no statistical significant changes in the two CM patterns after the three treatments in the 
four assessments (Table 8.14, Appendix 61 to Appendix 72). 
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 Baseline weeks: Mean: 513.696. Standard error: 71.539 
End of treatment weeks: Mean: 414.580. Standard error: 67.545 
p=0.000* 
Figure 8.7 Average OM consumption amongst all participants between baseline and end of 
treatment weeks (n=57) 
 Baseline weeks: Mean: 5.302. Standard error: 0.268 
End of treatment weeks: Mean: 5.029. Standard error: 0.298 
p=0.122 
Figure 8.8 Average pain intensity amongst all participants between baseline and end of 
treatment weeks (n=57) 
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 Total score of BDI:  
Baseline week: Mean: 20.088. Standard error: 1.384 
End of treatment week: Mean: 18.000. Standard error: 1.302 
p=0.014* 
 
Total SF36 score:  
Baseline week: Mean: 38.981. Standard error: 2.643 
End of treatment week: Mean: 40.830. Standard error: 2.424 
p=0.296 
Figure 8.9 BDI, and SF36 scores of all participants between baseline and end of treatment 
weeks (n=57) 
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Table 8.14 Repeated MANOVA for SF36, average OM, average pain, and BDI, and treatment 
group, and time (n=66) 
Outcome 
measure 
n Wilk’s Λ F Hypothesis 
df 
Error df p 
value 
partial 
η2 
Repeated MANOVA over time 
SF36 57 0.978 1.171b 1.000 51.000 0.284 0.022 
Average 
OM 
consumption 
57 
0.722 19.611 b 1.000 51.000 0.000 0.278 
Average 
pain 
intensity 
57 
0.959 2.204 b 1.000 51.000 0.144 0.041 
BDI 57 0.875 7.315 b 1.000 51.000 0.009 0.125 
Repeated MANOVA over time and CM patterns 
SF36 57 0.966 1.780 b 1.000 51.000 0.188 0.034 
Average 
OM 
consumption 
57 
0.988 0.598 b 1.000 51.000 0.443 0.012 
Average 
pain 
intensity 
57 
0.982 0.922 b 1.000 51.000 0.342 0.018 
BDI 57 0.966 1.772 b 1.000 51.000 0.189 0.034 
Repeated MANOVA over time and treatment group 
SF36 57 0.937 1.701 b 2.000 51.000 0.193 0.063 
Average 
OM 
consumption 
57 
0.925 2.060 b 2.000 51.000 0.138 0.075 
Average 
pain 
intensity 
57 
0.992 0.200 b 2.000 51.000 0.819 0.008 
BDI 57 0.998 0.054 b 2.000 51.000 0.948 0.002 
Repeated MANOVA over time, treatment group, and CM patterns 
SF36 57 0.948 1.407 b 2.000 51.000 0.254 0.052 
Average 
OM 
consumption 
57 
0.940 1.632 b 2.000 51.000 0.206 0.060 
Average 
pain 
intensity 
57 
0.986 0.358 b 2.000 51.000 0.701 0.014 
BDI 57 0.915 2.356 b 2.000 51.000 0.105 0.085 
* Indicate statistical significance (P<0.05) 
b. Exact statistic 
SF36: Medical outcome short form health survey 36 items 
BDI: Beck Depression Inventory 
CM: Chinese medicine 
OM: Opioid medication 
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8.4 Discussion 
8.4.1 Summary of findings  
This chapter aimed to 1) identify the group difference between the CM “heat” and “cold with 
deficiency” patterns; 2) identify if CMPQ could assess changes after treatment and if different 
treatments induced different changes; 3) identify which pattern responded best to REA 
treatment; 4) find out if the CM “heat” and “cold with deficiency” patterns differed in 
treatment response in the four outcome measures (average pain intensity, average OM 
consumption, SF36 and BDI) between baseline weeks and the end of treatment weeks. 
For aim number one, CM heat pattern (cluster four) was associated with a better QoL and 
mild depression over CM cold with deficiency pattern (cluster five) at baseline week. 
For aim number two CMPQ could capture changes in signs and symptoms after treatments. 
Real EA group participants reported improvement in nausea symptom and perception of 
treatment where less of them felt nothing improves their pain; SEA group participants 
reported improvement in painful regions, pain at fixed location, participant’s response to 
reading and keeping their mind off pain, and nausea, dizziness, and poor appetite symptoms, 
and at the same time SEA group reported more pain aggravation to cold weather; and PMM 
alone group participants reported improvement in the numbness sensation, pain aggravated by 
movement, response to warm/hot shower, and poor memory, at the same time they also 
reported deteriorated response in more pain in between the shoulder blade, and more pain 
aggravation by cold weather.  
For aim number three, there were differences in how the two patterns responded to REA 
treatment based on CMPQ items. Chinese medicine heat pattern (cluster four) reported better 
results to REA in comparison to CM cold with deficiency pattern (cluster five) where CM 
heat pattern had more pain alleviation to hot packs. Chinese medicine heat pattern reported 
slightly better to REA in having one more symptom improved than CM cold with deficiency 
pattern. Neither of the two patterns reported best response to REA treatment. 
For aim number four, there was no significant difference in treatment responses of the two 
CM patterns over time for average pain intensity and average OM consumption, QoL, and 
depression.  
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Chinese medicine pain questionnaire was developed and designed to standardise and assist 
CM consultation. Evaluating the presence/absence of symptoms after treatment is a common 
practice in CM. According to Chinese Medicine Board of Australia, the requirement of the 
patient case record includes noting down the relevant changes of the ongoing conditions 
during the subsequent consultation 1081. The results of this project indicated CMPQ captured 
minor changes in symptoms (Table 8.15).  
8.4.2 Association of CM clusters with other outcome measures 
Chinese medicine heat pattern (cluster four) was associated with better QoL and depression in 
comparison to CM cold with deficiency pattern (cluster five) despite the two patterns had 
similar pain intensity and OM usage. Other similar studies related to the association between 
pain and other outcome measures included TMD and perceived physical symptoms, 
psychological, coping and psychosocial variables 1082. Suvinen et al. found the 41 female TMD 
participants could be classified into simple (22%), intermediate (41%), and complex (37%) 
clusters 1082. The three clusters did not differ significantly in the pain intensity, which was 
similar to the current study. The simple cluster contained patient who had mainly physical 
symptom and low scores on psychological and psychosocial variables. The psychological 
variables included the Coping Strategies Questionnaire, Illness Behaviour Questionnaire, BDI, 
and Beck Anxiety Inventory. The psychosocial variables were part one of Multidimension 
Pain Inventory. The complex cluster had considerable psychological and psychosocial 
dysfunction irrespective of the severity of the physical symptoms. The intermediate cluster 
had abilities to manage and cope with their conditions irrespective of the physical or 
psychosocial dysfunctions.  
The current study differed from them in the participants recruited were CMP and the 
interpretation of cluster was in CM way. Other similar study who also used CM understanding 
to interpret the meaning of clusters included Hao 1083 who developed a CM headache 
questionnaire, used factor and cluster analysis to group symptoms of tension type headache, 
and compared participants’ disability using Migraine Disability Assessment Questionnaire 
(MIDAS) 1084 and psychological stress using Perceived Stress Scale scores 1085. MIDAS 
evaluates the disability using the number of days patients suffering from reduced productivity 
due to headache, number of days having headache, and severity of headache. Hao’s study had 
identified four clusters. In CM interpretation, cluster one was ascendant hyperactivity of CM 
liver Yang, cluster two was dual deficiency of Qi and blood, and cluster three was CM liver 
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depression forming fire, and cluster four was a nonspecific cluster. Of these four clusters, 
although the overall MIDAS score, and the number of headache days did not differ in the four 
clusters, cluster one was of moderate headache intensity and disability, and performed the best 
in perceived coping ability of stress among the four clusters. Cluster two on the other hand 
had the worst headache and highest disability. Cluster three had moderate headache intensity 
and severe disability. Cluster four had the mildest headache intensity, moderate disability and 
was free from mental comorbidity. Of the four cluster’s perceived stress, cluster one and two 
seemed to cope stress better than cluster three and four as stated by Hao 1083. The findings of 
this project and Hao’s study highlight that apart from the pain severity, medication usage, 
disability, depression, and QoL, CM pattern identification can further sub group chronic pain 
patient and these subgroups may or may not differ in standard assessments. 
The association between CM pattern and QoL have been explored in other studies 1086,1087. Luo 
et al. finds diabetic patients with Qi deficiency pattern had lower QoL in every aspects of WHO 
Quality of Life (WHOQOL-BREF) and SF12 1086 when compared with participants without Qi 
deficiency pattern. Song et al. finds obese women with CM liver depression and Qi stagnation 
pattern had the lowest mental component summary (MCS-12) score in comparison to the 
control group but not in physical component summary (PCS-12) and WHOQOL-BREF 1087. 
The control group comprised of obese patients who could not be classified into any of the 
predefined five CM patterns, including “CM spleen deficiency with dampness obstruction”, 
“CM stomach heat with dampness obstruction”, “CM liver depression and Qi stagnation”, 
“both CM spleen and CM kidney deficiencies”, and “Yin deficiency with internal heat”. The 
results of the current study was similar to Luo et al.’s study where participants with deficiency 
pattern scores the worst 1086 but different from Song et al.’s result where CM liver depression 
and Qi stagnation pattern scores the worst QoL emotionally but not physically 1087. Such 
difference may be due to the participants recruited and the QoL assessment utilised, and the use 
of OM for pain control indicated the participants’ CMP was more advanced 1073. Song et al. 
pre-defined CM patterns based on literature review 1087 and the current project utilised 
scientific sound cluster analysis to group the symptom presentation. 
8.4.3 Consideration of statistical analysis and sample size  
The project utilised Cochran’s Q test to analyse changes in the dichotomous CMPQ items. 
Assumptions one and three of Cochran’s Q pre-requisites were met but assumption two was 
only partially met where the participant recruitment was from a convenience sample and not 
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randomly selected from the population. The inclusion criteria of the recruited participants 
included the use of OM for more than three months. Opioid medication is a controlled 
schedule eight substance and requires the permit from the government for long term use 1088. 
Such requirement made random sampling impossible. Other studies have also used 
convenience sample and used Cochran’s Q analysis to analyse the outcome 1089,1090. 
Choosing only the participants who provided both baseline and end of treatment weeks made 
the sample size smaller. It was necessary to use this approach as no last value carried forward 
was used for CMPQ. It was not suitable to take the data of participants who dropped out of 
the study to compare their other outcome measure using last value carried forward due to no 
CMPQ data at later stage. It was necessary to remove these participants and statistically it is 
acceptable to remove data that were missing complete at random, also known as complete 
case analysis 1091. 
The sample size became smaller when sub grouped by the treatment groups and the CM 
patterns. This impacts on the results. It was observed Cochran’s Q test requires at least four 
participants to show improvements/deteriorations in one symptom to achieve p<0.05. The 
greyed items in Table 8.15 indicate the groups with less than four participants presenting with 
such symptom in baseline week. This small sample size made it difficult to detect changes in 
these items. And with the baseline differences, as shown in Table 8.3, Table 8.4, and Table 8.5 
(p. 270 to 274), this limited the comparability amongst the groups. However, a small sample 
size can have large p value for statistically significant difference 1092(p576), not to mention the 
p<0.05 achieved in the Cochran’s Q analysis, and Cochran’s Q analysis is comparing within 
individual changes and not group changes. This further enhanced the validity of the results. 
8.4.4 Interpretation of findings - number of pain regions  
The ANOVA results showed significant differences amongst the three treatment groups at 
baseline week when totalling the pain regions for the three treatment groups amongst 
participants who also provided data for both baseline and end of treatment weeks (REA 
M=6.56, SEA M=11.00; PMM alone: M=7.00). Overall, SEA group had the greatest 
improvement in pain regions amongst the three treatment groups. This difference in change 
perhaps reflects a baseline difference. 
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8.4.5 Interpretation of findings – sensitivity to temperature  
Amongst all the symptoms that showed statistically significant differences, REA was the group 
with no deteriorations whereas SEA and PMM alone both have two symptom deteriorations. 
Importantly only REA showed no further pain aggravation by cold weather, whereas SEA and 
PMM alone both had their pain further aggravated by cold weather (Table 8.15). Such finding 
consistently occurred in both CM heat and CM “cold with deficiency” patterns in SEA and cold 
with deficiency pattern in PMM alone (Table 8.16). Due to there were less than four 
participants to improve, such finding did not show in CM heat pattern in PMM alone (Table 
8.16).  
Comparatively, CM heat pattern had enough participants for improvement in pain alleviated by 
“hot packs” in all three treatment groups. Only REA group showed improvement (Table 8.16). 
Chinese medicine “cold with deficiency” pattern either had insufficient participants for 
improvement in REA and SEA groups or was showing no significant difference in PMM alone 
group (Table 8.16).  
Hay et al. compared painful stimulation by von Frey hairs, electrical stimulation, and cold 
pressor on noncancer chronic pain patients taking OM in comparison to those not taking OM 
found the tolerance time to cold pressor of patients on OM (18.1-19.7 ± 1.9-2.6 seconds) was 
shorter than the OM naive patients (30.7 ± 3.9 seconds) 1093. Zahari et al. had also found similar 
findings in OM dependent patients and OM naive patients, the cold pressor tolerance time of 
the two groups was 34.17 seconds (95% CI 24.86, 43.49) and 61.36 seconds (52.23, 70.48) 
(p<0.001), respectively. Both studies showed cold intolerance in patients taking OM.  
The current study adds two newer information to this finding in 1) REA group although were 
still on OM, their sensitivity to cold weather did not increase whereas SEA and PMM alone 
groups both had their pain further worsened by cold weather; and 2) CM heat pattern reported 
improved sensitivity to hot packs in alleviating their pain after REA. These may perhaps be due 
to acupuncture increased surface temperature 1094. An OM review found OM induced 
hyperthermia/hypothermia depending on the animal species and the dose of OM, where high 
dose of OM induced hypothermia and low dose of OM induced hyperthermia 1095. The baseline 
comparison showed no statistically significant difference between the three treatment groups in 
OM consumption (Table 8.6) nor was there any difference when the two CM patterns were 
compared (Appendix 29). How much this non-sensitivity to cold temperature was due to the 
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effect of REA and the better response in pain alleviated by “hot packs” due to REA within CM 
heat pattern is unknown due to small sample size. The mechanism of this new information 
awaits further research to identify. 
8.4.6 Interpretation of findings – other symptoms 
For the two CM patterns, due to small sample size and uneven distribution of symptoms 
amongst the two patterns and the three treatment groups, it was not possible to identify which 
pattern responded best to REA. 
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Table 8.15 Comparison of significant changes between baseline and end of treatment weeks amongst the three treatment groups and their baseline 
week data 
Domain Sub-categories Item 
Treatment group and changes 
REA (n=27) SEA (n=22) PMM alone (n=17) 
Significant 
changes 
Number of 
baseline 
week yes 
Significant 
changes 
Number of 
baseline 
week yes 
Significant 
changes 
Number of 
baseline 
week yes 
Pain regions 
Upper limb Upper arm
+ 
NS 
6 I 12 NS 
4 
Forearm+ 2 8 1 
Front of the body Side of the body 3 D 3 0 
Back of the body Between shoulder blades 9 NS 10 D 3 Sacrum 8 I 7 NS 6 
Pain quality & Numbness 10 NS 9 I 7 Fixed location 12 I 13 NS 6 
Pain aggravators Environmental changes Cold weather 15 D 10 D 8 Exercises or sporting Any movement 6 NS 6 I 6 
Pain alleviators 
Environmental changes Warm/hot shower 9 11 I 5 
Physiological and psychic 
changes 
Reading 4 I 2 
NS 
3 
Keeping my mind off pain 11 5 7 
Other Nothing I 5 NS 2 1 
Other symptoms & 
Nausea I 8 
I 
9 2 
Dizziness 
NS 
6 9 5 
Poor appetite 9 8 5 
Poor memory 10 NS 11 I 12 
+Indicates significant difference between groups in baseline week  
Shaded item means improvement seen in one group but one of the other two groups has less than four participants having such item in baseline 
week. Such rule also applies to “nothing” in pain alleviator but does not apply to the rest of the pain alleviator.  
& no sub category for pain quality and other symptoms 
D: Deterioration; I: Improvement; NS: Not significant; 
REA: Real electro acupuncture; SEA: Sham electro acupuncture; PMM alone: Pain medication management alone 
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Table 8.16 Comparison of significant changes between baseline and end of treatment weeks amongst the CM heat pattern (cluster four) and the CM 
“cold with deficiency” pattern (cluster five) and their baseline week data 
Domain Sub-categories Item 
Treatment group and changes 
REA (n=21) SEA (n=21) PMM alone (n=15) 
Cluster 4 (n=13) Cluster 5 (n=8) Cluster 4 (n=11) Cluster 5 (n=10) Cluster 4 (n=6) Cluster 5 (n=9) 
S. 
C.
Number of 
baseline 
week yes 
S. 
C.
Number of 
baseline 
week yes 
S. 
C.
Number of 
baseline 
week yes 
S. 
C.
Number of 
baseline 
week yes 
S. 
C.
Number of 
baseline 
week yes 
S. 
C. 
Number of 
baseline 
week yes 
Pain 
region Lower limb 
Calf 
NS
1 
NS
3 
I 
6 
NS
0 
NS
1 
NS 
3 
Front of the 
leg+ 0 1 7 2 0 4 
Pain 
quality & 
Fixed 
location 4 I 7 NS 4 I 8 3 3 
Numbness 6 
NS
1 4 
NS
4 2 I 4* 
Pain 
rhythm & 
All the time 8 7 I 9 8 5 
NS 
4 
Worse when 
first get up I 6 4 NS 2 3 2 3 
Pain 
aggravator 
Environmental 
changes Cold weather NS 6 5 D 5 D 4 3 D 5 
Pain 
alleviator 
Environmental 
changes Hot packs
+ I 3 5 
NS
5 NS 9 2 
NS 
5 
Other Keeping busy 
NS
3 3 2 
I 
3 3 1 
Other 
symptoms & 
Swollen 
joints 1 2 5 4* 3 0 
Dry stools+ 0 0 0 4* 0 1 
Poor 
appetite+ 3 3 I 4* NS 4 0 5 
Nausea 2 4 5* 4 1 1 
Dizziness+ 1 2 NS 2 I 6 1 4 
S.C.: Significant changes 
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+Indicates significant difference between groups in baseline week 
*indicates participants who had the symptom all improved from this symptom. 
Shaded item means improvement seen in one group but one of the other groups has less than four participants having such item in baseline week. 
Such rule does not apply to pain alleviator. 
& no sub category for pain quality and other symptoms 
D: Deterioration; I: Improvement; NS: Not significant; 
REA: Real electro acupuncture; SEA: Sham electro acupuncture; PMM alone: Pain medication management alone 
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8.4.7 Comparison with other OM studies 
When compared with other opioid detoxification researches, they used different outcome 
measures to CMPQ and included pain severity subscale of the Multidimensional Pain Inventory 
and Center for Epidemiologic Studies–Depression scale 1096 or cold pressor to assess pain 
tolerance 1097. The pain severity subscale of the Multidimensional Pain Inventory focuses on the 
severity of pain at present, in the last week, as well as the severity of suffering due to pain. The 
uniqueness of CMPQ was in assessment of complete disappearance of symptoms whereas the 
other three assessments were on a scale and focused on changes in severity, and the spectrum of 
symptoms covered in CMPQ, included the six domains (refer to Chapter 5 CMPQ item 
generation (p. 152)), was far greater than any of the three assessments mentioned. Especially 
the accompanying symptom domain which focuses on the other physical and mental 
symptoms. This domain is linked through the CM theory and is unique to CM. 
Limitations of the study: 
1) Sample size was small for all three groups. This was due to that patients did not want to 
reduce OM. Within the EAOM trial, 556 potential participants met the inclusion criteria 
and only 151 consented to participate the trial. The dropout from the EAOM trial made the 
sample size even smaller and intention to treat analysis was not applied. Although the 
sample size was small, the differences between them in the changes within the treatment 
group and the clusters via Cochran’s Q test were significant (p<0.05). The association 
between the CM patterns, SF36, and BDI were also significant taking Bonferroni 
correction into consideration. Potentially there were differences between the CM patterns 
in QoL and depression. Such possibility awaits further research in the CM heat pattern and 
the CM “cold with deficiency” pattern type participants. 
2) Variability of the CMPQ data was limited by the dichotomous format. Such format limited 
the assessment of changes although the presence/absence of a symptom was the basis of 
CM diagnosis.  
3) The EAOM trial treatment protocol was limited to four main points to induce the release 
of endorphin plus other points to address the side effect of OM. This method was not 
commonly used in acupuncture practice and the results from the treatment did not represent 
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the common practice 136(p14-21). The REA treatment effect on CMPQ is thus limited to this 
type of protocol. 
Implication for research 
Based on the results of the study, CMPQ may be able to reflect changes after acupuncture 
treatments. Further studies with large sample size, more variety of CMP, likert-scaled response 
in CMPQ, are recommended for evaluating the differences between the two clusters of CMP 
patients who take OM for pain control.  
Implication for clinical practice 
Chinese medicine pattern identification can further sub-group CMP despite of their similarities 
in OM consumption and pain intensity and may help assess changes in clinical presentation. 
The two CM patterns provide additional indicators of change, such as if pain can be relieved by 
hot pack, and if pain is aggravated by cold weather. The significance of such information is 
meaningful to CM practitioners. 
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9. General discussion and Conclusion 
9.1 Summary of findings  
The objectives of the project included 1) identifying the comorbidities and symptomatologies 
of CMP through a SR; 2) developing and validating a CMPQ for pattern identification in CMP 
patients who are OM users; 3) differentiating the CM patterns of CMP who use OM for pain 
control using cluster analysis; and determine the cluster differences in demography, pain 
intensity and OM consumption, depression, QoL, and disability; and 4) determining the 
differences between patterns and clinical outcomes of EA based on the change in CMPQ 
symptoms, pain intensity, OM consumption, depression, and QoL. 
9.1.1 The Systematic review 
Seventy two English studies were identified in the SR through searches in English databases. 
Overall, the finding reflected high associations between CMP and comorbidities and/or 
accompanying symptoms, particularly the association between chronic SP and other types of 
pain (such as headache, migraine, chronic back or neck pain, arthritis, or other chronic pain) 
(OR 1.33-7.9), and the association between arthritis and heart diseases/symptoms (OR 3.1-8.7). 
Overall the SR showed a high association between CMP and mental disorders (OR 1.48 - 6.2) 
and headache/migraine (OR 1.33 – 7.0). 
9.1.2 Development of CMPQ 
The development of CMPQ included the literature review, item generation, and internal group 
discussion. The resultant CMPQ contained 187 items grouped into six domains. These items 
could be understood from the CM perspective and formed CM patterns. 
9.1.3 The essential properties of CMPQ 
The CMPQ demonstrated good face and content validities, test-retest reliability (correlation 
coefficient=0.846 for overall questionnaire, and above 0.7 for all domains except for the pain 
quality and pain rhythm domain where the correlation coefficients were between 0.49-0.556), 
and internal consistency (Cronbach’s α=0.931). Items related to OM side effects were assessed 
for responsiveness. Of these items, bowel movement as pain alleviator and skin itch as 
accompanying symptom showed responsiveness to REA and there was no symptom responding 
to PMM alone. 
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9.1.4 Clusters of CMP and CM interpretation of the clusters  
The current study identified two main clusters and their corresponding CM patterns. They were 
CMP due to heat pattern (cluster four) and CMP due to “cold with deficiency” pattern (cluster 
five). The CM patterns were different from the ones listed in the textbooks 132(p706-708,890-895) 
1022(p963,973,976,984,987,995,996,1002,1005,1007,1012,1014,1017,1019,1023,1032,1034,1042,1045,1047,1051,1054,1062,1069,1078,10
94,1097,1107,1108,1116,1131,1136,1158,1168,1171,1172,1176,1177,1306,1325,1536,1538,1541-1548,1554-1557,1567-1570,1574-1576,157
9-1581,1583,1584,1586-1588,1631-1635,1642-1644,1650-1651,1652-1653,1654-1656)1020(p981-1047,1059-1118)1021(p308-335). The 
grouping of CMP sub types was by scientifically sound factor and cluster analyses and data 
from real patients rather than expert opinion or data from uncertain sources as described in the 
CM classics. Using cluster analysis to group symptoms had been used in CM pattern research 
1050,1098. 
9.1.5 Association with other outcome measures 
The study had found CM heat pattern (cluster four) was associated with better overall QoL 
and mild depression whereas CM “cold with deficiency” pattern (cluster five) was associated 
with the worse overall QoL and moderate depression.  
9.1.6 Evaluating effects of treatments on the symptoms of participants 
The CMPQ was able to detect minor changes amongst the three treatment groups. The CMPQ 
showed REA was the only group that did not show symptom deterioration. On the other hand, 
SEA showed the most improvement in symptoms followed by REA and PMM alone. Real EA 
was the only group that showed no deterioration in pain worsened by cold weather whereas 
SEA and PMM alone both had deterioration in response to cold weather. 
9.1.7 Effect of treatment on subgroups and outcome measures 
Chinese medicine heat pattern (cluster four) responded to REA with a slightly better result as 
fewer participants reported their pain became worse when they first got up and more 
participants felt that hot packs alleviated their pain when compared with the CM “cold with 
deficiency” pattern which showed improvement in pain at fixed location only. There was no 
pattern that responded best to REA. Only OM consumption and BDI improved over time 
without group differences. There were no statistical significant changes associated with the 
two clusters and the three treatment groups over time for QoL and average pain intensity. 
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9.2 Strengths and limitations of the project 
9.2.1 Strengths of the project 
9.2.1.1 A holistic view of CMP 
The SR, to the best knowledge of the authors, is the first to systematically evaluate the 
comorbidities/accompanying symptoms of CMP that was not limited to a particular kind of 
CMP such as LBP or arthritis. The approach views CMP from a holistic approach instead of 
the individual type of CMP alone. In comparison to previous SRs on comorbidities, this SR 
has more included studies (n=72), whereas prior studies included 16 studies on LBP and 
respiratory disorders 1099. The SR also identified the common comorbidities amongst chronic 
SP and arthritis and the association between arthritis and chronic SP.  
9.2.1.2 The CM evaluation process 
Based on the author’s knowledge, this is the first study to evaluate the effect of treatment 
from a CM perspective by using CMPQ for CMP who take OM for pain control. The 
multidimensionality of CMPQ enables the assessment of a much broader range of symptoms. 
Many changes are not captured by simply assessing the intensity of pain, OM consumption, 
SF36, and BDI. For instance, the accompanying nausea, dizziness, poor appetite, poor memory, 
reduction in the number of painful sites, the change in painful sensation (e.g. numbness to less 
numbness), and the increased/decreased sensitivity towards cold weather are common 
presentations of CMP, but are not captured using the standard assessment tools. To the best 
knowledge of the author, evaluating outcomes from a CM perspective was not utilised in pain 
management centres in Melbourne, Victoria, Australia. Without detailed evaluation 1) 
treatment effects may not be fully captured in a pain management centre; and 2) treatments 
may not be tailored to each individual patient. See further discussion in Chapter 9.5 
Preliminary effect of treatment on subgroup of participants (p. 305).  
 
9.2.1.3 The two distinctive and meaningful patterns of CMP who use OM for 
pain control 
In addition, the current study also identified the two key CM subgroups of CMP i.e. Chinese 
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medicine heat pattern and CM cold with deficiency pattern. More importantly the two 
meaningful patterns were identified based on advanced statistical analyses (factor analysis and 
cluster analysis) combined with experts’ opinions rather than the latter alone which is the 
approach that has been used in textbooks. The CM heat pattern and CM cold with deficiency 
pattern differ in their nature- the CM heat pattern includes “red and hot joints, palms, and face”, 
and skin itch whereas the CM cold with deficiency pattern includes cold extremities, feeling 
cold easily, poor concentration/memory/appetite, low libido, dizziness, stuffiness in the chest, 
shortness of breath, night sweating, feeling tired easily, and catching cold easily. These two 
distinct subgroups also differed in their QoL and depression. Chinese medicine heat pattern 
shows less severe depression and better QoL when compared with CM cold with deficiency 
pattern. 
Other studies have also identified cold and heat patterns in RA. Metabonomically, the cold 
pattern of RA may have higher rates of fat and protein mobilization, whereas for the heat pattern, 
the oxidative stress and collagen destruction may be more severe 1100. Chinese medicine heat 
pattern is associated with elevated plasma concentrations of glycochenodeoxycholate, proline, 
saturated and mono-unsaturated phosphatidylcholine but decreased levels of urea, free fatty 
acid and polyunsaturated phosphatidylcholine 1100. Furthermore, CM cold and heat patterns of 
RA were associated with 29 and 19 differential metabolites respectively 1101. The common 
metabolites involved in both CM patterns were perturbation of amino acid metabolism, 
carbohydrate metabolism and lipid metabolism. Specifically, metabolic perturbations in protein 
and collagen breakdown, decreased glycolytic activity and aerobic oxidation, and increased 
energy utilization were associated with CM cold pattern but not in the CM heat pattern 1101. 
These findings support the differences between the CM cold pattern and CM heat pattern at the 
molecular level and from the metabolic perspective. These information further support the 
usefulness of CM knowledge in differentiating syndromes and identifying sub-groups of CMP. 
9.2.1.4 A rapid and simplified CM pattern identification process 
The CMPQ items were designed based on the CM eight guiding principles. This method 
enabled quick CM pattern identification. Based on the CM patterns identified, a practitioner 
can select the appropriate treatment for the CMP patients. Whether using acupuncture only or 
using moxibustion concurrently, the practitioner needs to treat patients based on the CM pattern 
identified for a better outcome 1102. 
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9.2.2 Limitations of the project 
9.2.2.1 Language restriction in SR 
The SR included only English literature and no Chinese literature was found in the English 
database searches. Literature in other languages were excluded. Egger et al. argued English 
literatures tended to show statistical significant results and excluding non-English literatures 
produced a biased results 1103. However, Morrison et al. investigated the effect of English and 
non-English literatures on systematic review and found no systematic bias from the use of 
English language restriction 1104. Including only English language studies in the SR should not 
impact on the validity of the results. 
9.2.2.2 Low NOS score in SR 
The quality appraisal was assessed with NOS. The low score of the NOS limited the 
interpretability of the results. For this reason, findings were only confirmed if more than one 
study reported the same results as the chance for multiple studies to report the same false 
association is low. 
9.2.2.3 Limitation of the SR data 
The design of the SR did not allow for the causal relationship evaluation. It is not possible to 
ascertain whether the comorbidities/accompanying symptoms caused the CMP, vice versa, or 
they are simply just associated with each other. It will be helpful to identify the nature of the 
relationship or mechanisms underlying these co-existing diseases/accompanying symptoms for 
the better treatment/management of the patient’s overall health. 
9.2.2.4 Number of non-menopausal females was limited 
The majority of the included female participants were at the post-menopausal stage (69% of 
females, 42 out of 56 females). Such a small sample may produce random error if the data on 
gynaecological symptoms (such as menstrual cycle related symptoms or vaginal discharges) 
were taken into consideration when cluster analysis was used 1105. These gynaecological 
symptoms were subsequently removed in factor and cluster analysis to prevent distortion of 
the factors and clusters. 
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9.2.2.5 Dichotomous outcome 
The dichotomous response limited the flexibility of changes. Participants who only had mild 
improvement would not show changes. Only significant changes from presence to absence or 
vice versa of a symptom would show changes.  
9.2.2.6 Small sample size 
The sample size was relatively small, but sufficient for assessing the validities and reliabilities. 
When the sample was divided into treatment groups and when drop outs were taken into 
consideration, the sample size became smaller for each group, varying from 28 to 45 at week 
five, and 17 to 28 at end of treatment week. Although such a small sample size may lead to 
random error when evaluated the treatment effects 1105, the statistical significance level was 
adjusted for small sample size. 
9.3 CM pattern identification and subgroups of CMP  
This project used factor and cluster analysis to group the symptoms. Both statistical methods 
have been used in both CM and western medicine to sub-group symptoms within a 
disease/condition 1016,1053. When identifying the patterns of symptom cluster, it is necessary to 
engage CM experts to evaluate the symptoms. The advantage of evaluating the patterns using 
CM knowledge is that the existing CM theory explains the complex relationship between and 
among the symptoms. Furthermore, there are existing treatment principles and treatments for 
each pattern. 
In comparison to the modern textbook, differences exist between the current finding and the 
textbooks 132(p890-895). The 10 types of CM patterns for Bi syndrome are, wind dampness Bi 
obstruction (风湿痹阻), cold dampness Bi obstruction (寒湿痹阻), cold and heat mixture (寒
热错杂), damp heat Bi obstruction (湿热痹阻), heat toxin Bi obstruction (热毒痹阻), static 
blood Bi obstruction (瘀血痹阻), phlegm turbidity Bi obstruction (痰浊痹阻), phlegm stasis Bi 
obstruction (痰瘀痹阻), deficiency of both Qi and Yin (blood) (气阴(血)两虚), deficiency of 
both CM liver and CM kidney (肝肾两虚) 132(p890-895). Bi syndrome, as explained in Chapter 
2.6.3 How does CM view and differentiate CMP (p. 36), includes pain in the 
joint/muscle/bone/tendon, and is consistent with the painful regions of the recruited participants. 
The possible reasons for the differences between the results of the current project and the 
 302 
 
textbooks may be the use of OM, the use of factor and cluster analysis, and the use of the CM 
eight guiding principles. Due to long term consumption of OM, which is a restricted medication 
1106, the participants in the current study were very specific whereas the patients described in the 
textbook were more general and would less likely have included any symptoms associated with 
the use of OM. As previously reported, the methods of CM pattern identification used in the 
textbooks about Bi syndrome were the combination of six pathogenic factor diagnosis, Qi 
blood and body fluid diagnosis, and CM Zang Fu pattern identification (Table 9.1), but not the 
CM eight guiding principles method of diagnosis. The CM eight guiding principles diagnosis 
is the leading pattern identification method and classifies all patterns into six key patterns 
(cold versus heat, deficiency versus excess, interior versus exterior) with two overarching 
categories (Yin and Yang). It is used to re-classify and simplify patterns identified using other 
methods. For this reason, it is more appropriate and easier to research sub-groups of CMP 
using the CM eight guiding principles as a starting point.  
Table 9.1 Methods of CM pattern identification for Bi syndrome  
CM pattern 
identification 
Six 
pathogenic 
factor 
diagnosis 
Qi blood 
and body 
fluid 
diagnosis 
CM Zang Fu 
pattern 
identification 
CM eight 
guiding 
principles 
diagnosis 
Wind dampness 
Bi obstruction 
(风湿痹阻) 
x   Cold, excess, 
exterior 
Cold dampness 
Bi obstruction 
(寒湿痹阻) 
x   Cold, excess, 
exterior 
Cold and heat 
mixture (寒热错
杂) 
   Cold and heat  
Damp heat Bi 
obstruction (湿
热痹阻) 
x   Heat, excess, 
interior 
Heat toxin Bi 
obstruction (热
毒痹阻) 
x   Heat excess, 
interior 
Static blood Bi 
obstruction (瘀
血痹阻) 
 x  Excess, interior 
Phlegm turbidity 
Bi obstruction 
(痰浊痹阻) 
 x  Excess, interior 
Phlegm stasis Bi 
obstruction (痰
 x  Excess, interior 
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CM pattern 
identification 
Six 
pathogenic 
factor 
diagnosis 
Qi blood 
and body 
fluid 
diagnosis 
CM Zang Fu 
pattern 
identification 
CM eight 
guiding 
principles 
diagnosis 
瘀痹阻), 
Deficiency of 
both Qi and Yin 
(blood) (气阴
(血)两虚) 
 x  Deficiency, 
interior 
Deficiency of 
both CM liver 
and CM kidney 
(肝肾两虚) 
  x Deficiency, 
interior 
Information extracted from 132(p890-895) 
CM: Chinese medicine 
 
Discrepancies in textbook patterns and those identified in research also exist in other study that 
used factor and cluster analysis to research fatty liver 1060. According to the CM textbook, and a 
CM and western medicine integrated book on liver disease 1107(p221)132(p863-866), fatty liver is 
similar to accumulation syndrome (积聚) in CM and has the following CM patterns; 1) Qi 
stagnation and dampness obstruction (气郁湿阻), 2) phlegm and Qi mutual stagnation (痰气互
结) 3) Qi stagnation and blood stasis (气滞血瘀) 4) CM liver stagnation and Qi stagnation (肝
郁气滞), 5) food turbidity obstruction and stagnation (食浊阻滞) 6) heat stagnation and Fu 
organ excess(热结腑实) 7) Qi and blood obstruction and stagnation (气血阻滞), 8) Qi knotting 
and blood stasis (气结血瘀), 9) damp heat knotting with toxins (湿热结毒) 10) antipathogenic 
factor deficiency with stagnation and stasis (正虚瘀结). The finding from the fatty liver study 
(n=793) 1060 resulted in however seven clusters. The authors evaluated the symptoms within 
the clusters and diagnosed five out of seven of them with 1) retention of phlegmatic dampness 
due to CM spleen deficiency (脾虚痰湿中阻) (32.0%), 2) Yin deficiency of CM liver and CM 
kidney (肝肾阴虚) (18.5%), 3) phlegm accumulating with stagnation due to CM spleen 
deficiency (脾虚痰瘀互结) (11.5%), 4) internal accumulation of damp-heat due to CM spleen 
deficiency (脾虚湿热内蕴) (10.2%), and 5) dampness obstruction due to CM liver Qi 
stagnation and CM spleen deficiency (肝郁脾虚湿阻) (8.3%). The remaining two clusters 
were asymptomatic (13.6%), and CM pattern-uncategorizable (5.8%). This clinical study 
showed a combination of excess and deficiency patterns with CM organ involvements instead 
of just the excess, deficiency, or a combination of them. The authors listed the signs and 
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symptoms within the clusters and labelled them with CM patterns. Such discrepancy 
illustrates the differences between theory and reality. Reality is more important than theory. 
When in reality, the CM heat and CM cold with deficiency patterns are more predominant, both 
patterns deserve more attention. In clinical practice, it is more important to focus on these 
patterns than rarely occurring patterns such as cluster one and three (n=1 each, 1%) in Chapter 
7.3.3 Cluster analysis (p. 236). Chinese medicine textbook information needs to be 
evidence-based. If the CM textbook based on experts’ opinion differs from research data, 
revisions of the textbook are then required. If the textbook contains symptoms that are rarely 
occurring, such as “windy day” as pain alleviator, it should be acknowledged in the textbook. 
More research in CM pattern identification reflecting the health conditions in reality is needed. 
9.4 Effect of treatment captured by CMPQ 
The effect of treatment captured by CMPQ indicated 1) CMPQ as an outcome measure was 
able to capture treatment effects that were not detectable using other outcome measures in the 
three treatment groups, and 2) REA group had no symptom deterioration and two symptom 
improvements, SEA group had two symptom deteriorations with nine symptom improvements 
and PMM alone group had two symptom deteriorations and four symptom improvements. 
Such noticeable differences were not captured by simply examining the OM consumption, 
average pain, SF36, and BDI. Such differences are less likely due to different degrees of OM 
reduction among the three groups given all groups reduced OM dosages without any 
statistically significant differences. It is important to note the difference captured by CMPQ 
was within groups, but not between groups. The between group analysis was not made because 
there were excessive numbers of comparisons (CMPQ has 163 main items for comparison) 
and multiple baseline incomparabilities. Due to small sample size and the multiple 
incomparabilities between the treatment groups, caution is advised when interpreting the 
treatment results. 
Another method of comparison between treatments is by comparing the number of symptoms 
recorded at different time points. Such an approach is used in SF36 and McGill Pain 
Questionnaire 1024. Chinese medicine pain questionnaire could follow this method which is 
meaningful to both the patients and from the statistics perspective. Future development could 
incorporate the likert scale and this summing up the number of symptoms approach to compare 
the treatment results.  
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9.5 Preliminary effect of treatment on subgroup of participants 
In CM, the treatments strategy for the two patterns identified should differ 136(p5-15). For CM 
heat pattern, clearing heat method should have been used and for CM “cold with deficiency” 
pattern, warming and tonifying methods should be adopted. In acupuncture practice, applying 
filiform needles or blood letting using three edge needle are used to treat CM heat pattern 
whereas filiform needling and moxibustion treatment are prescribed for CM “cold with 
deficiency” pattern 136(p3). Overall, CM heat pattern, with statistical significant improvement 
for two symptoms, performed slightly better than CM “cold with deficiency” pattern, with 
statistical significant improvement for one symptom, as assessed in CMPQ. Part of the reason 
may be the study protocol did not take the individualised treatment into consideration. In the 
EAOM trial, only EA was used without moxibustion. That is, the trial acupuncture protocol 
might be more appropriate for subjects with the CM heat pattern.  
Brinkhaus et al. identified five groups of CM patterns in LBP patients based on the individual 
doctor’s CM pattern identification 1108. They were 1) Bi syndrome patterns (24%), including Bi 
syndrome, cold, damp, heat, and wind patterns; 2) Qi and blood stagnation patterns (24%), 
including Qi and blood stagnation, blood stagnation, and Qi stagnation which also included CM 
liver Qi stagnation; 3) CM kidney deficiency patterns (34%), including general CM kidney 
deficiency, CM kidney Yang deficiency, CM kidney Yin deficiency, and CM kidney Qi 
deficiency; 4) CM liver and CM spleen Qi deficiency patterns (6%), including CM liver Qi 
deficiency, and CM spleen Qi deficiency; and 5) other diagnosis (11%). Such diverse CM 
patterns require different approaches to treat them according to CM principles. Their treatment 
results were published separately and involved comparing acupuncture, minimal acupuncture, 
and UC treatments 1109. Their acupuncture treatment was based on local and distal points 
without taking CM pattern identification into consideration. The trial acupuncturist could use 
additional ear points/trigger points/other points. Minimal acupuncture utilised different points 
and shallow needling. They found acupuncture was better than UC in improving pain and there 
was no significant difference between acupuncture and minimal acupuncture. Another 
acupuncture study by Cherkin et al. 1110 compared standardised acupuncture, individualised 
acupuncture, sham acupuncture, and UC. This study did not report the CM patterns of the 
participants. From both Brinkhaus’s and MacPherson’s studies (MacPherson’s study was 
formerly described in Chapter 7.4.2 CM patterns: heat and cold patterns (p. 254)) 1065,1108, it is 
clear the deficiency pattern and cold pattern exist in LBP. Cherkin had found no difference 
between standardised and individualised acupuncture and having any kind of acupuncture 
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treatment was better than UC. Neither Brinkhaus nor Cherkin mentioned the use of 
moxibustion. This may be the reason why there was no difference between acupuncture and 
minimal/sham acupuncture, and no difference between individualised and standard 
acupuncture treatment. An individually tailored treatment incorporating moxibustion or heat 
therapy when indicated may provide a better outcome for the individualised acupuncture 
treatment. Research in acupuncture clinical studies should focus on developing acupuncture 
treatments for CM heat pattern and CM cold pattern separately rather than a fixed acupuncture 
treatment protocol without incorporating moxibustion to enhance the acupuncture treatment 
outcome. 
9.6 Implications for future research 
Based on the current project, the following recommendations are made: 
1) Further research on CMPQ validation is recommended for there were changes 
associated with treatments not captured in other outcome measures. 
2) Conduct a larger study involving more varieties of CMP, focusing on CM heat pattern 
and CM cold with deficiency pattern participants with and without taking OM for their 
pain control are required to further evaluate the validity and reliability of CMPQ. 
3) It is also necessary to modify CMPQ to enable identification of the effects of treatment 
of these two CM patterns. Changing the dichotomous outcome format to likert scale in 
CMPQ will enable a better assessment of the changes in patients. This will help better 
understand the treatment effect on patients, and provide a scoring method for treatment 
effect comparison. The rarely selected items should be removed. Like other 
questionnaire developments, this is the first step in developing CMPQ. More 
adjustments and developments are needed before CMPQ can be used as an outcome 
measure in clinical trials.  
4) The patterns identified need to be considered when designing future acupuncture 
clinical trials. 
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9.7 Implications for clinical practice 
In clinical practice, it is proposed that CMP patients be assessed using a holistic approach in 
which the comorbidities and/or accompanying symptoms are assessed together. This may help 
in identifying whether patients have other major health problems. Patients should be informed 
of the comorbidities that are highly associated with their disorder, for instance, the high risk of 
comorbidities such as hypertension and heart attack in chronic SP/arthritis patients. 
Preventative measures/advice should be implemented to improve the overall wellbeing of 
patients. Routine screening/check-ups for those high-risk comorbidities should be conducted 
periodically for CMP patients. 
Currently this version of CMPQ still needs further research in order to ensure its criterion and 
construct validities and inter rater reliability. Further revision is also required to improve the 
content of CMPQ. It is not suitable as the sole means of patient case history collection and CM 
pattern identification. Instead, the revised version of CMPQ can be used by western medicine 
doctor to understand the multi-dimensionality of CMP symptom presentation, leading to a 
better understanding of a total picture of the patients, including pain and non-pain presentation. 
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Appendices 
Appendix 1 Description of different reviews on surgery for musculoskeletal pain 
Study Included 
studies 
Included 
participants 
Condition/disease Intervention Comparison 
group 
Follow up Conclusion Comment 
Tamaoki 
et al. 89 
3 174 Acromioclavicular 
dislocation of 
shoulder 
Fixation of 
acromioclavicular 
joint 
Arm support 
with a sling 
One year There is insufficient 
evidence to 
recommend surgery for 
acromioclavicular 
dislocation. 
There were 
fixation 
failures in 
the three 
trials. Two 
trials 
reporter 
surgery 
significantly 
delayed 
return to 
work. 
Verdugo 
et al. 85 
4 317 Carpal tunnel 
syndrome 
Surgery Splinting 3/6/12 
months 
Surgery is better than 
splinting for carpal 
tunnel syndrome 
Incidence of 
complication 
is 
significantly 
higher than 
splinting 
(RR: 1.38, 
95% CI 1.08 
- 1.76) 
Coghlan 
et al. 90 
14 829 Rotator cuff 
disease 
Open or 
arthroscopic 
subacromial 
decompression, 
arthroscopic 
decompression 
active non 
operative 
treatment 
(exercise 
programme, 
physiotherapy 
regimen of 
The follow 
up times 
were not 
unified and 
each trial 
was 
described 
Due to heterogeneity 
amongst trials, no firm 
conclusion is drawn on 
the effectiveness or 
safety of surgery for 
rotator cuff diseases. 
There is silver 
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Study Included 
studies 
Included 
participants 
Condition/disease Intervention Comparison 
group 
Follow up Conclusion Comment 
exercise and 
education, or 
graded 
physiotherapy 
strengthening 
program) 
by its 
defined 
follow up 
times. 
evidence* for no 
difference between 
open/arthroscopic 
subacromial 
decompression and 
active non-operative 
treatment for 
impingement and a 
silver evidence for no 
difference between 
arthroscopic and open 
subacromial 
decompression. 
Jacobs et 
al. 87 
16 1581 Sciatica due to disc 
herniation 
Open discectomy Other types of 
minimal 
invasive 
discectomy 
No defined 
follow up 
time in the 
SR. Each 
study has 
its own 
follow up 
time. 
The author concluded 
the effectiveness of 
open discectomy and 
other types of minimal 
invasive discectomy 
could not be confirmed 
when compared to each 
other due to the limited 
amount and quality 
evidence. 
 
Drazin et 
al. 86 
18 84 athletes 
and 279 
non-athletes 
Symptomatic 
spondylolysis 
Surgery No comparison 
group. 
Not 
described 
by all 
studies 
except for 
one who 
had a mean 
follow up 
Acceptable results are 
seen with the repair 
techniques. Ideal 
patients is less than 20 
years old with minimal 
or no listhesis and no 
degenerative changes 
of the disc. 
Limitation in 
sports is 
expected 
5-12 months 
after surgery. 
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Study Included 
studies 
Included 
participants 
Condition/disease Intervention Comparison 
group 
Follow up Conclusion Comment 
time of 
10.9 years.
Manchik
anti et al. 
88 
5 336 Disc protrusion and 
disc decompression
Nucleoplasty Observational 
studies with no 
comparison 
group 
Minimal 
12 months 
follow up 
was 
required.  
There is level II-3 
evidence (“evidence 
obtained from multiple 
time series with or 
without the 
intervention” 88.) for 
mechanical lumbar 
percutaneous disc 
decompression with 
nucleoplasty in 
treatment of leg pain. 
 
* Silver evidence indicated the included studies did not meet all the following four criteria:  
1.Sample sizes of at least 50 per group. If the studies did not find a statistically significant difference, the studies are adequately powered for a 20% 
relative difference in the relevant outcome.  
2. Blinding of patients and assessors for outcomes. 
3. Handling of withdrawals> 80% follow up (imputations based on methods such as Last Observation Carried Forward acceptable.)  
4. Concealment of allocation. 
Silver ranking would also include evidence from at least one study of nonrandomised cohorts who did or did not receive therapy or evidence 
from at least one high quality case-control study. A randomised trial with a “head to head” comparison of agents is considered silver ranking 
unless a reference is provided to a comparison of one of the agents to placebo showing at least a 20% relative difference (description extracted 
from Coghlan et al. 90). 
CI: Confidence interval 
SR: Systematic review
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Appendix 2 Reported complications of surgery 
Study Complications 
Tamaoki et al. 
89 
Surgery for acromioclavicular dislocation (n=27) 1111: coracoclavicular screw cut out of the clavicle (7.4%), and coracoclavicular 
screw broke (3.7%). 
 
Surgery for complete acromioclavicular separation (n=11) 1112: screw pull-out that occurred within 48 hours of surgery (13.3%). 
 
Phemister procedure (n=41) 1113: superficial infection (n=6) (14.6%), five of these being associated with migration of smooth 
Kirschner wires, wire breakage across the acromioclavicular joint (n=16) (39.0%) with 12 of them had errors in surgical 
technique (29.3%). 
Verdugo et al. 
85 
Carpal tunnel surgery (n=87) 1114: painful or hypertrophic scar (60.9%); stiffness of wrist, hand, or fingers (27.6%), skin irritation 
(21.8%), wound haematoma (11.5%), wound infection (5.7%); severe pillar pain (2.3%), and reflex sympathetic dystrophy 
(1.1%). 
 
Open carpal tunnel release surgery (n=25) 1115: mild to moderate wound pain (36%), wound haematomas (8%). 
Coghlan et al. 
90 
Open subacromial decompression (n=2) 1116: 5% Superficial wound infection. 
Arthroscopic acromioplasty (n=32) 1117: operative stiffness (12.5%) 
Arthroscopic (closed percutaneous) acromioplasty (n=23) 1118: pain (39.1%), capsulitis (21.7%), atrophy of the deltoid muscle 
(8.7%), deep wound infection (4.3%) 
 
Open acromioplasty (n=30) 1117: operative stiffness (10.0%) 
Open acromioplasty (n=23) 1118: pain (39.1%). 
 
Open rotator cuff repair using non-absorbable braided No. 3 Ethibond (0.7 mm diameter) and a modified Mason Allen technique) 
(n=50) 1119: pain (4%), infection (4%). 
Open rotator cuff repair using 1.0 mm absorbable braided PDS cord and a modified Kessler technique (n=50) 1119: pain (4%), 
infection (2%). 
 
Open anterior acromioplasty using either Neer’s technique or a modified technique not detaching the deltoid origin (n=10 in 
either group) 1120: delayed wound healing (5%). 
Jacobs et al. 87 No/limited reporting of complication. The SR itself did not find reporting of complications. 
Drazin et al. 86 Repair of Pars Interarticularis Defect by Segmental Wire Fixation (n=20) 1121: wire breakage (10%), wire pulled out on one side 
(5%). 
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Study Complications 
Direct repair of spondylolytic defects (n=4) 1122: unilateral screw breakage (25%), residual complaints of persistent, intermittent 
low back soreness (25%). 
 
Repair of the pars Interarticularis Defect with a cable-screw construct (n=7) 1123: Prolonged bone graft site pain (14.3%) 1123, 
fracture of a cable after an altercation with another boy (14.3%).  
 
Buck’s repair of the spondylolytic lesion (n=10) 1124: Operative drill breakage (10%). 
 
Scott’s fusion (n=3) 1125: non-union (66%) 
 
Direct repair with a hook screw 1126 (n=113): pseudoarthroses (13.3%), loosening of nuts (6.2%), wound sloughing (5.3%). 
 
Scott wiring technique (n=22) 1127: urinary retention (9.1%), superficial wound infection (9.1%), wire rupture (9.1%), donor site 
pain (13.6%) 
Manchikanti et 
al. 88 
Percutaneous disc decompression using coblation technology (n=53) 1128: increased symptom (3.8%), soreness at needled site 
(76% within 24 hours and 0% at two week follow up), new numbness and tingling sensation (26% within 24 hours and 15% at two 
week follow up), increased intensity of pre-procedural back pain (15% within 24 hours, and 4% at two week follow up), new area 
of back pain (15% within 24 hours and 0% at two week follow up). 
SR: Systematic review 
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Appendix 3 NOS assessment of the included comorbidities of CMP studies – case controlled studies (total 68 studies) 
Selection Comparability Exposure 
Study 
Is the case 
definition 
adequate
Representativeness 
of the cases 
Selection 
of 
controls 
Definition 
of 
controls 
Comparability of 
cases and 
controls on the 
basis of the 
design or 
analysis 
Ascertainment 
of exposure 
Same method 
of 
ascertainment 
for cases and 
controls 
Non-response 
rate 
Aguglia et al. 214 0 1 0 0 0 0 1 1 
Aristeguieta et 
al. 215 0 0 0 0 0 0 1 1 
Arnold et al. 216 0 0 1 0 0 0 1 1 
Atkinson et al. 
175 0 0 0 1 0 0 1 1 
Asmundson et 
al. 174 0 0 0 0 0 1 1 1 
Ayers et al. 237 0 1 ncp ncp ncp ncg ncp 0 
Ayoubi et al. 238 0 1 1 1 0 0 1 0 
Bair et al. 183 0 1 0 1 0 1 1 1 
Baruth et al. 239 0 0 ncg ncg ncg ncg ncg ncg 
Bazzichi et al.241 0 0 1 1 0 0 1 0 
Bernatsky et al. 
184 0 0 0 0 0 0 0 0 
Bischoff-Ferrari 
et al. 181 1 1 ncg ncg ncg ncg ncg ncg 
Black, Goodwin, 
& Markides, 185 0 1 0 1 0 0 1 0 
Blackman et al. 
2013 234 0 1 0 1 2 0 1 0 
Blackman et al. 
2011 217 0 1 0 1 0 0 1 nsg 
Braden et al. 186 0 1 0 0 2 0 1 nsg 
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Selection Comparability Exposure 
Study 
Is the case 
definition 
adequate
Representativeness 
of the cases 
Selection 
of 
controls 
Definition 
of 
controls 
Comparability of 
cases and 
controls on the 
basis of the 
design or 
analysis 
Ascertainment 
of exposure 
Same method 
of 
ascertainment 
for cases and 
controls 
Non-response 
rate 
Buist-Bouwman 
et al. 187 0 1 0 1 2 0 1 nsg 
Cakit et al. 188 0 1 0 0 0 0 1 1 
Carbonell-Baeza 
et al. 218 0 0 0 0 0 0 ncg ncg 
Ciapparelli et al. 
189 0 0 0 0 0 0 ncg ncg 
Dominick et al. 
231 0 1 0 1 2 0 1 nsg 
Fernandez-de-L
as-Penas et al. 
190 
0 1 1 1 0 0 1 0 
Fitzgerald et al. 
219 1 1 0 0 0 0 ncg 0 
Gili et al. 191 0 0 0 0 2 0 1 0 
Gureje et al. 192 0 1 0 1 0 0 1 nsg 
Hägg et al. 193 0 0 1 1 0 0 1 1 
Hoogeboom et 
al. 220 1 1 0 0 0 0 ncg nsg 
Ijzelenberg et al. 
168 0 0 0 ncg 0 0 1 nsg 
Ismail et al. 242 0 0 1 1 0 0 1 0 
Kane et al. 221 0 0 0 ncg ncg 0 ncg 0 
Kauppila et al. 1 1 ncg ncg 0 1 ncg nsg 
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Selection Comparability Exposure 
Study 
Is the case 
definition 
adequate
Representativeness 
of the cases 
Selection 
of 
controls 
Definition 
of 
controls 
Comparability of 
cases and 
controls on the 
basis of the 
design or 
analysis 
Ascertainment 
of exposure 
Same method 
of 
ascertainment 
for cases and 
controls 
Non-response 
rate 
194 
Klemenc-Ketiš 
et al. 222 0 1 ncg ncg 0 0 ncg nsg 
Korszun et al. 195 1 0 ncg ncg ncg 1 ncg 0 
Kurtze et al. 196 0 1 ncg ncg 0 0 ncg nsg 
Lee et al. 2012 
223 0 0 ncg ncg 0 0 ncg 0 
Lee et al. 2007 
166 0 1 ncg ncg 0 0 ncg nsg 
Ligthart et al. 240 0 1 ncg ncg ncg ncg ncg ncg 
Linder et al. 197 1 0 ncg ncg 0 0 ncg 0 
Mäkelä et al. 198 0 0 ncg ncg 0 0 ncg 0 
Malmgren 
Olsson et al. 199 0 0 0 1 0 0 1 0 
Mangani et al. 
200 1 0 ncg ncg 0 0 ncg 0 
L. A. 
McWilliams, 
Cox, & Enns, 
2003 176 
0 0 1 0 2 0 1 nsg 
L. A. 
McWilliams, 
Goodwin, & 
Cox, 2004 177 
0 0 1 1 2 0 1 nsg 
Lachlan A. 
McWilliams & 0 0 1 0 2 0 1 nsg 
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Selection Comparability Exposure 
Study 
Is the case 
definition 
adequate
Representativeness 
of the cases 
Selection 
of 
controls 
Definition 
of 
controls 
Comparability of 
cases and 
controls on the 
basis of the 
design or 
analysis 
Ascertainment 
of exposure 
Same method 
of 
ascertainment 
for cases and 
controls 
Non-response 
rate 
Bailey, 2010 232 
L. A. 
McWilliams & 
Higgins, 2013 
224 
0 0 ncg ncg ncg 0 ncg 0 
Nilsdotter et al. 
180 1 1 0 1 0 0 1 0 
Polatin et al. 178 0 0 ncg ncg ncg 0 ncg 0 
Raab et al. 235 1 0 0 0 ncg 1 0 0 
Rat et al. 236 1 1 ncp ncp ncg ncg ncg ncg 
Rehm et al. 225 0 0 ncg ncg ncg 0 ncg 0 
Sareen et al. 202 0 0 0 1 2 0 1 nsg 
Schofield et al. 
233 0 0 1 1 0 0 1 nsg 
Schur et al. 203 0 0 1 1 2 0 1 0 
Shillam et al. 226 1 0 ncg ncg ncg 0 ncg nsg 
Sipilä et al. 204 0 0 ncg ncg ncg 0 ncg nsg 
Siu et al. 229 0 0 ncg ncg ncg 0 ncg 0 
Stupar et al. 179 0 0 ncg ncg ncg 0 ncg 0 
Tamber et al. 213 0 0 0 1 2 0 1 nsg 
Tashjian et al. 205 1 0 0 0 0 0 ncg 0 
Tikiz et al. 182 0 0 0 1 0 0 0 0 
Tsang et al. 206 0 0 0 1 2 0 1 nsg 
van Dijk et al. 207 1 0 0 0 ncg 0 ncg 0 
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Selection Comparability Exposure 
Study 
Is the case 
definition 
adequate
Representativeness 
of the cases 
Selection 
of 
controls 
Definition 
of 
controls 
Comparability of 
cases and 
controls on the 
basis of the 
design or 
analysis 
Ascertainment 
of exposure 
Same method 
of 
ascertainment 
for cases and 
controls 
Non-response 
rate 
Verri et al. 208 0 0 0 0 ncg 0 1 1 
Von Korff et al. 
167 0 1 0 1 0 0 1 nsg 
Wesseling et al. 
230 1 0 0 ncg ncg 0 ncg 0 
Whitson et al. 209 1 0 0 0 ncg 0 1 0 
Williams Russo 
et al. 212 1 1 ncg ncg ncg 1 ncg 0 
Wolf et al. 211  1 0 0 ncg ncg 0 ncg 0 
Ncg: no control group 
Nsg: no separated into groups 
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Appendix 4 NOS assessment of the included comorbidities of CMP studies – cohort studies (total 4 studies) 
Selection Comparability Outcome 
Study 
Representativeness 
of the exposed 
cohort 
Selection 
of the 
non 
exposed 
cohort 
Ascertainment 
of exposure 
Demonstration 
that outcome of 
interest was not 
present at start of 
study 
Comparability 
of cohorts on 
the basis of the 
design of 
analysis 
Assessment 
of outcome
Was 
follow-up 
long enough 
for outcomes 
to occur 
Adequacy of 
follow up of 
cohorts 
Raphael et 
al. 201 1 ncg 1 0 ncg 0 1 0 
Singh et 
al. (hip 
OA) 227 
1 ncg 1 0 ncg 0 1 0 
Singh et 
al. (knee 
OA) 228 
1 0 1 0 0 0 1 nsg 
Wolfe et 
al. 210  1 ncg 1 0 ncg 0 1 0 
Ncg: no control group 
Nsg: no separated into groups 
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Appendix 5 Mental and behavioural disorders as comorbidity or accompanying symptoms of chronic SP – percentage data within sample - 1 
Studies 
Major depression/depression 
Dysthymic 
disorder GAD 
All 
anxiety 
disorders 
Obsessive 
compulsive 
disorder 
Panic 
disorder 
Alcohol use 
disorder 
Abuse or 
dependence on 
other substances 
Atkinson 
et al. 175 Life time prevalence of major 
depressive episode: 32% 
 
Diagnosed with a major depressive 
episode:21.6% 
 
Episodes of depression during the 
last six months :  
Almost all back pain patients have 
recurrent major depression (exact 
number not given.) 
Single episode: 1 (3.2%)  
Two episodes: 4 (12.9%)  
Three episodes: 9 (29%) 
Four episodes: 2 (6.5%) 
Five or more episodes: 15 (48.4%) 
 
Onset of depression before pain: 
41.9% 
onset after age of pain initiation was 
58.1% 
Prevalence: 
23.7% 
Lifetime 
rates: 
22.7%.  
6 month 
prevalence: 
13.4% 
All 
anxiety 
disorders 
pooled 
together: 
21.6% 
Lifetime 
rates: 13.4%
Lifetime 
rates: 8.2% 
Prevalence 
rate: 7.2% 
Lifetime 
prevalence: 
64.9% 
 
Prevalence rate: 
12.4% 
 
The proportions 
developing their 
illness before 
and after age of 
pain onset:  
before pain 
onset: 80.9%  
after pain onset: 
19.1%  
 
History of onset 
of alcohol use 
disorders was 
not changed by 
chronic pain. 
The use of cannabis: 
11.3%  
The prevalence for 
other substance 
abuse or dependence 
disorders: 4.1% 
Hägg et al. 
193 
Major depression (diagnosed with 
Zung Depression Scale): 9% No data 
Polatin et 
al. 178 
Life time major depression (as 
assessed with Structured clinical 
interview for DSM-III-R): 64% 
Life time 
dysthymia: 
2% 
Life time 
GAD: 2% 
Life time 
Anxiety 
disorders: 
19% 
Obsessive 
compulsive 
disorders: 
2% 
Panic 
disorders: 
3% No data 
Substance 
abuse:36% 
psychoactive 
substance use 
disorders: 36% 
Verri et al. Major depression disorder (single Dysthymia: GAD: 23 No data Obsessive Panic No data 
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Studies 
Major depression/depression 
Dysthymic 
disorder GAD 
All 
anxiety 
disorders 
Obsessive 
compulsive 
disorder 
Panic 
disorder 
Alcohol use 
disorder 
Abuse or 
dependence on 
other substances 
208 episode in progress): 2 (5.7%) 
 
Major depression disorder (in full 
remission): 4 (11.4%) 
 
Recurrent major depression disorder: 
1 (2.8%) 
7 (20%) (65.7%) compulsive 
disorder: 0 
disorder: 1 
(2.8%) 
Von Korff 
et al. 167 
 
 
Compared with general public without chronic SP: 
Major depression: 12.6% (SE:0.7) 
Dysthymia: 
5.6% 
(SE:0.6) 
GAD: 6.4% 
(SE:0.7) 
Any 
anxiety: 
26.5% 
(SE:1.2) No data 
Panic 
disorder: 
4.8% 
(SE:0.5) 
Alcohol abuse or 
dependence: 
4.0% (SE:0.6) 
Alcohol 
dependence: 
2.1% (SE:0.4) 
Any substance: 4.8% 
(SE:0.8) 
 
Mental disorders not 
associated with 
chronic SP are: drug 
abuse or 
dependence, drug 
dependence. 
Whitson et 
al. 209 
For vertebral fracture group, there are 
211 participants and the percentage of 
accompanying symptoms and 
comorbidities are as following: 
 
Symptoms in previous month: feeling 
sad, depressed, or blue: 33.2% 
depression or anxiety: 21.8% No data 
Symptoms 
in 
previous 
month: 
anxiety, 
worry, or 
tension: 
45.7% 
depression 
or anxiety: 
21.8% No data 
Schofield 
et al. 233 
Depression/mood affective disorders: 
5.4% No data 
Linder et Depression episode: 26.1% No data 
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Studies 
Major depression/depression 
Dysthymic 
disorder GAD 
All 
anxiety 
disorders 
Obsessive 
compulsive 
disorder 
Panic 
disorder 
Alcohol use 
disorder 
Abuse or 
dependence on 
other substances 
al. 197  
Recurrent depression: 24.4% 
GAD: Generalized anxiety disorder 
SE: Standard error 
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Appendix 6 Mental and behavioural disorders as comorbidity or accompanying symptoms of chronic SP – percentage data within sample - 2 
Studies Mood 
disorder Phobia 
Somatoform 
disorder Bipolar PTSD Other 
Atkinson 
et al. 175 
No data At least one psychiatric 
disorder (other than tobacco 
use disorder): 81.4% 
A psychiatric disorder 
occurred recently in pain 
patients: (41.2%) 
Polatin et 
al. 178 
No data 
Phobic disorders: 
(11%) 
Somatoform pain 
disorder: (97%) 
Somatization: (1%) 
Hypochondriasis: 
(1%) 
Bipolar: (2%) PTSD: (1%) 
Psychotic disorders: (3%),  
others Axis I disorders: (3%) 
 
The percentage of each Axis 
II disorder is listed as the 
following:  
Paranoid PD: (33%) 
Schizoid PD: (4%) 
Schizotypal PD: (4%) 
Passive-aggressive PD: 
(12%) 
Self-defeating PD: (10%) 
Dependent PD: (3%) 
Obsessive compulsive PD: 
(6%) 
Avoidant PD: (14%) 
Histrionic PD: (4%) 
Narcissistic PD: (5%) 
Antisocial PD: (5%) 
Borderline PD: (15%) 
Not otherwise specified PD: 
(2%) 
Schofield 
et al. 233 No data 
Mental/behavioural 
disorders: 10.2% 
Verri et al. No data Simple phobia: 9 Somatoform No data Other classes of diagnosis: 2 
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Studies Mood 
disorder Phobia 
Somatoform 
disorder Bipolar PTSD Other 
208 (25.7%) 
Social phobia: 0 
disorders: 12 (34.3%) (5.7%) 
No axis I disorders: 6 
(17.1%) 
Von Korff 
et al. 167 
Any mood: 
17.5% 
(SE:1.1) 
Social phobia: 8.3% 
(SE:0.8) 
Specific phobia: 
12.5% (SE:1.0) 
 
Mental disorders not 
associated with 
chronic SP are: 
agoraphobia without 
panic  
No data 
Bipolar I or II: 4.4% 
(SE:0.6) 
PTSD: 7.3% 
(SE:0.7) 
All mental disorders: 35.0% 
(SE:1.7) 
PTSD: Post traumatic stress disorder 
PD: Psychotic disorder 
SE: Standard error 
SP: Spinal pain 
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Appendix 7 Mental and behavioural disorders as comorbidity or accompanying symptoms of chronic SP – OR - 1 
Studies 
Major 
depression/depression
Dysthymic 
disorder GAD 
All anxiety 
disorders 
Panic 
disorder  
Alcohol use 
disorder 
Abuse or 
dependence 
on other 
substances 
Buist-Bouwman 
et al. 
187 
Compared with general public without chronic SP: 
No data 
Anxiety disorder: 
1.6 (1.3-2.0) No data 
Substance use: 
1.3 (0.9-1.8). 
Gureje et al. 192 Compared with general public without chronic SP: 
No data 
Any anxiety 
disorder: 1.5 
(0.9-2.5) No data 
Any substance 
disorder: 3.2 
(1.2-8.0) 
Hägg et al. 193 Compared with general 
public without back 
pain: 
 
Major depression: 6.2 
(1.9–20.6) No data 
McWilliam et al. 
2004 177 
Compared with general public without chronic SP: 
Depression: 1.87 
(1.49-2.36) No data 
GAD: 2.54 
(1.67-3.85) No data 
Panic 
attacks: 2.69 
(2.00-3.62) No data 
Tsang et al. 206 Compared to international general public without chronic SP: 
Depression-anxiety 
disorder: 2.0 (1.8-2.1). No data 
Depression-anxiety 
disorder: 2.0 
(1.8-2.1). No data 
Von Korff et al. 
167 
Compared with general public without chronic SP: 
Major depression: 2.5 
(2.0-3.1) 
Dysthymia: 3.2 
(2.3-4.5) 
GAD: 2.6 
(2.0-3.5) 
Any anxiety: 2.3 
(1.9-2.7) 
Panic 
disorder: 2.0 
(1.5-2.6) 
Alcohol 
abuse or 
dependence: 
1.6 (1.2-2.2) 
Any substance: 
1.6 (1.2-2.2) 
 
Mental 
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Studies 
Major 
depression/depression
Dysthymic 
disorder GAD 
All anxiety 
disorders 
Panic 
disorder  
Alcohol use 
disorder 
Abuse or 
dependence 
on other 
substances 
Alcohol 
dependence: 
2.0 (1.4-2.9) 
disorders not 
associated with 
chronic SP are: 
drug abuse or 
dependence, 
drug 
dependence. 
GAD: Generalized anxiety disorder 
SP: Spinal pain 
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Appendix 8 Mental and behavioural disorders as comorbidity or accompanying symptoms of chronic SP – OR - 2 
Studies Suicidal ideation, 
suicide plan, and 
suicide attempt 
Mood 
disorder Phobia Bipolar PTSD  Other 
Braden et al. 186 Compared with general public without chronic SP: 
Suicidal ideation: 1.4 
(1.2-1.6)(P<0.001) 
Suicide plan: 1.5 
(1.1-1.9)(P<0.01) 
Suicide attempt: 1.6 
(1.3-2.1)(P<0.001)  No data 
Buist-Bouwman et 
al. 
187 
Compared with general public without chronic SP: 
No data 
Mood 
disorder: 1.7 
(1.3-2.2) No data 
Gureje et al. 192 Compared with general public without chronic SP: 
No data 
Any mood 
disorder: 2.2 
(1.2-4.0) 
Any mental 
disorders: 1.7 
(1.2-2.5) No data 
Von Korff et al. 167 Compared with general public without chronic SP: 
No data 
Any mood: 
2.5 (1.9-3.2) 
Social phobia: 1.7 
(1.3-2.2) 
Specific phobia: 2.1 
(1.7-2.6) 
 
Mental disorders not 
associated with 
chronic SP are: 
agoraphobia without 
panic 
Bipolar I or 
II: 2.0 
(1.4-2.9) 
PTSD: 
2.6 
(2.1-3.3) 
All mental disorders: 2.3 
(1.8-2.9) 
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Studies Suicidal ideation, 
suicide plan, and 
suicide attempt 
Mood 
disorder Phobia Bipolar PTSD  Other 
Lachlan A. 
McWilliams & 
Bailey et al. 232 
No data 
Compared with general 
public without chronic SP: 
 
Attachment style ratings (OR 
adjusted for gender, marital 
status, education level, race, 
age, and the other attachment 
style ratings): 
Secure: 0.91 (0.84–0.98) 
Avoidant: 1.16 (1.08–1.25) 
Anxious: 1.08 (0.98–1.19) 
Comorbidities/accompanying symptoms of no association were italicised 
PTSD: Post traumatic stress disorder 
SP: Spinal pain 
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Appendix 9 Mental and behavioural disorders/symptoms as comorbidity/accompanying 
symptoms of arthritis 
Studies Percentage of 
comorbidity/accompanying 
symptoms 
OR and 95% CI 
Lee et al. 166 Beijing participants (percentage and 
SE): 
Mood disorder: 
Major depressive disorder with 
hierarchy: 3.9% (SE: 1.8) 
 Dysthymia: 1.1% (SE: 0.5) 
 Any mood: 3.9% (SE: 1.8) 
Anxiety disorders: 
GAD: 2.3% (SE: 0.5) 
 Panic disorder: 0.4% (SE: 0.4) 
 Agoraphobia without panic: 0 
 PTSD: 0 
 Social phobia: 0 
 Specific phobia: 3.5% (SE: 2.3) 
 Any anxiety: 5.3% (SE: 2.3) 
Substance disorder: 
 Alcohol abuse or dependence: 4.3% 
(SE: 0.9) 
 Alcohol dependence: 1.7% (SE: 1.5) 
 Drug abuse or dependence: 0.2% (SE: 
0.0) 
 Drug dependence: 0 
 Any substance: 4.5% (SE: 0.9) 
Any mental disorder: 10.5% (SE: 3.1) 
Compared with general public 
without arthritis: 
 
Beijing:  
Dysthymia: 4.0 (1.1-14.4) 
GAD: 2.4 (1.3-4.5). 
 
Non-significant: 
Major depression disorder with 
hierarchy: 1.8 (0.5-6.6) 
Any mood disorder: 1.7 
(0.5-6.2) 
Panic disorder: 1.0 (0.1-10.1) 
Specific phobia: 2.3 (0.5-10.5) 
Any anxiety: 1.8 (0.7-4.5) 
Alcohol abuse or dependence: 
1.9 (0.9-4.1) 
Alcohol dependence: 2.4 
(0.4-15.9) 
Drug abuse or dependence: 2.6 
(0.2-42.7) 
Any substance: 1.9 (0.9-4.0) 
All mental disorders: 1.6 
(0.8-3.1) 
Shanghai participants: 
Mood disorder: 
 Major depression disorder with 
hierarchy: 5.7% ( SE: 3.6) 
 Dysthymia: 0.3% (SE: 0.3) 
 Any mood: 5.7% (SE: 3.6) 
Anxiety disorders: 
 GAD: 3.6% (SE: 3.5) 
 Panic disorder: 0 
 Agoraphobia without panic: 0 
 PTSD: 0.8% (SE: 0.6) 
 Social phobia: 0 
 Specific phobia: 7.5% (SE: 4.2) 
 Any anxiety: 7.9% (SE: 4.2) 
Substance disorder: 
 Alcohol abuse or dependence: 0.5% 
(SE: 0.4) 
 Alcohol dependence: 0.5% (SE: 0.4) 
 Drug abuse or dependence: 0 
 Drug dependence: 0 
 Any substance: 0.5% (SE: 0.4) 
Any mental disorder: 10.0% (SE: 4.3) 
Shanghai:  
Major depression disorder with 
hierarchy: 8.0 (1.7-38.4) 
Any mood disorder: 5.7 
(1.3-26.1) 
GAD: 15.4 (2.9-83.3) 
Specific phobia: 6.9 (1.3-37.0) 
Any anxiety: 5.9 (1.3-25.9) 
Any mental disorder: 3.7 
(1.2-11.4) 
 
Non-significance:  
Dysthymia: 0.8 (0.1-8.0) 
Alcohol abuse or dependence: 
1.0 (0.2-5.6) 
Alcohol dependence: 1.9 
(0.3-13.2) 
Any substance disorder: 1.0 
(0.2-5.4) 
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Studies Percentage of 
comorbidity/accompanying 
symptoms 
OR and 95% CI 
Van Dijk et al. 207 Psychiatric diseases: 26.3% 
No data 
Wolfe et al. 210 The cross-sectional prevalence of 
self-reported depression: 15.2% (95% 
CI 14.7-15.7%).  
 
The annualized incidence (new case 
after entry to study) rate for 
self-reported depression: 5.5 (95% CI 
5.3-5.7) per 100 patient years.  
 
The estimated cumulative risk of 
self-reported depression at 9 years 
follow up: 38.3% (95% CI 36.6-40.1%)
Black et al. 185 
No data 
Compared with general public 
without arthritis: 
 
Depressive symptoms:1.87 
(1.58-2.22) 
Braden et al. 186 Compared with general public 
without arthritis: 
 
After adjusted for 
sociodemographic factor (age, 
gender, race/ancestry, marital 
status, education status, religion, 
log-transformed income: 
 
Suicidal ideation: 1.7 (1.4-2.1) 
Suicidal plan: 2.0 (1.5-2.6) 
Suicide attempt: 1.4 (95% CI 
1.0-1.8) 
 
But if they were adjusted further 
with lifetime mood or anxiety 
disorder, lifetime alcohol or 
drug abuse/dependence, then 
OR did not show significant 
difference.  
Sareen et al. 202 Compared with general public 
without arthritis: 
 
After adjusting for age, gender, 
low income, education, 
past-year mental disorders 
(major depression, dysthymia, 
bipolar disorder, alcohol use 
disorder and substance use 
disorder): 
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Studies Percentage of 
comorbidity/accompanying 
symptoms 
OR and 95% CI 
Any past-year anxiety disorder: 
2.28 (1.58-3.29). 
 
After adjusted for any bone or 
joint condition versus without 
bone or joint condition: 
PTSD: 2.52 (1.67-3.81),  
Panic attacks: 2.00 (1.22-3.28). 
 
But there is no significant 
difference for agoraphobia 
without panic [2.23 (0.97–
5.11)], GAD [1.13 (0.60–2.13)], 
social phobia [0.96 (0.66–
1.39)], and simple phobia [1.22 
(0.78–1.93) for any bone or joint 
condition versus without bone 
or joint condition. 
Tsang et al. 206 Compared to international 
general public without arthritis:
 
Depression-anxiety disorder: 
1.6 (1.4-1.7) 
McWilliams et 
al. 2004 177  
Compared with general public 
without arthritis: 
 
Depression: 1.48 (1.16-1.88) 
Panic attacks: 2.09 (1.54-2.83) 
GAD: 2.17 (1.42-3.33) 
McWilliams et 
al. 2003 176 
Compared with general public 
without arthritis: 
 
Any mood disorder: 2.78 
(2.06-3.75) 
Depression: 2.82 (2.05-3.89) 
Dysthymia: 2.07 (1.26-3.42) 
Any anxiety disorder: 2.86 
(2.06-3.97) 
GAD: 2.30 (1.45-3.67) 
Panic disorder with or without 
agoraphobia: 4.27 (2.39-7.61) 
Simple phobia: 2.20 (1.43-3.38)
Social phobia: 1.92 (1.31-2.82) 
Agoraphobia with or without 
panic: 3.19 (1.87-5.46) 
Post-traumatic stress disorder: 
3.69 (2.40-5.68) 
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Studies Percentage of 
comorbidity/accompanying 
symptoms 
OR and 95% CI 
Buist-Bouwman 
et al. 187 
Mental disorder: 28.1% 
Compared with general public 
without rheumatism: 
 
Anxiety disorder is 1.4 (1.1-1.8)
Mood disorder is 1.5 (1.1-2.0)  
Substance use is 1.8 (1.3-2.6) 
Williams Russo 
et al. 212 
 
Psychiatric disease and/or Geriatric 
Depression Scale (GDS) > 11: 4 (7.84%) 
(for these four patients, one was for 
mania-depression and on medication, 
one was for depression and on 
medication, the other two were for 
probable depression as GDS>11). 
No data 
Blackman et al. 
2011 217 
For arthritis/other joint problems, 25.9% 
(95% CI 20.0-32.0) of them have 
long-term emotional, developmental or 
behavioural problem, and 22.1% (95% 
CI 16.2-29.3) of them have 
ADD/ADHD. 
 
Of the arthritic/other joint problems 
children, 26.0% (95% CI 19.8-33.4) 
have difficulties in learning, 
understanding or paying attention, 
12.5% (95% CI 8.5-18.0) of them have 
difficulties in speaking, communicating 
or being understood, 33.4% (95% CI 
26.5-41.3) of them have difficulty with 
feeling anxious or depressed, 27.1% 
(95% CI 20.6-34.8) of them have 
difficulty with behaviour problems, such 
as acting out, fighting, bullying or 
arguing. 
Fitzgerald et al. 
219 
The prevalence listed below are the 
combined results of both groups 
(“standard exercise” group and “agility 
and perturbation” group): 
 
Depression: 32 (17.5%) 
Memory problems: 15 (8.2%) 
Hoogeboom et 
al. 220 
For knee and/or hip OA (n=401):  
Depressed (Hospital Anxiety and 
Depression Scale ≥ 8): 99 (24%)  
Klemenc-Ketiš 
et al. 222 
Depression: 23 (20.6%) 
Anxiety: 25 (22.3%) 
Compared to GP-visiting 
general public without 
osteoarthritis and rheumatic 
diseases: 
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Studies Percentage of 
comorbidity/accompanying 
symptoms 
OR and 95% CI 
The OR for 
osteoarthritis/rheumatic 
diseases patients to have 
depression based on Zung 
depression score≥50 was 1.23 
(95% CI 0.62-2.41) and to have 
anxiety based on Zung anxiety 
score ≥50 was 2.59 (95% CI 
1.29-5.20). 
L. A. 
McWilliams & 
Higgins et al. 224 
Borderline personality disorder 
symptoms during the past year: 1553 
(27.3%) 
No data 
Singh et al. (knee 
OA) 228 
Primary total knee arthroplasty: 
Two year follow up: 
Anxiety: 6% 
Depression: 11% 
 
Five year follow up:  
Anxiety: 5% 
Depression: 8% 
 
Revision total knee arthroplasty: 
Two year follow up:  
Anxiety: 5% 
Depression: 8% 
 
Five year follow up:  
Anxiety: 3% 
Depression: 6% 
Lachlan A. 
McWilliams & 
Bailey et al. 232 
No data 
Compared with general public 
without arthritis: 
 
Attachment style ratings (OR 
adjusted for gender, marital 
status, education level, race, 
age, and the other attachment 
style ratings): 
Secure: 0.94 (0.85–1.03) 
Avoidant: 1.15 (1.04–1.28) 
Anxious: 1.07 (0.93–1.23) 
Blackman et al. 
2013 234 
Of the chronic bone, joint, muscle 
problem children, their prevalence (SE) 
for the following conditions were: 
ADHD: 29% (3.4) 
Depression: 20.9% (3.4) 
Anxiety: 20.3% (2.9) 
Learning disability: 38% (3.3) 
Behaviour problem at least 12 months: 
Compared with general public 
without arthritis (participants 
were all children): 
 
Of the chronic bone, joint, 
muscle problem children, their 
ORs for the following 
conditions were: 
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Studies Percentage of 
comorbidity/accompanying 
symptoms 
OR and 95% CI 
27.1% (2.5) 
 
Of the chronic bone, joint, muscle 
problem children, their prevalence (SE) 
for the following emotional and 
behavioural problems: 
Emotional functioning: 
 Feels worthless or inferior:10.8% (2.9)
 Is unhappy, sad, or depressed: 10.8% 
(2.9) 
ADHD: 3.3 (2.2-4.9) 
Depression: 5.1 (3.2-8.2) 
Anxiety: 4.1 (2.7-6.1) 
Learning disability: 4.7 
(3.3-6.5) 
Behaviour problem at least 12 
months: 4.2 (3.2-5.6) 
Raab et al. 235 Psychiatric disorders: 32 (9.3%) 
 Depression: 17 (4.9%) 
 Anxiety disorder: 7 (2%) 
No data 
Nilsdotter et al. 
2003 180 Psychiatric disease: 2.6% 
Comorbidities/accompanying symptoms of no association were italicised 
ADHD: Attention deficit hyperactive disorder 
CI: Confidence interval 
GAD: Generalized anxiety disorder 
GP: General practitioner 
OA: Osteoarthritis 
OR: Odds ratio 
PTSD: Post traumatic stress disorder 
SE: Standard error 
 
Appendix 10 Diseases/symptoms of the genitourinary system as comorbidity or accompanying 
symptoms of chronic SP 
Studies Percentage of comorbidity/accompanying 
symptoms 
OR and 95% CI 
Whitson et al. 
209 Incontinence: 35.6% 
No data 
Schofield et al. 
233 Genitourinary system diseases: 2% 
Hägg et al. 193 
No data 
Compared with general 
public without back pain  
 
Back pain during 
pregnancy: 2.3 (1.1-4.5) 
Back pain during 
menstruation: 2.7 (1.5-5.1), 
Increased number of 
deliveries: 1.6 (1.1-2.1) 
CI: Confidence interval 
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Appendix 11 Other comorbidities/accompanying symptoms or findings of chronic SP 
Studies Percentage of 
comorbidity/accompanying symptoms
OR and 95% CI 
Hägg et al. 193 
Smoking: 42% 
general morbidity: 35% 
Compared with general public 
without back pain: 
Smoking: 2.3 (1.6 - 3.6) 
General morbidity: 3.6 (2.2 - 5.9) 
 
Compared with general public 
with non-chronic back pain: 
Smoking:1.6 (1.0 - 2.6) 
General morbidity: 1.0 (0.6 – 2.2)
Von Korff et 
al. 167 
HIV: 0.3% (SE:0.1) 
Cancer: 0.8% (SE:0.4) 
Any physical disease: 55.3% (SE:1.8) 
All mental, pain or physical disorder: 
87.1% (SE:1.1) 
Compared with general public 
without chronic SP: 
HIV: 5.0 (1.9-13.0) 
Any physical disease: 2.0 (1.7-2.4)
All mental, pain or physical 
disorder: 4.4 (3.5-5.6) 
Cancer: 0.8 (0.3-2.1) 
Whitson et al. 
209 
Dizziness or lightheaded: 20.9% 
Cancer: 26.1% 
Amputation: 0.5% 
No data 
Schofield et 
al. 233 
Injury/accident: 14.0% 
Neoplasms (tumours/cancers): 0.3% 
Other: 7.8% 
Comorbidities/accompanying symptoms of no association were italicised 
CI: Confidence interval 
SE: Standard error 
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Appendix 12 Diseases/symptoms of the genitourinary system as comorbidity or accompanying 
symptoms of arthritis 
Studies Percentage of comorbidity/accompanying symptoms OR and 95% 
CI 
Van Dijk et 
al. 207 
Urogenital disease: 44.4% 
Renal disease: 11.2% 
No data 
Mangani et 
al. 200 
Of the entire group, the prevalence of comorbidities are as 
following: 
Renal disease: 2.8% 
Fitzgerald 
et al. 219 
The prevalence listed below are the combined results of both 
groups (“standard exercise” group and “agility and 
perturbation” group): 
Kidney disease: 2 (1.1%) 
Hoogeboom 
et al. 220 
 
For hip and/or knee OA (n=401): 
Kidney/liver disease: 4 (1%) 
Singh et al. 
(hip OA) 227 
Primary total hip arthroplasty: 
Two year follow up: 
Renal disease: 5% 
 
Five year follow up:  
Renal disease: 4% 
 
Revision total hip arthroplasty: 
Two year follow up:  
Renal disease: 4% 
 
Five year follow up:  
Renal disease: 3% 
Singh et al. 
(knee OA) 
228 
Primary total knee arthroplasty: 
Two year follow up: 
Renal disease: 6% 
 
Five year follow up:  
Renal disease: 4% 
 
Revision total knee arthroplasty: 
Two year follow up:  
Renal disease: 4% 
 
Five year follow up:  
Renal disease: 2% 
Wesseling 
et al. 230 
For self-reported comorbidity of >1% prevalence: 
Chronic urolithiasis: 16 (1.6%) 
Prolapsed uterus: 42 (4.2%) 
Raab et al. 
235 
Diseases of the kidneys or the urinary tract: 16 (4.7%) 
 Renal insufficiency: 1 (0.3%) 
 Kidney stone: 4 (1.2%) 
Gynaecological diseases: 12 (5%) 
Ayers et al. 
237 Renal disease: 3.1% 
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Studies Percentage of comorbidity/accompanying symptoms OR and 95% 
CI 
Nilsdotter et 
al. 2003 180 Kidney disease: 0% 
CI: Confidence interval 
OR: Odds ratio 
 
Appendix 13 Ear, nose, throat, and eye disorders comorbidity of arthritis 
Studies Percentage of comorbidity/accompanying 
symptoms 
OR and 95% 
CI 
Van Dijk et al. 207 Eye, ear, nose, throat and larynx disease: 96.1% 
No data 
McWilliam et al. 2003 
176 
Blindness, deafness, or severe visual or hearing 
impairment: 9.9% 
CI: Confidence interval 
OR: Odds ratio 
 
Appendix 14 Circulatory diseases/symptoms as comorbidity/accompanying symptoms of 
fibromyalgia 
Studies Percentage of comorbidity/accompanying symptoms OR and 95% CI or 
other findings 
Bernatsky 
et al. 184 
The comorbidities of the 180 participants are as following: 
Hypertension/vascular: 18 (10%) 
No data 
Shillam et 
al. 226 
Cold hands: 113 (66%) 
Bruising easily: 113 (66%) 
CI: Confidence interval 
OR: Odds ratio 
 
Appendix 15 Other findings of fibromyalgia 
Studies Other findings 
Carbonell-Baeza 
et al. 218 
The results of the Fibromyalgia Impact Questionnaire were reported in the 
order of median, 25th percentile, 75th percentile: 
 
Pain (n=108): 7.2, 6, 8.5 
Fatigue (n=109): 8.8, 7.5, 9.55 
Rested (n=109): 9.2, 8, 9.6 
Stiffness (n=109): 8.1, 6.35, 9.4 
Anxiety (n=109): 6.9, 5.2, 9 
Depression (n=109): 6.5, 4.55, 8.35 
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Shillam et al. 226 Others: 
Sensitivity to light or sound: 128 (75%) 
Profuse sweating or feeling hot: 125 (73%) 
Skin tenderness: 134 (78%) 
Accident prone: 97 (57%) 
Swelling: 104 (61%) 
Inability to enjoy life: 101 (59%) 
Pelvic pain: 59 (35%) 
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Appendix 16 Chinese medicine pain questionnaire 
 389 
 
 390 
 
 391 
 
 
 392 
 
Appendix 17 Beck Depression Inventory 
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Appendix 18 Medical Outcome 36-Item Short Form Health Survey 
 395 
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Appendix 19 Roland Morris Disability Questionnaire 
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Appendix 20 Pain and medication diary 
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Appendix 21 Items removed from the test-retest reliability analysis 
Domain Items 
Pain quality Not known 
Pain rhythm Not known 
Pain aggravator Environmental changes-windy days 
Others-not known 
For female patient-Before period 
For female patient-during period 
For female patient-after period 
Pain alleviator Environmental changes-windy days 
Others-everything 
Others-not known 
Others-other 
For female patient-Before period 
For female patient-during period 
For female patient-after period 
Other symptoms Watery diarrhoea 
For female patients-abdominal pain during or before periods 
For female patients-low back pain during or before periods 
For female patients-dark blood 
For female patients-light blood (pink) 
For female patients-bleeding with clots 
For female patients-excessive bleeding 
For female patients-light bleeding 
For female patients-delayed periods  
For female patients-early periods  
For female patients-irregular periods  
For female patients-excessive watery discharge- 
For female patients-yellow discharge 
 
 
Appendix 22 Baseline week frequency analysis of pain regions (n=106) 
Pain regions Frequency Percentage
Head, neck and shoulder regions 
Neck 48 45.30% 
Shoulder 38 35.80% 
Shoulder blades 31 29.20% 
Back of the head 18 17.00% 
Sides of the head 16 15.10% 
Frontal head 15 14.20% 
Vertex 6 5.70% 
Upper limbs 
Upper arm 31 29.20% 
Wrist 23 21.70% 
Fingers 22 20.80% 
Hand 21 19.80% 
Elbow 18 17.00% 
Forearm 18 17.00% 
Lower limbs 
Hip 46 43.40% 
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Pain regions Frequency Percentage
Knee 43 40.60% 
Thigh 36 34.00% 
Calf 33 31.10% 
Ankle 32 30.20% 
Front of the leg 25 23.60% 
Toes 24 22.60% 
Sole 19 17.90% 
Heel 15 14.20% 
Front of the body trunk 
Groin 21 19.80% 
Chest 16 15.10% 
Side of the body 9 8.50% 
Stomach 8 7.50% 
Abdomen 8 7.50% 
Back of the body trunk 
Lower back 82 77.40% 
Buttocks 40 37.70% 
Middle back 36 34.00% 
Sacrum 36 34.00% 
Between shoulder blades 35 33.00% 
Items greater than 40% were bolded and items less than 5% were italicised. 
 
Appendix 23 Baseline week frequency analysis of pain quality and pain rhythm (n=106) 
Pain quality Frequency Percentage Pain rhythm Frequency Percentage
Sharp 62 58.50% All the time 79 74.50% 
Fixed location 50 47.20% Worse at the end of the day 45 42.50% 
Numbness 39 36.80% Worse when first get up 43 40.60% 
Dull pain with 
weakness 36 34.00% Fluctuate 28 26.40% 
Burning 35 33.00% Worse in the afternoon 22 20.80% 
Dull 28 26.40% 
Worse during the 
day, better at 
night 
18 17.00% 
Moving from one 
spot to another 23 21.70% 
Worse at night, 
better during the 
day 
18 17.00% 
Hot 22 20.80% Worse in the morning 8 7.50% 
Pulling 21 19.80% Worse at lunch time 4 3.80% 
Pricking 20 18.90% Recurrent 1 0.90% 
Cold 11 10.40% Not known 0 0% 
Distending 11 10.40%   Not known 1 0.90% 
Items greater than 40% were bolded and items less than 5% were italicised. 
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Appendix 24 Baseline week frequency analysis of pain aggravator (n=106) 
Pain aggravator Frequency Percentage
Environmental changes 
Cold weather 58 54.70% 
Weather change 28 26.40% 
Hot weather 22 20.80% 
Wet weather 11 10.40% 
Windy days 9 8.50% 
Exercises of sporting 
Standing 69 65.10% 
Physical work 68 64.20% 
Walking 66 62.30% 
Lifting 57 53.80% 
Sitting 55 51.90% 
Going up/down stairs 54 50.90% 
Bending 53 50.00% 
Driving 40 37.70% 
Any movement 28 26.40% 
Lying down 22 20.80% 
Physiological and psychic changes 
Stress 59 55.70% 
Bad night sleep 56 52.80% 
Being emotional 42 39.60% 
Being hungry 9 8.50% 
After eating 2 1.90% 
Others 
Household chores 53 50.00% 
Pressure on the area 36 34.00% 
Everything 26 24.50% 
Sex 20 18.90% 
Not known 0 0% 
For female patients (n=15) 
Before period 6 40.0% 
During period 6 40.0% 
After period 1 6.70% 
Items greater than 40% were bolded and items less than 5% were italicised. 
 
Appendix 25 Baseline week frequency analysis of pain alleviator (n=106) 
Pain alleviators Frequency Percentage
Environmental changes 
Hot packs 57 53.80% 
Warm/hot shower 45 42.50% 
Warm/hot bath 31 29.20% 
Hot weather 16 15.10% 
Cold packs 9 8.50% 
Cold weather 3 2.80% 
Wet weather 1 0.90% 
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Pain alleviators Frequency Percentage
Windy days 0 0% 
Exercises of sporting 
Resting 47 44.30% 
Lying down 41 38.70% 
Gentle massage 39 36.80% 
Gentle exercise 26 24.50% 
Walking 20 18.90% 
Sitting 13 12.30% 
Any movement 9 8.50% 
Driving 5 4.70% 
Standing 3 2.80% 
Physiological and psychic changes 
Pain killer 85 80.20% 
Keeping my mind off pain 39 36.80% 
Sleep 33 31.10% 
Being with other people 25 23.60% 
Deep breathing 21 19.80% 
Watching TV 19 17.90% 
Pressure on the pain area 14 13.20% 
Bowel movement 12 11.30% 
Reading 12 11.30% 
Alcohol 10 9.40% 
Eating 4 3.80% 
Belching 3 2.80% 
Working 3 2.80% 
Being hungry 1 0.90% 
Others 
Keeping busy 33 31.10% 
Nothing 11 10.40% 
Household chores 6 5.70% 
Sex 2 1.90% 
Everything 2 1.90% 
Not known 0 0% 
For female patients (n=15) 
During period 4 26.7% 
After period 0 0% 
Before period 0 0% 
Items greater than 40% were bolded and items less than 5% were italicised. 
 
Appendix 26 Baseline week frequency analysis of other symptoms (n=106) 
Other symptoms Frequency Percentage 
Feeling tired easily 70 66.00% 
Insomnia 57 53.80% 
Limited movement 55 51.90% 
Poor concentration 53 50.00% 
Poor memory 53 50.00% 
Feeling depressed 48 45.30% 
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Other symptoms Frequency Percentage 
Low libido 46 43.40% 
Constipation 44 41.50% 
Night sweating 42 39.60% 
Irritable 42 39.60% 
Feeling hot easily 41 38.70% 
Feeling cold easily 37 34.90% 
Swollen joints 35 33.00% 
Sweat upon mild activities 34 32.10% 
Feeling nervous easily 34 32.10% 
Dizziness 33 31.10% 
Frequent urination at night 30 28.30% 
Skin itch 29 27.40% 
Cold hands and feet 28 26.40% 
Thirsty 28 26.40% 
Nausea 28 26.40% 
Poor appetite 27 25.50% 
Dry or sore throat 25 23.60% 
Frequent urination 25 23.60% 
Short of breath 25 23.60% 
Dry skin 23 21.70% 
Heavy sensation in the body 22 20.80% 
Sigh often 22 20.80% 
Reflux 22 20.80% 
Need deep breathing 19 17.90% 
Flushed face 17 16.00% 
Red and hot joints 16 15.10% 
Leak when sneezing or cough 16 15.10% 
Abdominal distention 15 14.20% 
Indigestion 14 13.20% 
Cold joints 11 10.40% 
Cold lower back or knees 11 10.40% 
Dry stools 11 10.40% 
Stuffiness in the chest 11 10.40% 
Distension sensation in the 
abdomen 10 9.40% 
Catch cold easily 9 8.50% 
Mushy stools 8 7.50% 
Hot palms 6 5.70% 
Belching 5 4.70% 
Watery diarrhoea 0 0% 
Items greater than 40% were bolded and items less than 5% were italicised. 
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Appendix 27 Baseline week frequency analysis of gynaecological symptoms for female 
participants (n=15) 
Gynaecological symptoms Frequency Percentage
Abdominal pain during or before periods 5 33.30% 
Low back pain during or before periods 5 33.30% 
Dark blood 5 33.30% 
Irregular periods 3 20.00% 
Excessive bleeding 2 13.30% 
Bleeding with clots 2 13.30% 
Light bleeding 1 6.70% 
Delayed periods 1 6.70% 
Yellow discharge 0 0% 
Light blood (pink) 0 0% 
Early periods 0 0% 
Excessive watery discharge 0 0% 
Items greater than 40% were bolded and items less than 5% were italicised. 
 
Appendix 28 List of sham acupoints and their location 
Sham 
acupuncture 
points for each 
real acupuncture 
points 
Description of location  
Medial volar aspects of the forearm 
Hegu (L14)  With palm facing the chest, the point is located eight body units distal to 
the olecranon between the Heart and Small Intestine meridians. Needle is 
inserted perpendicularly. 
Shousanli (LI10)  On the medial aspect of the forearm, four body units proximal to sham 
LI4.  
Zhigou (TE6)  On the medial surface of the forearm, five body units distal to the 
olecranon, between sham LI10 and LI4. 
Dorsal lateral aspect of the forearm 
Shenmen (HT7)  On the dorsal lateral aspect of the forearm, six body units distal to the 
lateral epicondyle. 
Yinxi (HT6)  Two body units proximal to sham HT7.  
Neiguan (PC6)  Two body units proximal to sham HT6 (Four body units proximal to 
sham HT7). 
Lateral aspect of the leg 
Zusanli (ST36)  On the lateral aspect of the leg, two body units anterior and two body 
units proximal to BL58 (Feiyang), i.e. two body units proximal to sham 
ST40. 
Fenglong (ST40 )  On the lateral aspect of the leg, two body units anterior to BL58 
(Feiyang). 
Medial aspect of leg 
Taixi (KI3)  One body unit directly proximal to the real acupoint KI7 (Fuliu) and one 
body unit posterior. 
Fuliu (KI7)  Two body unit directly proximal to the real acupoint and one body unit 
posterior (one body unit proximal to sham KI3). 
Sanyinjiao (SP6)  On the medial aspect of the leg, four body units distal to the medial end 
of the popliteal crease. 
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Sham 
acupuncture 
points for each 
real acupuncture 
points 
Description of location  
Yinlingquan (SP9) Three body units distal to the medial end of the popliteal crease. 
Anterior aspect of the thigh 
Xuehai (SP10)  Two body units proximal to the upper mid point of the boarder of the 
patella. 
Head 
Baihui (GV20) 1.5 cm above and lateral to Yintang (EX-NH 3) between GB and BL 
meridians.  
Yintang (EX-NH 
3). 
1.5 cm above and lateral to Yintang (EX-NH 3) between GB and BL 
meridians. Same as sham GV20. Only use unilateral point. When both 
GV20 and Yintang are needled, only use one sham point. . 
Back 
Geshu (BL17)  Four body units lateral to the spinous process of the sixth thoracic 
vertebrae. 
Feishu (BL13)  Four body units lateral spinous process of the T3. 
Abdomen 
Tianshu (ST25)  One body unit lateral and one body unit proximal to the umbilicus.  
GuanYuan (CV4) Four body units later to the real point on either side. 
 
Appendix 29 Association of CM patterns and outcome measures 
Multivariate Testsa 
Effect Value F Hypothesis df Error df Sig. 
Partial Eta 
Squared 
Intercept 
Pillai's Trace 0.984 802.988 b 4.000 52.000 0.000 0.984 
Wilks' Lambda 0.016 802.988 b 4.000 52.000 0.000 0.984 
Hotelling's Trace 61.768 802.988 b 4.000 52.000 0.000 0.984 
Roy's Largest Root 61.768 802.988 b 4.000 52.000 0.000 0.984 
Clusters 
Pillai's Trace 0.197 3.199 b 4.000 52.000 0.020 0.197 
Wilks' Lambda 0.803 3.199 b 4.000 52.000 0.020 0.197 
Hotelling's Trace 0.246 3.199 b 4.000 52.000 0.020 0.197 
Roy's Largest Root 0.246 3.199 b 4.000 52.000 0.020 0.197 
Tests of Between-Subjects Effects 
Source Dependent Variable 
Type III 
Sum of 
Squares
df Mean Square F Sig. 
Partial Eta 
Squared 
Clusters 
Average of OM at 
baseline weeks 
296546.8
93 1 296546.893 1.017 0.318 0.018 
Average of average 
intensity of baseline 
weeks 
1.413 1 1.413 0.342 0.561 0.006 
Total score of BDI at 
baseline week 973.728 1 973.728 10.426 0.002 0.159 
Total SF36 score at 
baseline week 3060.285 1 3060.285 8.752 0.005 0.137 
CM heat pattern and CM cold with deficiency pattern 
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Dependent Variable CM patterns N Mean 
Std. 
Error 
95% Confidence Interval 
Lower Bound Upper Bound
Average of OM at 
baseline weeks 
CM heat 
pattern 30 445.268 98.595 247.679 642.857 
CM cold 
with 
deficiency 
pattern 
27 589.726 103.928 381.449 798.003 
Average of average 
intensity of baseline 
weeks 
CM heat 
pattern 30 5.451 0.371 4.708 6.194 
CM cold 
with 
deficiency 
pattern 
27 5.136 0.391 4.352 5.919 
Total score of BDI at 
baseline week 
CM heat 
pattern 30 16.167 1.764 12.631 19.703 
CM cold 
with 
deficiency 
pattern 
27 24.444 1.860 20.717 28.172 
Total SF36 score at 
baseline week 
CM heat 
pattern 30 45.933 3.414 39.091 52.774 
CM cold 
with 
deficiency 
pattern 
27 31.258 3.599 24.046 38.470 
a. Exact statistic 
b. Exact statistic 
BDI: Beck depression inventory 
CM: Chinese medicine 
OM: Opioid medication 
SF36: Medical outcome short for health survey 36 items 
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Appendix 30 Summary of frequency analysis of baseline week and end of treatment week 
Domain  Symptoms 
REA SEA PMM alone 
Baseline 
week 
(n=45) 
End of 
treatment 
week (n=28)
Baseline 
week 
(n=28) 
End of 
treatment 
week (n=23) 
Baseline 
week 
(n=28) 
End of 
treatment 
week (n=17) 
Pain 
regions 
Lower back 77.86% 71.40% 75.00% 78.30% 82.00% 88.20%
Hip 42.20%   46.40% 52.20% 42.90% 41.20%
Neck 42.20%   60.70% 65.20%     
Knee     46.40% 52.20%   52.90%
Between 
blades     42.90% 47.80%   41.20%
Calf           41.20%
Middle 
back     42.90%       
Front of the 
leg     42.90%     41.20%
Hand       43.50%     
Ankle     42.90%       
Sacrum           41.20%
Shoulder     50.00% 65.20%   41.20%
Buttocks     50.00%       
Thigh     46.40% 52.20%   41.2%, 
Upper arm     50.00%       
Pain 
quality 
Sharp 62.20% 46.40% 60.70% 52.20% 53.60% 64.70%
Fixed 
location 48.90%   53.60%   42.90% 47.10%
Burning   42.90%       41.20%
Dull pain 
with 
weakness 
      43.50% 46.40%   
Numbness     42.90%       
Pain 
rhythm 
All the time 77.80% 60.70% 82.10% 65.20% 71.40% 64.70%
Worse 
when first 
get up 
44.40%           
Worse at 
the end of 
the day 
44.40%   42.90%     41.20%
Worse at 
night, better 
during the 
day 
      43.50%     
Pain 
aggravator 
Physical 
work 66.70% 60.70% 64.30% 65.20% 60.70% 58.80%
Standing 66.70% 64.30% 57.10% 60.90% 71.40% 76.50%
Walking 66.70% 46.40% 50.00% 56.50% 64.30% 64.70%
Household 60.00% 42.90% 46.40% 47.80%   47.10%
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Domain  Symptoms 
REA SEA PMM alone 
Baseline 
week 
(n=45) 
End of 
treatment 
week (n=28)
Baseline 
week 
(n=28) 
End of 
treatment 
week (n=23) 
Baseline 
week 
(n=28) 
End of 
treatment 
week (n=17) 
chores 
Cold 
weather 57.80% 46.40% 42.90% 78.30% 60.70% 76.50%
Sitting 53.30% 53.60% 57.10% 52.20% 46.40% 47.10%
Bending 51.10% 53.60% 42.90% 47.80% 50.00% 47.10%
Lifting 51.10% 53.60% 53.60% 56.50% 60.70% 58.80%
Stress 51.10% 50.00% 60.70% 52.20% 53.60% 35.30%
Going 
up/down 
stairs 
48.90% 42.90%     64.30% 58.80%
Driving 48.90%           
Bad night 
sleep 46.70% 50.00% 57.10% 65.20% 60.70% 41.20%
Pressure on 
the area 46.70%           
Being 
emotional     46.40%       
Pain 
alleviator 
Pain killer 88.90% 85.70% 71.40% 73.90% 78.60%   
Resting 48.90% 46.40%     46.40% 41.20%
Lying down 44.40%         41.20%
Hot packs 42.20% 57.10% 71.40% 78.30% 53.60% 64.70%
Keeping my 
mind off 
pain 
40.00% 46.40%   52.20% 46.40%   
Warm/hot 
shower     50.00% 60.90%   52.90%
Keeping 
busy       43.5%,     
Gentle 
massage         46.40%   
Other 
symptoms 
Feeling 
tired easily 62.20% 60.70% 71.40% 82.60% 71.40% 64.70%
Insomnia 55.60% 53.60% 53.60%   46.40% 52.90%
Low libido 53.30%       46.40% 47.10%
Feeling 
depressed 48.90%   42.90% 52.20% 46.40% 47.10%
Limited 
movement 46.70% 50.00% 50.00% 52.20% 64.30% 47.10%
Constipatio
n 46.70%   42.90%     41.20%
Poor 
concentratio
n 
44.40% 42.90% 57.10% 56.50% 57.10% 52.90%
Night 44.40% 46.40%       41.20%
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Domain  Symptoms 
REA SEA PMM alone 
Baseline 
week 
(n=45) 
End of 
treatment 
week (n=28)
Baseline 
week 
(n=28) 
End of 
treatment 
week (n=23) 
Baseline 
week 
(n=28) 
End of 
treatment 
week (n=17) 
sweating 
Feeling hot 
easily 42.20%           
Poor 
memory 40.00% 42.90% 57.10% 47.80% 60.70% 47.10%
Nausea     42.90%       
Feeling cold 
easily     46.40% 47.80%   41.20%
Feeling 
nervous 
easily 
    42.90% 52.20%     
Irritable   42.90% 46.40% 47.80% 42.90% 52.90%
Thirsty       43.50%     
Dizziness     46.40%       
Empty cell means percentage of symptom not over 40% 
 
Appendix 31 Baseline week pain region frequency – REA (n=45) 
Pain regions Frequency Percentage
Head, neck and shoulder regions 
Neck 19 42.20% 
Shoulder blades 12 26.70% 
Shoulder 11 24.40% 
Frontal head 7 15.60% 
Back of the head 7 15.60% 
Sides of the head 6 13.30% 
Vertex 4 8.90% 
Upper limbs 
Upper arm 10 22.20% 
Fingers 8 17.80% 
Hand 7 15.60% 
Forearm 6 13.30% 
Wrist 6 13.30% 
Elbow 4 8.90% 
Lower limbs 
Hip 19 42.20% 
Knee 16 35.60% 
Calf 15 33.30% 
Thigh 13 28.90% 
Ankle 11 24.40% 
Toes 8 17.80% 
Sole 6 13.30% 
Front of the leg 5 11.10% 
Heel 5 11.10% 
Front of the body trunk 
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Pain regions Frequency Percentage
Groin 10 22.20% 
Chest 5 11.10% 
Abdomen 4 8.90% 
Stomach 3 6.70% 
Side of the body 3 6.70% 
Back of the body trunk 
Lower back 35 77.80% 
buttocks 15 33.30% 
Between shoulder blades 14 31.10% 
Middle back 13 28.90% 
Sacrum 13 28.90% 
Items greater than 40% were bolded and items less than 5% were italicised. 
 
Appendix 32 Baseline week pain quality and rhythm frequency – REA (n=45) 
Pain quality Frequency Percentage Pain rhythm Frequency Percentage
Sharp 28 62.20% All the time 35 77.80% 
Fixed location 22 48.90% Worse when first get up 20 44.40% 
Burning 17 37.80% Worse at the end of the day 20 44.40% 
Numbness 15 33.30% Fluctuate 13 28.90% 
Hot 14 31.10% Worse in the afternoon 10 22.20% 
Pulling 11 24.40% 
Worse during the 
day, better at 
night 
7 15.60% 
Moving from one 
spot to another 11 24.40% 
Worse at night, 
better during the 
day 
4 8.90% 
Dull 11 24.40% Worse in the morning 2 4.40% 
Dull pain with 
weakness 11 24.40% Recurrent 1 2.20% 
Pricking 9 20.00% Worse at lunch time 1 2.20% 
Cold 4 8.90% Not known 0 0% 
Distending 3 6.70%  Not known 0 0% 
Items greater than 40% were bolded and items less than 5% were italicised. 
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Appendix 33 Baseline week pain aggravator frequency – REA (n=45) 
Pain aggravator Frequency Percentage
Environmental changes 
Cold weather 26 57.80% 
Weather change 11 24.40% 
Hot weather 11 24.40% 
Wet weather 4 8.90% 
Windy days 4 8.90% 
Exercises of sporting 
Standing 30 66.70% 
Walking 30 66.70% 
Physical work 30 66.70% 
Sitting 24 53.30% 
Lifting 23 51.10% 
Bending 23 51.10% 
Going up/down stairs 22 48.90% 
Driving 22 48.90% 
Lying down 9 20.00% 
Any movement 8 17.80% 
Physiological and psychic changes 
Stress 23 51.10% 
Bad night sleep 21 46.70% 
Being emotional 15 33.30% 
Being hungry 4 8.90% 
After eating 1 2.20% 
Others 
Household chores 27 60.00% 
Pressure on the area 21 46.70% 
Sex 11 24.40% 
Everything 9 20.00% 
Not known 0 0% 
Items greater than 40% were bolded and items less than 5% were italicised. 
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Appendix 34 Baseline week pain alleviator frequency – REA (n=45) 
Pain alleviator Frequency Percentage
Environmental changes 
Hot packs 19 42.20% 
Warm/hot shower 17 37.80% 
Warm/hot bath 12 26.70% 
Cold packs 5 11.10% 
Hot weather 5 11.10% 
Cold weather 2 4.40% 
Wet weather 1 2.20% 
Windy days 0 0% 
Exercises of sporting 
Resting 22 48.90% 
Lying down 20 44.40% 
Gentle massage 12 26.70% 
Gentle exercise 9 20.00% 
Walking 7 15.60% 
Any movement 5 11.10% 
Sitting 4 8.90% 
Standing 2 4.40% 
Driving 1 2.20% 
Physiological and psychic changes 
Pain killer 40 88.90% 
Keeping my mind off pain 18 40.00% 
Sleep 15 33.30% 
Deep breathing 10 22.20% 
Being with other people 10 22.20% 
Watching TV 7 15.60% 
Pressure on the pain area 5 11.10% 
Reading 5 11.10% 
Bowel movement 4 8.90% 
Alcohol 4 8.90% 
Eating 3 6.70% 
Working 2 4.40% 
Belching 1 2.20% 
Being hungry 0 0% 
Others 
Keeping busy 15 33.30% 
Nothing 6 13.30% 
Household chores 4 8.90% 
Sex 0 0% 
Everything 0 0% 
Not known 0 0% 
Items greater than 40% were bolded and items less than 5% were italicised. 
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Appendix 35 Baseline week other pain accompanying symptom frequency – REA (n=45) 
Item Frequency Percentage
Feeling tired easily 28 62.20% 
Insomnia 25 55.60% 
Low libido 24 53.30% 
Feeling depressed 22 48.90% 
Limited movement 21 46.70% 
Constipation 21 46.70% 
Night sweating 20 44.40% 
Poor concentration 20 44.40% 
Feeling hot easily 19 42.20% 
Poor memory 18 40.00% 
Feeling cold easily 17 37.80% 
Irritable 16 35.60% 
Sweat upon mild activities 14 31.10% 
Feeling nervous easily 14 31.10% 
Swollen joints 13 28.90% 
Thirsty 13 28.90% 
Frequent urination at night 13 28.90% 
Dry skin 12 26.70% 
Poor appetite 12 26.70% 
Reflux 12 26.70% 
Skin itch 12 26.70% 
Cold hands and feet 11 24.40% 
Nausea 11 24.40% 
Dizziness 10 22.20% 
Heavy sensation in the body 9 20.00% 
Dry or sore throat 9 20.00% 
Frequent urination 9 20.00% 
Need deep breathing 8 17.80% 
Short of breath 8 17.80% 
Indigestion 7 15.60% 
Flushed face 7 15.60% 
Leak when sneezing or cough 7 15.60% 
Sigh often 7 15.60% 
Red and hot joints 6 13.30% 
Cold joints 5 11.10% 
Distention sensation in the abdomen 5 11.10% 
Catch cold easily 5 11.10% 
Abdominal distention 5 11.10% 
Mushy stools 4 8.90% 
Stuffiness in the chest 4 8.90% 
Cold lower back or knees 3 6.70% 
Hot palms 3 6.70% 
Belching 3 6.70% 
Dry stools 1 2.20% 
Watery diarrhoea 0 0% 
Items greater than 40% were bolded and items less than 5% were italicised. 
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Appendix 36 Baseline week pain region frequency – SEA (n=28) 
Pain regions Frequency Percentage
Head, neck and shoulder regions 
Neck 17 60.70% 
Shoulder 14 50.00% 
Shoulder blades 10 35.70% 
Back of the head 8 28.60% 
Sides of the head 4 14.30% 
Frontal head 3 10.70% 
Vertex 2 7.10% 
Upper limbs 
Upper arm 14 50.00% 
Elbow 10 35.70% 
Wrist 10 35.70% 
Fingers 10 35.70% 
Forearm 9 32.10% 
Hand 8 28.60% 
Lower limbs 
Hip 13 46.40% 
Thigh 13 46.40% 
Knee 13 46.40% 
Front of the leg 12 42.90% 
Ankle 12 42.90% 
Calf 9 32.10% 
Toes 8 28.60% 
Heel 5 17.90% 
Sole 5 17.90% 
Front of the body trunk 
Chest 8 28.60% 
Groin 3 10.70% 
Side of the body 3 10.70% 
Stomach 1 3.60% 
Abdomen 1 3.60% 
Back of the body trunk 
Lower back 21 75.00% 
Buttocks 14 50.00% 
Between shoulder blades 12 42.90% 
Middle back 12 42.90% 
Sacrum 11 39.30% 
Items greater than 40% were bolded and items less than 5% were italicised. 
 
Appendix 37 Baseline week pain quality and rhythm frequency – SEA (n=28) 
Pain quality Frequency Percentage Pain rhythm Frequency Percentage
Sharp 17 60.70% All the time 23 82.10% 
Fixed location 15 53.60% Worse at the end of the day 12 42.90% 
Numbness 12 42.90% Worse when first get up 9 32.10% 
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Pain quality Frequency Percentage Pain rhythm Frequency Percentage
Dull pain with 
weakness 10 35.70% 
Worse at night, 
better during the 
day 
8 28.60% 
Dull 9 32.10% Fluctuate 7 25.00% 
Burning 7 25.00% 
Worse during the 
day, better at 
night 
6 21.40% 
Pricking 6 21.40% Worse in the afternoon 6 21.40% 
Cold 5 17.90% Worse in the morning 4 14.30% 
Pulling 5 17.90% Worse at lunch time 3 10.70% 
Distending 5 17.90% Recurrent 0 0% 
Moving from one 
spot to another 5 17.90% Not known 0 0% 
Hot 3 10.70% 
 Not known 0 0% 
Items greater than 40% were bolded and items less than 5% were italicised. 
 
Appendix 38 Baseline week pain aggravator frequency – SEA (n=28) 
Pain aggravator Frequency Percentage
Environmental changes 
Cold weather 12 42.90% 
Weather change 8 28.60% 
Hot weather 5 17.90% 
Wet weather 3 10.70% 
Windy days 2 7.10% 
Exercises of sporting 
Physical work 18 64.30% 
Standing 16 57.10% 
Sitting 16 57.10% 
Lifting 15 53.60% 
Walking 14 50.00% 
Bending 12 42.90% 
Lying down 11 39.30% 
Going up/down stairs 11 39.30% 
Any movement 8 28.60% 
Driving 7 25.00% 
Physiological and psychic changes 
Stress 17 60.70% 
Bad night sleep 16 57.10% 
Being emotional 13 46.40% 
Being hungry 2 7.10% 
After eating 1 3.60% 
Others 
Household chores 13 46.40% 
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Pain aggravator Frequency Percentage
Everything 7 25.00% 
Pressure on the area 6 21.40% 
Sex 4 14.30% 
Not known 0 0% 
Items greater than 40% were bolded and items less than 5% were italicised. 
 
Appendix 39 Baseline week pain alleviator frequency – SEA (n=28) 
Pain alleviators Frequency Percentage
Environmental changes 
Hot packs 20 71.40% 
Warm/hot shower 14 50.00% 
Warm/hot bath 10 35.70% 
Hot weather 4 14.30% 
Cold packs 2 7.10% 
Cold weather 1 3.60% 
Wet weather 0 0% 
Windy days 0 0% 
Exercises of sporting 
Gentle massage 11 39.30% 
Gentle exercise 10 35.70% 
Lying down 9 32.10% 
Resting 9 32.10% 
Walking 7 25.00% 
Sitting 6 21.40% 
Standing 1 3.60% 
Any movement 1 3.60% 
Driving 1 3.60% 
Physiological and psychic changes 
Pain killer 20 71.40% 
Keeping my mind off pain 8 28.60% 
Being with other people 8 28.60% 
Sleep 8 28.60% 
Deep breathing 6 21.40% 
Pressure on the pain area 6 21.40% 
Watching TV 6 21.40% 
Alcohol 3 10.70% 
Reading 3 10.70% 
Belching 1 3.60% 
Bowel movement 1 3.60% 
Working 1 3.60% 
Eating 0 0% 
Being hungry 0 0% 
Others 
Keeping busy 7 25.00% 
Nothing 4 14.30% 
Household chores 2 7.10% 
Sex 1 3.60% 
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Pain alleviators Frequency Percentage
Everything 1 3.60% 
Not known 0 0% 
Items greater than 40% were bolded and items less than 5% were italicised. 
 
Appendix 40 Baseline week other pain accompanying symptom frequency – SEA (n=28) 
Item Frequency Percentage
Feeling tired easily 20 71.40% 
Poor concentration 16 57.10% 
Poor memory 16 57.10% 
Insomnia 15 53.60% 
Limited movement 14 50.00% 
Feeling cold easily 13 46.40% 
Irritable 13 46.40% 
Dizziness 13 46.40% 
Constipation 12 42.90% 
Feeling nervous easily 12 42.90% 
Feeling depressed 12 42.90% 
Nausea 12 42.90% 
Swollen joints 11 39.30% 
Cold hands and feet 11 39.30% 
Feeling hot easily 11 39.30% 
Night sweating 11 39.30% 
Dry or sore throat 9 32.10% 
Thirsty 9 32.10% 
Poor appetite 8 28.60% 
Short of breath 8 28.60% 
Skin itch 8 28.60% 
Heavy sensation in the body 7 25.00% 
Low libido 7 25.00% 
Sweat upon mild activities 7 25.00% 
Dry skin 6 21.40% 
Frequent urination at night 6 21.40% 
Frequent urination 6 21.40% 
Sigh often 6 21.40% 
Reflux 6 21.40% 
Red and hot joints 5 17.90% 
Cold lower back or knees 5 17.90% 
Dry stools 5 17.90% 
Need deep breathing 5 17.90% 
Abdominal distention 5 17.90% 
Stuffiness in the chest 5 17.90% 
Indigestion 4 14.30% 
Flushed face 4 14.30% 
Cold joints 3 10.70% 
Distention sensation in the abdomen 3 10.70% 
Hot palms 3 10.70% 
Leak when sneezing or cough 3 10.70% 
 440 
 
Item Frequency Percentage
Mushy stools 1 3.60% 
Catch cold easily 1 3.60% 
Watery diarrhoea 0 0% 
Belching 0 0% 
Items greater than 40% were bolded and items less than 5% were italicised. 
 
Appendix 41 Baseline week pain region frequency – PMM alone (n=28) 
Pain regions Frequency Percentage
Head, neck and shoulder regions 
Neck 11 39.30% 
Shoulder 11 39.30% 
Shoulder blades 9 32.10% 
Sides of the head 6 21.40% 
Frontal head 5 17.90% 
Back of the head 3 10.70% 
Vertex 0 0% 
Upper limbs 
Upper arm 6 21.40% 
Wrist 6 21.40% 
Elbow 4 14.30% 
Hand 4 14.30% 
Fingers 4 14.30% 
Forearm 2 7.10% 
Lower limbs 
Hip 12 42.90% 
Knee 11 39.30% 
Thigh 10 35.70% 
Ankle 9 32.10% 
Front of the leg 7 25.00% 
Calf 7 25.00% 
Sole 7 25.00% 
Toes 7 25.00% 
Heel 4 14.30% 
Front of the body trunk 
Groin 8 28.60% 
Stomach 4 14.30% 
Chest 3 10.70% 
Abdomen 3 10.70% 
Side of the body 3 10.70% 
Back of the body trunk 
Lower back 23 82.10% 
Sacrum 11 39.30% 
Middle back 10 35.70% 
buttocks 10 35.70% 
Between shoulder blades 8 28.60% 
Items greater than 40% were bolded and items less than 5% were italicised. 
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Appendix 42 Baseline week pain quality and rhythm frequency – PMM alone (n=28) 
Pain quality Frequency Percentage Pain rhythm Frequency Percentage
Sharp 15 53.60% All the time 20 71.40%
Dull pain with 
weakness 13 46.40% 
Worse when first 
get up 11 39.30%
Fixed location 12 42.90% Worse at the end of the day 11 39.30%
Numbness 11 39.30% Fluctuate 6 21.40%
Burning 11 39.30% 
Worse during the 
day, better at 
night 
5 17.90%
Moving from one 
spot to another 6 21.40% 
Worse at night, 
better during the 
day 
5 17.90%
Dull 6 21.40% Worse in the afternoon 5 17.90%
Pricking 5 17.90% Worse in the morning 2 7.10%
Pulling 4 14.30% Recurrent 0 0%
Hot 4 14.30% Worse at lunch time 0 0%
Distending 3 10.70% Not known 0 0%
Cold 2 7.10% 
 Not known 1 3.60% 
Items greater than 40% were bolded and items less than 5% were italicised. 
 
Appendix 43 Baseline week pain aggravator frequency – PMM alone (n=28) 
Pain aggravators Frequency Percentage
Environmental changes 
Cold weather 17 60.70% 
Weather change 7 25.00% 
Hot weather 5 17.90% 
Wet weather 3 10.70% 
Windy days 3 10.70% 
Exercises of sporting 
Standing 20 71.40% 
Walking 18 64.30% 
Going up/down stairs 18 64.30% 
Physical work 17 60.70% 
Lifting 17 60.70% 
Bending 14 50.00% 
Sitting 13 46.40% 
Any movement 10 35.70% 
Driving 10 35.70% 
Lying down 1 3.60% 
Physiological and psychic changes 
Bad night sleep 17 60.70% 
Stress 15 53.60% 
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Being emotional 11 39.30% 
Being hungry 3 10.70% 
After eating 0 0% 
Others 
Household chores 11 39.30% 
Pressure on the area 9 32.10% 
Everything 9 32.10% 
Sex 4 14.30% 
Not known 0 0% 
Items greater than 40% were bolded and items less than 5% were italicised. 
 
Appendix 44 Baseline week pain alleviator frequency – PMM alone (n=28) 
Pain alleviators Frequency Percentage
Environmental changes 
Hot packs 15 53.60% 
Warm/hot shower 10 35.70% 
Warm/hot bath 8 28.60% 
Hot weather 6 21.40% 
Cold packs 2 7.10% 
Cold weather 0 0% 
Wet weather 0 0% 
Windy days 0 0% 
Exercises of sporting 
Gentle massage 13 46.40% 
Resting 13 46.40% 
Lying down 11 39.30% 
Gentle exercise 6 21.40% 
Walking 5 17.90% 
Any movement 3 10.70% 
Sitting 2 7.10% 
Driving 2 7.10% 
Standing 0 0% 
Physiological and psychic changes 
Pain killer 22 78.60% 
Keeping my mind off pain 13 46.40% 
Sleep 9 32.10% 
Bowel movement 6 21.40% 
Deep breathing 5 17.90% 
Being with other people 5 17.90% 
Watching TV 5 17.90% 
Reading 4 14.30% 
Pressure on the pain area 2 7.10% 
Alcohol 2 7.10% 
Eating 1 3.60% 
Being hungry 1 3.60% 
Belching 1 3.60% 
Working 0 0% 
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Others 
Keeping busy 10 35.70% 
Sex 1 3.60% 
Everything 1 3.60% 
Nothing 1 3.60% 
Household chores 0 0% 
Not known 0 0% 
Items greater than 40% were bolded and items less than 5% were italicised. 
 
Appendix 45 Baseline week other pain accompanying symptom frequency – PMM alone 
(n=28) 
Item Frequency Percentage
Feeling tired easily 20 71.40% 
Limited movement 18 64.30% 
Poor memory 17 60.70% 
Poor concentration 16 57.10% 
Insomnia 13 46.40% 
Low libido 13 46.40% 
Feeling depressed 13 46.40% 
Irritable 12 42.90% 
Sweat upon mild activities 11 39.30% 
Swollen joints 9 32.10% 
Feeling hot easily 9 32.10% 
Night sweating 9 32.10% 
Constipation 9 32.10% 
Frequent urination 9 32.10% 
Dizziness 9 32.10% 
Frequent urination at night 8 28.60% 
Sigh often 8 28.60% 
Short of breath 8 28.60% 
Poor appetite 7 25.00% 
Feeling nervous easily 7 25.00% 
Skin itch 7 25.00% 
Heavy sensation in the body 6 21.40% 
Feeling cold easily 6 21.40% 
Dry or sore throat 5 17.90% 
Flushed face 5 17.90% 
Thirsty 5 17.90% 
Dry stools 5 17.90% 
Dry skin 5 17.90% 
Leak when sneezing or cough 5 17.90% 
Need deep breathing 5 17.90% 
Nausea 5 17.90% 
Cold hands and feet 4 14.30% 
Abdominal distention 4 14.30% 
Reflux 4 14.30% 
Red and hot joints 3 10.70% 
Indigestion 3 10.70% 
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Item Frequency Percentage
Cold lower back or knees 3 10.70% 
Mushy stools 3 10.70% 
Cold joints 2 7.10% 
Distention sensation in the abdomen 2 7.10% 
Catch cold easily 2 7.10% 
Stuffiness in the chest 2 7.10% 
Belching 2 7.10% 
Hot palms 0 0% 
Watery diarrhoea 0 0% 
Items greater than 40% were bolded and items less than 5% were italicised. 
 
Appendix 46 End of treatment week pain region frequency – REA (n=28) 
Pain regions Frequency Percentage
Head and shoulder regions 
Neck 9 32.10% 
Shoulder blades 9 32.10% 
Shoulder 8 28.60% 
Frontal head 5 17.90% 
Back of the head 3 10.70% 
Sides of the head 2 7.10% 
Vertex 0 0.00% 
Upper limb 
Wrist 6 21.40% 
Hand 5 17.90% 
Fingers 5 17.90% 
Upper arm 4 14.30% 
Elbow 1 3.60% 
Forearm 1 3.60% 
Lower limb 
Hip 11 39.30% 
Knee 9 32.10% 
Thigh 8 28.60% 
Calf 6 21.40% 
Toes 6 21.40% 
Ankle 5 17.90% 
Heel 5 17.90% 
Sole 5 17.90% 
Front of the leg 4 14.30% 
Front of the body 
Groin 6 21.40% 
Abdomen 4 14.30% 
Side of the body 3 10.70% 
Chest 2 7.10% 
Stomach 1 3.60% 
Back of the body 
Lower back 20 71.40% 
Middle back 11 39.30% 
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Pain regions Frequency Percentage
Between shoulder blades 9 32.10% 
Sacrum 6 21.40% 
Buttocks 6 21.40% 
Items greater than 40% were bolded and items less than 5% were italicised. 
 
Appendix 47 End of treatment week pain quality and rhythm frequency – REA (n=28) 
Pain quality Frequency Percentage Pain rhythm Frequency Percentage
Sharp 13 46.40% All the time 17 60.70% 
Burning 12 42.90% Fluctuate 9 32.10% 
Fixed location 9 32.10% Worse in the afternoon 9 32.10% 
Pricking 9 32.10% Worse when first get up 9 28.60% 
Numbness 9 32.10% Worse at the end of the day 7 25.00% 
Hot 9 32.10% 
Worse at night, 
better during the 
day 
5 17.90% 
Moving from one 
spot to another 7 25.00% 
Worse in the 
morning 4 14.30% 
Dull 7 25.00% Worse during the day, better at night 2 7.10% 
Pulling 6 21.40% Worse at lunch time 1 3.60% 
Dull pain with 
weakness 6 21.40% Recurrent 0 0.00% 
Distending 4 14.30% Not known 0 0.00% 
Cold 3 10.70% 
 Not known 0 0.00% 
Items greater than 40% were bolded and items less than 5% were italicised. 
 
Appendix 48 End of treatment week pain aggravator frequency – REA (n=28) 
Pain aggravators Frequency Percentage
Environmental changes 
Cold weather 13 46.40% 
Weather change 7 25.00% 
Hot weather 7 25.00% 
Wet weather 3 10.70% 
Windy days 0 0.00% 
Exercises or sporting 
Standing 18 64.30% 
Physical work 17 60.70% 
Sitting 15 53.60% 
Lifting 15 53.60% 
Bending 15 53.60% 
Walking 13 46.40% 
Going up/down stairs 12 42.90% 
Driving 8 28.60% 
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Lying down 7 25.00% 
Any movement 6 21.40% 
Physiological and psychic changes 
Bad night sleep 14 50.00% 
Stress 14 50.00% 
Being emotional 10 35.70% 
After eating 0 0.00% 
Being hungry 0 0.00% 
Others 
Household chores 12 42.90% 
Pressure on the area 10 35.70% 
Everything 6 21.40% 
Sex 2 7.10% 
Not known 2 7.10% 
Items greater than 40% were bolded and items less than 5% were italicised. 
 
Appendix 49 End of treatment week pain alleviator frequency – REA (n=28) 
Pain alleviators Frequency Percentage
Environmental changes 
Hot packs 16 57.10% 
Warm/hot shower 8 28.60% 
Hot weather 7 25.00% 
Warm/hot bath 6 21.40% 
Cold packs 4 14.30% 
Cold weather 3 10.70% 
Wet weather 0 0.00% 
Windy days 0 0.00% 
Exercises or sporting 
Resting 13 46.40% 
Gentle exercise 10 35.70% 
Lying down 9 32.10% 
Gentle massage 9 32.10% 
Walking 6 21.40% 
Sitting 5 17.90% 
Any movement 5 17.90% 
Standing 1 3.60% 
Driving 1 3.60% 
Physiological and psychic changes 
Pain killer 24 85.70% 
Keeping my mind off pain 13 46.40% 
Sleep 10 35.70% 
Being with other people 9 32.10% 
Deep breathing 8 28.60% 
Reading 8 28.60% 
Watching TV 7 25.00% 
Bowel movement 6 21.40% 
Pressure on the pain area 4 14.30% 
Working 2 7.10% 
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Pain alleviators Frequency Percentage
Eating 1 3.60% 
Belching 1 3.60% 
Being hungry 0 0.00% 
Alcohol 0 0.00% 
Others 
Keeping busy 10 35.70% 
Household chores 2 7.10% 
Sex 1 3.60% 
Everything 1 3.60% 
Nothing 0 0.00% 
Not known 0 0.00% 
Items greater than 40% were bolded and items less than 5% were italicised. 
 
Appendix 50 End of treatment week other symptom frequency – REA (n=28) 
Item Frequency Percentage
Feeling tired easily 17 60.70% 
Insomnia 15 53.60% 
Limited movement 14 50.00% 
Night sweating 13 46.40% 
Irritable 12 42.90% 
Poor concentration 12 42.90% 
Poor memory 12 42.90% 
Feeling cold easily 11 39.30% 
Feeling hot easily 11 39.30% 
Constipation 11 39.30% 
Low libido 11 39.30% 
Feeling depressed 10 35.70% 
Cold hands and feet 9 32.10% 
Thirsty 9 32.10% 
Sweat upon mild activities 9 32.10% 
Frequent urination at night 8 28.60% 
Reflux 8 28.60% 
Swollen joints 7 25.00% 
Indigestion 7 25.00% 
Dry skin 7 25.00% 
Feeling nervous easily 7 25.00% 
Flushed face 6 21.40% 
Poor appetite 6 21.40% 
Red and hot joints 5 17.90% 
Cold joints 5 17.90% 
Heavy sensation in the body 5 17.90% 
Dry or sore throat 5 17.90% 
Hot palms 5 17.90% 
Need deep breathing 5 17.90% 
Belching 5 17.90% 
Nausea 5 17.90% 
Dizziness 5 17.90% 
 448 
 
Item Frequency Percentage
Skin itch 5 17.90% 
Leak when sneezing or cough 4 14.30% 
Sigh often 4 14.30% 
Short of breath 4 14.30% 
Abdominal distention 4 14.30% 
Catch cold easily 3 10.70% 
Distention sensation in the abdomen 2 7.10% 
Cold lower back or knees 2 7.10% 
Watery diarrhoea 2 7.10% 
Frequent urination 2 7.10% 
Stuffiness in the chest 2 7.10% 
Mushy stools 1 3.60% 
Dry stools 1 3.60% 
Items greater than 40% were bolded and items less than 5% were italicised. 
 
Appendix 51 End of treatment week pain region frequency – SEA (n=23) 
Pain regions Frequency Percentage
Head and shoulder regions 
Neck 15 65.20% 
Shoulder 15 65.20% 
Shoulder blades 9 39.10% 
Back of the head 8 34.80% 
Sides of the head 7 30.40% 
Frontal head 4 17.40% 
Vertex 3 13.00% 
Upper limb 
Hand 10 43.50% 
Elbow 9 39.10% 
Upper arm 8 34.80% 
Fingers 8 34.80% 
Wrist 7 30.40% 
Forearm 4 17.40% 
Lower limb 
Hip 12 52.20% 
Thigh 12 52.20% 
Knee 12 52.20% 
Ankle 8 34.80% 
Toes 7 30.40% 
Sole 6 26.10% 
Front of the leg 5 21.70% 
Calf 5 21.70% 
Heel 4 17.40% 
Front of the body 
Side of the body 8 34.80% 
Chest 7 30.40% 
Stomach 4 17.40% 
Abdomen 2 8.70% 
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Pain regions Frequency Percentage
Groin 2 8.70% 
Back of the body 
Lower back 18 78.30% 
Between shoulder blades 11 47.80% 
Middle back 9 39.10% 
Buttocks 9 39.10% 
Sacrum 4 17.40% 
Items greater than 40% were bolded and items less than 5% were italicised. 
 
Appendix 52 End of treatment week pain quality and rhythm frequency - SEA (n=23) 
Pain quality Frequency Percentage Pain rhythm Frequency Percentage
Sharp 12 52.20% All the time 15 65.20% 
Dull pain with 
weakness 10 43.50% 
Worse at night, 
better during the 
day 
10 43.50% 
Numbness 9 39.10% Worse at the end of the day 9 39.10% 
Dull 8 34.80% Worse when first get up 8 34.80% 
Moving from 
one spot to 
another 
7 30.40% Worse in the afternoon 7 30.40% 
Pulling 6 26.10% Worse during the day, better at night 6 26.10% 
Fixed location 6 26.10% Fluctuate 4 17.40% 
Cold 5 21.70% Worse in the morning 4 17.40% 
Pricking 5 21.70% Worse at lunch time 1 4.30% 
Burning 5 21.70% Recurrent 0 0.00% 
Hot 3 13.00% Not known 0 0.00% 
Distending 1 4.30% 
 Not known 1 4.30% 
Items greater than 40% were bolded and items less than 5% were italicised. 
 
Appendix 53 End of treatment week pain aggravator frequency – SEA (n=23) 
Pain aggravators Frequency Percentage
Environmental changes 
Cold weather 18 78.30% 
Weather change 4 17.40% 
Hot weather 4 17.40% 
Windy days 3 13.00% 
Wet weather 2 8.70% 
Exercises or sporting 
Physical work 15 65.20% 
Standing 14 60.90% 
Walking 13 56.50% 
Lifting 13 56.50% 
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Pain aggravators Frequency Percentage
Sitting 12 52.20% 
Bending 11 47.80% 
Going up/down stairs 8 34.80% 
Driving 8 34.80% 
Lying down 7 30.40% 
Any movement 5 21.70% 
Physiological and psychic changes 
Bad night sleep 15 65.20% 
Stress 12 52.20% 
Being emotional 8 34.80% 
Being hungry 1 4.30% 
After eating 0 0.00% 
Others 
Household chores 11 47.80% 
Pressure on the area 7 30.40% 
Everything 5 21.70% 
Sex 4 17.40% 
Not known 0 0.00% 
Items greater than 40% were bolded and items less than 5% were italicised. 
 
Appendix 54 End of treatment week pain alleviator frequency – SEA (n=23) 
Pain alleviators Frequency Percentage
Environmental changes 
Hot packs 18 78.30% 
Warm/hot shower 14 60.90% 
Warm/hot bath 7 30.40% 
Hot weather 6 26.10% 
Cold packs 2 8.70% 
Cold weather 1 4.30% 
Wet weather 0 0.00% 
Windy days 0 0.00% 
Exercises or sporting 
Gentle massage 9 39.10% 
Resting 9 39.10% 
Walking 5 21.70% 
Lying down 5 21.70% 
Sitting 5 21.70% 
Gentle exercise 5 21.70% 
Driving 4 17.40% 
Any movement 1 4.30% 
Standing 0 0.00% 
Physiological and psychic changes 
Pain killer 17 73.90% 
Keeping my mind off pain 12 52.20% 
Sleep 7 30.40% 
Pressure on the pain area 6 26.10% 
Reading 6 26.10% 
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Pain alleviators Frequency Percentage
Deep breathing 5 21.70% 
Being with other people 4 17.40% 
Bowel movement 3 13.00% 
Watching TV 3 13.00% 
Alcohol 2 8.70% 
Being hungry 1 4.30% 
Working 1 4.30% 
Eating 0 0.00% 
Belching 0 0.00% 
Others 
Keeping busy 10 43.50% 
Nothing 4 17.40% 
Sex 1 4.30% 
Everything 1 4.30% 
Household chores 1 4.30% 
Not known 0 0.00% 
Items greater than 40% were bolded and items less than 5% were italicised. 
 
 
Appendix 55 End of treatment week other accompanying symptom frequency – SEA (n=23) 
Other symptoms and Frequency Frequency Percentage
Feeling tired easily 19 82.60% 
Poor concentration 13 56.50% 
Limited movement 12 52.20% 
Feeling nervous easily 12 52.20% 
Feeling depressed 12 52.20% 
Feeling cold easily 11 47.80% 
Irritable 11 47.80% 
Poor memory 11 47.80% 
Thirsty 10 43.50% 
Cold hands and feet 9 39.10% 
Insomnia 9 39.10% 
Constipation 9 39.10% 
Dry or sore throat 8 34.80% 
Feeling hot easily 7 30.40% 
Night sweating 7 30.40% 
Need deep breathing 7 30.40% 
Short of breath 7 30.40% 
Swollen joints 6 26.10% 
Heavy sensation in the body 6 26.10% 
Dry skin 6 26.10% 
Sweat upon mild activities 6 26.10% 
Red and hot joints 5 21.70% 
Cold joints 5 21.70% 
Frequent urination at night 5 21.70% 
Catch cold easily 5 21.70% 
Stuffiness in the chest 5 21.70% 
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Other symptoms and Frequency Frequency Percentage
Skin itch 5 21.70% 
Indigestion 4 17.40% 
Cold lower back or knees 4 17.40% 
Flushed face 4 17.40% 
Frequent urination 4 17.40% 
Sigh often 4 17.40% 
Reflux 4 17.40% 
Dizziness 4 17.40% 
Leak when sneezing or cough 3 13.00% 
Low libido 3 13.00% 
Poor appetite 3 13.00% 
Distention sensation in the abdomen 2 8.70% 
Abdominal distention 2 8.70% 
Nausea 2 8.70% 
Watery diarrhoea 1 4.30% 
Mushy stools 1 4.30% 
Dry stools 1 4.30% 
Belching 1 4.30% 
Hot palms 0 0.00% 
Items greater than 40% were bolded and items less than 5% were italicised. 
 
Appendix 56 End of treatment week pain region frequency – PMM alone (n=17) 
Pain regions Frequency Percentage
Head and shoulder regions 
Shoulder 7 41.20% 
Neck 5 29.40% 
Shoulder blades 5 29.40% 
Frontal head 3 17.60% 
Sides of the head 3 17.60% 
Back of the head 3 17.60% 
Vertex 1 5.90% 
Upper limb 
Upper arm 4 23.50% 
Wrist 4 23.50% 
Fingers 4 23.50% 
Hand 2 11.80% 
Elbow 1 5.90% 
Forearm 1 5.90% 
Lower limb 
Knee 9 52.90% 
Hip 7 41.20% 
Thigh 7 41.20% 
Front of the leg 7 41.20% 
Calf 7 41.20% 
Toes 6 35.30% 
Ankle 4 23.50% 
Heel 4 23.50% 
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Pain regions Frequency Percentage
Sole 4 23.50% 
Front of the body 
Groin 4 23.50% 
Stomach 2 11.80% 
Chest 1 5.90% 
Abdomen 1 5.90% 
Side of the body 1 5.90% 
Back of the body 
Lower back 15 88.20% 
Between shoulder blades 4 41.20% 
Sacrum 7 41.20% 
Middle back 6 35.30% 
Buttocks 5 29.40% 
Items greater than 40% were bolded and items less than 5% were italicised. 
 
Appendix 57 End of treatment week pain quality and rhythm frequency – PMM alone (n=17) 
Pain quality Frequency Percentage Pain rhythm Frequency Percentage
Sharp 11 64.70% All the time 11 64.70% 
Fixed location 8 47.10% Worse at the end of the day 7 41.20% 
Burning 7 41.20% Worse when first get up 5 29.40% 
Dull 6 35.30% Fluctuate 4 23.50% 
Pricking 3 17.60% 
Worse at night, 
better during the 
day 
4 23.50% 
Numbness 3 17.60% Worse during the day, better at night 3 17.60% 
Dull pain with 
weakness 3 17.60% 
Worse in the 
afternoon 3 17.60% 
Cold 2 11.80% Worse in the morning 2 11.80% 
Pulling 2 11.80% Recurrent 1 5.90% 
Moving from one 
spot to another 2 11.80% Not known 1 5.90% 
Hot 2 11.80% Worse at lunch time 0 0.00% 
Distending 1 5.90% 
 Not known 0 0.00% 
Items greater than 40% were bolded and items less than 5% were italicised. 
 
Appendix 58 End of treatment week pain aggravator frequency – PMM alone (n=17) 
Pain aggravators Frequency Percentage
Environmental changes 
Cold weather 13 76.50% 
Wet weather 4 23.50% 
Weather change 4 23.50% 
Windy days 3 17.60% 
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Pain aggravators Frequency Percentage
Hot weather 2 11.80% 
Exercises or sporting 
Standing 13 76.50% 
Walking 11 64.70% 
Physical work 10 58.80% 
Lifting 10 58.80% 
Going up/down stairs 10 58.80% 
Sitting 8 47.10% 
Bending 8 47.10% 
Driving 6 35.30% 
Lying down 3 17.60% 
Any movement 2 11.80% 
Physiological and psychic changes 
Bad night sleep 7 41.20% 
Stress 6 35.30% 
Being emotional 5 29.40% 
After eating 1 5.90% 
Being hungry 1 5.90% 
Others 
Household chores 8 47.10% 
Pressure on the area 4 23.50% 
Everything 4 23.50% 
Sex 3 17.60% 
Not known 0 0.00% 
Items greater than 40% were bolded and items less than 5% were italicised. 
 
Appendix 59 End of treatment week pain alleviator frequency – PMM alone (n=17) 
Pain alleviators Frequency Percentage
Environmental changes 
Hot packs 11 64.70% 
Warm/hot shower 9 52.90% 
Hot weather 3 17.60% 
Warm/hot bath 3 17.60% 
Cold packs 2 11.80% 
Cold weather 0 0.00% 
Wet weather 0 0.00% 
Windy days 0 0.00% 
Exercises or sporting 
Lying down 7 41.20% 
Resting 7 41.20% 
Gentle massage 6 35.30% 
Gentle exercise 4 23.50% 
Sitting 3 17.60% 
Any movement 1 5.90% 
Driving 1 5.90% 
Standing 0 0.00% 
Walking 0 0.00% 
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Pain alleviators Frequency Percentage
Physiological and psychic changes 
Pain killer 17 100.00% 
Keeping my mind off pain 6 35.30% 
Sleep 5 29.40% 
Deep breathing 3 17.60% 
Bowel movement 3 17.60% 
Being with other people 3 17.60% 
Reading 3 17.60% 
Watching TV 3 17.60% 
Belching 1 5.90% 
Pressure on the pain area 1 5.90% 
Alcohol 1 5.90% 
Eating 0 0.00% 
Being hungry 0 0.00% 
Working 0 0.00% 
Others 
Keeping busy 4 23.50% 
Nothing 3 17.60% 
Sex 2 11.80% 
Everything 0 0.00% 
Household chores 0 0.00% 
Not known 0 0.00% 
Items greater than 40% were bolded and items less than 5% were italicised. 
 
Appendix 60 End of treatment week other pain accompanying symptom frequency – PMM 
alone (n=17) 
Other symptoms Frequency Percentage
Feeling tired easily 11 64.70% 
Insomnia 9 52.90% 
Irritable 9 52.90% 
Poor concentration 9 52.90% 
Limited movement 8 47.10% 
Poor memory 8 47.10% 
Low libido 8 47.10% 
Feeling depressed 8 47.10% 
Feeling cold easily 7 41.20% 
Night sweating 7 41.20% 
Constipation 7 41.20% 
Feeling hot easily 6 35.30% 
Sweat upon mild activities 6 35.30% 
Feeling nervous easily 6 35.30% 
Dry skin 5 29.40% 
Poor appetite 5 29.40% 
Dizziness 5 29.40% 
Swollen joints 4 23.50% 
Flushed face 4 23.50% 
Frequent urination at night 4 23.50% 
 456 
 
Other symptoms Frequency Percentage
Frequent urination 4 23.50% 
Cold joints 3 17.60% 
Cold hands and feet 3 17.60% 
Dry or sore throat 3 17.60% 
Hot palms 3 17.60% 
Watery diarrhoea 3 17.60% 
Sigh often 3 17.60% 
Need deep breathing 3 17.60% 
Short of breath 3 17.60% 
Cold lower back or knees 2 11.80% 
Thirsty 2 11.80% 
Leak when sneezing or cough 2 11.80% 
Reflux 2 11.80% 
Nausea 2 11.80% 
Red and hot joints 1 5.90% 
Heavy sensation in the body 1 5.90% 
Mushy stools 1 5.90% 
Dry stools 1 5.90% 
Catch cold easily 1 5.90% 
Stuffiness in the chest 1 5.90% 
Skin itch 1 5.90% 
Distention sensation in the abdomen 0 0.00% 
Indigestion 0 0.00% 
Abdominal distention 0 0.00% 
Belching 0 0.00% 
Items greater than 40% were bolded and items less than 5% were italicised. 
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Appendix 61 Average OM consumption amongst REA, SEA, and PMM alone before and after 
treatment 
 REA: Baseline weeks: Mean: 591.353. Standard error: 120.406. End of treatment weeks: Mean: 
429.575. Standard error: 114.826. 
SEA: Baseline weeks: Mean: 522.949. Standard error: 117.076. End of treatment weeks: Mean: 
429.113. Standard error: 111.651. 
PMM alone: Baseline weeks: Mean: 410.699. Standard error: 141.222. End of treatment weeks: 
Mean: 363.653. Standard error: 134.678. 
*p=0.000 
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Appendix 62 Average pain intensity amongst REA, SEA, and PMM alone before and after 
treatment 
REA: Baseline weeks: Mean: 4.740. Standard error: 0.452. End of treatment weeks: Mean: 
4.563. Standard error: 0.518. 
SEA: Baseline weeks: Mean: 5.598. Standard error: 0.439. End of treatment weeks: Mean: 
5.170. Standard error: 0.504. 
PMM alone: Baseline weeks: Mean: 5.728. Standard error: 0.530. End of treatment weeks: 
Mean: 5.514. Standard error: 0.608. 
p=0.144 
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Appendix 63 Total BDI score amongst REA, SEA, and PMM alone before and after treatment 
REA: Baseline weeks: Mean: 17.558. Standard error: 1.991. End of treatment weeks: Mean: 
15.168. Standard error: 2.034. 
SEA: Baseline weeks: Mean: 20.950. Standard error: 1.936. End of treatment weeks: Mean: 
18.423. Standard error: 1.978. 
PMM alone: Baseline weeks: Mean: 24.833. Standard error: 2.335. End of treatment weeks: 
Mean: 22.972. Standard error: 2.386. 
*p=0.009 
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Appendix 64 Total SF36 score amongst REA, SEA, and PMM alone before and after treatment 
REA: Baseline weeks: Mean: 41.131. Standard error: 3.968. End of treatment weeks: Mean: 
47.577. Standard error: 3.682. 
SEA: Baseline weeks: Mean: 39.238. Standard error: 3.858. End of treatment weeks: Mean: 
39.659. Standard error: 3.580. 
PMM alone: Baseline weeks: Mean: 31.983. Standard error: 4.654. End of treatment weeks: 
Mean: 30.896. Standard error: 4.318. 
p=0.284 
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Appendix 65 Average OM consumption amongst REA, SEA, and PMM alone before and after 
treatment – cluster 4 
REA: Baseline weeks: Mean: 393.5223. Standard error: 96.96596. End of treatment weeks: 
Mean: 306.1061. Standard error: 99.27312. 
SEA: Baseline weeks: Mean: 633.9922. Standard error: 231.36724. End of treatment weeks: 
Mean: 537.0635. Standard error: 236.75248. 
PMM alone: Baseline weeks: Mean: 211.3896. Standard error: 73.66412. End of treatment 
weeks: Mean: 145.9207. Standard error: 84.27099. 
p=0.802 
CM: Chinese medicine 
PMM alone: Pain medication management alone 
OM: Opioid medication 
REA: Real electro acupuncture 
SEA: Sham electro acupuncture 
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Appendix 66 Average pain intensity amongst REA, SEA, and PMM alone before and after 
treatment – cluster 4 
 REA: Baseline weeks: Mean: 4.5593. Standard error: 0.55864. End of treatment weeks: Mean: 
4.3973. Standard error: 0.74371. 
SEA: Baseline weeks: Mean: 6.2510. Standard error: 0.50255. End of treatment weeks: Mean: 
5.4831. Standard error: 0.66731. 
PMM alone: Baseline weeks: Mean: 5.9167. Standard error: 0.86739. End of treatment weeks: 
Mean: 5.4976. Standard error: 1.05552. 
p=0.649 
CM: Chinese medicine 
PMM alone: Pain medication management alone 
REA: Real electro acupuncture 
SEA: Sham electro acupuncture 
VAS: Visual analogue scale 
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Appendix 67 Total BDI score amongst REA, SEA, and PMM alone before and after treatment – 
cluster 4 
 REA: Baseline weeks: Mean: 9.6154. Standard error: 1.94652. End of treatment weeks: Mean: 
10.4615. Standard error: 2.28320. 
SEA: Baseline weeks: Mean: 20.0000. Standard error: 2.01810. End of treatment weeks: Mean: 
16.5455. Standard error: 2.00619. 
PMM alone: Baseline weeks: Mean: 23.3333. Standard error: 5.84618. End of treatment weeks: 
Mean: 22.5000. Standard error: 7.52662. 
p=0.189 
BDI: Beck depression inventory 
CM: Chinese medicine 
PMM alone: Pain medication management alone 
REA: Real electro acupuncture 
SEA: Sham electro acupuncture 
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Appendix 68 Total SF36 score amongst REA, SEA, and PMM alone before and after treatment 
– cluster 4 
 REA: Baseline weeks: Mean: 55.6907. Standard error: 4.75574. End of treatment weeks: Mean: 
56.1955. Standard error: 5.25455. 
SEA: Baseline weeks: Mean: 38.7595. Standard error: 4.38211. End of treatment weeks: Mean: 
40.0909. Standard error: 4.81189. 
PMM alone: Baseline weeks: Mean: 37.9410. Standard error: 9.40913. End of treatment weeks: 
Mean: 34.7569. Standard error: 9.95014. 
p=0.773 
CM: Chinese medicine 
PMM alone: Pain medication management alone 
REA: Real electro acupuncture 
SEA: Sham electro acupuncture 
SF36: Medical outcome short form health survey 36 items 
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Appendix 69 OM consumption amongst REA, SEA, and PMM alone before and after treatment 
– cluster 5 
 REA: Baseline weeks: Mean: 789.1844. Standard error: 236.47300. End of treatment weeks: 
Mean: 553.0438. Standard error: 218.59999. 
SEA: Baseline weeks: Mean: 411.9060. Standard error: 73.16018. End of treatment weeks: 
Mean: 321.1634. Standard error: 71.41975. 
PMM alone: Baseline weeks: Mean: 610.0077. Standard error: 220.96726. End of treatment 
weeks: Mean: 581.3856. Standard error: 77.54145. 
p=0.168 
CM: Chinese medicine 
PMM alone: Pain medication management alone 
OM: Opioid medication 
REA: Real electro acupuncture 
SEA: Sham electro acupuncture 
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Appendix 70 Average pain intensity amongst REA, SEA, and PMM alone before and after 
treatment – cluster 5 
 REA: Baseline weeks: Mean: 4.9205. Standard error: 0.52584. End of treatment weeks: Mean: 
4.7281. Standard error: 0.50900. 
SEA: Baseline weeks: Mean: 4.9443. Standard error: 0.82533. End of treatment weeks: Mean: 
4.8568. Standard error: 0.71616. 
PMM alone: Baseline weeks: Mean: 5.5397. Standard error: 0.64878. End of treatment weeks: 
Mean: 5.5302. Standard error: 0.76502. 
p=0.935 
CM: Chinese medicine 
PMM alone: Pain medication management alone 
REA: Real electro acupuncture 
SEA: Sham electro acupuncture 
VAS: Visual analogue scale 
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Appendix 71 Total BDI score amongst REA, SEA, and PMM alone before and after treatment – 
cluster 5 
 REA: Baseline weeks: Mean: 25.5000. Standard error: 3.59563. End of treatment weeks: Mean: 
19.8750. Standard error: 3.08474. 
SEA: Baseline weeks: Mean: 21.9000. Standard error: 2.89233. End of treatment weeks: Mean: 
20.3000. Standard error: 2.17077. 
PMM alone: Baseline weeks: Mean: 26.3333. Standard error: 2.53311. End of treatment weeks: 
Mean: 23.4444. Standard error: 1.93011. 
p=0.450 
BDI: Beck depression inventory 
CM: Chinese medicine 
PMM alone: Pain medication management alone 
REA: Real electro acupuncture 
SEA: Sham electro acupuncture 
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Appendix 72 Total SF36 score amongst REA, SEA, and PMM alone before and after treatment 
– cluster 5 
 REA: Baseline weeks: Mean: 26.5703. Standard error: 7.89021. End of treatment weeks: Mean: 
38.9583. Standard error: 4.38784. 
SEA: Baseline weeks: Mean: 39.7167. Standard error: 6.46276. End of treatment weeks: Mean: 
39.2271. Standard error: 5.24358. 
PMM alone: Baseline weeks: Mean: 26.0255. Standard error: 2.24997. End of treatment weeks: 
Mean: 27.0347. Standard error: 2.10140. 
p=0.118 
CM: Chinese medicine 
PMM alone: Pain medication management alone 
REA: Real electro acupuncture 
SEA: Sham electro acupuncture 
SF36: Medical outcome short form health survey 36 items 
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